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Each year, the rate of incidence of obesity, and obesity related diseases in the 
developed world continue to rise. To date, very few of these cases have been 
attributed to known monogenic causes, with the majority of cases thought to have a 
polygenic basis. This highlights the importance of studying polygenic animal models, 
such as described in this thesis. Previously, the discovery of four body fat quantitative 
trait loci (QTL) had been reported in an F 2 cross between the long-term divergently 
selected fat (F) and lean (L) -lines of mice, differing five-fold in total body fat. A 
congenic line for the Fob3 QTL region on mouse chromosome 15 (mChrl5) was 
generated by backcrossing the L-line QTL region to the F-line using marker assisted 
selection. This thesis reports the use of this line in a more detailed QTL mapping 
analysis, which shows that the Fob3 QTL consists of at least two smaller QTL (Fob3a 
and Fob3b) with effects at different developmental stages. Our analysis illustrates the 
genetic complexity of polygenic traits such as obesity where even small effects can be 
influenced by multiple loci. 
In addition, a microarray approach has been used to compare gene expression 
differences in liver and brown adipose tissue between the F-line and a Fob3b-
containing congenic line. Using 15,000 cDNAs, this microarray analysis identified 
several unknown and known mChrl5 differentially expressed transcripts. Differential 
expression of genes outwith mChrlS indicates that Fob3b may affect the cholesterol 
biosynthesis pathway, and possibly also the glycolysis pathway. Northern analysis 
was used to confirm the microarray results for the most promising candidates and to 
perform a detailed developmental and tissue distribution analysis on the unknown 
mChrl5 differentially expressed transcripts, whilst Q-PCR has been used to confirm 
the candidates involved in the cholesterol biosynthesis pathway. The analysis 
demonstrates the use of microarrays as a powerful tool to help find potential candidate 
genes for the QTL effects, and identify perturbed metabolic pathways that could help 
in the future functional characterisation of causal genes. 
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CHAPTER ONE 
INTRODUCTION 
INTRODUCTION - OBESITY: 1.1 
1.1 	OBESITY 
1.1.1 	ABSTRACT 
Obesity is a multigenic quantitative trait, however many of the genes and gene 
products involved are as yet unidentified. Elucidating the complexities of obesity 
could bring about lucrative drug opportunities for preventing, halting or even 
reversing obesity within the human population, especially in the Western world. 
Many industries would benefit from advances in understanding obesity, such as the 
farming industry, where for example, production costs and costs of fat tissue removal 
can be reduced to meet the public's demand for leaner meat products. 
The following review provides a summary of the models used to investigate the 
genetic basis of obesity, and highlights the major pathways and the genes involved in 
this highly complex polygenic phenotype. 
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1.1.2 	REVIEW OF OBESITY 
1.1.2.1 The need to tackle 'globesity' 
So far as humans are concerned, obesity is one of today's most visible public health 
problems, characterised by the Body Mass Index (BMI)' where a BMI of 30 or 
greater is considered obese, and a BMI between 25 and 29.9 is considered 
overweight (NIH - National Institutes of Health, 1998). It is a complex chronic 
disease, and the tendency to become fat is determined by the individuals' genetics 
and the environment - that is, lack of physical activity combined with abundant high-
fat, energy rich food. 
The obesity epidemic (Zwillich, 2001) is not restricted to industrialized societies, as 
is popularly believed. In developing countries, it is estimated that over 115 million 
people suffer from obesity-related problems (WHO 2001). The most obese nation, 
the USA, where 61% of the population is either overweight or obese, is now easily 
matched by many nations not traditionally described as 'Western'. Indeed this 
escalating global epidemic of overweight and obesity - 'globesity' - is overrunning 
many parts of the world, transcending the barriers of age, sex and socio-economic 
groups. In 1995, it was estimated that 200 million people worldwide were obese, 
with a further 18 million children under-five classified as overweight. By the year 
2000, the number of obese adults had risen to over 300 million. 
Interestingly, men have a higher incidence of being overweight, whilst women have 
a higher incidence of obesity, the reasons for this are not fully understood. Obesity 
poses a major risk for serious diet-related noncommunicable diseases for both men 
and women. These include diabetes mellitus, cardiovascular disease, hypertension, 
stroke, arthritis, depression and certain cancers - including breast, colon, prostate, 
endometrium, cervix, ovary, kidney, and the gallbladder (Wolk et al. 2001). Recent 
Body Mass Index, or BMI, is an index used to determine whether a patient is overweight. BMI is 
calculated by dividing a person's body weight in kilograms by their height in meters squared (weight 
[kg]/height [rn] 2) or by using the conversion with pounds and inches squared (weight [Ibs]Iheight [in] 2 
x704.5). 
For further information visit: http://www.cdc.gov/nccdphp/dnpalobesitylbasics.htm.  
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evidence suggests that overweight and obesity can account for up to 14% of all 
deaths from cancer in men, and 20% in women (Calle et al. 2003). Other health 
consequences range from increased risk of premature death due to serious chronic 
conditions that reduce the overall quality of life, and either burdens the state health 
budget or raises insurance premiums. 
Dieting, whilst sound in principle, has consistently been shown to be ineffective, 
with weight gain resuming once the dieting regimen has been ceased. The most 
popular current regimen is the 'Atkins diet' (1999). The principle of the Atkins diet 
relies on the basis that carbohydrate is the first fuel to be metabolized, and that if no 
(or very little) carbohydrate is ingested, the body resorts to burning fat as its main 
energy source, resulting in weight loss without calorific restriction. However, the 
effect of the Atkins diet remains to be proven, as does its safety (Foster et al. 2003). 
The scope for drug-based solutions hence remains very large and thus also lucrative. 
Obesity is a highly heritable trait, with a heritability estimate for BMI in humans of 
around 50 to 70% (Stunkard et al. 1986; Allison et al. 1996; Koeppen-Schomerus et 
al. 2001). Therefore the obvious route to establishing the pathways that ultimately 
lead to obesity, would be to examine the genetics of the disease. There are three 
general routes to obesity: first, a relative increase in energy consumption, second, a 
relative decrease in energy expenditure, and third, an enhanced preference for storing 
energy in fat cells. Any "fat" genes will inevitably interfere or influence one of these 
three systems. The following discussion summarises the most significant advances 
and discoveries made in genetics and molecular biology that have been implicated in 
obesity phenotypes. These are discussed firstly in the context of the genetic models 
in which these discoveries were made [1.1.2.2], and secondly in the context of the 
pathways in which these factors are involved [1.1.2.3]. 
1.1.2.2 	Genetic models of obesity 
Since the first association study that showed a genetic link to obesity in humans 
(Bouchard et al. 1990), there have been hundreds more, linking over 70 candidate 
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genes to the human obese phenotype (Chagnon et al. 2003). Other species have also 
been used, such as pigs (Nagamine et al. 2003) and chickens (Dietrich et al. 1999), 
however, it is mouse and rat models that constitute the bulk of research into the 
obesity syndrome. The most utilised of these models, the monogenic mouse models, 
are discussed below with respect to their phenotypes and the molecular mechanisms 
that lead to those phenotypes. A more exhaustive list of these models may be 
obtained from the reviews by Butler & Cone (2001), Tschop & Heiman (2001), 
Brockmann & Bevova (2002), and Chagnon et al. (2003). Other models that are 
increasingly being used to investigate obesity, such as knock-out and transgenic 
mouse models, polygenic animal models and in vitro cell culture approaches are also 
discussed. 
1.1.2.2.1 	Monogenic animal models - spontaneous mutants 
There are now over 300 documented molecular genetic markers, chromosomal 
regions and genes that relate to, or are linked with, human or murine obesity 
phenotypes (Chagnon et al. 2003). This large number of genetic components and 
various environmental factors makes obesity a highly complex trait, with few well-
characterised mechanisms and pathways. 
Thus far only nine genes from spontaneous mutant rodent models have been cloned 
for obesity (see list below). These mutations are mainly in genes that regulate energy 
intake. Presumably, amongst the other 300 identified markers and chromosomal 
regions there will also be mutations in genes involved in the other pathways leading 
to obesity, i.e., the pathways involved in energy expenditure and partitioning. 
As more research is carried out, some of these murine mutations seen in models are 
also being identified as causes of obesity in human homologues, although at a very 
low level of incidence, indicating that there is still much work to be done before the 
polygenic basis of human obesity is fully understood. 
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There are nine models as follows: 
1 	Agouti signalling protein (Ay in mice but denoted as ASIP in humans) - 
characterised as the Agouti yellow (Ar) mutation (Leibel et al. 1997). 
2 
	
	Attractin (Atm) - characterised as the 'mahogany mutation' (formerly denoted 
as mg) (Nagle et al. 1999; Gunn et al. 1999). 
3 	Leptin (Lep) - characterised as the 'obese mutation' (formerly denoted as ob) 
(Zhang et al. 1994). 
4 	Leptin Receptor (Lepr) - characterised as the 'diabetes mutation' (formerly 
denoted as db) (Tartaglia et al. 1995). 
5 	Carboxypeptidase E (Cpe) - characterised as the 'fat mutation' (Naggert et al. 
1995). 
6 	Tubby (Tub) - characterised as the 'tubby mutation' (Kleyn et al. 1996). 
7 	Lpinl - characterised as the fatty liver dystrophy mutation (formerly fid), 
(Peterfy et al. 2001). 
8 	Growth hormone releasing hormone (Ghrhr) - characterised as the little 
mutation (Donahue & Beamer 1993). 
All of the above mutations are recessive, except for the Agouti yellow mutation, 
which is dominant and lethal when homozygous. The variability in phenotypic 
effects of the single gene mutations (some of which are discussed below in more 
detail) demonstrates the multiple pathways, the substantial interactions between the 
single-gene mutations and the genetic background involved in obesity. It is likely 
that many more interacting proteins are involved, which as yet are unidentified. If 
this were not so, the phenotypic effects displayed by the monogenic obesity models, 
would be more similar to each other - as observed with the Lep and Lepr mutants, 
which are members of same signalling pathway (discussed below). 
Agouti (A 3') (mChr2; hChr20) 
Agouti yellow mutant 
There are six dominant Agouti mutations in mice, all of which are characterised by 
obesity, hyperinsulinemi a, hyperphagia, hypercorticosteronism and greater linear 
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growth (Yen et al. 1994). In mice, expression of the agouti gene normally takes place 
only in the testes and in the skin during hair growth which results in the yellow hair 
pigment. The wild type (agouti) mouse hair is composed of alternate bands of black 
and yellow melanin; this results from the transient expression of agouti during the 
hair-growth cycle. It has also been shown that Agouti-yellow mutants are both 
yellow and obese due to ectopic overexpression of the normal agouti protein, the 
most significant site for this is proposed to be the brain. 
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Fig 1.1.1: The conflicting pathways involved in obesity of the Agouti signalling pathway. 
Normally Ay affects hair and coat colour by acting on melanocyte stimulating 
hormone (MSH) and melanin concentrating hormone (MCH) (Rance and Baker, 
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1979). Evidence suggests that Ay mimics the action of MCH (Fan et al. 1997) and 
Agouti-related protein (Agrp) (011mann et al. 1997) to antagonise MSH in the brain 
at the melanocortin-4 receptor (MC4R) which is known to suppress food intake [see 
Fig 1.1.1]. More recently, it has been shown that Agouti plays a role in regulating 
leptin, via a mechanism not mediated by MC4R. It has been demonstrated that 
Agouti increases both leptin synthesis and secretion, whilst insulin only enhances 
leptin synthesis. An increased level of leptin induced by Agouti (hence activating the 
reduction of energy-uptake, leading to a feeling of satiety), may serve as a 'damage 
limitation' response, caused by the agouti-induced obesity via the MC4R mechanism 
(Claycombe et al. 2000). Fig [1.1.1] illustrates the two conflicting pathways that 
agouti has been suggested to act upon. In humans, ectopic overexpression of agouti 
does not occur, remaining localised to hair and testes and hence obesity due to agouti 
mutations is never observed (Kucera et al. 1996). 
Attractin (mg/Atm) (mChr2; hChr20) 
Mahogunin, ring finger 1 (mdl Mgrnl) (mChrl6; hChrl6) 
Mahogany and Mahoganoid mutations 
The mahogany (mg) and mahoganoid (md) mutations were originally identified as 
natural suppressors of A'-induced yellow pigmentation. Both mutations have since 
been shown to repress agouti-induced obesity (Lane & Green, 1960; Miller et al. 
1997; Dinulescu et al. 1998). While mg and md are located on different 
chromosomes, they generate the same phenotype which suggests that they are 
involved in the same pathway. With the exception of hyperphagia, homozygous mg 
suppresses the phenotypes of the lethal yellow obesity syndrome: adult-onset obesity, 
hypennsulinemia, hyperleptinemia, hyperglycemia, and increased linear growth. 
When mg/mg A r/a mice are compared to wild-type values, they have normal body 
size, adiposity, insulin, and leptin levels (Dinulescu et al. 1998). 
The mg gene encodes a transmembrane form of attractin (Atm). It is expressed in 
many tissues and within the brain it has a wide but discrete distribution in specific 
populations of neurons. Major sites in the CNS include the hippocampus, 
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hypothalamus, and primary olfactory cortices. Within the hypothalamus, it is found 
in the arcuate, ventromedial, and paraventricular nuclei which are involved in energy 
homeostasis (Lu et al. 1999). 
The mg mutants are presumed to elicit increased signalling at the melanocortin (MC) 
receptors (MC1/4-R). Weight analysis of Mc4r KO mice indicates no difference 
between animals homozygous at the mg locus and wild type. The protein product of 
mg has thus no effect on energy homeostasis in the absence of MC4R, suggesting 
that it acts at, or upstream of MC receptors (Miller et al. 1997; Nagle et al. 1999). 
Several potential models have been proposed to illustrate the interaction between mg 
and the melanocortin system. Robinson et al. (2000) discusses these in more detail. 
Leptin (Lep) (mChr6; hChr7) & Leptin-receptor (Lepr) (mChr4; hChrl) 
Obese and Diabetes mutants 
The Leptin protein (LEP) is transcribed and secreted only from adipose tissue. Since 
the discovery of the Leptin gene (Zhang et al. 1994), much work has been carried out 
involving LEP, and this has instigated a huge amount of research into the genetics of 
obesity. Consequently, the molecular systems involved in obesity reviewed here, 
although far from complete and highly complex, are now better understood. 
LEP functions in conjunction with the Leptin receptor (LEPR) (Tartaglia et al. 1995) 
which is located in hypothalamic nuclei (Chen et al. 1996; Lee et al. 1996). LEPR is 
a member of the class I cytokine receptor family, which uses the Janus kinase/signal 
transducer and activator of transcription pathway as a major signalling route. 
Together they form a ligand-receptor pair, which provides a molecular identification 
and signalling system to the brain concerning the status of energy stores in the form 
of adipose. A defect, or total lack of either of these proteins due to their close 
interaction, results in the same phenotype of marked obesity. 
The indicators of a Lep or Lepr mutant in mice occur after the first few days of life, 
manifesting initially in the form of defective thermogenesis (Himms-Hagen 1985). 
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Somatic fat is increased after just two weeks, and by three weeks animals are fat and 
hyperphagic (Boulange et al. 1979; Joosten & van der Kroon, 1974). Other 
symptoms include a relatively decreased level of energy expenditure and severe 
insulin resistance. When leptin is injected into homozygous job  mutant mice, (mice 
that lack a functioning Leptin gene), weight loss is observed. The effects are reversed 
when the administration of leptin ceases (Pelleymounter et al. 1995; Halaas et al. 
1995; Campfield et al. 1995). 
Lep expression appears to be triggered by decreased levels of triglyceride stores in 
adipocytes. LEP is released from these cells into the blood stream where it interacts 
with LEPR in the hypothalamus, the nerve centre for food intake and energy 
expenditure. The subsequent mechanisms are thought to involve a cascade of 
neurochemical markers that presently number close to fifty (see Beck 2000 & 
Williams et al. 2000 for reviews). The most significant of these are thought to be 
neuropeptide Y (NPY), the MCs and a group of recently discovered peptides termed 
orexins (also referred as hypocretins) all of which are involved in the processes of 
regulating energy uptake [Fig 1.1.2]. 
NPY is the most potent stimulator of food intake known (Kalra et al. 1991). It is 
expressed widely in the nervous system but predominately in a specific hypothalamic 
region - the arcuate nucleus (Sakurai et al. 1998). In Lep0i/Lep0!  and Lepr"YLepr' 
mice, NPY is overexpressed. This is because in normal mice Lep acts as an inhibitor 
of NPY expression (Stephens et al. 1995). 
The hypothalamic MC neuronal system produces peptides all derived from a 
common precursor, pro-opiomelanocortin (POMC). The most important of these 
concerning feeding is a-MSH. Orexins, when injected intracerebroventrically into 
wild type rats, have shown a dramatic ten fold increase in food intake (Sakurai et al. 
1998) and these findings have been reinforced in mice and pigs (Dyer et al. 1999). 
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Fig 1.1.2: The feedback loop of Leptin signalling - mutations in which can lead to obesity. 
Controllers of leptin expression are matters of further complexity. Factors that are 
extrinsic of adipocytes implicated thus far include insulin (MacDougald et al. 1995), 
glucocorticoids, beta-adrenergic ligands and cytokines (see Leibel et al. 1997 for 
review). 
Obesity due to Lep/Lepr mutations have also been observed in humans (Montague et 
al. 1997; Clement et al. 1998). However, these cases appear to be rare in the general 
population, and cannot account for the current human obesity epidemic. 
0 * 
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Carboxypeptidase E (Cpe) (mChr8; hChr4) 
Fat mutant 
Fat mice carrying a mutation in the Cpe gene progressively develop moderate obesity 
starting between 8 and 12 weeks, with females exhibiting obesity sooner than the 
males. The phenotype of mutant homozygous Cpet  mice includes severe 
hyperproinsulinemia and transient hyperglycaemia, as seen in LepolJ  and Lepi" 
mutants (Naggert et al. 1995). 
It is thought that CPE is required for excising residues at the C-terminus of 
prohormone intermediates such as proinsulin. Consequently, disruptive Cpe results in 
increased proinsulin, but since this hyperproinsulinemia in itself does not lead to 
obesity, the full mechanism remains elusive. The perceived role of CPE as a 
processor of prohormones and proneuropeptides obviously could have profound 
effects on other molecules, which are known to be involved in food intake and 
energy expenditure, such as MSH, POMC and corticotropin releasing factor (CRF, 
also known as corticotropin releasing hormone (CRH)). 
Whilst a mutation in CPE for humans giving rise to obesity has not yet been 
identified, a mutation in the gene prohormone convertase 1, has been (Jackson et al. 
1997; Koritschoner et al. 2001). Proconvertases, like PC], act proximally to CPE in 
the pathway and humans bearing this mutation have similar phenotypes as 
homozygous Cpefat  mice. 
Insulin signalling protein (Tub) (mChr7; hChrll) 
Tubby mutant 
Of the single obesity mutations discovered in mice, the Tubby mutation has the 
smallest effect (Noben-Trauth et al. 1996). TUB protein is highly conserved across 
species, however the metabolic and physiologic mechanisms of TUB are not clear, 
and as yet its precise function is unknown. There is no known case of obesity in a 
human subject as a result of mutations in the Tubby homologue (TUB - insulin 
signalling protein). 
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Signs of obesity in mice do not appear until after 12 weeks of age and 
hyperglycaemia is never exhibited. Hyperinsulinemia progresses steadily however, 
until it is 10-20 times greater than in lean counterparts (Coleman & Eicher 1990). 
Murine mutations in Tub, in addition to obesity, can also lead to retinal degeneration 
and hearing loss. Similar characteristics are observed in two human sensory-obesity 
syndromes called Alstrom's and BardetlBiedl, neither of which has candidate genes 
ascribed to them. 
It has been shown that Tub is expressed at high levels in the hypothalamus. This has 
led to the hypothesis that a lack of Tub protein may result in apoptosis of neural 
cells, resulting in a breakdown of the normal control mechanisms for food intake 
and/or energy expenditure (Kleyn et al. 1996). Structural studies on the Tub protein 
and Tubby like proteins (TULPs), have implicated this family of proteins as 
transcription factors (Boggon et al. 1999). A link has also been made with Thyroid 
hormone (TH), a known regulator of energy metabolism, which has been recently 
shown to regulate the expression of Tub (Koritschoner et al. 2001). In addition, 
hypothyroidism in rats was found to alter Tub mRNA and protein, leading to the 
Tubby phenotype. The precise mechanisms concerning how these mutant mice and 
rats become obese however, remain unclear. 
Lipini (fldiLpini) (mChrl2; hChr2) 
Fatty liver dystrophy mutant 
Mutations in the Lpinl gene in mice have features of human lipodystrophy, 
characterized by loss of body fat, fatty liver, hypertriglyceridemia and insulin 
resistance. Lpinl encodes a novel nuclear protein. It's mRNA is expressed at high 
levels in adipose tissue, which is induced during differentiation of pre-adipocytes. 
This indicates that the Lpinl protein is required for normal adipose tissue 
development (Peterfy et al. 2001). 
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Growth hormone releasing hormone (Ghrhr) (mChr6; hChr7) 
Dwarf 'Little' mutant 
The mouse mutation 'little' lit (Beamer & Eicher, 1976), is due to a mutation at the 
growth hormone releasing hormone (Ghrhr) locus. A nucleotide substitution replaces 
an asparagine with a glycine residue in the extracellular domain of the receptor 
molecule GHRHR in lit mutant mice (Lin et al. 1993). GHRHR is yet another 
hypothalamic hormone that acts upon the pituitary to induce release of growth 
hormone (GH) (Godfrey et al. 1993). 
From about 2 weeks of age onward, homozygotes are smaller than normal, adult 
weight is two-thirds that of controls with reduced male fertility (Eicher & Beamer, 
1976). However, despite a dramatic decrease in body weight and skeletal growth, 
there is a marked increase in percent body fat (Donahue & Beamer, 1993). Although 
classically the Gh-Ghrhr axis is a model for 'growth', there is clearly a marked 
impact on obesity as a result of mutation in these genes and other related members of 
the pathway, which have also been observed in humans (Donahue & Beamer, 1993; 
Cai & Hyde, 1999). 
1.1.2.2.2 	Knock out (KO) and over-expression transgenic animal models 
There are 39 genes involved in obesity that have been identified through KO and 
transgenic methods (Robinson et al. 2000; Brockmann & Bevova 2002; Chagnon et 
al. 2003). This list is rapidly increasing, aided by high-throughput phenotyping of 
large ENU and gene-trap derived mutant mice (Stanford et al. 2001; Brown & 
Hardisty, 2003). Many of these genes are involved in the pathways described below. 
Seven additional KO models for obesity have been reported in the 12 months since 
Chagnon et al. (2003). These KOs are listed in Table [1.1.1] and are hence 
interesting candidates that may be future targets for the control of obesity. 
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Table 1.1.1: Transgenic knock-out (KO) rodent models of obesity. 
Mouse Human 
Chr Gene Effect Chr Gene 	Product Reference: 
19 Scdl <Fat 10 SCD 	Stearoyl-00A desaturase Ntambi at al. 2002 
18 Cidea <Fat 18 CIDEA Cell death-inducing DNA fragmentation factor Zhou et al. 2003 
1 Gpr7 >Fat (m) 8 	GPR7 	G protein-coupled receptor 7 Ishii at al. 2003 
1 Ncoa I >Fat 2 	NCOA1 Nuclear receptor coactivator 1 Picard et al. 2003 
1 Ncoa2 <Fat 8 	NCOA2 Nuclear receptor coactivator 2 Picard et al. 2003 
11 Sparc >Fat 5 	SPARC Secreted acidic cysteine rich glycoprotein Bradshaw et al. 2003 
<Fat, >Fat indicates reduced and increased body fat in KO respectively; (m) indicates males only. 
	
1.1.2.2.3 	Polygenic mouse models for obesity 
Polygenic models of obesity are also available for analysis and have been used 
extensively to isolate quantitative trait loci (QTL) for obesity using genome wide 
scans. There are two main variations to using polygenic models, the first involves the 
use of inbred strains that differ naturally in the levels of adiposity (or related trait), 
and the second involves lines of mice that have been divergently selected over time 
for high and low adiposity. 
Crosses between high and low lines (both for inbred lines and selected lines), have 
been carried out examining a diverse range of obesity related QTL. These have 
included heat-loss (Moody et al. 1999), dietary-induced obesity (West et al. 1994; 
West et al. 1994b; York et al. 1996; York et al. 1997), and QTL for specific fat 
deposits, such as mesenteric, gonadal and subcutaneous fat pads (Taylor et al. 2001). 
The mouse lines and QTL involved in these crosses are described further in 
Brockmann & Bevova (2002). The divergently selected Fat (F) and Lean (L) - lines 
on which the present study is founded upon are discussed in more detail in section 
[1.2.3]. 
1.1.2.2.4 	In vitro models 
An additional approach to genetic investigation that is revealing vital aspects of the 
mechanisms that lead to obesity is in vitro cell culture. These studies are centred on 
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determining the mechanisms involved in adipogenesis, which is described in more 
detail below [1.1.2.4.1] 
Studies into adipocyte differentiation, due to legal and/or ethical restrictions, have 
mostly been carried in mouse or hamster cell lines. The commonly used lines are 
listed in Table [1.1.2], which can be divided into two categories: pluripotent 
fibroblasts, which can differentiate into cells other than adipocytes, or unipotent 
preadipocytes, that is, cell lines that have become 'committed' to being adipocytes. 
The most widely used of these lines, are the 3T3 (Green & Meuth, 1974), and 0b17 
(Negrel et al. 1978). The origins of these lines are briefly summarised in Ntambi & 
Kim (2000). 
Table 1.1.2: Cell lines used for study of adipose differentiation. 





















The different mouse models and molecular systems available for studying obesity, 
which have been discussed here, have contributed significantly towards the 
understanding of the mechanisms and pathways that lead to obesity. Some of the 
better-understood pathways that have been characterised are discussed in the 
following section. 
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1.1.2.3 	Pathways involved in obesity 
The pathways described here are not necessarily independent of each other; on the 
contrary their mechanisms interact and regulate each other through complex 
interactions. The pathways that lead to obesity and adiposity are discussed here 
within the context of energy consumption, energy expenditure and energy storage. 
Energy Consumption 
The energy consumption pathway is a complex negative feedback system for the 
control of food consumption. This occurs at multiple levels, involving signalling to 
the brain-hypothalamic neurons that detect the present physiological state, which 
responds accordingly to release hormones that either stimulate or suppress the 
requirement to continue feeding. 
Many of the genes that are involved in this feedback system have been discussed 
above, which include the Lep / Lepr adipose to hypothalamus signalling. There are 
however, a number of other peripheral signal molecules that communicate with the 
hypothalamus to control energy intake which require discussion. 
Cholecystokinin receptor A (Cckar) (mChr9; hChr3), 
Cholecystokinin (Cckar) is released from the duodenum during feeding and acts on 
different fibres of the vagus nerve to inhibit feeding, effectively operating as a 'meal 
termination' signal (Smith & Gibbs, 1994). It was identified in the Otsuka Long-
Evans Tokushima Fatty (OLETF) mutant rat which exhibits late onset 
hyperglycemia, mild obesity, clinical onset of diabetes mellitus (DM) and overall 
resembles human non-insulin dependent DM (NIDDM) in its clinical and pathologic 
features (Kawano et al. 1994). 
Ghrelin (Ghrl) (mChr6; hChr3) 
Ghrelin, is a hormone released by the stomach, and was originally found to be a 
growth hormone secretion stimulator (Kojima et al. 1999). It has recently been found 
to have its own receptors in the hypothalamus resulting in strong orexigenic effects 
(Mitchell et al. 2001). Levels of GHRELIN in humans peak before meals and drop 
sharply after meals, effectively operating as a 'meal initiation' signal in contrast to 
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CCKAR (Cummings et al. 1994). Both Cckar and Ghrl respond quickly in response 
to dietary changes to activate or inhibit further food consumption, whereas Lep 
operates over a much larger time frame, signalling only when "enough" fat has been 
accumulated or lost. 
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Fig: 1.1.3: Multilayered feedback signalling of fed/unfed state. Green arrows indicate signals to 
turn off feeding, blue arrows are signals to switch on feeding. 
Insulin (Ins!!) (mC/zr7; hChrl 1) 
Insulin is one of the most widely studied molecules and is released from the pancreas 
in response to glucose levels in blood and stimulates glucose uptake into cells. Like 
leptin, insulin circulates in plasma at concentrations that are proportional to body fat 
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content, and evidence suggests that insulin receptors are present in the arcuate 
nucleus of the hypothalamus and follow a similar molecular pathway to that of 
leptin, which leads to reduced food intake (with increased insulin levels) (Bruning et 
al. 2000). 
Peptide YY3.36 (PYY336) (mChrl 1; hChrl 7) 
Peptide YY336 (PYY 336), is released from endocrine L-cells in the gastrointestinal 
tract in response to indirect stimulation to the proximal gut and direct stimulation of 
the L-cells by luminal contents (Adrian et al. 1985; Greeley et al. 1989). The amount 
secreted is proportional to calorie intake and recent studies of administration of this 
hormone to mice have shown that it inhibits food intake, and hence reduces weight 
gain. The mechanisms involved are relatively unclear, although evidence suggests 
that PYY336 acts to reduce Npy in the same manner that Leptin does (Batterham et 
al. 2002, Sainsbury et al. 2002). PYY336 hence effectively operates as a 'meal 
quantification' signal. 
Energy expenditure 
A key mechanism in weight loss is brought about through energy expenditure (Rippe 
& Hess, 1998). This occurs both through increased physical activity (Ross & 
Janssen, 2001) and activity-independent thermogenesis that takes place in various 
tissues (Jessen, 1980; Argyropoulos & Harper 2002). Both of these forms of energy 
expenditure are controlled by mitochondria, the 'power houses' of each cell. 
Uncoupling Proteins (UCPs) 
Mitochondria synthesize adenosine triphosphate (ATP) from adenosine diphosphate 
(ADP) and inorganic phosphate. Oxygen diffuses into the mitochondrial matrix and 
reduces nicotinamide adenine dinucleotide (NADH) or fatty acids (FAs), releasing 
electrons into the electron transport chain. This pumps protons into the mitochondrial 
matrix that in turn generates a proton motive force in the inner membrane. This then 
pumps the protons back into the matrix via the membrane bound ATP synthase 
enzymes. ATP synthase couples the proton transport across the membrane to ADP 
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phosphorylation generating ATP, hence oxidative phosphorylation (Lodish, et al. 
1995). Uncoupling of respiration occurs when oxygen is still consumed, but ATP is 
not generated. This is thought to occur by either proton leakage, that is, the 
mitochondnal membrane leaks resulting in protons entering the membrane not being 
coupled to ADP phosphorylation, or through proton 'slippage', which is thought to 
occur when the proton pumps fail to extrude protons but continue to transport 
electrons. Such uncoupling favours the wastage of energy, and ultimately the 
dissipation of energy as heat. This obviously has major metabolic and weight control 
implications for organisms (Ricquier & Bouillaud 2000). 
When leptin plasma levels increase, or environmental temperature dips below the 
optimum, signals are sent from the hypothalamus, through the central nervous system 
(CNS) to various tissues, resulting in the uncoupling of mitochondrial respiration. 
Mitochondrial membrane-bound proteins have been shown to be directly correlated 
with 'proton leakage' and hence have been termed uncoupling proteins (Ucps). So 
far, there have been a number of highly conserved and tissue specific Ucp 
homologues found in mammals (Ucps have also been found in plants, but these will 
not be discussed here, see table [1.1.3] (Laloi et al. 1997; Maia et al. 1998). The most 
important Ucp identified for activity-independent thermogenesis or cold induced 
thermogenesis so far (at least in mice), is Ucpl. Ucpl is predominantly found in 
brown adipose tissue (BAT) and serves to induce respiratory uncoupling and 
thermogenesis in order to maintain body temperature in cold environments 
(Enerback, 1997). Ucp3 is found mainly in muscle and Ucp2 is found in a number of 
tissues (Ricquier & Bouillaud, 2000). Two other mitochondrial carriers have been 
identified and termed Bmcpl (brain mitochondrial carrier protein —1) and Ucp4. 
Both are only expressed in the brain and possess uncoupling properties, however 
their homology to the other Ucps is very low (Mao et al. 1999; Sanchis et al. 1998). 
Ucps release heat by dissipating the proton gradient present across the inner- 
mitochondnal membrane when electrons pass along the respiratory chain (Garlid et 
al. 1998). This mechanism is most pronounced in BAT as carried out by Ucpl (see 
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Ricquier & Bouillaund, (2000b) for review). BAT is hence sometimes referred to as 
an energy-dissipating organ. 
Table 1.1.3: Properties of uncoupling protein homologues. 
Chromosome 
ISOFORM location Expression 
Ucpl 
Mouse: 8; BAT 
Human: 4 
Mouse: 7; Many tissues, 
Ucp2 Human: 11 especially Intestine, 
lung and spleen. 
Ucp3 
Mouse: 7; Muscle (and BAT to a 
Human: 11 small extent) 
Ucp4 Human:6 Brain 
Bmcpl Mouse X; CNS 
Human X 
See Ricquier and Boulliaud 2000b for review. BAT (brown adipose tissue); Bmcp (brain 
mitochondrial carrier protein-1); CNS (central nervous system) 
The genes Ucp2 and Ucp3 are adjacent to each other on the same chromosome, 
mChr7 and hChrl 1, which suggest a duplication event. Ucpl is found on mChr8 and 
hChr4, and has an upstream enhancer (Kozak et al. 1994), which is activated by 
retinoids, TH, cAMP, activator protein-1 (Ap-1)-related factors and 
thiazolidinedi ones (see Ricquier and Boulliaud, (2000b) for review). Interestingly 
cAMP, Cebpce and Cebp/3 (the Cebp transcription family is discussed later), locate 
proximally to the Ucpl gene promoter, and have been shown to regulate Ucpl 
transcription (see Ricquier and Boulliaud for review 2000b). These are the very same 
transcription factors that have been implicated in other metabolic and obesity causing 
pathways such as adiposity differentiation (discussed later). Much research on the 
UCP2 and UCP3 proteins has been carried out, however their precise functions are 
not as clear as that of UCP1 and are still in debate, as reviewed by Porter (2001). 
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Energy Storage 
The final major class of pathways that lead to obesity is that of energy storage and 
partitioning. Obesity occurs when adipose cells increase in size, due to increased 
triglyceride accumulation. This is termed hypertrophic obesity and gives rise to mild 
obesity. More severe obesity, termed hyperplastic obesity, occurs as an increase in 
fat cell number - adipogenesis. It is established that this occurs firstly with the 
proliferation of preadipocytes followed by terminal differentiation. Of course both 
hypertrophy and hyperplasia can and usually do occur together (see Grimaldi (2001) 
for review). 
Adipocytes develop from precursor cells, called preadipocytes, which in turn are 
derived from pluripotent fibroblasts. There may also be an intermediate cell type 
termed "adipoblast" (Ailhaud, 1997). Although much is known about the pathway 
from stem cell to adipose cell, it is far from complete. Many of the molecules and 
transcription mechanisms involved have been identified, although their exact 
mechanisms of action are not fully elucidated, see Fig [1.1.4]. Much of this work has 
been done through the addition of cocktails to preadipocyte cell cultures, effectively 
kick-starting the terminal differentiation to adipocytes (reviewed in Ntambi & Kim 
2000), although it is not known how these processes are initiated in vivo. 
Transcription factors have been identified that regulate the differentiation, gene 
expression and lipid content of adipose cells. After the addition of these 'cocktails' 
the first group of genes to be activated are Fos, fun, JunB and Myc (Cornelius et al. 
1994). Two main families of transcriptional regulators follow these, they are the 
CCAAT/enhancer binding proteins (C/ebp), and the Peroxisome proliferator 
activated receptor (Ppar) families. 
C/ebps have been implicated as regulators of differentiation of multiple cell types, 
including hepatocytes, adipocytes and macrophages. There are eight isoforms within 
the C/ebp family derived from 6 genes Cebpci, -fi, —y, —5 —e, & (also known as 
Chop or Gadd\153)(see Lekstrom-Himes & Xanthopoulos (1998) for review). It is 
accepted that these isoforms are important transcription factors in energy 
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metabolism. The Cebpa isoform has been shown to be expressed only after 
parturition and is most highly expressed in adipose tissue and the liver (Birkenmeier 
et al. 1989). Knockout Cebpa mice are normal at birth, but die within a matter of 
hours due to hypoglycaemia, probably due to disruptions in the glycogen synthase 
pathway. Likewise, in mice that lack either of the two isoforms Cebpfl and Cebpä, 
adipose tissue is dramatically reduced resulting in hypoplastia (Tanaka et al. 1997). 
For a review on the metabolic effects of each isoform see Roesler (2001). 
Similarly, members of the Ppar family have been identified as key molecules for 
adipogenesis. The Ppars are ligand activated, nuclear hormone receptor transcription 
factors, currently accepted as four isoforms Ppara, -13, —y and -& Table [1.1.4] gives 
details of expression sites and activators of the Ppar gene isoforms. 
Table 1.1.4: Properties of Ppar isoforms. 
ISOFORM 	 Expression 	 Activated by: 
Pparct 	liver, BAT, small intestine, skeletal 	Unsaturated - LCFA, 
muscle and heart 	 leukotriene B4, 8 HEA 
Pparfl ubiquitous - higher in brain, adipose and 	Unknown 
eDithelium 
Ppary WAT, BAT, placenta, large intestine, 	TZD compounds, 15d- 
macrophages 	 PGJ2 
Most widely expressed isotype - high 	Saturated and 
Pparö 	levels in WAT cardiac muscle, kidney unsaturated- LCFA, 
and small intestine 	 prostacyclin 
See Grimaldi (2001) and Rosen et al. (2000) for reviews. LCFA (long chain fatty acids); 8 HEA (8(S)-
hydroxy-eicosatetraenoic acid); TZD (thiazolidinedione); 1 5d-PGJ2 (1 5-deoxy-D 12, 14-prostacyclin 
J2) 
Ppara has been shown to be involved in mature onset obesity through lipid 
homeostasis in mice, and that there is sexual dimorphic control on circulating lipids 
and fat storage. Male knockouts show considerable hepatic enlargement, whereas 
females developed more pronounced obesity (Costet et al. 1998). A more recent 
study working on congenic mouse lines, argues that although Ppara is involved in 
lipid homeostasis, it is not associated with obesity (Akiyama et al. 2001) and hence 
this is an issue that needs to be clarified. 
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Fig 1.1.4: The route to adipogenesis. 
The most impacting homologue is Ppary, which exists in two forms, Pparyl - which 
is expressed at low levels in many tissues, and Ppary2 - which is mainly expressed in 
adipose tissues (Fajas et al. 1997) and is induced early in adipose cell differentiation 
(Tontonoz et al. 1994). Ppary forms a close association with retinoid X receptor-
alpha (RXR() forming a heterodimer, and together are thought to be a primary 
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heterodimer can convert fibroblasts into bona fide adipocytes (Tontonoz et al. 1994). 
The adipogenic properties of Ppary are enhanced by the presence of insulin (Hu et al. 
1995), and many other extracellular signals and coactivators have been reported to be 
involved. 
Another major transcription factor involved is sterol regulation element binding 
proteins, (Srebp, known as Srebfl in mice, also referred to as adipocyte 
determination and differentiation-dependent factor 1 (Addi)). Srebfs are lipid 
synthesising transcription factors for cholesterol and FA synthesis. A sterol-sensing 
molecule, Srebf-activating protein (Scap), has been shown to form a complex with 
Srebfs which moves the Srebf from the ER to the Golgi for proteolytic processing 
into an active transcription factor. Experiments suggest that three isoforms, Srebf-la, 
-ic, and -2, have different roles in lipid synthesis. Srebf-lc is involved in FA 
synthesis; Srebf-2 is involved in the regulation of cholesterol synthesis; whilst Srebf-
la is expressed in growing cells, providing both cholesterol and FAs that are required 
for membrane synthesis (see Spiegelman & Flier (1996), and Shimano (2002) for 
reviews). The complexity of the mechanism is furthered by the discovery of Insulin-
induced gene 1 (Insig-1), (Yang et al. 2002), which binds to Scap, blocking Srebf 
and hence preventing it from acting as a transcription factor (Li et al. 2003). High 
cholesterol levels also prevent Srebf from leaving the ER and hence also block its 
transcriptional potential (Nohturfft et al. 2000). Adipogenesis pathways are clearly 
complex, and only ,a few of the major players illustrated in figure [1.1.4] have been 
touched upon here. 
Adipose tissue is composed of differentiated adipocytes, endothelial cells, blood 
cells, fibroblasts and preadipocytes that are at various stages of differentiation. 
However, adipose tissue in mammals exists in two forms, brown (BAT) and white 
adipose tissue (WAT). Both in humans and in rodents, WAT develops during late 
gestation and the first weeks post-natal. WAT serves primarily to store energy, and 
BAT, which has noticeably increased numbers of mitochondria, acts to dissipate it 
(Lowell and Flier, 1997). Most studies of adipogenesis have focused on the 
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development of WAT, the primary site of storage for triglycerides and the release of 
FAs in response to changing energy needs. 
The mechanisms leading to the differentiation of BAT are less clearly understood. 
Insulin and its receptor (IR), as well as Insulin-like growth factor I (IGF-I), and its 
receptor - IGF-IR, have been shown to be involved (Mur et al. 2003), and have been 
linked with the RASIMAPK (mitogen-activated protein kinases) pathway (Porras et 
al. 1998). 
It has been shown that brown and white adipose cells differentiate through separate 
lineages from the preadipocyte stage (Moulin et al. 2001a). Evidence for 
intermediary cell types between the preadipocyte and the terminal adipocytes for 
each of the brown and white cell types - pre-brown.-adipocytes and pre-white-
adipocytes respectively, has be shown (Moulin et al. 2001b). It has also been 
suggested that transdifferentiation takes place between BAT and WAT cells (Cinti 
2002), however the rates at which these events were observed were rather low, and 
clearly not all white cells turn to brown and vice versa. It remains to be seen if all 
WAT cells can transdifferentiate to BAT and visa versa, or if this can only occur 
from a pre-preadipocyte cell stage. The potential for this to occur in humans remains 
questionable, since although BAT has been found in abundance in newborns and 
infants, the amount of natural BAT in adults is very low (Mar Gonzalez-Barroso et 
al. 2000). The implications therefore of activating this tissue type in adult humans 
may result in adverse effects especially in regards to thermoregulation. Nonetheless, 
the ability to convert WAT - the body's energy storage sink, into BAT - the body's 
energy dissipating organ, may be of high therapeutic value. 
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1.1.3 	CONCLUSION 
The changing environment in the human population towards high-fat diets and 
decreased physical activity is certainly a problem that needs to be addressed urgently. 
A change of diet and lifestyle however, may not only be difficult to implement on a 
global level, but also it may not be sufficient, since the spread of obesity is so fast 
that some researchers are proposing that a virus may be responsible for the rapid 
increase of incidence in overweight and obesity in the human population (Holmes, 
2000). 
The genetic and metabolic systems involved in energy homeostasis need to be 
clarified, so that a strategy to halt and reverse obesity on an individual and a global 
scale can one day be achievable. 
Major pathways and mechanisms have already been uncovered, notably that of the 
Leptin, Npy, Agrp, and MC pathways. However the most significant aspect about the 
data that has been accumulated over time is that obesity is a highly complex trait 
with many genes, hormones and pathways involved. Inevitably, a single mis-
regulated or mutated gene, common in every obesity case almost certainly does not 
exist. More likely, multiple genes contributing small effects will need to be targeted 
for any given case. 
The elucidation and discovery of novel loci and genes involved in the various 
pathways described here that can lead to an obese phenotype, should gather further 
pace now that the human and mouse genomes have been sequenced. Many of these 
new genes will help add to the pathways, and perhaps entirely new pathways will 
appear. 
In the following chapters, an approach towards identifying and characterising 
precisely such loci is reported. The remainder of this chapter discusses the 
approaches and techniques used with emphasis on those applied in this study, those 
of quantitative trait locus (QTL) analysis and microarray analysis. 
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1.2 	QUANTITATIVE TRAIT LOCI (QTL) 
1.2.1 	ABSTRACT 
Quantitative trait loci (QTL) mapping has proven to be a very powerful technique for 
identifying and ultimately cloning novel genes. This has been achieved in many 
organisms, from plants to insects and mammals. Whilst many other techniques are 
available for identifying novel genes, such as N-ethyl-N-nitrosourea (ENU) 
mutagenesis, and targeted gene knockout methods, these techniques are not optimal to 
identify genes involved in complex quantitative traits, such as weight, height and 
susceptibility to various diseases. The aim of the following review is to highlight 
strategies for QTL identification and fine mapping and their importance in identifying 
genes involved in complex traits. Specific emphasis is applied to the Fob3 mouse 
obesity QTL, on which this study is focused, providing background into mouse lines 
used and relevant analyses carried out prior to the original work presented in this thesis. 
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1.2.2 	METHODS TO DETECT AND FINE MAP QTL 
'Blending inheritance', the stick used to beat Mendel's genetic theory of 'particulate 
inheritance' was not reconciled until early on in the 20 th  century with the realization that 
blending inheritance could be due to the transmission of many 'particles', i.e. genes, 
having small effects, that could also be affected by the environment. Sax (1923) is 
credited for illustrating the first association between genetic markers and quantitative 
phenotypes when it was noticed that seed-coat pigmentation in beans were associated 
with differences in bean weight. 
Quantitative-trait loci (QTL) refer to loci underlying quantitative characters such as 
height and weight, such traits are usually polygenic traits, controlled by many genes 
each contributing a small effect, that are affected by environmental conditions. QTL 
detection is carried out using crossbreeding experiments, usually in model organisms 
that have high reproductive rates, coupled with short generation intervals. The most 
prominent models are the plant Arabidopsis (Mitchell-Olds & Pedersen 1998), the 
invertebrate Drosophila (Mackay 1995), and mice (Rikke & Johnson, 1998). In addition, 
many QTL studies have been carried out on maize (Doebley 1998) and rice (McCouch 
& Doerge 1995), not only for their properties as model organisms but also for their 
importance as major food crops. Most of the research into obesity has been carried out 
using mice, rats and pigs. 
1.2.2.1 	Approaches to QTL detection and low resolution 
mapping 
The general approach for locating QTL (for obesity in mice for instance), involves 
taking two lines of a species that either naturally deviate widely from each other in the 
chosen trait, or have been selected over many generations to deviate from each other. 
This approach is not a necessity, as two lines can have the same mean phenotypic value, 
yet vary genetically due to complementary patterns of positive and negative allelic 
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effects. However a large difference between the lines improves the possibility of 
detecting QTL of large effects, which are in turn easier to fine map and consequently 
clone. The lines with opposing phenotypes, that is the 'low-line' for any given trait 
(such as leanness - and is assumed to be homozygous for lean/non-fat causing alleles), is 
crossed with the 'high-line' (such as fatness - which is hence assumed to be 
homozygous for fat causing alleles). Approaches using both naturally divergent lines 
and selected divergent lines have been demonstrated to work well, with some examples 
listed in Table [1.2.1]. 
Table 1.2.1: Examples of QTL experiments - utilising high and low lines of various traits. 
Naturally divergent lines 
High 	Low 	 Trait 	 Species 	Reference 
C57BLI6J CAST/Ei 	Adiposity 	 Mouse Pomp. 1997 
Columbia Landsberg erecta Aluminium tolerance Arabidopsis Hoekenga et al. 2003 
Morex 	Steptoe 	Granule volume 	Barley 	Borem et al. 1999 
Divergently selected lines 
High 	Low 	 Trait 	 Species 	Reference 
Fat-line 	Lean-line 	Obesity Mouse Horvat et al. 2000 
Line F Line S Average daily gain Pigs 	Clutter et al. 1998 
The resulting F1 population is heterozygous (by descent) for each allele, and hence for 
any QTL. An F2 population is thus needed (so that comparisons can be made between 
high homozygotes, heterozygotes and low homozygotes at each locus), produced by 
inter-se mating of the F1 s. The alternative 'standard' QTL strategy (to generating an F2 
population) is to generate a backcross (BC) population. The heterozygotes are then 
crossed back to one of the parental lines. However this strategy is less powerful when 
detecting additive effect QTL, since only heterozygote effects can be detected. 
Recombination events during gamete formation in the F1s will result in a shuffling of the 
chromosomal regions into a number of combinations. The scale of variation, in terms of 
allelic QTL inheritance, will be dependent on the number of QTL present [Fig 1.2.1]. 
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For instance, if there is only one QTL there will be three possible contributions of 
variation. Where there are two QTL then there will be nine potential different 
possibilities (Pomp 1997). Hence one can see that the greater the number of QTL 
present, the more continuous the phenotype distribution becomes. 
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Fig 1.2.1: Allelic possibilities of one and two-QTL respectively. When more QTL are present, there are 
a greater number of intermediate phenotypes between extreme lines. 
A QTL is located using statistical analysis to ascertain that the genotype has an effect on 
particular phenotype. Genotypes are determined using highly variable genetic markers 
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such as microsatellite markers, single nucleotide polymorphisms (SNPs), random 
amplified polymorphic DNA markers (RAPD), amplified fragment length 
polymorphisms (AFLP), and restriction fragment length polymorphisms (RFLPs). If a 
population is surveyed at a particular marker, and found that the genotype at this marker 
has statistically significant effect on a particular phenotype, then it is said that a QTL for 
that phenotype occurs at around that location. 
However, this does not imply that the marker or genetic polymorphism is responsible for 
the phenotype or that it contributes to the phenotype directly. It merely shows that the 
entire segment of genetic information with which that marker is 'linked' to has a 
significant effect. The length of this segment can be deduced by observing the results 
from adjacent makers. 
M , 
4 
M 2 	M, 	 M, 
Fig 1.2.2: Principles of single marker analysis. 
Figure 1.2.2 illustrates how, with only one marker available, the QTL is associated to the 
entire chromosome. With three markers available, given that the phenotype is only 
statistically significant at marker Ml, then the QTL is isolated to the region spanning the 
distance of the flanking markers. The more markers are available, the narrower the target 
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region containing the QTL becomes (assuming that there is enough recombinants to be 
detected). 
Single marker analysis: For each marker there are two alleles, each derived from the 
gametes of certain individual's parents. In an outbred population the number of different 
alleles at a particular marker can be large, but when comparing the alleles between two 
inbred populations (with large differences in the phenotype of interest), then there are 
only two different alleles at any given marker, and hence three possible genotypes in the 
F2 - (A1A1), (A1A2), and (A2A2). All the individuals in the F2 population derived from 
two different inbred populations must possess one of these three genotypes, and using 
analysis of variance, for instance, one can asses if the mean of the phenotype for each of 
these three genotypic classes, is significantly different from each other, which would 
indicate the presence of a QTL. This is known as a single marker QTL analysis. 
Interval mapping: A more powerful approach to QTL detection than the single marker 
analysis is QTL analysis utilizing the information between adjacent markers, termed 
interval mapping (IM). Lander & Botstein (1989) developed IM using a maximum 
likelihood (ML) algorithm, which has been enhanced over time. The more notable 
enhancements now allow for the test of multiple linked QTL (Jansen 1993; Zeng 1994; 
Kao et al. 1999) and the minimization of computational requirements through the 
application of regression analysis (Haley & Knott 1992; Xu, 1998). 
IM interrogates the data set, one marker-interval at a time and constructs a putative QTL 
for testing by performing a likelihood ratio test (LRT) (Lander & Botstein, 1989) or 
regression analysis (Haley & Knott, 1992), for each position within that interval. The 
position with the highest test statistic (that is, LOD score for ML analysis and F value 
for regression analysis) within a chromosome is the most likely location of the QTL if it 
exceeds a certain "significant" threshold value. 
INTRODUCTION - QTL: 1.2 	 33 
Establishing an appropriate significance threshold must be carefully considered. This is 
because mapping involves multiple tests across the genome, which means that 
significance thresholds must be correspondingly more stringent (Lander and Kruglyak 
1995). Permutation tests have been described which address this problem by calculating 
empirical thresholds specific for a data set and an appropriate range of the genome 
(Churchill & Doerge 1994; Doerge &Churchill 1996). 
In IM, the assumption is that a QTL is located between two markers. Therefore, the two-
locus marker genotypes each contain mixtures of QTL genotypes (in an F2 population 
these would be: MTAIAIM2AIAI, MlAIAlM2Al, MIAIAIM2A2A2, M1AIA2M2AIAI, 
MIAIA2M2AIA2, Ml AIA2M2A2A2) MlA2A2M2A1A13 MlA2A2M2A1A2, Ml A2A2M2A2A2). 
Maximum likelihood involves searching for QTL parameters that give the best 
approximation for quantitative trait distributions that are observed for each marker class. 
Models are evaluated by computing the likelihood of the observed distributions with and 
without fitting a QTL effect (Lander & Botstein, 1989). 
TM by regression analysis is essentially the same as the method of basic QTL analysis 
except that phenotypes are regressed on the QTL genotypes. Since the QTL genotypes 
are unknown, they are replaced by probabilities estimated from the nearest flanking 
markers. Lynch & Walsh, (1998) provide a step-by-step description of the algorithms 
involved for both the ML and regression approaches. 
1.2.2.2 	Approaches to higher resolution QTL mapping 
Following the initial identification of a QTL region through a whole genome F2 (or BC) 
scan, the logical progression is to then fine-map the QTL. Various tools and strategies 
have been devised to do this for multiple species, the following list highlights some of 
the designs implemented in mouse experiments. 
Advanced intercross lines (AIL) 
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In an AIL strategy, an F2 population is generated from high and low lines, and is then 
randomly inter-crossed for multiple generations, F3, F4. . .Fx. This increases the number 
of recombination events, which inherently provides more power in detecting QTL. For 
instance, in the F10 population, a 20cM QTL interval can be reduced to just 4cM 
(Darvasi & Soller, 1995). 
Chromosome substitution strains (Css) 
Css (also known as 'consomics') are generated by marker-assisted selection 
backcrossing to select an entire chromosome from one line onto the background of 
another. A one-way ANOVA can be carried out by strain to the background strain for 
any particular trait to locate QTL on any particular chromosome. The Css containing a 
QTL can then be used to generate recombinants by backcrossing to the background 
strain for further fine mapping, either by an interval specific congenic strain, or 
recombinant progeny testing approach (discussed below). These lines of mice can be 
kept as frozen embryos, serving as a resource in the anticipation of the discovery of QTL 
for any particular trait. This can lead to an increase in speed and efficiency for mapping, 
as independent investigators need not spend years generating their own backcrossed 
recombinant lines (Nadeau et al. 2000). 
Heterogeneous stocks (HS) 
Genetically HS are essentially controlled outbred mice. Such lines are similar to AIL, 
but differ in that more than two strains are used (usually eight or more), which are out-
bred (to each other) for a number of generations prior to the experiment. With each 
generation of crossing, the number of recombinations increases until each chromosome 
is a mosaic of the haplotypes of the initial inbred strains. HS crossed for up to 60 
generations have been successfully used to fine map QTL (Talbot et al. 1999; Mott et al. 
2000), although it has been shown that between 10-15 generations are sufficient (Valdar 
et al. 2003). The high density of recombinants provides much power to finely map QTL 
for as many traits that segregate between the originating inbred lines. QTL for traits that 
are not different between the founding lines can also be fine mapped by creating an F2 
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population by crossing the HS with an inbred strain, possessing an extreme of the 
desired trait (Mott & Flint, 2002). 
Interval specific congenic strains (ISCS) 
ISCS are generated by marker-assisted selection backcrossing, to select a small-defined 
region presumably containing the target QTL from a donor into a recipient line. The aim 
of this strategy is the removal of genetic background influences, and hence any effect on 
phenotype is due to the introgressed segment, which can be interrogated further or 
compared against other ISCS containing different sizes of introgressed target regions 
(Wright, 1952; Breese & Mather, 1957; Darvasi, 1997). In addition, the ISCS approach 
allows detection of multiple QTLs within the target region and possible linked epistatic 
effects (Darvasi, 1997). 
Linkage disequilibrium (LD) & association mapping 
In LD mapping, the QTL-causing allele is presumed to have occurred uniquely in a 
population on a single haplotype background. Over time, recombination erodes the size 
of this initial haplotype that remains intact and is associated with the QTL effect. LD has 
been extensively used as a mapping tool for isolating QTL in outbred mouse lines and 
for humans (Terwilliger & Weiss, 1998). 
Multiple cross mapping (MCM) 
MCM effectively operates by generating or pooling data from multiple crosses, usually 
F2 crosses, from various inbred strains, e.g. AXB BXC CXD (Hitzemann et al. 2003). If 
in these crosses, an identical QTL is detected, then MCM can be used to significantly 
reduce the QTL interval. The underlying principle is that maps from multiple crosses 
contain an embedded haplotype structure derived from the common lineage of the inbred 
strains. This structure contains information that can be used with an appropriate 
algorithm (Hitzemann et al. 2003) to reduce the size of the QTL-containing target 
interval. This strategy has also been applied to data that has been generated for QTL 
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from different studies, over a large space of time from different groups (Korstanje et al. 
unpublished data). 
Recombinant inbred lines (RIL) 
RIL are derived from the systematic brother—sister mating of selected pairs of an 
intercross between two inbred strains. The ratio of alleles from the two donor lines is 
1:1. RIL serve as a permanent equivalent of a fully genotyped F2 population (Bailey, 
1971; Swank & Bailey, 1973; Brockman & Bevova, 2002). However, it is a more 
powerful tool than the standard F2 as multiple measurements for each trait can be 
obtained for each RIL genotype. This improves the estimation of QTL by sex and QTL 
by environment interaction effects, as the same set of genotypes can be assessed in both 
sexes, and in different environments, providing a more accurate estimate of the 
genotypic values (see Mackay (200 1) for review). 
Recombinant congenic strains (RCS) 
As with recombinant inbred lines, RCS can serve as a permanent pseudo-F 2 population. 
These are produced by limited backcrossing of F1 animals to one of the parental strains 
and subsequent brother—sister mating. The segments of alleles originating from the 
parent, to which the mice were backcrossed, are larger and more frequent than the 
second parental line (Demant & Hart, 1986). This approach is very useful when 
investigating polygenic complex traits, as these traits are affected by multiple interacting 
QTL. RCS reduce the genetic complexity of a standard F2 design, and hence are useful 
once the genome wide scan has revealed multiple QTL, as any interactions between the 
multiple QTL can be better assessed. 
Recombinant progeny testing (RPT) 
The use of RPT is typically combined with the use of interval specific congenic strains, 
whereby new recombinant progeny are generated using an interval specific congenic 
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strain. Each recombinant mouse is backcrossed or intercrossed so that many mice are 
produced with the same recombination in the next generation, producing the progeny-
test population. The progeny-test population is genotyped and phenotyped and high-
resolution mapping is achieved by the pattern of which recombinant progeny maintain 
the QTL effect, and which ones do not (Shrimpton & Robertson, 1988). This is the 
technique that has been employed in this study, and the strategy employed is presented 
in section [2.1.2]. 
Many of these strategies are now also being used in initial screens, in preference to the 
classical F2 and BC approaches. Indeed the field has advanced to in silico mapping 
approaches, that is, comparing the genotypes of multiple inbred strains to the multiple 
phenotypes (as determined by the Mouse Phenome Project), in order to determine 
putative QTL (Grupe et al. 2001). 
1.2.2.3 	Cloning of QTL 
QTL mapping alone is still limited to a resolution of 0.1-1.0% of a genome, around 1.4-
14cM in the mouse (Paterson 1995; Dietrich et al. 1996). This invariably equates to a 
large segment of DNA containing many hundreds of candidate genes, and thus, until 
recently, the cloning of QTL has proved difficult. The recent application of better 
cloning techniques using bacterial and yeast artificial chromosomes (BACs and YAC5), 
expression tools such as differential display and microarrays, and the completion of 
genome sequence projects, have helped to isolate the first genes from QTL and promise 
to continue to do so. Alpert and Tanksley (1996), resolved a QTL for tomato weight to a 
segment of DNA less than 150Kb. They then went on to isolate and clone it within a 
YAC. They have since isolated the single-gene ORFX, from the cloned QTL, which 
appears to be expressed early in floral development and controls carpel cell number. 
They proved the effect of the gene by transforming tomato plants having the partially-
recessive QTLJiv2.2 with cosmids having non-overlapping sequences of the QTL target 
region. One of those cosmids (cos50 - matching to the ORFX gene) resulted in the 
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significant reduction in the fruit weight from the progeny of the transformed plants 
(Frary et al. 2000). 
The first gene identified to be responsible for a mammalian QTL, was APP in humans, 
shown to influence Alzheimer's disease (Goate et al. 1991). As this was a human study, 
proof relied on the demonstration that the mutation was present in all affected 
individuals and absent from normal family members and rare, or absent in the normal 
population. As of 2002, a further 28 genes for QTL had been identified, from either 
human, mouse, rat or pig species as reviewed by Korstanje & Paigen, (2002). Several 
more have been discovered since, including one that affects muscle growth, fat 
deposition and size of the heart in pigs, caused by mutation in the Igf-II gene (Van Laere 
et al. 2003). 
As more genes for QTL are being uncovered in experimental animal models, proof that a 
gene is responsible for the QTL effect, is also being demonstrated more robustly using 
molecular approaches involving knockout and over-expression transgenics. The first 
such proof was shown in mice by Cormier et al. (1997), proving that secretory 
phospholipase (Pla2g2a) conferred resistance to intestinal tumourigenesis. After 
mapping the QTL Mom] to a 4cM region, they then generated a cosmid-transgene over-
expressing the candidate gene Pla2g2a. The transgene caused a reduction in tumour 
multiplicity and size, comparable to that conferred by a single copy of the resistance 
allele of Mom]. 
There is no defined research path for demonstrating proof that a specific gene is 
responsible for a QTL effect. Methodologies such as quantitative complementation, 
essentially the systematic knocking-out of candidate genes within a QTL region, have 
proved successful but remain expensive and time consuming (Cormier et al. 1997; Frary 
et al. 2000; Flint and Mott, 2001). More recently, broader guidelines have been 
suggested for demonstrating evidence that supports a candidate for a QTL (Biola et al, 
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2003). This evidence may follow from experiments involving transgenics, KOs, knock-
ins, knock-down and knock-up (using RNAi for instance), and in vitro cell culture tests. 
Further technological advancements such as microarray technology will allow the 
discovery of the genes responsible for the QTL effects to progress more rapidly, as 
shown by Aitman et al. (1999). The continued improvement of microarrays as a tool, 
coupled with better, more advanced QTL and fine-mapping approaches (discussed 
above), will help identify considerably more genes responsible for QTL. 
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1.2.3 	OBESITY QTL STUDIES AND THE FAT & LEAN 
LINES 
The Human gene map has so far catalogued more than 300 genes, markers and 
chromosomal regions that are associated with human obesity (Chagnon et al. 2003). Of 
these, 68 are obesity QTL found in human studies. The majority however, are QTL for 
obesity or body weight (Bw), mapped using animal models (168), primarily murine, as 
reviewed by Brockmann and Bevova (2002), but also including rats and pigs (Chagnon 
et al, 2003). Unfortunately, many of these animal QTL are not investigated further by 
fine-mapping approaches, since they have small effects on the overall phenotype. 
As of 2002, there had been a total of 31 whole genome QTL scans for obesity and 
related traits using the mouse as a model, a further 12 in the rat, 20 in the pig, and one in 
chickens (Chagnon et al. 2003). Since this review, two further studies have been 
reported in mice (Giesen et al. 2003; Smith-Richards et al. 2003); a further nine studies 
have been reported in pigs (Nagamine et al. 2003; Sanchez et al. 2003; Evans et al. 
2003; Szyda et al. 2003; Quintanilla et al. 2003; Milan et al. 2003; Varona et al. 2002; 
Ovilo et al. 2002; MacNeil et al. 2002), and three in chickens (Li et al. 2003; Ikeobi et 
al. 2003; Sewalem et al. 2002). 
Carrying out QTL studies in humans is hindered by the fact that the population is 
outbred, and environmental influences cannot be properly accounted or controlled for. 
Relatively small, inbred populations however, do exist and have been exploited for 
determining specific Mendelian inheritance disorders. Using such populations to locate 
loci involved in complex trait disorders is very demanding and often yields results with 
low significance estimates (Deng et al. 2002). Human association studies and linkage 
disequilibrium analysis has proved successful to some extent, with 71 candidate genes 
being identified thus far from 232 studies (Chagnon et al. 2003). Since knock-out, 
transgenic or other definitive experiments cannot be carried out in humans, for many of 
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these genes conclusive proof and further characterisation of their function and 
mechanism remain to be demonstrated. The mouse has clearly become the most popular 
QTL animal model due to several advantages: there are many inbred lines available; the 
generation interval is relatively short; and now the mouse genome is fully sequenced and 
hence is saturated with markers. The pig has become a close second favourite for the 
obvious economic benefits that identifying desirable lean traits will bring to its breeders. 
Of the QTL found using mouse models, many may be repeats since the mapping 
techniques used do not create accurate positioning that would allow the clear 
dissociation between neighbouring QTL. In addition, there is large variation between the 
methods of phenotyping from study to study by way of assessing adiposity and fatness, 
with some studies using an adipose index and others the body-mass index for whole 
body fat (Perusse et al. 2001). Indeed, whilst some studies give putative QTL for 
obesity, others go on to describe precise locations for certain fat depots such as QTL for 
gonadal fat weight (Moody et al. 1999) and epididymal fat (Ueda et al. 1999), or go on 
to describe that the obesity manifests at a specific age (Collins et al. 1993; Keightley et 
al. 1996; Keightley et al. 1998; Ueda et al. 1999). It is unclear how many of the body 
weight QTL reported are related to obesity and adiposity, as body weight is a composite 
trait. 
The lack of a standard procedure for phenotyping means that assessing the discovery of 
novel QTL is more difficult. In fact, the situation is complicated further, since many 
QTL studies have been carried out examining obesity related traits such as diabetes, 
atherosclerosis and hypertension. Whilst it may be expected that unique QTL exist for 
each of these diseases, it would also be expected that many of these QTL would give rise 
to obesity in addition to these diseases (Pomp 1997). A detailed genotypic screen clearly 
needs to be paralleled with a standardised phenotypic screen. This issue may now begin 
to be resolved with the Mouse Phenome Project (MPP) (Paigen & Eppig, 2000) [and the 
paralleled Human Phenome Project (Freimer & Sabatti, 2003)]. Originally the MPP was 
conceived to analyse the various inbred strains, which could be compared to each other 
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genetically and phenotypically providing yet another route of identifying QTL. The 
same standardised phenotypic measurements however, are now being used to screen F2-
cross populations, in addition to ENU and gene-trap mutants. This should aid any 
associations between mutants and QTL and help identify the genes responsible. 
1.2.3.1 	The Fat (F) and Lean (L) lines 
Mouse QTL studies are usually initiated by crossing well-characterised low-fat/weight 
mouse strains, such as CAST/Ei (a sub-species of M.,n.castaneus) or Mus spretus (11-
12g at 5 weeks of age), against the heavier lines such as NJ or C57BL/6J (17-20g at 5 
weeks of age). This study is based on novel lines of mice, the Fat (F) and Lean (L) - 
lines, described here. 
Fig 1.2.3: Mice from Fat (bottom), Lean (left) and congenic FIW!SI)  (top) lines. (Photo kindly provided 
by Dr. Lutz BUnger, 2003). 
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The lines of mice involved in this study (pictured in Fig [1.2.3]) derive from a base 
population, which originated from a cross between two inbred lines JU and CBA, and 
one outbred strain CFLP (Sharp et al. 1984). Mice were either selected for high-fat or 
low-fat percentage (denoted Fat (F)-lines and Lean (L)-lines respectively). After 53 
generations of selection, at 14 weeks of age, there was a five-fold difference of 
percentage body fat (fat% - estimated from the dry matter weight by freeze-drying) 
between the F and L lines (mean 23% and 4% respectively for each line) (Figs 1.2.3; 
1.2.4). However, there is little difference between non-fat body weights, although 
interestingly, the L-line exhibits a greater rate of food intake than the F-line (Lutz 
BUnger, personal communication). These lines therefore provide a novel and suitable 
resource for investigating candidate genes and pathways involved in obesity. 
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Fig 1.2.4: Divergent selection of Fat (F) and Lean (L) lines - showing the development of fat content of 
14 week old males in the outhred F and L - lines. The start of the inbred lines is marked by non-filled in, 
enlarged symbols (at generation 48). Reproduced with permission, (Bunger & Hill. 1999b). 
INTRODUCTION - QTL: 1.2 	 44 
Extensive research has already been undertaken on the selectively divergent mouse F 
and L-lines, on which the search for obesity QTL is being carried out. Early biochemical 
experiments carried out at the 2025th  generations of selection showed that the activities 
of certain enzymes giving rise to NADPH, an essential cofactor for lipogenesis, were 
two-fold higher in the F-line, than in the L-line (Asante et al. 1989). A difference 
between F and L-line activity of 2-3.5 times, was found for specific enzymes required 
for de novo fatty acid synthesis in the gonadal fat pad (GFP) of young mice. These 
included the activities of ATP-citrate lyase, acetyl-CoA carboxylase, fatty acid 
synthetase, cytoplasmic malate dehydrogenase, malic enzyme and pyruvate kinase. 
ATP-citrate lyase, acetyl-CoA carboxylase, fatty acid synthetase and malic enzyme were 
significantly higher in the Fat than the Lean lines, and the differences were more 
pronounced in the GFP than in the liver. However, the activity of pyruvate kinase was 
found to be unchanged in both liver and the GFP. Malate dehydrogenase activity was 
significantly lower in adipose tissue in the F- compared to the L-lines at ten weeks of 
age, but not at five weeks or in liver tissue (Hastings & Hill 1990). A study into the flux 
of lipogenesis in these lines at the 26th  generation, showed a greater rate in the F-line in 
both liver and GFP (20% and 120-300% respectively). The most profound differences 
were observed at 5 weeks of age, as opposed to 10 weeks, which was the age at which 
selection took place (Asante eta]. 1991). 
Initial experiments of intraperitoneal leptin administration to the F-line showed that the 
Fat-line remains sensitive to leptin in a dosage dependent manner (BUnger & Hill 1997). 
More detailed analysis revealed that plasma leptin levels in F, L and C (control) -lines 
differ greatly, with the fattest mice having 20 times more than the control mice and 60-
300 times more than the lean mice. A very high correlation between the leptin levels and 
fat% was also shown in fed and fasted F-line mice, suggesting a phenomenon of leptin 
resistance (BUnger et at. 1999). 
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Further analysis involving the introgression of Lep0b  and Leprdb mutations causing leptin 
production and leptin receptor deficiency, was carried out in both the F and L-lines. The 
results echoed those of the leptin administration experiments, showing that the 
differences between the lines were maintained after the introgression of the mutations, 
and hence the genes responsible for the line divergence must act independently of the 
leptin regulatory system (Bunger et al. 2003). 
Gene expression differences in the orexigenic neuropeptide NPY, which has been shown 
to be involved in the leptin pathway (amongst other molecular pathways) to affect 
feeding responses, has also been examined (Boswell et al. 1999). Levels of NPY mRNA 
in the hypothalamus and cerebral cortex of ad libitum-fed and fasted F and L-line mice 
were examined, however NPY gene expression differences were confined to the 
hypothalamus. 
Under ad libitum-fed conditions, hNPY mRINA levels did not significantly differ 
between the F and L-lines. Overnight fasted L-line mice (18-20h), have a significant 
increase in hNPY mRNA (P<0.05) of 31% compared to fed L-line mice, however there 
is no difference between the fed and fasted F-line mice. Levels of plasma leptin in the F-
line were at least 30-50 times higher in fasted and fed mice relative to fasted and fed L-
line mice. Plasma leptin levels in the F-line decreased significantly by 48% after fasting 
(P<0.05), but no difference was detectable in the L-line. Hence, in contrast to other 
rodent models, obesity in the F-line is not associated with increased hNPY gene 
expression in the fed state. The decreased sensitivity of hNPY gene expression to fasting 
in the F-line is consistent with an inhibitory effect of higher circulating leptin levels 
(Boswell et al. 1999). 
In the 'normal' situation food intake leads to an increase in plasma leptin that in turn 
decreases hNPY and hunger is blocked, with the opposite effects occurring when food 
intake is delayed or reduced. In the F-line however, the decreased leptin levels in the 
fasted state do not lead to increased NPY levels as one would expect. This provides 
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further evidence that the leptin pathway is not causing the disparity in the obese 
phenotype between these lines, as clearly alternative mechanisms must be acting on 
NPY in the fasted state to suppress NPY gene expression. 
The effects of thyroid hormone (TH) deficiency on both the F and L lines have similarly 
been investigated (BUnger et al. 1998). The results show that although both TH is 
involved to a significant extent in the fatness of these lines, they are not the only causes 
for the differences between the lines. TH deficiency in the F-line reduced percentage fat 
from 27.5% to 16.2%, and from 4.8% to 3.8% in the L-line. Hence, the five-fold 
difference in fat% between the lines was maintained, showing that the differences 
between the F and L-lines are not attributable to differences in TH (Bunger et al. 1998). 
Research examining the importance of growth hormone (GH) in these lines (BUnger & 
Hill 1999a), which is known to promote leanness in animals, has also shown that 
although the increase in fat% induced by GH deficiency is greater in males than it is in 
females, the differences exerted by the selection processes between the lines, as with 
TH, are still maintained. 
1.2.3.2 	The discovery of the four Fob QTL 
The aim of this research is to help elucidate genes that are involved in one or more of the 
pathways responsible for the selection response observed between the F and L-lines. The 
approach used involves three major steps: first, the identification of QTL for obesity in a 
mouse model; second, the fine mapping of these QTL; and third, the characterisation of 
these QTL in mice and then in humans, using molecular techniques. 
The first step has already be achieved, four QTL for obesity found between the F and L-
lines, were identified through a genome-wide scan and reported upon (Horvat et al. 
2000) [Fig 1.2.5]. The second and third steps are the raison d'être of this study. 
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right side of the chromosome bar, QTL (bold) and the candidate genes with potential role in the control of 
obesity are listed (reproduced with permission from Horvat et al. (2000)). 
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An F 1  generation was produced through reciprocal matings of the outbred F and L-lines 
at generation 53. Matings within the F1 population were set up to produce an F2 
generation. Molecular markers, in the form of informative microsatellite markers, were 
then chosen and used across the genome, to provide a genome scan for QTL and hence 
yield 'multipoint mapping' results. 
The data was then analysed according to the maximum likelihood IM procedure 
(Keightley et al. 1998). Logio of the likelihood ratio (LOD) scores showed that there 
were four QTL in the F2, on mouse chromosomes 2, 12, 15 and X termed Fob] (for F-
line obesity QTL 1), Fob2, Fob3 and Fob4 respectively. The QTL with the highest LOD 
score was Fob3 (on mChrlS), with an LOD score of 11.3, and accounting for 
approximately 14.4% of the F2 phenotypic variance for fat. The peak of the QTL was 
located between marker D15Mit63 and Dl5Mitl59 with a two-LOD support interval 
spanning from 15 to 45 cM from the centromere. 
1.2.3.3 	Using QTL analysis to fine-map Fob3 on mouse 
chromosome 15 (mChrl5) 
Although the intention is to fine map each of the Fob QTL, this study focuses on Fob3, 
the QTL with the highest LOD score, and to contribute towards the fine mapping and 
characterisation of the Fob3 QTL causative agents. A congenic line was generated 
(Pamela Mackay, Lutz BUnger & Simon Horvat, unpublished) by marker-assisted 
backcrossing, selecting for L-line alleles at the QTL region from mChrlS, backcrossing 
to the F-line. The congenic line was then used to generate a population of new 
recombinants and a progeny-test population of the recombinants was analysed to further 
map the QTL. The procedures used are described in more detail in section [2.1.1.1]. The 
analysis reveals a more complicated result than was anticipated, although such results 
may prove to be the norm, rather than the exception. 
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1.2.3.4 	Other obesity QTL on mChrl 5 
A number of obesity QTL have already been mapped to mChrl 5, these include one 
member of the multigenic obesity QTL family Mob4 - 6.7cM (Warden et al. 1995). This 
QTL has been shown to be responsible for a 5.9% difference in mesenteric fat between 
Mus spretus and C57BL/6J mice. Three members of the dietary obesity QTL family 
Dob4 - 18.3cM; Dob9 - 12.3cM; and Dob3 - 22.8cM have been found on mChrl5 from 
crosses between AKR/J and SWRIJ mice (West et al. 1994; York et al. 1996). AKRIJ 
mice are sensitive to dietary obesity when fed a high fat diet while SWRIJ mice are 
resistant. In addition, two members of the polygenic fatness QTL family Pfat4 - 18.0cM 
and Pfat5 - 35cM have been identified on mChrl5 from mice that had undergone a 
long-term selection for weight gain (Pomp 1997). Finally Bl/Bw - a QTL for body 
length, and suggestive for Bw (Mehrabian et al. 1998), has been found on mChrlS. 
Many QTL have also been found in the rat, pig and chicken. Of these, some are syntenic 
to mChrl5, such as the rat Chr7 QTL bw/gkl, shown to contribute up to 24% of body 
weight (Gauguier et at. 1996). However as the genomic maps of these species are still 
far from completion, making direct comparisons at this stage is difficult, especially for 
the chicken. 
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1.2.4 	CONCLUSION 
QTL analyses have proved very useful thus far in identifying large genomic regions that 
contribute to a particular trait, and whilst some of these have and are being fine mapped 
to single genes, the vast majority remain uncharacterised. The main reason for this may 
be that many of these QTL are indeed constituents of multiple QTL with smaller effects 
that give an inflated estimate of the true effect when detected as a single QTL. This has 
been demonstrated previously in silico (Visscher & Haley 1996), and in in-vivo mouse 
models (Legare at al. 2000). 
Ultimately, pursuing QTL that are shown to have small effects becomes harder, as larger 
populations are required to establish significance. It is probable however, that for the 
complex traits that afflict humans, such as obesity, the solutions will come from 
treatments that target many small-effect genes, rather than treatments that target single-
gene mutations of large effect. 
The F and L mouse obesity lines used in this study are clearly a powerful model for 
studying the polygenic basis of obesity. Previous research on these lines exclude known 
pathways as the causative agents for the five-fold difference in body fat between the 
lines, including the leptin and thyroid hormone pathways, making them a good model 
for identifying novel obesity causing factors. 
Of the four original obesity QTL identified between the F and L divergently selected 
mouse lines, congenic lines containing the QTL regions for the mChrl2 (Fob2), mChrl5 
(Fob3) and mCbrX (Fob4) have been generated. Whilst this study is focused on further 
mapping and characterizing the Fob3 QTL, the other congenic lines may also prove 
useful resources for identification of other genes on those chromosomes involved in 
obesity. 
INTRODUCTION - QTL: 1.2 
	
51 
1.3 	NUCLEIC ACID MICROARRAYS 
1.3.1 	ABSTRACT 
The genomes of many organisms have now been fully sequenced including that of 
the human (Lander et al. 2001) and the mouse (Waterston et al. 2002). The functions 
of many of the genes - both known and unknown/predicted - found so far, are 
however, uncharacterised. Microarrays herald the field of 'transcriptomics', the study 
of all the transcripts - although not necessarily genes, i.e. protein coding. The aim of 
transcriptomics is to find and document the existence of all the transcripts from a 
particular organism or system (e.g. culture cells) - at all time points. Once this is 
established for any particular system, then the system can be profiled under multiple 
conditions, identifying condition-dependent expression differences that can help 
establish gene function. Identifying gene expression differences within a system may 
lead to treatments to correct, or enhance the system by means such as siRNA 
knockdown, overexpression, or knockout of a target gene-transcript. Alternatively, 
these changes in expression can point to differences in protein expression, which 
may then be investigated further. 
The following review describes the basic chemistry and principles of microarrays, 
the current technology and procedures for array generation, the procedures, 
guidelines and standards for data analysis, and finally practical applications, 
experimental design and validation requirements are discussed with reference to the 
practical requirements and approach of this study. 
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1.3.2 	REVIEW OF MICROARRAYS 
Three years ago (1999), there were more published reviews on microarrays than 
primary research papers applying them. Today however, a simple PubMed search 
reveals an overwhelming amount of literature where this technology has been 
utilised, and as predicted by Lander (1999), the techniques have now become 
established, and the costs reduced allowing any lab to utilise the technology should 
they wish to do so. It should be stressed however, that microarrays are a 'tool' for 
expression based experimentation, and must be used in conjunction with various 
other molecular techniques to verify and confirm results. Since many expression 
differences never translate into protein translation differences, nor do they provide 
any information towards cause and effect of the differences observed, using 
microarrays alone may never be a sufficient enough diagnostic tool. 
It is beyond the scope of this study to discuss protein-arrays (proteomics), however it 
should be noted that any future diagnostic or genome based study, will naturally be 
coupled to whole proteome studies, using technologies similar to those used for 
nucleic acid microarrays discussed here - except that antibodies, aptamers, 
recombinant proteins, small-molecule drugs, whole-cells or microdissected cell-
lysates, will be substituted for the cDNAs or oligonucleotides used in microarrays 
(reviewed by MacBeath 2002). Already groups have developed and are using chips 
with over 5000 antibodies from the S.cerevisiae proteome, and it is expected that 
similarly large quantity chips will be available for other organisms, notably human 
and mouse in the near future (Zhu et al. 2001; Gershon, 2003). 
Microarrays are currently the most comprehensive tool for the approach of whole 
system gene-expression profiling, providing a 'snap-shot' image of how one gene's 
expression compares to that of the other genes in any given tissue, during any given 
time in development, reproductive stage, disease state, or nutritional situation. 
Linking subtle differences in gene expression should also help to elucidate a clearer 
understanding of many complex traits. It should be noted however that it is not the 
only tool for mass-examination of the transcnptome. Differential Display (DD) is a 
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technique that has proved highly successful in the hands of many groups (Liang, 
2002). DD operates through the use of a set of random primers that amplify portions 
of mRNAs in a target sample. The PCR products are then run on sequencing gels and 
the intensities of the PCR products are compared as indicators of differences in gene 
expression (Liang & Pardee 1992). The main benefit of DD analysis is that many 
experimental conditions can be compared at the same time on a single gel. In 
comparison, microarray technology is currently limited in that only pair-wise 
comparisons can be made on any slide. However, the DD technique and amount of 
laboratory time required to screen an exhaustive amount of the transcripts is 
considerably more demanding that carrying out microarray analysis. 
Serial analysis of gene expression (SAGE) is another such transcriptome wide 
analysis technique, which has been used with great success in many laboratories. In 
SAGE, double stranded cDNA is prepared from the target tissue and cleaved with a 
restriction endonuclease that on average cuts every transcript at least once. The 3' 
ends of the resulting cDNA fragments are purified using streptavidin-coated 
magnetic beads and the resulting cDNA fragments divided into two populations. 
Each population is ligated to a different linker containing a type ITS restriction 
endonuclease (tagging enzyme) recognition sequence. These enzymes cleave DNA at 
a distance of up to 20 bps away from their recognition site. The two cDNA 
populations are hence digested resulting in the generation of a short sequence 
consisting of the linker and a short portion of its adjacent cDNA. Blunt ends are 
created and the two populations are ligated to each other and total cDNA amplified 
by PCR, resulting in the generation of products with two tags (ditag) orientated tail to 
tail with an anchoring enzyme recognition site at either end. Following cleavage at 
each anchoring enzyme recognition sequence and concatenisation of 'ditags' via this 
site, products are cloned and individual clones consisting of at least 25 tags (25-75) 
selected for sequencing (Velculescu et al. 1995). A restriction of SAGE technology 
is that only one pair-wise comparison can be made, this makes experiments where 
multiple experimental conditions are required extremely demanding, in comparison 
to microarrays where multiple pair-wise comparisons can easily be carried out. 
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Presently, SAGE and DD have key benefits over microarrays, specifically that they 
are non-biased approaches, in that all available mRNAs in the tissue under 
investigation are being examined. In microarrays however, the experiment is limited 
to the contents of the slide, which for many experiments thus far consists of a defined 
cDNA library, or a specifically chosen set of oligonucleotides. This however is 
rapidly changing as whole-genome microarrays come online (discussed below). 
With SAGE, multiple sample comparisons side-by-side can be processed, low 
abundance transcripts are included in the analysis, and only small amounts of RNA 
are required. However, with the power and high-throughput capability, coupled with 
the availability of cDNAs from whole genomes, it is clear to see why most 
transcriptome studies use microarrays as their preferred technology. Hundreds of 
thousands of different transcripts can now be examined at the same time for changes 
of expression, and whilst the technology is not without its drawbacks - currently, that 
of cost - it is proving a very fruitful tool with real biomedical discoveries being 
made. 
Today's microarrays are based on a technique developed by Edwin Southern 
(Southern, 1975), which exploits the basic principle of Watson and Crick bonds. 
Southern showed that labelled nucleic acid molecules can be used to interrogate 
nucleic acids bound to a solid membrane. The technology was used to examine 
genomic DNA differences probing against DNA bound to a cellulose membrane. 
This technology quickly progressed from being able to examine the hybridisation of 
one DNA molecule against whole genomic DNA, to examining one-cDNA molecule 
against whole-RNA, (Alwine et al. 1977). Multiple comparisons were introduced by 
Kafatos et al (1979), as the 'Dot-Blot', allowing effectively whole-cDNA to be 
examined against many trapped probes (cDNA) at the same time. The dot-blots 
advanced to the macro-arrays, filter based technologies, which for the first time 
allowed thousands of probes to be trapped and analysed simultaneously as reviewed 
by Bowtell (1999). 
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It is these technical advances, exploiting the basic genetic principles that have 
brought about microarrays, which today allow for whole-cDNA against whole-
cDNA comparisons, expanding the vista of genomic interactions and mechanisms. 
Indeed the beauty of microarrays is that two different whole-cDNAs are hybridised 
against the immobilised cDNA or oligo panel to reveal expression differences 
between them. 
The other main difference between microarrays and the hybridisation technologies 
that preceded it, is that it is based on a rigid, impermeable substrate, usually glass, 
although many other substrates are used, such as quartz, as used for Affymetrix chips 
(Affymetrix, CA, USA) (Southern et al. 1999). 
This technology, although at a functionally productive state, is constantly 
developing, and various combinations of approaches have been developed and 
implemented, each with its own positive and negative aspects. There are three main 
areas to take into consideration when carrying out an expression study. The first 
consideration is whether to have cDNAs spotted, or use synthetically generated 
oligonucleotide microarrays. The second element to consider is sample preparation, 
and finally data analysis and interpretation. A discussion on each of these follows 
below. 
1.3.2.1 	Array generation 
There are generally two types of nucleic acid microarrays; cDNA and 
oligonucleotide arrays. Initially cDNA spotted slides were the most popular. These 
consist of cDNA libraries which are constructed from specific tissues, being 
amplified by PCR and non-covalently bound onto coated glass microscope slides, 
(known as 'spotting') (Schena et al. 1995; Duggan et al 1999). Many laboratories 
have their own cDNA libraries, which can be spotted directly onto slides, or can 
collaborate with a group that have an arrayer - reducing their costs. This is a 
preferred route for some studies, as global clustering methods can be applied to 
elucidate functions for unknown ESTs. 
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96 (or 384) well plate 
containing purified 
cDNA library 
Fig 1.3.1: Spotting eDNA microarray slides. Schematic shows the general principles involved for a 
1-pin robot. 1) Robotic spotting pin locates desired cDNA arranged 96 or 384 well plates. Pin is 
lowered and a micro-volume of cDNA is drawn up. 2) Pin draws up and moves to spotting position on 
glass slide. 3&4) Pin lowers to a height just above the surface of the slide, a small pressure is applied 
and the cDNA droplet attaches to the slide by capillary pressure. Pin may then move to another slide 
position and spot a replicate of the cDNA, or moves off to a wash station where the pin is cleaned 
before moving back to the cDNA library to locate a different clone. 
Typically cDNA products spotted onto microarrays range from 0.6-2.4kb transcripts 
from known genes, although it is often desirable to spot uncharacterised ESTs, as the 
expression data derived may provide information as to the functions of the genes 
they represent. Each 'feature' spotted onto a microarray, is created by depositing 
purified PCR products at nanolitre volumes of concentrations at around 100- 
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500.igIml. This is achieved using robots, known as 'arrayers', which pick-up and 
drop-down the PCR products from 96 or 384 well-plates containing the PCR 
products [Fig 1.3.1]. 
The spots are deposited in a high-density grid format then dried or may also be fixed 
to the slide by ultraviolet radiation. The nature of the binding of the cDNAs to the 
substrate is less uniform than that obtained from oligo-synthesised arrays. Since the 
PCR products are deposited in their double-stranded nature, the contact points are 
unclear and not within the control of the manufacturing process. This has the 
potential therefore, to be a source of variation between spots of the same PCR 
product in addition to alluding to differences between different PCR products, which 
may not be real (Duggan et a! 1999; Cheung et al. 1999). 
Robotic technology has also developed very rapidly, borrowing technologies from 
ink-jet printers and semiconductor manufacturing. For cDNA spotting this is usually 
carried out using what is essentially a capillary tube that applies small but uniform 
pressure changes - in the same way ink-jet printers operate. The pins used (in cDNA 
arraying) are typically stainless steel and deposit droplets of 100-150pm in diameter, 
this is clearly a limiting factor in terms of the number of spots that can ultimately be 
spotted on a single slide, and hence other groups are developing silicon based pins 
that can deposit droplets as small as 38jtm wide (Tsai and Kim, 2002). Initially the 
robots were equipped with only 1-pin, but now arrayers are available with as many as 
48 as in the QARRAY MAX robot (Genetix, Hampshire, UK). 
Oligonucleotide arrays, in contrast to cDNA arrays, are covalently bound [Fig 1.3.2, 
1.3.3]. The surface of the glass, or quartz, is seeded with oligoethylene glycols, these 
allow the initiation of the growth of the oligonucleotide synthesised in situ on the 
slide, using robots (Cheung et al. 1999). This has the disadvantage that the bases 
nearest the surface of the glass are less accessible than the bases further away, 
ultimately affecting the binding affinity of the target. This has been overcome to 
some extent by employing 'spacers' (Shchepinov et al. 1997). The other 
disadvantage of oligo-based arrays compared to cDNA arrays, is that the sequences 
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seeded on the arrays are short-chained. Two main consequences of this are firstly the 
Tm (melting temperatures of the duplexes formed during hybridisation), varies 
considerably; and that the truncated sequences result in reduced specificity for 
binding. Both of these issues may result in false conclusions being drawn from an 
experiment. However, this too is being improved upon simply by increasing the 
number of nucleotides (nt) seeded, from the previous standard of 20-25nt to 40-80nt 
(van't Veer et al. 2002). 
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Fig 1.3.2: Oligonucleotide slides made using photolithographic technology (GeneChip® Arrays). 
1)Array substrate is made of a quartz wafer, which is washed to ensure uniform hydroxylation across 
its surface. Quartz is naturally hydroxylated, allowing the attachment of chemicals, such as linker 
molecules to position the probes on the arrays. The wafer is placed in a bath of silane, which reacts 
with the hydroxyl groups forming covalently linked molecules (red squares). The silane film provides 
a uniform hydroxyl density to initiate probe assembly. Linker molecules, attached to the silane matrix, 
provide a surface that may be spatially activated by light. 2) Probe synthesis occurs in parallel, 
resulting in the addition of an A, C, T, or G nucleotide to multiple growing chains simultaneously. 
Photolithographic masks are used to define which oligonucleotide chains will receive a nucleotide in 
each step. UV-light is shone over the mask whereby the exposed linkers become 'deprotected' and are 
available for nucleotide coupling. 3) The desired features are hence activated and 4) a solution of a 
single type of deoxynucleotide with a removable protection group is flushed over the surface. The 
nucleotide attaches to the activated linkers, initiating the synthesis process. 5) In the following 
synthesis step, another mask is placed over the wafer to allow the next round of deprotection and 
coupling (6,7). 8) The process is repeated until the probes reach their full length. Figure is modified 
from the Affymetrix homepage. 
For oligo-based arraying, robotic technology has progressed with two main 
technologies, that of photolithography, as championed by Affymetnx (Lipshutz et al. 
1999), and that of inkjet printing technologies (Hughes et al. 2001), as in the arrayers 
supplied by Rosetta Inpharmatics LLC part of Merck & Co. Inc (NJ, USA). Figures 
[1.3.2] & [1.3.3] describe the general principles involved in both technologies. 




Fig 1.3.3: Oligonucleotide slides made using ink-jet technology. 1) A layer of nucleotides is 
deposited on the microarray surface. B) Layers are then applied in turn to generate thousands of 
different x-mers. 
The nature of these commercial technologies allows them to spot significantly 
greater numbers of sequences than cDNA arrays, with Affymetrix now boasting a 
chip having over 500,000 unique oligonucleotides each (Human Genome U133 Set, 
www.affymetrix.com ) (Bouchie, 2002). This means that oligo-based arrays can have 
a high number of probe redundancies, that is, multiple independent repeats of a given 
gene, with sequences representing a different part of the gene and hence designed to 
hybridise to different parts of the mRNA. This differs to cDNA arrays where usually 
the same cDNA clone - and hence sequence - is usually just spotted twice in a 
different location. The high redundancy of oligonucleotides greatly helps to reduce 
the signal-to-noise ratio and lowers the rate of false positives. 
The oligo-based technologies are set to improve further. Whilst cDNA spotting 
technologies are struggling to reduce spot diameters to 38jtm, semiconductor-like 
photoresist processes are being developed to reduce features on oligo-based arrays to 
just 2.tm, potentially allowing one hundred million probes, to be arrayed on a single 
chip (Beecher et al. 1997). 
The ideal technology would be one that combined the benefits of the relatively 
cheap, long-chained cDNA sequences, with the single-tethered, single-stranded 
technology of the oligo-arrays. One can foresee a time in the future when the 
economies of scale of commercial chips, and the need for cross experiment 
standardisation will force independent laboratories to abandon the cDNA approach. 
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1.3.2.2 	Target preparation 
Both for oligo- and cDNA-microarrays, the targets for the immobilised probes are 
prepared from total RNA prepared from a tissue (whole, or micro-dissected), cell 
culture or flow-sorted cells. Radiolabelling of the target has been previously used for 
arrays (Zhao et al. 1995). However the tendency of the signal from strongly bound 
hybridisations to drown out the information from neighbouring weakly bound 
hybridisations has lead to the more robust application of fluorescently labelled 
targets. The most commonly used are indocarbocyanine (Cy3), which fluoresces 
green (500-550nm), and indo4jcarbocyanine (Cy5), which fluoresces red (649-
670nm). A range of other dyes is also used, however Cy3 and Cy5 have become the 
paired standard, as they are bright and intense colors with narrow, spectrally distinct 
emission bands that are relatively photostable. 
Another consideration should be noted here, that most labeling reactions target single 
deoxynucleotides, for instance Cy-dUTP would generate cDNA with fluorescently 
labelled uracils. Therefore, when comparing expression levels of different 
transcripts, some bias may arise, since some may be A-T rich and hence fluoresce 
more than others, which are G-C rich, even though the same amount of transcript is 
present. 
The fluorophores are bound to deoxynucleotide-triphosphate groups (dNTP5). 
Reverse transcriptase (usually Moloney murine leukemia virus (M-MLV) or avian 
myeloblastosis virus (AMy)), an oligo-dT primer and the RNA template are 
combined with the fluorophore. This mixture is then allowed to react in the dark, 
generating 3'end, complementary fluoro-labeled stable DNA that is then hybridized 
on the array. An alternative method that is proving more efficient in the generation of 
labeled template, is that of using random primers and the Kienow fragment of DNA 
polymerase I (Smith et al. 2003). Both techniques, direct reverse-transcription and 
Kienow, are described in more detail in section [2.2.3.3]. 
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1.3.3 	SOFTWARE TOOLS 
The main public databases for microarray gene expression data are discussed below 
[1.3.4.6]. Here, a brief description of the various other tools that have been 
developed to obtain, analyse and present microarray data is given. Since these 
packages are in a dynamic competitive market, and hence a new product may enter 
and dominate the market in a short period of time, the aim here is to provide an 
overview of the capabilities and applications that are available rather than an 
exhaustive list of the current products available. 
1.3.3.1 	Image capture & data extraction 
The first software tool required in a microarray experiment is one for image capture. 
This software is usually bundled with the laser scanner, and although various free 
packages have been developed to assist scientists where the bundled packages have 
been inadequate in the past, it seems now that this software has been developed to a 
high standard, having integrated data manipulation and analysis application. 
Amongst many others, these include; GenePix Pro (Axon Instruments, CA, USA), 
and QuantArray (PerkinElmer, MA, USA). 
Where laboratories are using older scanners or scanners that were not developed 
specifically for microarray data capture, then the freely available package 
ScanAlyze, (Eisen Lab, University of California at Berkeley, USA), proves very 
adequate in extraction of the data. 
1.3.3.2 	Data analysis software 
There are many data analysis programs now available, mostly from academic 
institutions keen to avoid the large licensing fees associated with commercial 
programs, and also from labs developing new algorithms for normalisation and 
clustering experiments. Most of these programs however, are either very good at 
analysing the data or good at presenting the data, but few do both. A current list of 
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these 	can 	be 	found 	at 	the 	following 	web 	site: 
[www.cbi.pku.edu.cn/mirror/wli/microarray/soft.html].  
The current market leader in commercial microarray analysis software is GeneSpring 
(Silicon Genetics, CA, USA), and offers various advantages to other software, in that 
in has both good analysis and presentation capabilities, in addition to many data 
mining utilities with links and access to other databases, including information on the 
most popular commercial chips for Affymetrix. 
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1.3.4 	DATA ANALYSIS 
The amount of data generated from microarray experiments is very large. 
Consequently the data has to be handled, processed and mined in a robust high-
throughput manner that generates reliable results that are repeatable and verifiable. 
The procedures and aspects of data analysis, from hybridised slide to identification of 
differentially expressed genes, are discussed here. 
1.3.4.1 	Extraction 
Scanners utilising laser technology are used to scan for fluorescence in the channels 
expected, for instance to detect the emission of Cy3 and Cy5. For any particular 
slide, at each scanned pixel, information is gathered and stored as a binary value 
corresponding to the intensity of fluorescence for each channel. A pre-formed grid 
corresponding to the locations of the features is then overlaid. The grid contains the 
coordinate information, which references any particular feature's known 
characteristics. 
TIF images of the scans are produced, the grids overlaid and, for each feature, two 
values of average (mean or median) hybridisation efficiency are obtained, one for 
each of the samples labelled with a different fluorophore. The mean intensity for 
each channel is obtained by summing the value of all pixel intensities for any given 
feature, divided by the number of pixels. 
1.3.4.2 	Normalisation & meta-analysis 
Background fluorescence is an indicator of where/if the hybridisation procedure has 
progressed uniformly throughout the slide. Frequently, this does not occur uniformly 
and this can be a source of bias and error in the results. Normalisation for 
background is therefore applied as a standard for obtaining 'truer' results. This is 
achieved by removing background fluorescence for each channel, from the value 
obtained from the fluorescence for each feature. There are various methods for doing 
this, all of which have been employed in various published experiments. Generally, 
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background can be extracted 'globally'. This is done by taking into account the 
general emission for each channel across the whole slide - where there are no 
predicted features, i.e. all the spaces between features and the edges of the slides 
(Quackenbush, 2002). This has the disadvantage of not taking into account regional 
differences on the slide, whereby during the hybridisation process, the sample, for 
instance labelled in the green (Cy3) channel may have localised more to one end of 
the slide, then to another. A way of getting around this is to carry out a sub-grid 
specific subtraction method. This is done by removing the global background of each 
sub-grid, i.e. calculated from the spaces between the features only in that grid - from 
the features that it contains. Better still, is the process of removing the local 
background from each feature, i.e. the background found between one feature and its 
immediate eight neighbours. Various software exist that allow for this to be done 
semi-automatically, although it can also be done manually quite simply using 
spreadsheet packages (Quackenbush, 2002). 
Once the emission for each channel has been obtained, and corrected for its 
background, the ratio of one channel to the other (eg, green:red ratio) is calculated. 
This gives the proportion of gene expression for a particular gene from under one set 
of conditions, compared to that of the gene expression under the second set of 
conditions. 
Multiple controls, discussed below, have been devised to ensure that bias and errors 
are limited. In addition to background normalisation, microarrays typically have 
'blank' spots spotted onto the array. If high fluorescence is observed at these spots 
then clearly the integrity of the slide was somehow compromised. Multiple repeats of 
hybridisations are carried out and the reasons and benefits for these are described 
below [1.3.4.4]. Same sample hybridisations are also encouraged, here cDNA from 
the same experiment is labelled in both green and red channels and hybridised to the 
slide. Once the data is normalised for background, all spots should be observed as 
either black, no hybridisation in either channel, or as yellow, equal hybridisation in 
each channel. If any spots are observed not to behave in this manner, then those spots 
can be flagged as dubious, when considering the full data set. If many spots behave 
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unexpectedly, then this would again be an indicator that either the slides or the 
hybridisation protocol have been compromised. Higher-level normalisation 
approaches have been developed to account for the variation introduced by dyes, 
different pools of samples and other variables that contribute to systematic bias. 
Some of the more frequently implemented approaches include; locally weighted 
linear regression (Lowess) (Yang et al. 2002) reviewed in Quankenbush (2002), and 
the use of mixed models where both random and fixed effects can be modelled. The 
mixed model approach has been adopted for this study and is described in more 
detail in section [2.2.4.4]. 
1.3.4.3 	'Cut-offs' 
Significance thresholds 
The accepted significance level for a statistical test is usually either the 0.05 or 0.01a 
levels. However given that for any microarray experiment thousands of features are 
examined at the same time, these significance levels are inappropriate. For example, 
an array with 10,000 features would yield 500 false positives if a 0.05 significance 
threshold were applied. Multiple testing (as in the QTL analysis discussed 
previously) must be accounted for. 
The Bonferroni correction is a simple adjustment, based on the number of 
independent tests, in this case the number of different features on the array that can 
be applied. The desired significance a level is chosen and divided by the number of 
features being examined, giving a corrected experiment-wide a level. Therefore, in 
the case of a 10,000-feature array with a desired 0.05a the corrected a level would 
be reduced to 5x10 6 . 
Fold changes 
Microarray gene expression studies are able to identify significant differences as low 
as 1 .2fold (Gibson, 2003). However many studies do not consider any difference that 
falls below commonly used thresholds (2- to 3-fold), logically arguing that a large 
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fold difference in gene expression is required to account for a significant biological 
difference. Nonetheless these thresholds remain arbitrary. 
There is an inherent problem with this selection cut-off. A gene with low absolute 
expression will have a greater inherent error in its measured levels. Hence it will tend 
to numerically meet any given fold change cut-off, even if the gene is not truly 
differentially expressed. The inverse also holds true, where a highly expressed gene 
has less measured error, it may not meet an arbitrary fold change cut-off of 2-fold 
even when it is truly differentially expressed (Claverie, 1999; Mariani et al. 2003). 
Various methods have attempted to tackle this issue. The 'limit fold change model' 
which is useful when replicates and statistical power are poor, operates by adjusting 
the cut-off according to the mean intensity of the gene (Mutch et al. 2002). A second 
method introduced by Mariani et al. (2003) allows for technical variability to be 
described and accommodated by a 'variable fold change' threshold. 
However, despite these useful models an experiment may generate hundreds of 
significantly differentially expressed features that just fall short of the fold change 
threshold - arbitrarily chosen, or adjusted according to the models mentioned here. 
Additionally, many features may be found to high fold changes but fall just short of 
a significance threshold. A novel approach for selecting features that have both 
highly significant P-values and large fold changes is presented here in section 
[2.2.4.5]. 
1.3.4.4 	Reliability - Repeatability - Ratification 
Although the quality of microarray data is certainly improving, precision, reliability 
and repeatability of microarray results is still an issue, especially comparing identical 
samples across platforms (Lee et al. 2000). Large discrepancies have been found in 
studies where alternative technologies have been used to verify microarray results 
(reviewed by Petricoin et al 2002). 
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The main advances on improving the reliability of microarray data is to introduce 
replicate measurements as described previously [1.3.2.1]. This is done in two main 
ways, firstly by spotting/seeding the same probe multiple times on the same array, or 
multiple unique sequences for the same genes. The second is to repeat the same 
hybridisation on multiple slides, previously an absolute requisite, given that the two 
commonly used labels Cy3 and Cy5 were known to incorporate into the target cDNA 
unevenly. Many kit suppliers have apparently rectified this, although the practise to 
dye-swap the targets on repeat slides remains a standard procedure. Whilst both of 
these measures increase the statistical power and hence significance for any given 
probe, repeat hybridisations remain costly, and duplicate spotting reduces the amount 
of different probes and hence measurements that can be made. 
Controls of various sorts have also been developed. Spotting of bacterial genes serve 
as negative controls and gauge the background hybridisation levels. Sample spikes 
and positive bacterial probes serve to assess the signal linearity and general 
performance of the array. Probe sequence optimisation with mis-match probes, 
allows the assessment of cross-hybridisation. 
Despite the measures and controls introduced, a window for error remains for any 
individual measurement. Ratification of the differentially expressed targets is thus 
required, usually through Northern analysis and/or quantitative RT-PCR. 
1.3.4.5 	Presentation and Interpretation 
The volume of data from microarrays varies widely, ranging from only a few 
thousand data points, to hundreds of thousands, and now even millions of data 
points. Interpreting such data can be daunting to say the least, and impossible without 
using powerful software at each stage. Many groups have developed their own 
software to handle and store this data, and below, some of the most widely, currently 
used applications are discussed. 
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There are two main forms of data presentation used for publication of data, reflecting 
the two main forms of data that can be obtained from microarray experiments. The 
first is the presentation of simple fold changes between individual features. This is 
done by focusing on one feature at a time, usually the features with the greatest fold 
changes. Bar charts displaying the intensity values can be used, and occasionally this 
is accompanied with the false colour image scan of the actual feature. Alternatively 
the fold changes of all the spots can be displayed simultaneously as scatter plots for 
each hybridisation, or as an average of all the hybridisation repeats. This data 
provides two vital pieces of information about the experiment; (i) it provides 
information about individual features that can be investigated further; and (ii) it 
provides information on how one condition generally affects global gene expression 
compared to the second condition. 
The second form of data that can be obtained, usually from much larger experiments, 
is clustering analysed data. In this case, comparisons are made across multiple 
conditions and hence multiple slides to examine similarity between expression 
patterns using a correlation coefficient (e.g. Pearson's). First, individual genes are 
clustered, and then clusters are clustered, generating a hierarchical phylogenetic tree 
of related gene expression patterns. Clustering results in the data being subdivided 
into groups of genes of similar functions, generating gene expression maps. On the 
horizontal plane, each line represents the same feature, with green indicating high 
expression and red indicating low expression relative to the reference for each 
expression. Each column represents a different experiment and hence experimental 
conditions. The beauty of this type of analysis is that genes of similar functions can 
be observed to behave, in expression terms, in similar ways. The functions of 
unknown genes on the same slides can hence be predicted, or at least guessed at, by 
matching up their expression patterns to the patterns of expression of the known 
clusters of genes. Many groups have done this successfully, using the S.cerivisiae 
genome, the first eukaryotic genome to be fully sequenced (Shoemaker et al. 1996, 
Eisen et al. 1998; Su et al. 2002; Slonim et al. 2002). 
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13.4.6 	Standards - MIAME 
The vast amount of data generated from each experiment, and infinite number of 
possible experiments, means that comparing data sets between different groups can 
be very difficult. Especially given the large number of different variations for 
extracting, normalising, presenting and interpreting data, and of course differences in 
hybridisation protocols. Various groups have called for standardisation of data 
handling and storing, especially with regards to publications, and application of 
funding for future projects. This has led to a number of initiatives; the most widely 
accepted so far, is that of the "minimum information about a microarray 
experiment", MIAME (Brazma et al. 2001), spearheaded by the Microarray Gene 
Expression Data Society (MGED) [www.mged.org ]. The Microarray Gene 
Expression (MAGE) project is an initiative that has set out to address standards in 
data representation (Spellman et al. 2002). It has done so through the XML-based 
language, MAGE-ML, which allows the transfer of data from one database to 
another. Finally, the MGED ontology group, in collaboration with the MAGE and 
MIAMI groups, have set out to define controlled vocabularies to be used in the 
MAGE-ML files and hence expression databases and repositories, so that ultimately 
comparing the datasets between groups and experiments may be easier and more 
-accurate (http://mged.sourceforge.net/ontologies/index.php).  
It is a publication requirement for many journals now, that microarray data be 
deposited in a publicly available database. Many of the larger groups such as at 
Stanford (http://genome-www5.stanford.edu ) and the University of Pennsylvania 
(http://www.cbil.upenn.edu!RAD), have developed their own to meet this demand, 
however community inspired databases have also been set up. The main public gene 
expression repositories are that of ArrayExpress, run by the European Bioinformatics 
Institute (EBI) [www.ebi.ac.uk/microarray],  and the Gene Expression Omnibus 
(GEO), (Edgar et al. 2002), are now following MIAME guidelines, or similar 
guidelines. 
Given that even these standardising doctrines may not be enough to allow direct 
comparisons between experiments carried out at different laboratories, statistical 
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algorithms are being developed to directly compare the gene expression data 
generated across experiments and even technological platforms (Wright et al. 2003; 
Ferl et al. 2003). 
The data and presentation of the microarray experiments carried out as part of this 
study have been done with MIAME guidelines in mind. Additionally, all data files 
have been converted to MAGE-ML format through use of GeneSpring. 
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13.5 	MICROARRAYS & the Fob3 QTL 
The aim of using microarrays in this study is to examine the gene expression 
differences between the F-line and the congenic F' 5D-line in metabolically relevant 
tissues. Primarily, mChrl 5 gene expression differences are sought so that potential 
causative agents of the Fob3 obesity QTL may be identified. In addition, the 
identification of differentially expressed known metabolic genes, or genes involved 
in any of the pathways described in section [1.1.2], are sought, so that the pathways 
responsible for the Fob3 QTL may be elucidated. 
The most ideal microarrays for this study may have been mChrl 5 specific arrays, or 
otherwise a 'metabolome' array, that is an array with all known metabolically 
relevant genes, however such arrays at the time of this study were not available. 
The arrays used here are 15,000 eDNA arrays from post- peri and pre-implantation 
mouse embryos, kindly donated by the NIA-NTH through HGMP. The protocols used 
were carried out in collaboration with the MRC-microarray facility at Harwell, UK. 
Whilst these arrays are not optimal for this study, they do have the benefit that many 
of the cDNAs spotted are from unknown genes (estimated at 50%), with more than 
500 mapping to mChrlS, allowing therefore, for the identification of potential novel 
obesity related genes. 
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1.3.6 	CONCLUSION 
Microarray technology has already proved highly successful in many fields, and the 
ongoing improvement and refinement in all aspects of the technology will lead to 
even more successful applications. The technology used in this study will have 
inevitably been superseded by better, larger and more reliable methods at time of 
print. Nonetheless, successful application of the technology is demonstrated, 
bringing to light a number of differentially expressed genes between the F- and 
congenic F'' 5 ' - lines, that otherwise would have been considerably more difficult 
to detect under conventional methods. 
The vast majority of microarray studies carried out thus far have focused on 
identifying expression differences between samples, although the technology can and 
has been used for genotypic analysis, utilizing the vast amount of single nucleotide 
polymorphisms (SNPs) as reviewed by Lipshutz et al. (1999). Now that most of the 
technical difficulties that had previously troubled this technology have been 
addressed, the full potential of microarrays is being tested. Microarrays may be used 
to help address; RNA expression changes in early drug screening and non-clinical 
toxicological studies, to predict unwanted side effects; and as biomarkers for clinical 
samples to examine cancers for instance. In the future they may be used as a quality 
control system for biological consumables, such as blood products and vaccines to 
examine purity and safety levels (Petricoin et al. 2002). The true limit of this 
technology may be limited only by our imaginations. 
INTRODUCTION - MICROARRAYS: 1.3 	 73 
CHAPTER TWO 
MATERIALS AND METHODS 
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2.1 	QTL ANALYSIS & TECHNIQUES 
2.1.1 	PILOT STUDY 
Prior to attempting fine mapping of the Fob3 QTL in a larger-scale cross, a small pilot 
study was set up to determine whether the QTL from the L-line had been successfully 
introgressed into the F-line background. The methods and techniques discussed here 
refer specifically to those used for the pilot study. Common techniques and methods 
used for both the pilot and main study are given in the second part [2.1.2]. 
2.1.1.1 	Breeding strategy - small scale F 2 cross & 
generation of congenic mouse lines 
To generate congenic lines, F and L-line mice were crossed and the heterozygous 
progeny repeatedly backcrossed to the F-line. The purpose was to create mouse lines 
that are genetically similar, but differ only at the Fob3 QTL region - the congenic line 
would be essentially F-line background, but contain L-line alleles within the Fob3 QTL 
region. Markers on mChrl5 were used to select mice with approximately a 40cM region 
originating from the L-line, shown to be responsible for the Fob3 QTL (Horvat et al. 
2000). The markers used were; Dl5Mitl75 (6.7cM), Dl5Mitl38 (15.4 cM), Dl5Mitl84 
(25 cM), Dl5Mit63 (29 cM), Dl5Mitl05 (42 cM) and Dl5Mitl07 (50.2 cM); numbers 
in brackets are positions in cM given by the MGI at the time of selection. F-line alleles 
were chosen for marker D15Mitl75, the most proximal marker and L-line alleles chosen 
for all other markers. Mice were backcrossed a total of six times to the F-line [Fig 2.1.1], 
producing a congenic line termed here F' 5 ' - " (f-line with k-line on chromosome j, 
where x is the number of backcrosses undergone). At BC5, L-line alleles at the other 
three QTL on mChr2, 12 and X identified in the original F2 cross (Horvat et al. 2000), 
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were selected against using markers for these chromosomes, to eliminate any effect 
which might have been retained from these by chance. 
F-line crossed to L-line 
4o EF-line) 
x Z;~) 
BC 1 produced 
(1st backcross population) 
x 
Marker assisted selection (MAS), 
choosing mice with L-line alleles 
on Chr15 and backcrossing 




Figure 2.1.1: Schematic representation of Fob3 introgression. 
After the 6th  backcross (BC6) the estimated F-line background is around 98.4%. At the 
current estimation, the mouse genome possesses —30,000 genes (Kamal et al. 2002), this 
would mean that the BC6 congenic line population might contain up to 480 L-line gene 
variants. It is paramount therefore, to have congenic lines with as high an estimated 
background from one line, so that when comparisons are made between the lines, the 
trait being examined, is only affected by a gene, genes or QTL within the selected target 
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region, and not due to a random non-selected region. Whilst a greater number of 
backcrosses would have been ideal, given the time-cost constraints, six backcrosses were 
achieved. Nonetheless when comparing these lines, the differences between the lines can 
confidently be attributed to genetic differences within the Fob3 region, which should be 
verifiable experimentally. 




FF* FL LL 
iii::: 
I 	 I 
11  X 1  11 II I 
FL 	LL 	FF*/ 
hrI5 (FC L) F-line 
Figure 2.1.2: Schematic representation of the pilot-study QTL progeny-test population. FF* - F-
line-type mice; FL - heterozygotes; LL - homozygote congenic FchrIlL  mice. 
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A small-scale F2 population was set up to assess whether the Fob3 region was 
transferred successfully or that this QTL region still retains the effect in the background 
of the F-line genome. Some BC5-F 1 , but mostly BC6-F 1 heterozygotes, were inter se 
mated for the production of an F2 population. The scheme in [Fig 2.1.2] illustrates the 
approach taken. F2 mice derived from BC5 heterozygote mice are termed here BC5-F 2 , 
similarly from BC6 heterozygotes (BC6-F 2). 
The F2 mice produced include F-line-type mice (FF*),  which are homozygous F-line 
within the Fob3 region, heterozygotes (FL), and homozygote congenic mice F15L  (LL), 
which are homozygotes for the L-line alleles within the Fob3 region. The heterozygote 
F2 mice were mated to either F.linefFF*  mice or congenic Fc115L  mice. Their progeny 
were phenotyped and genotyped as described in section [2.1.3 & 2.1.4]. The data 
obtained were analysed using single marker analysis and interval mapping using the 
QTL Cartographer software. 
2.1.1.2 	Production of a linkage map 
Genotypic data were uploaded into the ResSpecies database (Roslin Institute; 
http://www.resspecies.org ). This is designed to check for genotypic errors based on the 
genotype of the parents in the previous generation. It also has the ability to format the 
data for running in other programs such as CriMap (Lander and Green, 1987). For the 
pilot study, data from 12 polymorphic markers on mChrl5, spanning four generations 
(BC5-F 1 , BC6-F 1 , BC5-F2 and BC6-F2) were checked and corrected for errors. Errors 
may have arisen due to incorrect genotype scoring or pedigree structure and data 
corrected or excluded from the analysis. 
The data were exported into CriMap v2.4 (Lander & Green 1987). CriMap allows 
construction of multilocus linkage maps assessing support relative to the alternative 
locus orders, generating LOD tables and detecting data errors. The aim is to identify the 
locus order having the highest likelihood, and identify alternative orders with their 
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respective likelihoods. As it is impossible to consider all possible orders for a large set 
of loci, a strategy that makes decisions on the basis of subsets of the loci is implemented. 
The 'build' procedure in CnMap is the main strategy for achieving the best locus order. 
In the absence of any prior information concerning locus order, such as physical 
localization data, a pair of linked and highly informative loci are chosen as 'ordered loci' 
in order to accelerate the map construction process. The first locus in the list of 'inserted 
loci' (that is, all the other loci not in the 'ordered loci' list) is placed in each possible 
interval in the map. The resulting locus orders are then tested for compatibility with the 
database; each order not excluded is subjected to full maximum likelihood estimation. 
The order having the highest logio likelihood is found. Map building then proceeds by 
examining the next locus in the list and positioning it, until all loci in the list have been 
analysed. The Flipsn procedure was used to check the final order, as it examines 
permutations of successive triples or quadruples of loci for an improved map order 
(Lander & Green 1987). 
2.1.1.3 	Single marker analysis 
Single marker analysis examines the distribution of trait values separately for each 
marker locus. QTL detection was carried out using analysis of variance (ANOVA) under 
the GLM procedure of the SAS System for Windows (v 8.0). This was carried out on 
348 phenotyped F2 individuals (N=302 for fat%; N=348 for Bwl 15), comprising of 111 
BC5-F2s and 191 BC6-F2s. The effect of each marker was estimated using each marker 
as a fixed effect. For each trait at all 12 markers, litter, sex, and sex by genotype 
interactions were considered. 
Y = M + G + L + S + S*G + e 
	
[1] 
Here, M is the trait mean (fat%, bwl 15), G is the effect of the genotype (FF, FL, LL), L 
is the litter effect, S is the sex effect, S*G  is the sex-by-genotype interaction and e is the 
residual error. 
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2.1.1.4 	Interval mapping using QTL cartographer 
Interval mapping (IM), allows for analysis between each pair of adjacent markers, and 
allows for a more precise estimate of QTL effect and position, as opposed to just single 
marker analysis. Better still is composite interval mapping (CIM), which takes into 
account the interval between each adjacent markers, as well as some of the neighbouring 
markers in each analysis (Zeng 1993, 1994). This is a better model for this analysis as it 
takes into consideration multiple QTL effects, which might very well exist given that 
such cases have been found before, and also since the target region being examined here 
on mChr15 is rather large. 
M 	M 	M,. 	M: 
Figure 2.1.3: Composite interval mapping (CIM). The interval being examined by CIM is between 
markers M, and M, * . Addition of the adjacent markers M 1 and M 2 as cofactors absorbs the effects of 
any linked QTL to the left of marker M 1 and to the right of marker M +2  (flanking regions). Their 
inclusion, however, does not remove the effects of QTL that may be present in the two intervals, (M 1 M) 
and (M + M 2), flanking the interval of interest. 
QTL localisation was hence carried out utilizing the genetic map derived using CriMap, 
and IM and CIM. CIM was run in order to eliminate the background effect for any given 
point. The window size (w) was set at its default value of 10.0cM, as was the number of 
markers controlling for the genotype of the flanking regions (n - 5 markers) [Fig 2.1.3]. 
The analysis was carried out on the 191 (BC6-F2) and 111 (BC5-F2) phenotypes, both 
separately and combined. Males and females were analysed together (where a sex effect 
and sex-by-genotype interaction were taken into consideration) and separately. The data 
were analysed using the F2 model. Confidence intervals are given as LOD-support 
intervals, whereby the one-LOD support interval is defined by all the values that fall 
within the one-LOD score of the maximum value, and approximates to a 90% 
confidence interval; the two-LOD support interval approximates to a 95% confidence 
interval (Van Ooijen, 1992). 
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2.1.2 	MAIN QTL MAPPING STUDY 
This section describes the methods and techniques used for the larger fine-mapping QTL 
study, and for the common procedures used in both the pilot, and the main study. 
2.1.2.1 	Breeding strategy - for the purpose of progeny 
testing of recombinants 
Progeny testing involves the generation of recombinants in an interval believed to 
contain a QTL, propagating these recombinants, and then measuring the progeny's 
phenotypes so that the phenotypic value of each recombinant can be quantified. The 
mating scheme for the generation of these recombinants and the progeny-test population 
is described here and illustrated in Fig [2.1.4]. 
The BC6 x BC6 inter-cross Fig [2.1.2], in addition to generating the F 2 population 
analysed in the Pilot study, also generated homozygote congenic mice, which were then 
maintained by full-sib inbreeding. To generate recombinants within the Fob3 QTL 
region, a cross between a congenic male and the F-line was initiated. A single 
homozygote congenic FCI!5J  male, having L-line alleles from marker Dl5Mitl50 to 
marker Dl5Mit39, was crossed with nine F-line females. The resulting 42 heterozygous 
progeny were inter se mated in order to produce a population containing recombinants. 
220 progeny were generated, of which 41 were recombinants. 23 were male 
recombinants that were backcrossed to F-line and congenic F 15'-1ine females, to 
generate 789 progeny from 133 families. 
Since many more litters can be obtained by mating a recombinant male to many females, 
rather than recombinant females which are limited to small numbers of litters, the 18 
female recombinants were firstly backcrossed to F-line males. This generated 208 
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progeny from 35 families and from these, selected male progeny of the female 
recombinants possessing the desired recombinant genotype were in turn backcrossed to 
both F-line and congenic F' 51 -1ine female mice, generating an additional 182 progeny 
from 29 families. 
X 




F, 	 X 






(039%)  X I I I 
/ 	
F-line & 
I 	 I 
Progeny and 
grand-progeny 
 test population 
Fig 2.1.4: Mating scheme for generating the progeny-test population from F 2 mice, recombinant 
within the Fob3 QTL region. Thin and thick lines indicate chromosomal segments homozygous for the 
Lean-line and Fat-line alleles, respectively. The percentages of background L-line alleles exclusive of 
mChr15 are given in brackets. 
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The nature of the breeding strategy means that the progeny of recombinants have a 
further reduced proportion of non-Chr15 L-line alleles in their genomic background as a 
result of backcrossing to the F-line. All the recombinants are products of seven 
backcrosses, hence all progeny of recombinants are products of either seven or eight 
backcrosses (having only 0.78% and 0.39% background L-lines alleles respectively). All 
of the grandprogeny are products of at least eight, and in some cases nine, backcrosses to 
the F-line (having only 0.39% and 0.20% respectively), again further reducing the net 
amount of L-line alleles in the final progeny test population (see Fig 2.1.4). 
2.1.2.2 	Production of a linkage map 
The linkage map was constructed using CriMap as described in [2.1.1.2], with these 
additional markers: Dl5Mitl50, D15Mit234, Dl5Mitl56 and D15Mitl, bringing the 
total to 16 polymorphic markers. The order of the markers was confirmed by comparing 
to the Mouse Genome Sequencing Consortium (MGSC) map 
[http://www.ensembl.org/Mus_musculus/]  version 13.30.1. 
2.1.2.3 	Single marker analysis 
As a first step in the analysis, QTL detection was performed using single marker 
ANOVA. This was carried out on 1152 phenotyped individuals, using the GLM 
procedure of the SAS System for Windows (v 8.0). Each marker was fitted as a fixed 
effect. For each trait, all 16 markers were analysed in turn, using the following model: 
YMm +Gg+L+S +P+S*G+ e 
	
[2] 
Where M is the mean for any trait 'm'; G is the effect of the genotype g (1-3, FF, FL or 
LL); L is the litter effect; S is the sex effect (1-2, male or female); P is the parity effect 
(1-2, 1 for the first litter, 2 for not the first litter); S*G  is the sex by genotype interaction; 
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and e is the residual error. As rGFPwt measurements were only carried on males, and 
there was no parity effect detectable, only litter effects were fitted for this data set [3]. 
Y=MrGFPwt +G+L+e 	 [3] 
2.1.2.4 	Interval Mapping (IM) 
2.1.2.4.1 	Test for normalisation and transformation of raw data 
Prior to interval mapping, the residuals of all traits (Bw21, 42, 70, 98, 115, fat% and 
rGFPwt) were examined for normality. Kolmogorov-Smirnov, Anderson-Darling, 
skewness and kurtosis tests were all carried out using the NORMTEST macro 
(D'Agostino et al. 1990), which is based on proc Univariate for the SAS System for 
Windows (v 8.0). In addition, histograms and normal-percentile plots were generated 
and used to judge normality when the various tests gave conflicting results. 
2.1.2.4.2 	Single-QTL IM using a maximum likelihood (ML) approach 
Single-QTL analysis was carried out using two methods. The first method uses a ML 
approach, which was originally designed for progeny testing of recombinants to fine-
map an X-linked QTL, using a Unix based program written by Dr. Peter Keightley 
(Keightley et al, 1998; Liu et al, 2001a). The data were evaluated at 0.1cM intervals. 
As in the use of QTL Cartographer in the pilot study [2.1.1.4], confidence intervals are 
given as one- and two-LOD-drop support intervals, representing 90% and 95% 
confidence intervals, respectively. 
The analysis of this program requires a caveat. The program was originally written for 
an X-linked QTL, and consequently, reads the genotypes of the recombinant chromatids 
and assumes the genotype for the donor non-recombinant parent to be homogeneous, 
i.e., it will assume the haplotype for all markers to be either F-line (where the non- 
MATERIALS & METHODS - QTL ANALYSIS: 2.1 	 84 
recombinant donor is an F-line mouse), or L-line (where the donor is a congenic-line 
mouse). As a result, all the information at the proximal and distal ends of the Fob3 QTL 
region are not considered. The potential error is compounded by the use of multiple 
congenic sub-lines (although the F' 5D-subline was predominantly used) that differ in 
their genotypes at the ends of the Fob3 QTL region. 
2.1.2.4.3 	Single-QTL IM using a regression analysis approach 
The second method is based on regression analysis using SAS code. This analysis was 
carried out in collaboration with Dr. Julian Christians, who wrote the analysis code in 
SAS (SAS Institute, 1989) [Appendix A.3]. This second method was necessary for two 
reasons, firstly to confirm the ML analysis in the context of being able to consider all the 
genotypic data available without the caveat required in the ML analysis. Secondly, this 
approach allowed for multiple QTL to be considered, as described below. 
IM was carried out using the general linear model (GLM) procedure. Parity and sex 
were fitted as fixed effects, and litter size as a covariate. Each trait was fitted as an 
independent variable, with the additive and dominance coefficients as independent 
variables (Haley and Knott 1992), which were calculated at 1cM intervals. These 
coefficients took into account both the parental and progeny's genotypes, and accounted 
for the possibility of new recombination within the recombinant parent, but assumed 
complete interference, i.e., no double recombination within a meiosis. 
The F-statistics for the additive and dominance coefficients were used as a measure of 
support for these effects. Significance thresholds were determined empirically by 
permuting the marker data, as described by Churchill and Doerge (1994). Thresholds 
were obtained from 1000 permutations and are presented as F0.05 and 1 700 1 for 
significance at a = 0.05 and a = 0.01, respectively. 
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2.1.2.4.4 	Multiple-QTL IM using a regression analysis approach 
The strategy for the multiple QTL analyses was to add QTL to the model until the 
additional QTL was not significant. Two- and three-QTL analyses were performed by 
estimating the effects of two or three QTL at separate positions simultaneously, 
examining all possible pairs or triads of locations (on a 1 cM grid), and selecting the 
pair, or triad of locations, for which the model explained the most variation. Initial 
multiple-QTL analyses included epistasis, i.e., an additive-by-additive interaction term 
was added to the model. Other types of epistasis (i.e., additive-by-dominance, 
dominance-by-additive and dominance-by-dominance; see Cheverud et al. 2001) were 
not included because preliminary analyses revealed that the data were generally not 
suitable for estimating interactions involving dominance (i.e., the P-value for these terms 
were undefined); there were few or no cases where a family was heterozygous at one 
position and segregating at another. If the additive-by-additive interaction was not 
significant, this term was removed and the analysis was repeated assuming additivity. 
The significance of the additive and dominance effects in the multiple-QTL analyses 
were assessed using the threshold F-values determined for a single-QTL analysis. 
Confidence intervals (CI) for the location of QTL were calculated from 1000 
bootstrapped samples (Visscher et al. 1996). Bootstrapping of two- and three-QTL 
analyses would have been extremely computationally intensive, thus the position of each 
QTL was bootstrapped separately. For example, if a two-QTL analysis identified two 
QTL, A and B, at locations X and Y, respectively, the CI for the position of QTL A 
would be estimated by performing GLMs with one QTL at position Y and finding the 
position of a second QTL that maximised the F-value for the entire model. This analysis 
would be run for each of the 1000 bootstrap pseudo-samples. The Cl for the position of 
QTL B would then be estimated in a similar way, but by holding the position of one 
QTL fixed at X. All permutation, bootstrapping and multiple-QTL analyses were 
performed using SAS. 
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2.1.3 	MOUSE MICROSATELLITE GENOTYPING 
Microsatellite markers are specific sequences of DNA, which contain mono-, di-, tn-, or 
tetra tandem repeats. They are also known as simple sequence repeats (SSR), short 
tandem repeats (STR), or variable number tandem repeats (VNTR), for the purposes of 
this study however they are referred to simply as 'markers'. 
The markers used here are typically di-nucleotide repeats. The primers for the markers 
used were selected from the Whitehead-Institute, Centre for Genome Research database, 
(http://www.broad.mit.edu/cgi-binlmouse/gmap_search?database=mouserelease)  and 
ordered through MWG (Ebersberg, Germany). 
Table 2.1.1: Screened microsatellite markers. 
[Al Markers found to be polymorphic between the F and L -lines 
Name of Marker Forward sequence Reverse sequence Repeat 
Dl 5Mitl 75 ATAGCAACTAACAAAGACATACACACA ACCCA1TGCAGTGTAAAATTCC (CA) 
Dl 5Mitl 50 TrGTGGGATGAAGTGTGCAT TCAAATTTACAGGAAAAGAACAAGC (TG) 
Dl 5Mitl 38 TTCAATCCC1TTGTCAAATG CAAGACCCTAGATTCAGTCTACCC (TG) 
D1 5W5 CTTCCTAATTCCTGTCAAGCAAAT G1TCA1TGGTCAATGGAAACTTA (CA) 
Dl 5Mitl 84 TGTATTCACAAGCATATACTAACACCA TGGTAAG1TGAAGTCAACCTGG (AGAT) 
Dl 5Mitl 15 CATACCCACTGGTGCATCAC AGTGAATFCCATAAT1TTAAAGGACG (CA) 
D1 5W209 TrGTGCTTCACTAGATGTAGACCA 1TTATAGTTGCACATAAGCAGCA (TG) 
Dl 5Mit234 TGCATATFAGGAATGCCATTACA AAATGTGAAATAACAGTGTGGGA (CA)&(GA) 
Dl 5Mit63 ACCAATGATCG1TGATGCCT TAA1TFCACACTAGCAAAACCAAA (TG) 
D1 5W90 TGGTGTCCAAGTGTGCCTI C1TCTGCCTCTCTCTCTCTCG (CA) 
Dl 5Mitl 56 CCCACATCATGCACATATAGG AACAAATCAAGAACCAATTGGG (CA) 
Dl 5Mitl 05 ACTGGC1TATCTAGCATTCTCCC CATATGTCTTATCAGCCATGTCC (TG) 
D1 5W68 UCCATGTGAGTCCAAGCA GAACTGCCATTCAGAATATTTGG (CA) 
Dl 5Mitl AACATGGTCCCACAGGTGTC AGTAGAAGCTGCAGCCCTGG (CA) 
Dl 5Mitl 07 CAACACTrATACACTrGTGTCAGGG TCATGGTGGAACAGCAGAC (TG) 
D1 5W39 CATCAAGGGGATAGAGAGTTGG TGGGAATTGAGCCTGAGTCT (TG) 
[B] Non-polymorphic between the F and L -lin es  
D15M1t3 D15M1t27 D15MIt3O D15Mit50 D15Mit58 DI5MIt61 D15Mit67 
D15M1t91 D15Mitl03 D15Mit104 D15Mit106 D15Mitl21 D15Mit145 D15Mit152 
D15M1t159 D15M1t167 D15Mit179 D15Mit183 D15M1t188 D15Mit190 D15MIt191 
D15M4197 D15M1t213 D15Mit215 D15Mit216 D15M1t233 D15M1t235 D15Mit244 
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Markers were screened for polymorphisms between F-line and L-line genomic DNA 
extracted from spleens as described in [2.3.1], using a gradient PCR assay with the Taq 
Polymerase B protocol and reagents [2.1.3.1 to 2.1.3.3]. A list of the markers screened 
between the two lines is given in Table [2.1.1]. 
2.1.3.1 	PCR Protocol 
This protocol was modified from Laird et al. (1991). Genomic DNA was extracted from 
mouse ear-clips using the following procedure: 
• Lysate buffer was made and autoclaved. 
• Proteinase K (20mg/mL) was added to lysate buffer at a final concentration of 
1 0Opg/mL. 
• 60p.Lof Proteinase-K-lysis-buffer was added to the mouse earclips in 1.5rnL 
Eppendorfs and incubated for 3-4 hours at 55°C, inverting the tubes every 30mins. 
• Tubes were then centrifuged at 13,000 rpm for 2mins and Proteinase K is heat 
inactivated at 95-100 °C for lOmins. 
• Finally, tubes were centrifuged (13,000 rpm) for lOmins and lysate diluted 
immediately 1:25 fold with dH20 (3.tL1ysate in 125p.l) in 96 well microtiter plates, 
and stored at —20 °C. 
PCR reaction conditions were optimised for each marker's primer set pair, in oil free 
12p.L volumes (6p.L lysate DNA, 6p.L 2X-PCR reaction mixture), using 96-well 
polypropylene PCR plates on Hybaid JMBS thermocyclers. 
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Table 2.1.2: PCR conditions for each polymorphic marker primer pair. 
[A] Type of Taq polymerase used and annealing temperature 
Annealing Temp 
Marker name Taq Polyinerase °C (AT*) 
D15Mitl75 A 58 
D15Mitl38 A 58 
D15Mit5 A 58 
D15Mitll5 A 58 
D15Mitl84 A 58 
D15Mit63 A 58 
D15Mit68 A 59 
D15Mitl56 A 61 
D15Mit39 A 61 
D15Mitl A 64 
1315Mit209 B 58 
Dl5Mitl50 B 61 
D15Mit234 B 61 
D15Mit9O B 61 
D15MitlO5 B 61 
D15MitlO7 B 61 
[B] PCR conditions for each Taq polymerase 
Polymerase A TEMP C TIME (m:s) 
1 	CYCLE NO. 1 	94 05:00 







3 	CYCLE NO. 1 	72 05:00 
Polvmerase B 
1 	CYCLE NO. 	1 	94 22:00 
94 00:20 
2 	CYCLE NO. 	40 	AT* 01:00 
72 00:30 
3 	CYCLE NO. 	1 	72 05:00 
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2.1.3.2 	Agarose gel electrophoresis 
PCR products were separated on 4% Agarose gels (2% high-fidelity MetaPhor ® agarose, 
and 2% standard agarose MP), with 0.5x TBE buffer containing ethidium bromide 
(0.02j.xglmL). Samples were loaded with 4tL of cresol red loading buffer and run at 
6v/cm for 2-3 hours. 
2.1.3.3 	Reagents 
Lysate Buffer -autoclaved 
100mM Tris, pH 8.5 






Tag DNA Polymerase 'A' 
Taq Polymerase 
Used with lOX reaction buffer 




USB Corporation (OH, USA) 
FMC BioProducts (PA, USA) 
Boehringer (Ingeiheim/Rhein, Germany) 
Roche (Base!, Switzerland) 
Roche (Base!, Switzerland) 
Roche (Base!, Switzerland) 
Tag DNA Polymerase 'B' 
AmpliTaq Gold polymerase 
	
Roche (Base!, Switzerland) 
Used with lOX buffer II Roche (Base!, Switzerland) 
25mM M902  to final conc. of 2.5mM 
	
Roche (Base!, Switzerland) 
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Cresol Red 1mM 
Cresol red 
	
Sigma-Aldrich (MO, USA) 
Sucrose (60%) 
2mM dNTPs to final conc. of 200iM 
	
Amersham Pharmacia (Uppsala, Sweden) 
Proteinase K 
	
Roche (Basel, Switzerland) 
TBE buffer 	 Ambion (TX, USA) 
96 well microtiter PCR plates 	 ABgene (Surrey, UK) 
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2.1.4 	MOUSE PHENOTYPING 
2.1.4.1 	Body weight (Bw) measurements 
Mouse Bw measurements were taken at 21, 42, 70, 98 and 115 days of age (Bw21, 
Bw42, Bw70, Bw98 and Bwl 15 respectively). Mice were placed on a digital scale 
(Sartorius, LC 2200P) connected to a PC running Microsoft Windows 95. An Excel 
macro (written by Lutz Bunger and modified by Savvas Triantafyllou and loannis 
Stylianou) was used to read and store each weight. Weights, along with the mouse 
identifiers, pedigree and litter information, were stored and tracked safely in an Excel 
environment using macros written by Lutz Bunger (personal communication). 
2.1.4.2 	Gonadal fat pad weight (GFPWt) measurements 
Both male gonadal fat pads (GFP) were removed and weighed to give a total GFPwt 
using a fine digital scale (Mettler, Toledo A1354). Relative GEP weight (rGFPwt) was 
given as the ratio of the GFP to Bwl 15. The GFP was replaced in the abdominal cavity 
for downstream calculation of total body fat (fat%). 
2.1.4.3 	Body fat (fat%) measurements 
Water content has been demonstrated to be a robust indicator of the proportion of body 
fat (Hastings & Hill, 1989). The proportion of total body fat (fat%) therefore is 
estimated from the dry carcass weight (DM) proportion using the least square means 
estimates whereby a = 0.302, b=1.13 [4] and the correlation coefficient is 0.98, as 
determined by Hastings and Hill, (1989). 
Predicted fat% = (DMIBw115) x 113 —30.2 	 [4] 
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DM was calculated by taking the weight of freeze-dried mice. To freeze-dry mice, they 
were firstly thoroughly frozen at —20°C for several days. Once frozen, several insertions 
with a scalpel to the body and a deep cut in the skull were made. Additionally, the tail 
was scored with a scalpel every 2-3mm. This is done in order to allow effective 
evaporation of the water content of each mouse. Mice were left to dry in a freeze-drier 
for 4 days. 
It should be noted that generally the number of phenotyped mice for Bwl 15, is larger 
than that for the fat% trait. This is because some mice were used for line propagation - 
and hence were eligible for phenotyping at the Bwl 15 stage, but not for fat%, which 
requires the mouse to be euthanized, and because the freeze-drying process on occasion 
failed to go to completion and thus data from these mice were disregarded from the 
results. 
MATERIALS & METHODS - QTL ANALYSIS: 2.1 	 93 
2.1.5 	GENERAL ANIMAL HUSBANDRY 
Mice were fed ad libitum Rat and Mouse No. 3 diet [digestible crude oil, 3.8%; dc 
protein 20.2%, starches 33.9%; sugars 4.4; digestible energy 13.8MJIkg] from weaning 
onwards (Special Diet Services, Essex, UK), and maintained with controlled lighting (12 
h light) at a temperature of 21 ± 2 °C. Mice were weaned at 21 days of age and kept in 
sex-matched groups of three to twelve in plastic cages. Earclips were systematically 
taken for identification of each mouse, which was also used for genotyping. All 
procedures were authorized and approved by the Home Office (UK) under the Animals 
(Scientific Procedures) Act 1986. 
MATERIALS & METHODS - QTL ANALYSIS: 2.1 	 94 
2.2 	MICROARRAY ANALYSIS & 
TECHNIQUES 
This chapter describes the experimental design, molecular techniques and analysis 
methods that have been applied for obtaining global gene expression differences in the 
liver and brown adipose tissue, between a congenic line containing the Fob3b QTL 
region (F 5D) and the F-line. 
2.2.1 	TISSUE COLLECTIONS 
Two tissue collections were set up, the first primarily to collect tissue for RNA for 
microarray experiments, the second was primarily set up to collect samples for 
confirmation and downstream experiments on the results obtained from the microarrays. 
The three lines of mice used for these experiments (F, L and congenic hr15  
were maintained on one rack in the same room of the animal facility and cages were 
randomised in their position on a single cage rack to avoid any localised environmental 
effects. Each cage contained 8-12 animals each and all other conditions were as 
described in section [2.1.4]. 
2.2.1.1 	Protocol 
All tissues were placed into 2mL Eppendorf tubes and immediately snap-frozen in liquid 
nitrogen and then stored at —80 °C. Removal and freezing of tissues was carried out as 
speedily as possible so that RNA integrity was not compromised. Mice for dissecting 
were transferred at 08:00 hours into individually labeled cages with water but no food. 
This procedure attempted to standardize gene expression differences that might arise 
between mice due to pre-kill eating. 
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Mice were dissected three hours post isolation; one at a time, each mouse was 
transported individually in cages from the stock room to the dissecting room, and then 
processed which typically required 5mins. If more than ten mice were to be dissected in 
one day, the first ten would be isolated at 08:00 hours and next ten at 09:00 hours. Thus 
maintaining the 3 hr isolation period. All non-disposable dissecting instruments were 
autoclaved before use, and all disposable instruments used were sterile. Dissections were 
carried out in sterile Petri dishes. 
Tissue Collection 1: For this collection, tissues were taken from 60 - 98day old mice, 
comprising ten mice of each sex from the three lines (F-, L- and F' 15D congenic line). 
Mouse processing: Mice were cervically dislocated and decapitated. Brown adipose 
tissue (BAT) - interscapular brown adipose - was removed from the back of shoulders 
and stored as separate left and right depots. Similarly, left and right white fat (WAT) 
deposits recovered from gonadal fat pads were stored separately into tubes WATA and 
WATB respectively. The two lobes of liver, were also stored separately - the first upper 
lobe (always as LIVA), and the second lower lobe (as LIVB). 
Tissue Collection 2: For this collection, tissues were taken from 180 mice, 60 mice each 
at 28, 49 and 98 days of age. For each age group as in the first collection, comprised 10 
mice of each sex from the three lines (F-line, L-line and chrl  congenic line). 
Mouse processing: This was carried out as above for the first collection, with the 
following additional tissues removed and snap-frozen in liquid nitrogen: hypothalamus 
- which was removed first; muscle removed from a hind leg, - the skin was peeled back 
avoiding any fat deposits and slicing the muscle into pieces for easier homogenization 
downstream. Whole brain (minus the hypothalamus removed and stored separately); 
both Adrenals (into the same tube); one Kidney; Spleen; Heart; Pancreas; Lung; from 
the gastrointestinal tract, the stomach was removed - cut open and rinsed twice in lx 
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PBS in 7mL universals, before being snap-frozen. Similarly, a segment of approximately 
2cm of the duodenum, jejunum and ileum was each sliced open, rinsed twice in 1X 
PBS and stored separately. 
2.2.1.2 	Reagents 
PBS (autoclaved 1X) 
70% Alcohol made with autoclaved distilled H20 
Double autoclaved 2 .OmL Eppendorfs 
Disposable scalpels 
Falcon tubes 
7mL Universal tubes 
Liquid nitrogen 
Petri dishes 
Oxoid Ltd (Hampshire, UK) 
BDH AnalaR 
Eppendorf (Hamburg, Germany) 
Swann Morton (Sheffield, UK) 
Greiner Bio-One (Gloucestershire, UK) 
Greiner Bio-One (Gloucestershire, UK) 
Multiple suppliers 
Multiple suppliers 
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2.2.2 	RNA PREPARATION 
2.2.2.1 	RNA extraction 
RNA extraction was carried out using Trizol®  reagent following the manufacturer's 
guidelines (Invitrogen Ltd, Paisley, UK), with slight modifications. This method is based 
on the original Chomczynski and Sacchi (1987) guanidinium thiocyante 
phenol/chloroform method. The general protocol is described here. 
Samples were removed from —80°C storage into liquid nitrogen. Each sample was then 
transferred to a 30mL sterile tube containing an appropriate volume of cold Trizol®  as 
recommended by the manufacturer. The sample was then homogenised using a polytron 
homogeniser (PT 100, Kinematica Polytron ®), for 30seconds to 2mins depending on 
tissue type and volume. This was carried out in 'batches' appropriate to the downstream 
comparison. For instance, five male F-line liver samples would be processed followed 
by five male L-line liver samples. Between tissues, the homogeniser was washed twice 
with 40mL 0.2M NaOH in sterile Falcon tubes, followed by two washes of 40mL double 
autoclaved distilled water (ddH20) before finally being rinsed in 2mL of Trizol ® 
reagent. Between 'batches' (typically 5 or 6 samples from mice with the same sex-line-
age-tissue type), the homogeniser probe was washed three times with 0.2M NaOH, three 
times with ddH20 and once with a fresh 2mL sample of Trizol ® . 
Homogenised samples were either stored in their 30mL tube at —80°C for processing at a 
later stage, or processed immediately as described here: Homogenised samples, in 
volumes no more than 1 .5mL, were dispensed into double autoclaved 2.OmL Eppendorfs 
and 0.2mL of chloroform was added for each lmL of Trizol®.  Samples were vigorously 
shaken for 15 seconds and left to stand at room temperature (RT) for 1 Smins. Samples 
were then centrifuged at 12,000g at 4°C for 15mins. The aqueous layer was removed to 
fresh double autoclaved 2.OmL Eppendorfs and an equal volume of isopropanol added. 
Following an incubation period of lOmins at RT, samples were again centrifuged at 
MATERIALS & METHODS - MICROARRAY ANALYSIS: 2.2 	 98 
12,000g at 4°C for 1 Smins. The supernatant was then removed and the pellet washed by 
adding 75% ethanol (lmL of ethanol for each lmL of Trizol ® used) which was vortexed 
before centrifugation at 7,500g at 4°C for 5mins. The ethanol was poured off and the 
pellets were allowed to air-dry for 5-1 Omins before being re-dissolved in ddH 20. The 
amount of RNA obtained was on average 0.13jtglmg for low RNA yielding tissues such 
as BAT, or 0.35j.ig/mg for high yielding tissues such as liver. The samples were warmed 
to 65°C for lOmins with occasional vortexing. Finally, the samples were precipitated for 
long-term storage by the addition of 10% 3M-sodium acetate (NaAc) (pH 5.2), and 2.5 
volumes of 100% ethanol. 
2.2.2.2 	RNA quantification 
For quantification of RNA samples, the RNA ethanol precipitate was vortexed for 15 
seconds, and typically 50p.L transferred to a double autoclaved 0.5mL Eppendorf tube 
(for high yield tissues such as liver and brain, lOp.L was used). The sample was then 
centrifuged at 12,000g at 4°C for 1 Omins. The ethanol was removed and the samples left 
to air-dry for Smins. Samples were re-dissolved by adding 100iL ddH20 and heating the 
sample for lOmins at 65°C with vortexing. Finally the samples were centrifuged and 
quantified by measuring absorbance at 260 and 280nm (GeneQuant, Amersham 
Biosciences, Bucks, UK). 
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2.2.3 	MICROARRAYS 
The microarray protocols, experimental designs and analytical approaches described 
below, were carried out in collaboration with Claire Pritchard and her group at MRC 
Harwell. 
Microarray slides were kindly supplied by the HGMP MRC GeneService. Spotted on the 
slides were 15,000 mouse cDNAs from a clone set prepared by Dr Minoru Ko's 
laboratory (Tanaka et al. 2000), at the National Institute on Aging, part of the National 
Institutes of Health, USA. 
2.2.3.1 	Contents and format of slides 
The spotted cDNA clones are ESTs from a unique set of pre- and pen-implantation 
embryos, E12.5 female gonadlmesonephros, and newborn ovary, of which 78% are 
novel and 22% are known genes. A summary is given in Table [2.2.1], which is 
replicated from Tanaka et al. (2000), who generated the libraries. 
The average size of these ESTs is 1.5kb. The 15,000 cDNAs are spotted across two 
slides with 7,500 different cDNAs spotted twice on each slide [Fig 2.2.1]. Moreover, the 
spotted cDNA slides have additional features such as landing lights, to help orientate the 
grids, and empty spots as background controls. The spots are arranged in 48 grids of 
18x20 spots giving what is called the Metagrid. Clones were sequenced from 5' and 3' 
termini and the sequences have been deposited in GenBank (Tanaka et al. 2000). This 
information is available at the following NIA-NIH web site 
http://lgsun.grc.nia.nih.gov/cDNA/I  5k.html. 
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Table 2.2.1: Derivation of ESTs on the 15K 2-slide microarray set. 
Total for 	No. in 
each EST unique 	% 
Library 	Set Contribution 
E7.5 Extra-embryonic 10096 2132 14 
E7.5 Embryonic 2500 893 6 
Pre-implantation: 50 
Unfertilised eggs 3096 1225 8 
Fertilised eggs 3314 1019 7 
2-cell embryo 3684 1189 8 
4-cell embryo 3251 932 6 
8-cell embryo 3444 874 6 
16-cell embryo 3297 682 4 
E3.5 Blastocyst 5692 1708 11 
E12.5 Female gonad/mesonephros 7000 1471 10 
New born ovary 7000 3139 21 
Total 15264 
As these sequences were not highly annotated, so additional information was obtained 
by carrying out a BLAST of all 15,000 GenBank IDs to the Ensemble mouse genome 
server. This was carried out in order to obtain chromosomal location and position, 
specifically to identify all cDNAs that matched to mChrl5. Identifying the mapped Mbp 
location allows for relative positioning to the Fob3 QTL. Sequences were processed 
through a set of Perl scripts developed by the Roslin Bioinformatics Group (Speed & 
Law, unpublished). Briefly, each sequence was searched against assembled mouse 
chromosome sequences from the Ensemble assembly number 15.30.1 (6-May-2003) 
using NCB  blast (v2.2.3) using default parameters and a default cut-off score of 10. The 
top 3 hits for each sequence were reported. A final list of the mChrl 5 hits, with P-values 
less than 0.05 is available in appendix [B]. 























Slide ID 0904028088 
a. 
Fig 2.2.1: Microarray slide layout and contents: Metagrid consists of 48 grids. Each grid contains 180 
duplicated cDNAs, as well as controls and landing lights. 
2.2.3.2 	Experimental design 
The aim was to identify differentially expressed ESTs between the F-line and the 
congenic F 15D-line, which could be involved in obesity. An obvious candidate tissue 
to examine for such differences may be the hypothalamus. However, due to the low 
yields of RNA from a single hypothalamus, and the demand for large RNA quantities for 
these arrays, the hypothalamus was not chosen for the microarray study. The liver, 
brown adipose tissues (BAT) and white adipose tissue (WAT) were hence chosen as the 
next best candidate tissues, as these are tissues where many metabolic processes occur. 
However the RNA yield from WAT was also found to be too low at the time of this 
MATERIALS & METHODS - MICROARRAY ANALYSIS: 2.2 	 102 
study to proceed much further, thus all microarray analysis was carried out on BAT and 
liver tissue. Adult 98 day old female mice were used, as the early pilot QTL study 
indicated that the Fob3 QTL might be female specific, although subsequently shown not 
to be so, in the larger QTL study. 
For each tissue, pools of RNA derived from equal quantities from five individuals of the 
same mouse line, were generated. Only female mice were used, hence avoiding sex 
effects, and only first parity mice were used, hence avoiding parity effects. For each 
pool, the five individuals were taken from different litters to reduce litter effects, and as 
ten individuals for each line were available, two independent pools were generated for 
each line [Fig 2.2.2]. 
F-line 
	 F''D -line 
I 	I I [1 	[1 1st Panty litters 	 1-7 	[1 
t I 1 JEIJI  
l'i)()l I 
1. 	1 
Lu e I 	 I 	 Iii 
It \I 
P t 7j i 
i 
l'ouul I 	 Pool 2 
I I 
Liver Pool-i 	 Liver Pool-2 
BAT Pool-I BAT Pool-2 
Fig 2.2.2: Experimental design - derivation of pooled RNA. 
The following pools of RNA was generated: 
LiverF-line —Pool 1 	[LF11] 
Liver F-line - Pool 2 	[LF2 ] 
Liver Fchri5D  line - Pool I 	[LD 1 ] 
Liver Fchrl5D  line - Pool 2 	[LD2 ] 
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BATF-line —Pool 1 	[BF1f} 
BAT F-line - Pool 2 	[BF2 ] 
BAT Frl5Dline 
- Pool 1 	[BD1 ] 
BAT Fchr 	2 [BD2f] 
(L denotes Liver; F denotes F-line. D denotes congenic phriSDline.  1 denotes pool 1, 2 denotes pool 2; f 
denotes female). 
From this point onward, the term experiment', shall refer to one of the four aims of the 
hybridisations, namely: 
1 - to examine gene expression differences in liver on array set 1, 
2 - to examine gene expression differences in BAT on array set 1, 
3 - to examine gene expression differences in liver on array set 2, 
4 - to examine gene expression differences in BAT on array set 2, 
eDNA was generated from each pool as described below [2.2.3.31. Repeat hybridisations 
were carried out for each tissue, for the two different microarray sets. 
Dye swap 
hrIS 	 irI5I 




F-I ineFc r 5L 
	
-l ine F'hr151 
ool 	
001 
1 	2 	3 	4 
Fig 2.2.3: Experimental design - Replicates from independent eDNA pools and dye swaps. 
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Replicate hybridisations were processed using colour-swaps' whereby the dyes used for 
labelling the cDNA samples in the first hybridisation are swapped over, and all other 
variables are kept constant as in the arrays 1 and 2 in Fig [2.2.3]. Additional independent 
replicates (arrays 3 and 4) can be generated from the different pools of RNA. In 
addition, control hybndisations were set up, hybridising independent pools of otherwise 
identical origination, that is self-self' hybridisations (e.g. [BFI f][REDJ  v [BFI fIIGREENI). 
This was carried out in order to test the system before proceeding with the samples-
proper, and also to assess the amount of noise variation expected from hybridising 
independent pooled samples, that are otherwise identical in genotype and hence 
seemingly gene expression. 
2.2.3.3 	Hybridisation protocol 
For hybridisation to the microarray slides, two labelled cDNA targets are required. The 
protocols used for generating cDNA from RNA, labelled targets from cDNA and finally 
hybridised microarray slides are described here. Each progressive step is illustrated in 
Fig. 12.2.41. Two methods of labelling were used and compared, and are described here. 
These were direct labelling reverse transcriptase labelling with M-MLV-II and indirect 
labelling using Klenow. 
lReverse 
It 	cDNA 	 1P Hybridisatio ITranscriptio Target > 	
j 
Figure 2.2.4: General microarray - RNA to Slide hybridisation scheme 
Both indocarbocyanine (Cy3) and indodicarbocyanine (Cy5) are photosensitive and 
hence measures were taken to minimize exposure to light during the labeling, 
hybridization, washing, and scanning processes. The following reactions therefore, were 
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performed in double autoclaved light protecting amber Eppendorf tubes. Where possible 
all reactions were additionally carried out in foil-wrapped heat blocks and containers. 
From each RNA pool, 50pg of RNA ethanol precipitate was taken, spun down at 4°C for 
lOmins, then re-suspended in 95jiL of RNAse free water (Qiagen, West Sussex, UK). 
Some RNA pools were purified on Qiagen spin columns to assess if this significantly 
improved cDNA quality and yield further down stream. 
Reverse Transcription direct labelling with M-ML V-I! 
The following reaction mixture was set up (Ml) 
Total RNA 	 xj.tL (50p.g total) 
Oligo (dT) (T15) (0.5tg/pL) 8pL (4j.tg total) 	Promega (Southampton, UK) 
dH20 RNase-free 	to 24pi 	 Sigma-Aldrich 
These were then heated to 70°C x 5mm, then placed on ice for I min and spun down. 
The following master mix was made up (M2) 
RT buffer [5x] lOp.! Invitrogen Ltd 
0.1M DTT 5pi Invitrogen Ltd 
25 mM dATP, dTTP & dGTP lfl Invitrogen Ltd 
2.5mM dCTP 2j.tl Invitrogen Ltd 
1 mM Cy3 or Cy5 dCTP 4xl Amersham Biosciences 
RNase inhibitor 2t1 Invitrogen Ltd 
The M2 solution was added to the RNAIOligo (dT) solution (Ml) and mixed. 2.tL of the 
reverse transcriptase Moloney murine leukemia virus-I! (M-MLV-II) (Superscript II, 
Invitrogen Ltd) was added and incubated at 42°C for 1 hour. A further 1 L of M-MLV 
II was added after each hour. The half-life of M-MLV-II is 30-60mins at 37'C, therefore 
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staggering the application of the enzyme improves the quality of reaction during long 
incubations. After 4 hours, ltL of Rnase A was added and incubated at 37°C for 
20mins, and reactions were finally stopped with 5tL 0.5M EDTA. Unincorporated 
nucleotides were removed by running the samples down a Sephadex G50 column 
(Amersham Biosciences). The two alternatively labelled samples (Cy3 and Cy5) were 
combined, and blocking agents were added: 
10-20jtL Cot1 (1jig/pl) 
	
Invitrogen Ltd 
2j.tL Poly(dA) (8pgItl) 
	
Amersham Biosciences 
Samples were finally concentrated to 12.5tL in a SpeedVac®  evaporating centrifuge 
(Thermo Savant, MA, USA). 
Tariet Labellin2 with Kienow 
• Reverse transcription 
Ml was made up as described above, heated to 70°C x 5mm, and placed on ice for 1mm 
before being spun down. 
The following master mix was made up (M3) 
RT buffer [5x] lOjil Invitrogen Ltd 
0.1M DTT 5tl Invitrogen Ltd 
25 mM dNTPs (including dCTP) 2jtl Invitrogen Ltd 
RNAse inhibitor 1 jtl Invitrogen Ltd 
ddH20 6jtl Sigma-Aldrich 
M3 was added to the RNAJOligo(dT) solution (Ml) and mixed. 2L of M-MLV-II was 
added and incubated at 42°C for 1 hour. A further 1 p1 of M-MLV II was added after 
each hour. After 4 hours, ljiL of RNAse A was added and incubated at 37°C for 20mins. 
1st strand cDNA products were then purified using Qiagen PCR purification columns, 
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eluting with 50.IL ddH20. Ethidium bromide staining was used to assess the quality of 
cDNA by running 2.tL of the purified samples on 1% agarose gels. 
• Kienow labelling 
The following reactions were set up: 
Target cDNA 	 20il 
Random primer/Reaction buffer mix [2.5x] 	20jt1 
These were subsequently boiled for 5mins then cooled on ice. Whilst on ice, the 
following were added to the reactions: 
dNTP mix [I Ox] 	 5jil 	Invitrogen Ltd 
1 mM Cy5-dCTP or Cy3-dCTP 	3jil 	Amersham Biosciences 
Kienow (high conc.) 	 ljtL 	Invitrogen Ltd 
These were then allowed to incubate at 37°C for approximately 4 hours, although this 
step could have been allowed to proceed for anything between 1 and 18 hours. 5jiL of 
0.5M EDTA (pH 8.0) was added to stop each reaction. The contents of Cy-3 & Cy-5 
tubes were combined together in a clean tube, and blocking agents were added, 
specifically: 
10-20j.iL Cot1 (1jtg/il) 
	
Invitrogen Ltd 
2tL Poly(dA) (8.tg/l) 
	
Amersham Biosciences 
10% by volume 3M NaAc was added to the mixture and precipitated with 3 volumes of 
ethanol, keeping the samples on ice for 20mins. Samples were than spun down for 
20mins at 5°C and 13000rpm. Pellets were re-suspended in 12.5L ddH20. 
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Hybridisation 
37.5pL of microarray hybridisation solution was added to the 12.5tL of labelled target 
(total volume of sample hence rising to 50jil). The samples were incubated at 85°C for 
Smins, followed by incubation at 42°C for 30 - 60mins. 
The microarray glass slide was placed into a hybridisation cassette (Coming, Schiphol-
Rijk, Holland) and 15.tL of ddH20 was added to each water-well (one at each end of 
chamber) to ensure humidity [Fig 2.2.5]. The chamber was sealed and placed in a 
hybridisation oven at 42 °C for 30-60mins. If evaporation had caused great loss of the 






Chamber outer seals 
	
Lid clips 	________________________________________ 	 Rubber inner seal 
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to the top of the chamber) 	 air-right environment) 
±!!'   
Fig 2.2.5: Single slide hybridisation chamber Corning). 
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After the final hybridisation step of the labelled target, the samples were spun down for 
2mins at 13000rpm. Finally, before addition of the target samples, a heated cover-slip 
[Thickness No.1 22mm x 64mm] was dropped onto the slide. 
Labelled targets were drawn from their tubes carefully (avoiding any solid matter), and 
pipetted onto the slide as slowly and as consistently as possible, pipetting down and 
across the edge of the cover-slip, allowing capillary pressure to draw the target evenly 
across the surface of the array area of the slide. Clamping the lid to the base sealed the 
cassette, and the slides were allowed to hybridise at 45°C overnight. 
Washing and Scannin2 
All stages of slide washing were carried out at room temperature. In addition, great care 
was taken to avoid exposing any portion of the slides to air, as liquids drying on the slide 
surface can affect the quality of the array. Slides were placed in a slide rack containing 
1 litre of wash solution A and rocked gently until the cover slip fell off. The rack was 
then rapidly transferred to a second container with 1 litre of wash solution B where it 
was shaken vigorously for 5mins. Finally, the rack was transferred rapidly to a third 
container containing 1 litre of wash solution C, and again shaken vigorously for 2mins. 
Using forceps, and taking care to not to touch the slide surface, the slides were quickly 
transferred to individual foil-wrapped 50mL Falcon tubes, label-end facing the bottom, 
to ensure that any debris attached to the label, is spun away from the surface. Tubes 
were foil-wrapped to protect the fluorescent labels from being degraded by light. Tubes 
were then spun for 5mins at 600rpm at RT. 
After spinning down, slides were immediately inspected for liquid, and spun again in 
clean falcons if required. Once satisfied that all the fluid had been removed from the 
surface of the slides, they were scanned as described below [2.2.3.5] and then stored in 
fresh foil-wrapped 50mL tubes. 
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2.23.4 Buffers & Solutions 
12.5x] Random primer /Reaction buffer mix 
125 mM Tris (pH 6.8) 
12.5 MM M902 
25 mM 3-mercaptoethano1 
750 g/mL random octamers 




r  Ox] dNTP mix 
1.2 mM each dATP, dGTP, and dTFP 
0.6 mM dCTP 
ddH2O 
Wash Solutions - filtered through 0.2micron filters before use 
A 	[2x] SCC 
B 	[0. lx] SCC + 0.1% SDS 
C 	[0.lx]SCC 
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2.2.4 MICROARRAY DATA CAPTURE & ANALYSIS 
	
2.2.4.1 	Scanning and washing of slides 
Slides were scanned using an Affymetrix 428 (CA, USA) array scanner. If after the first 
scan, the image was judged to be sub-optimal, the scanning was repeated in a higher or 
lower 'gain' appropriately. Occasionally, background fluorescence was high, or streaky. 
In such cases the slides were subjected to an hour long soaking in isopropanol, which 
was then poured off, and the slides dried by spinning down as described above [2.2.3.3], 
before being scanned again. For some slides this was repeated up to three times. 
Washing in this manner decreased the spot fluorescence, in addition to the background 
fluorescence, and thus prolonged washing in this manner needed to be monitored - by 
scanning - so the slides were not over-washed. The best quality scans were judged and 
chosen by eye from a consensus of at least two people. The data, that is, the scanned 
images were acquired and stored as greyscale TIF images. 
2.2.4.2 	Pre-analysis manipulation 
The stored TIF images generated from the Affymetrix scanner were, in-turn, uploaded 
into a program called ImaGene (v4.1) (Biodiscovery Inc., CA, USA). Here, the images 
were orientated, and external data combined to the expression information for 
downstream analysis. This involves firstly the integration of a grid-file, which locates 
the precise position of each spot on the scanned slide-image. Each spot was then 
examined manually and boundaries for each spot were adjusted where the program was 
thought to have lapsed in precision. Poor quality spots that usually have arisen due to 
poor microarray spotting were 'flagged' automatically by ImaGene. This serves the 
function of bringing the spot to the attention of the operator when further processing the 
data, the program also allows manual flagging by the operator of additional spots, or 
remove flags if it is thought a spot has been flagged unnecessarily. Prior to further data 
processing, a second person verified the slide integrations. 
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Following grid integration, a gene ID file, supplied in this case by the NIA-NIH 
(http://lgsun.grc.nia.nih.gov/download.html)  was uploaded and merged with the data in 
ImaGene. Once merged, a text file is generated containing gene IDs with their associated 
mean and median expression signals for each channel (i.e. red and green), and their 
respective mean and median background signals. The data from each of these files was 
normalised and further processed as described below. 
2.2.4.3 	Data analysis: Normalisation with 'GeneSpring 
analysis' 
Two methods of data analysis are used in this study, a method which shall be referred to 
here as the 'GeneSpring analysis', and a 'significance testing' method described below, 
each of which has a different normalisation procedure [2.2.4.4]. 
The program GeneSpring was used as an initial low-level analysis. This program was 
used to examine the overall quality and general trends of the expression differences 
within each hybridisation using the graphical scatter plot interface. In addition, program 
functions were applied to filter for ESTs that met two strict selection criteria that were 
applied for identifying reliably differentially expressed ESTs, with the aim of 
minimising false positive detection. The first selection criterion is that differential 
expression must be of the order of two-fold or greater (2-fold+), and that secondly, this 
must be repeated in at least three of the four (or more) repeat array hybridisations. 
Where four or more array repeats were available, all the possible combinations (of three 
arrays) were analysed to reveal ESTs that met the selection criteria. Simple t-test P-
values are given for within-slide differences, as calculated using GeneSpring 
[http://www.silicongenetics.com ]. 
Methods for normalising microarray data have been developed and discussed in section 
[1.3.2.5], and the precise methods used for this study as described here. The first is that 
MATERIALS & METHODS - MICROARRAY ANALYSIS: 2.2 	 113 
of total or 'global' intensity normalisation, and is applied to the analysis used in 
conjunction with GeneSpring. The second normalisation procedure is used for higher-
level significance testing and is described below [2.2.4.4]. 
For both methods of normalisation, the data are transformed using a L092 
transformation, following the standard approach for microarray analysis (Nadon and 
Shoemaker, 2002) as microarray data sets are usually log-normal (rather than normal) 
(Kerr et al., 2000; Wolfinger et al., 2001; Hoyle et al., 2002). This corrects the data so 
that linear changes in the observations represent expression fold-changes, that is, 0 
represents normal expression, +1 represents two-fold over-expression, -1 represents 
two-fold under-expression etc. 
Notation for the following equations is adapted from Quackenbush 2002. Equation [5] 
gives the L092  ratio C, of red (R) minus red background signal (bR) to Green (G) minus 
background green signal (bG) for thef feature on any array. 
Cf = Log2f 
- bR 
[Gf —bR 
As discussed in [1.3.4.2], there are many reasons why one channel may generally be 
biased. Normalisation aims to make the intensities more comparable. The total 
expression and hence signal of one sample (i.e. either the Cy3 or Cy5 labelled sample), 
is expected to equal that of the second. Normalisation is thus carried out so that the mean 
ratio of each sample is equal to 1. This is done by summing the total expression intensity 
of one sample, and dividing by that of the second sample. Here, Narray is the number of 
features on an array, hence the normalisation factor is calculated as follows: 
Narray 
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Thus global normalisation (Cn) for any feature f, is calculated by multiplying the 'raw' 
ratio Cf by the factor in [6]: 





Whilst using a two-fold cut off is a reasonable, logical and repeatable approach for 
finding differentially expressed ESTs, it is nonetheless rather arbitrary, and hence the 
following higher-level statistical approach was performed in addition to the GeneSpring 
analysis. 
2.2.4.4 	Data analysis: Normalisation and Significance testing 
The significance of differential expression in liver and BAT between the two mouse 
lines was assessed for all 15,000 ESTs, using a mixed model coded in SAS (NC, USA). 
This was done for all four experiments, that is, liver cDNAs on the 1 " and 2nd  array sets; 
and BAT cDNAs on the 1st  and 2nd  array sets. 
The mixed model [8] adapted from Kerr & Churchill, (2001), is processed in two steps, 
based on the procedures described by Wolfinger et al. (2001). The reason for processing 
the model in two steps is that fitting all the variables in one-step results in main effects 
such as dye and array effects being non-significant. 
Yadgilps = J.t + Aa + Dd + Pp + ADad + ADIadi + LGig + AGag + DGdg + PGpg + SAGsag  + Cadgilps 	[8] 
Equation [8] is broken down into two components (the notation is described below), the 
first step [9] being a global normalisation step, removing array, dye, pool and grid bias 
using an analysis over all genes. 
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Step 1: 
Y adgilps = It + Aa + Dd + Pp + ADad + ADI adi + eadgilps 	 [911 
Where Yadgilps  is the normalised L092  background-corrected measurement from any EST g; .t represents 
the average background-corrected signal across all the factors in the experiment, D is a fixed dye effect (d: 
Cy3, Cy5); P is a random pool effect (p: 1 or 2); A is a random effect for any array a; I is random effect 
for any grid (1: 1-48) on an array; AD is the dye by array interaction; ADI is the dye by array by grid 
interaction; e is the stochastic error. 
The residuals from step 1 (R adgilps) are obtained by subtracting the fitted values for the 
effects from the Yad gilps values. The second step [10] is an EST-specific ANOVA using 
the residuals obtained from equation [9],  allowing a different variance for each gene. All 
the effects here are indexed by g and hence are EST specific effects (as opposed to the 
global effects modelled in equation [9]). 
Step 2: 
Radgilps = Lig  + Aag + Ddg  + Ppg + SAsag  + Sadgups 
	 [10] 
L is the fixed line effect (1: F-line or F 15D-line); A and D as above are random array and dye effects 
respectively; here also a spot by array (SA) interaction is introduced to account for the double spotting of 
each EST on each array; eagilp, is the stochastic error for each EST. 
As the goal is to assess the EST-specific Line effect, the estimates of primary interest are 
those of the Lig  effects. Differences between these effects are tested by using mixed-
model-based t-tests of all possible pair-wise comparisons within an EST. 
2.2.4.5 	Significance threshold and data transformation 
Correcting for multiple tests (Bonferroni adjustment) 
Given that for each array, 7680 independent tests are being carried out, if the a 
significance threshold was set to 0.05, then 384 false positive results would be obtained. 
An adjustment to the a level must hence be made such as a Bonferroni (Bonferroni, 
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1935). This is calculated as the desired a level for one test, divided by the total number 
of independent tests to give the experiment-wide threshold, hence 0.05/7680 - which 
reduces the alpha for each test to 0.0000065 1 (6.5 lx 10). 
• Data transformation (Significance of fold change (Sf) adjustment) 
With the GeneSpring analysis discussed above, an arbitrary two-fold threshold is 
applied. However with the higher-level significance analysis, a novel transformation of 
the data is introduced here 1101, termed the significance of fold change transformation. 
Sf= P-value 	 [10] 
Table 2.2.2: Significance of fold change (Sf) adjustment table. 
FC Log2FC 0.0000001 0.000001 0.00001 
P-value 
0.0001 0.001 0.01 0.1 
1 0 1 1 1 1 1 1 1 
1.1 0.138 1.09E-01 1.50E-01 2.05E-01 2.82E-01 3.87E-01 5.31E-01 7.29E-01 
1.2 0.263 1.44E-02 2.64E-02 4.84E-02 8.87E-02 1.63E-01 2.98E-01 5.46E-01 
1.3 0.379 2.24E-03 5.36E-03 1.28E-02 3.06E-02 7.32E-02 1.75E-01 4.18E-01 
1.4 0.485 4.00E-04 1.22E-03 3.74E-03 1.14E-02 3.50E-02 1.07E-01 3.27E-01 
1.5 0.585 8.04E-05 3.09E-04 1.19E-03 4.57E-03 1.76E-02 6.76E-02 2.60E-01 
1.6 0.678 1.79E-05 8.54E-05 4.07E-04 1.94E-03 9.24E-03 4.40E-02 2.10E-01 
1.7 0.766 4.38E-06 2.55E-05 1.49E-04 8.67E-04 5.05E-03 2.94E-02 1.72E-01 
1.8 0.848 1.16E-06 8.17E-06 5.75E-05 4.06E-04 2.86E-03 2.01 E-02 1.42E-01 
1.9 0.926 3.30E-07 2.78E-06 2.34E-05 1.98E-04 1.67E-03 1.41E-02 1.19E-01 
2 1.000 1.00E-07 1.00E-06 1.00E-05 1.00E-04 1.00E-03 1.00E-02 1.00E-01 
2.1 1.070 3.22E-08 3.78E-07 4.45E-06 5.23E-05 6.15E-04 7.23E-03 8.50E-02 
2.2 1.138 1.09E-08 1.50E-07 2.05E-06 2.82E-05 3.87E-04 5.31E-03 7.29E-02 
2.3 1.202 3.88E-09 6.17E-08 9.81E-07 1.56E-05 2.48E-04 3.95E-03 6.29E-02 
2.4 1.263 1.44E-09 2.64E-08 4.84E-07 8.87E-06 1.63E-04 2.98E-03 5.46E-02 
2.5 1.322 5.58E-10 1.17E-08 2.46E-07 5.16E-06 1.08E-04 2.27E-03 4.77E-02 
2.6 1.379 2.24E-10 5.36E-09 1.28E-07 3.06E-06 7.32E-05 1.75E-03 4.18E-02 
2.7 1.433 9.32E-11 2.52E-09 6.84E-08 1.85E-06 5.02E-05 1.36E-03 3.69E-02 
2.8 1.485 4.00E-11 1.22E-09 3.74E-08 1.14E-06 3.50E-05 1.07E-03 3.27E-02 
2.9 1.536 1.77E-11 6.08E-10 2.09E-08 7.17E-07 2.47E-05 8.47E-04 2.91E-02 
3 1.585 8.04E-12 3.09E-10 1.19E-08 4.57E-07 1.76E-05 6.76E-04 2.60E-02 
The table demonstrates a simulated data set of features with ranging P-values and fold changes (FC). A F-
value (i.e. greater statistical significance) and the large FC, results in a smaller Sf value and hence greater 
relevance for the experiment. Using the Bonferroni adjusted significance threshold of 6.5x10 6, all the 
features in the highlighted yellow range would be included for further consideration - noting that some 
have fold change of less than 2fold, and some have a P-value greater than 6.5x10 6 . 
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Effectively the significance of difference (P-value) of each EST is scaled by powering to 
the modulus of the Lo92 fold change of that EST. The aim of the transformation is to 
allow the fold change differences to be accounted for in a more inclusive manner than 
simply disregarding features that fall out with a certain threshold. It also ensures that 
features with very small P-values, i.e. are highly significant, but have small fold changes 
are emphasised more appropriately. This transformation therefore addresses the general 
issue that at low intensity, replicate variability is much higher than commonly used 
thresholds (two to three-fold). And at high intensity, replicate variability is lower than 
commonly used thresholds (Mariani et al. 2003). Table [2.2.2] below, demonstrates the 
effect of the transformation for selecting features for further analysis. 
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2.3 	GENERAL MOLECULAR TECHNIQUES 
This section provides protocols for the general molecular techniques used throughout 
this study. 
2.3.1 	DNA EXTRACTION 
DNA extraction was carried out using the GENTRA systems (MN, USA) PUREGENE ® 
isolation kit, according to the manufacturer's instructions, which is summarised here: 
Cell Lysis - 5-10mg of ground tissue is combined with 300jzL Cell Lysis Solution in a 
1.5mL centrifuge tube. This is homogenised with a microfuge tube pestle. 1.5L 
Proteinase K Solution (20 mg/ml) is added to the lysate and incubated at 55 °C for Mrs. 
A cell mixer (ThermoQuest, Basingstoke, UK) is used to constantly rotate the tubes. 
RNase Treatment - 1 .5L RNase A Solution (4 mg/ml) is added to the cell lysate. 
Sample is then inverted 25 times and incubated at 37 °C for 1 5-6Omins. 
Protein Precipitation - Sample is cooled to room temperature (RT), and 100/LL Protein 
Precipitation Solution is added to the RNase A-treated cell lysate. The mixture is 
vortexed at high speed for 20secs, followed by centrifugation at 13,000g for 3mins, 
forming a pellet of precipitated proteins. 
DNA Precipitation - The supernatant containing the DNA is transferred into a clean 
1.5mL centrifuge tube containing 300L 100% Isopropanol, and mixed by inverting 
slowly for lOmins on a cell mixer. The solution was centrifuged at 13,000g for 5mins, 
which yields a white DNA pellet. The supernatant was removed and the tube drained on 
clean absorbent paper. 300tL of 70% ethanol was added to the dried tube, and the DNA 
pellet was washed by inverting several times. The DNA sample was centrifuged again at 
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13,000g for 1mm, at the end of which the ethanol is carefully poured off. The tube is 
again inverted and drained on clean absorbent paper and allowed to air dry 10-15mins. 
DNA Hydration - 50L DNA Hydration Solution was added to each isolate and the 
DNA was re-hydrated by incubating for lhr at 65 °C, with periodic flicking of the tube to 
disperse the DNA. DNA was stored at —20 °C until required. 
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2.3.2 	NORTHERN ANALYSIS 
Northern analysis was carried out to confirm differential expression and to further 
characterise ESTs identified from the microarray experiments. Clones representing the 
differentially expressed ESTs [Table 2.3.2] were ordered from the HGMP 
(http://www.hgmp.mrc.ac.uklgeneservice/index.shtml) . Clones were grown, and probes 
prepared as described in section [2.3.3]. RNA samples were prepared as described in 
section [2.2.2] from tissues collected as described in section [2.2.1], and used to generate 
the northern blots. 
2.3.2.1 	Northern blot transfer 
RNA ethanol precipitates were vortexed for l5secs, and a volume containing lO.ig of 
total RNA aliquoted into fresh double autoclaved 2.OmL Eppendorfs. Where necessary, 
equal amount of RNA was pooled for a single sample. RNA samples (single or pools) 
were prepared as described below and loaded on 1% denaturing formamide agarose gels. 
All surfaces and instruments used here were treated for RNAses using RNAzap reagent 
(Ambion) and rinsed in ddH20. 
Preparation of RNA samples - RNA ethanol precipitates containing 1 Otg of RNA 
were centrifuged at 4 °C for 30mins. The supernatant was drawn off, and RNA pellets 
were washed by adding 85% ethanol, vortexing briefly followed by re-pelleting by 
spinning down again for 30mins. Supernatants were drawn off again and the pellets were 
air dried for 5-10mins. Pellets were re-suspended in 1 5j.tL of RNA sample buffer. 
Samples were then heated to 65°C for lOmins then cooled on ice. Samples were spun 
briefly and 4tL of Type III (6X) loading dye, and lj.tL of (Smg/ml) ethidium bromide 
added to each sample. Samples were mixed by gentle pipetting and loaded onto the 
agarose gel. 
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Running samples on a 1% Agarose-formaldehyde (lOOml) gel - ig of agarose 
(RNase free) was dissolved in 73mL of ddH20 in a conical flask. 1 OmL of i OX MOPS 
was added, and the agarose dissolved by boiling. The agarose-MOPS solution was 
allowed to cool in a fumehood to -65°C, whereupon 17mL of formaldehyde (38% w/w) 
was added. The solution was mixed thoroughly by swirling, then poured and set in a gel 
tank with a comb that have been cleaned with RNAzap and rinsed in ddH20 to remove 
any RNases that might degrade the RNA samples. 1X MOPS stock solution was used as 
running buffer. Gels were run in a fumehood at 4v/cm for 2hrs. 
Gel processing after electrophoresis - All surfaces and instruments were treated with 
RNAzap and rinsed in ddH20. Gels were photographed under UV then rinsed twice in 
ddH20 for 15mins, followed by two 30min rinses in lox SSC, to remove the majority of 
formaldehyde. 
Wet transfer - Six pieces of filter paper and 1 piece of nylon membrane were cut to the 
dimensions of the gel. For all Northern gels used in this study, the dimensions are 
200mm x 100mm. A glass plate was laid across a tank containing lOX SSC. A filter 
paper-wick (230mm by 500mm) was cut and laid over the glass plate so that the two 
narrow ends of the wick were in contact with the lOX SSC solution. The gel was placed 
upside-down onto the wick, and air-bubbles removed. Saran wrap was placed over the 
assembly and the area covering the gel excised. The nylon membrane was pre-wetted in 
ddH20, then in lOX SSC, placed over the gel, and air-bubbles removed. In turn, each of 
the 6 filter papers was wetted in i OX ssc, placed onto the membrane and smoothed out 
to remove air-bubbles. A towel-stack was placed on top, followed by a second glass 
plate and suitable weight. See Fig [2.3.1] for a diagram of the rig. 
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Figure 2.3.1 	Schematic of apparatus for wet transfer of Northern gel 
The transfer is allowed to occur overnight. Following transfer, the apparatus is 
dismantled, and the nylon membrane is marked for orientation, rinsed briefly in 2X SSC, 
and blotted dry on clean filter paper. The membrane is examined under UV to ensure 
that successful transfer has occurred. The nylon membrane is then baked for 2hrs at 
80°C to fix the RNA to the membrane. 
2.3.2.2 	Northern hybridisation 
Probe labelling 
Probe labelling was carried out using the Rediprime II DNA Labelling System 
(Amersham Biosciences, Buckinghamshire, UK), according to the manufacturer's 
guidelines, replicated here. For each labelling reaction, 5ng-25ng of insert DNA was 
added to a 0.5mL PCR tube. The volume was adjusted to 251iL with TE buffer, and the 
DNA was denatured for 5mins at 99 °C, and then placed on ice for 5mins. 
20jiL of TE buffer and 51iL  of 32P-dCTP were combined in a Rediprime reaction vial to 
dissolve the freeze-dried pellet. To this, the 25jiL of insert DNA was added and mixed 
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by pipetting. The contents were brought to the bottom of the tube by a brief spin, and 
then incubated at 37 °C for 20mins. The reaction was stopped by adding 5pL of 0.2M 
EDTA. Each labelled probe was then purified as described below. 
Labelled probe purification 
Probes were purified using Sephadex G50 NickTM  columns (Amersham Biosciences), to 
remove unincorporated nucleotides. To purify a sample, the storage buffer on the top of 
the column was poured off, and 3mls of TE buffer was added and allowed to run through 
the column. The labelled probe was pipetted onto the column and allowed to soak into 
the column. 40O.tL of TE buffer was added, and the flow-through collected. A further 
4001iL of TE buffer was added, and again collected. 
The second fraction contained the labelled probe. To measure the efficiency of the 
labelling reaction and purification, 4p.L of the second fraction was added to 3mls of 
scintillation fluid. Imin counts were taken using a Wallac 1410 scintillation counter 
(Amersham Pharmacia, Uppsala, Sweden). The labelled probe should have a specific 
activity between 1-3 x 1 O 9cpmlj.tg. If the count was outwith this range, probe preparation 
was repeated. 
Hybridisation 
This section describes the hybridisation protocol of the Northern blots prepared in 
section [2.3.2.1] with the probes prepared as described above. Each Northern blot 
membrane was pre-wetted in 50mM sodium phosphate (pH 7.2), and pre-hybridised for 
lhr at 65 °C in 20mL of 0.5M sodium phosphate (pH 7.2) containing 7% sodium 
dodecylsulphate (SDS), lOOmgImL of denatured salmon sperm DNA, and 25j.tg/mL of 
denatured tRNA. Hybridisation was carried out in glass bottles, rotating in a Biometra 
0V5 (Goettingen, Germany) hybridisation oven. 
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1.5 x 106cpmImL of denatured radiolabelled probe was added to the hybridisation 
solution and incubated overnight at 65°C. Following incubation, the hybridisation 
solution was discarded appropriately, and the membrane was rinsed in the in the 
hybridisation bottle with 50mM sodium phosphate with 0.1% SDS. This was followed 
by two 15min washes in 50mM sodium phosphate (pH 7.2) with 0.1% SDS at 65°C, and 
two 15min washes in 25mM sodium phosphate (pH 7.2) with 0.1% SDS at 65°C. 
Finally, membranes were exposed overnight at —80 0C to KodaklM BIOMAXTMMS film 
(Amersham Biosciences). Where signals were weak, exposure time was extended 
accordingly. 
Stripping of membrane for re-probing 
After hybridisation and analysis of each Northern blot, the blots were stripped by 
soaking in 500mL of boiling 0.1% SDS in ddH20, which was allowed to cool to RT. 
Blots were checked by exposure to KodakTM  BIOMAXTM-MS film overnight to ensure 
all the radiolabelled signal had been removed from the blot. Blots were wrapped in 
Saran wrap and stored at -20 °C until required for re-probing. 
2.3.2.3 	Phosphorimager analysis 
Phosphorimager analysis was used to quantify the radioactive signals hybridised to the 
Northern blots. Phosphonmager screens - Imaging Screen-K (Bio-Rad, Hertfordshire, 
UK) were cleared by exposing them to 15min of bright light using a Screen eraser-K 
(Bio-Rad). Membranes were wrapped in Saran-wrap (to protect the screens) and 
exposed to the screens inside Storage phosphor screens (Amersham Biosciences) 
overnight. If signals were weak, membranes were exposed for longer periods. Screens 
were then scanned using a phosphorimager scanner - Molecular Imager FX (Bio-Rad), 
and the images were quantitatively analysed using the specialised imaging software - 
PDQuest v6.2.0 (Bio-Rad). 
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2.3.2.4 	Solutions & buffers 
RNA sample buffer - made up to 100% with ddH20 and stored at —20 °C. 
50% deionised fonnamide 
18% formaldehyde 
10% lox MOPS 
10 x MOPS Electrophoresis Buffer 
Acetic acid/NaOH used to set pH at 7.0. Solution bottle is wrapped in foil and 
autoclaved. 
0.2M 3 [o-Morpholino]propane sulphonic acid 
0.05M NaAc 
0.O1M EDTA 
Type III (6X) loading dye 
0.25% Bromophenol Blue 
0.25% Xylene cyanol FF 
30% glycerol in ddH20. 
lOX SSC (sodium citrate buffer) 
Dissolve 87.65g of NaCl and 44.1g of sodium citrate in 800mL of distilled H20. 
Adjust the pH to 7.0 with a few drops of 1M HCI. 
Adjust the volume to 1 litre with additional distilled H2O. 
Sterilize by autoclaving. 
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2.3.3 	cDNA PROBE PREPARATION 
The preparation of cDNA probes for use in Northern analysis is described here. All 
clones were ordered from HGMP. 
2.3.3.1 	Protocol - Midi/mini prep 
When clones were received, they were streaked onto Luria Broth (LB) agar plates 
containing Ampicillin (100pg/ml) and allowed to grow overnight at 37 °C. Single 
colonies were then picked and inoculated into 5mL of LB-Amp (start culture). Start 
cultures were grown at 37 °C for 8hrs shaking vigorously at 300rpm. 
200tL of the start cultures were then added to 1 OOmL of LB-Amp, which were then 
grown at 37 °C overnight shaking at 300rpm. Once the cultures had been grown 
overnight, the QIAGEN plasmid midi kit and protocol (QIAGEN Plasmid Purification 
Handbook 12/02) were used to isolate the bacterial plasmids. This procedure is briefly 
described here. All centrifugation steps were carried out using a Beckman J2-21M/E 
(Beckman Coulter, Buckinghamshire, UK), unless otherwise stated. 
Cultures were transferred to 50mL coming centrifuge tubes and centrifuged at 6000g for 
15min at 4°C. All of the supernatant was poured off and the pellet was re-suspended in 
lOmL of Buffer P1 (P1), with RNase A added to a concentration of 100.tgIml. P1 
contains 50mM Tris-Cl, (pH 8.0), 10mM EDTA and serves for re-suspension of the 
bacteria. The process is aided by vortexing until no cell clumps remained. 
lOmL of Buffer P2 (P2) was then added and mixed gently but thoroughly by inverting 5-
6 times. P2 contains 200mM NaOH, 1% SDS (w/v) and serves to lyse the bacterial cells. 
Samples were then incubated at RT for 5mm. 
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lOmL of chilled Buffer P3 (P3) was then added and mixed immediately but gently by 
inverting 6 times, and incubated on ice for 30mm. P3 contains 3.OM potassium acetate 
(pH 5.5) and serves to precipitate the genomic DNA, proteins and cell debris. 
Samples were then centrifuged at 20,000g for 30min at 4 °C. The supernatant containing 
plasmid-DNA was poured into clean centrifuge tubes. The supernatant samples were 
then centrifuged again at 20,000g for 15min at 4 °C. This was done to reduce the amount 
of suspended or particulate material in the solution, which could clog the QIAGEN-tip 
filter in the next step. lOrnL of Buffer QBT (QBT) was loaded onto QIAGEN-tip 
columns to equilibrate the resin. QBT contains 750 mM NaCI, 50mM MOPS (pH 7.0), 
15% isopropanol (v/v), and 0.15% Triton  X-100 (v/v). 
Supernatants containing plasmid DNA were then promptly removed and applied to the 
equilibrated QIAGEN-tip 100 columns, and allowed to soak into the resin by gravity 
flow. 30mL of Buffer QC (QC) was added twice to wash each column. QC contains 
1.OM NaCl, 50mM MOPS (pH 7.0), 15% isopropanol (v/v), and serves to the wash the 
DNA by removing contaminants from the column. 
Finally the DNA was eluted with 1 5mL Buffer QF (1.25M NaCl, 50mM Tris-Ci (pH 
8.5), 15% isopropanol (v/v)), which was collected in clean 30mL tubes. Adding 10.5mL 
isopropanol to the eluate at RT precipitated the DNA. This was mixed and centrifuged 
immediately at 15,000g for 30mins at 4 °C. The supernatant was carefully decanted and 
the DNA pellet was washed with 5mL of 70% ethanol at RT. This in turn was 
centrifuged at 15,000g for lOmins and again the supernatant carefully removed and 
discarded. 
The resulting DNA pellets were air-dried for I Omins, and re-dissolved in 200pL ddH20. 
Yield was determined by adding 90p.L of ddH20 to I OIIL  of the elute and measuring 
absorbance at 260nm. 
MATERIALS & METHODS - GENERAL MOLECULAR TECHNIQUES: 2.3 128 
2.3.3.2 	Restriction digest 
Restriction digestion was used to isolate the DNA insert (probe) from the purified 
bacterial plasmids isolated in [2.3.3.1]. Appropriate restriction enzymes were chosen 
according to restriction enzyme cut sites available for each clone. Table [2.3.1] lists the 
restriction enzymes used in this study, and table [2.3.2] lists the enzymes used for each 
plasmid-clone. 20tg of purified plasmid DNA was added to a reaction mixture of 
lOOjtL, containing 10tL lox buffer (appropriate for each restriction enzyme), 2.5tL of 
each of the two restriction enzymes required at a concentration of 20pmoles. Reaction 
mixtures were left for either 2hrs or overnight at 37'C. 
Table 2.3.1: Restriction enzymes used in this study 
Restriction Enzyme 	Recognition and Cut site 
Notl 	 GC'GGCC_GC 
Sail 	 GTCGA_C 
EcoRl 	 GAATT_C 
Buffer H was used for all three enzymes listed above. Enzymes and buffers were from Roche Diagnostics 
(Basel, Switzerland). 
Table 2.3.2: Restriction enzymes used for each plasmid-clone. 
GenBank ID IMAGE ID Clone name Vector R Enzl R Enz2 
BG077950 	H3020H04 SQLE pSportl Not 1 Sail 
BG066896 	H3048C08 D15Ertd336 pSportl Not 1 Sail 
BG081526 	1-130661312 Dl5Ertd597 pSportl Not  Sail 
All clones were received in the host E.coli DH1OB. 
2.3.3.3 	Gel purification of probes 
Throughout the course of the project, two kits were used, both of which are based on the 
same chemistry and protocol described here (Sigma GenElute DNA cleanup kit; 
QiAquick Gel Extraction Kit Protocol). 
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The DNA fragment was cut with a clean, sharp scalpel from the 1% agarose gel, on 
which the digested sample was run on. The gel slice was then trimmed to minimize the 
agarose volume, and improve extraction efficiency. The gel slice was deposited into a 
sterile 2.OmL Eppendorf. Three volumes of Buffer QG/Gel solubilisation solution (GSS) 
to 1 volume of gel (100mg 1 00i.tL) were added. GSS contains guanidine thiocyanate, 
which breaks down the agarose gel. 
Where the volume of Buffer QG/GSS exceeded 2.OmL, the gel slice was divided into 
two 2.OmL Eppendorf tubes and processed separately until the final elution step. The 
samples were incubated at 55 °C for 10mm (or until the gel slice was completely 
dissolved). Vortexing the tubes every 2-3minutes during incubation aided dissolution of 
the samples. One gel volume of isopropanol was added to each sample and mixed. 
The samples were loaded onto the spin columns, in 2.OmL collection tubes, and spun at 
13,000rpm for 1mm. Where the volumes of the samples exceeded 700jtL, then the first 
700p.L were centrifuged, the flow through discarded, and the next 700.tL loaded - this 
was repeated until the entire sample had been loaded and eluted. 
The samples were then washed by adding 750j.tL of Buffer PE/Wash Solution (which 
contains ethanol) to the columns and centrifuged for 1mm. Again the flow through was 
discarded and an additional Imin spin at 13,000 rpm was carried out to remove further 
traces of ethanol. To elute the samples, the columns were placed into clean 2.OmL 
Eppendorfs, and 50L of ddH20 was pipetted to the center of the column's membrane 
and centrifuged for 1mm. Samples were quantified as described by spectophotometry, 
aliquoted as 5iL stocks in 0.5iL Eppendorfs and stored at —20 °C until required. 
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2.3.4 	SEQUENCING 
Sequencing of the purified clones was carried out either manually as described here, or 
commercially by outsourcing to DNAShef (Edinburgh, UK). Manual sequencing was 
carried out using the fmol® DNA Cycle Sequencing System from Promega Corporation 
(Wisconsin, USA), following the manufacturer's instructions. 
2.3.4.1 	Preparing sequencing gel 
Plate cleaning - Bottom glass plates were cleaned with 5M sodium hydroxide and 
rinsed thoroughly with dH20 until all traces of the sodium hydroxide was removed. The 
plate was then cleaned with 70% ethanol and dried. The top plate (notched) was cleaned 
with dH20, dried, then a small amount of glass-shield was applied to the inside facing 
surface and spread evenly. This was allowed to dry and cleaned with 70% ethanol. 
Rig assembly - A plastic spacer was placed down either side of the bottom plate. The 
top plate with the glass-shield coated side down was placed on top of the spacers and the 
plates were clamped together with two bulldog clips on either side. 
Pouring Gel - lOOmls HR1000 denaturing gel solution (Amersham Pharmacia) was 
added to a 250mL Buchner flask with a rubber bung in the top. A water pump was used 
to de-gas for 2-3mins, and the de-gassed solution was carefully poured into a beaker. To 
this, 500pL of 10% ammonium persulphate and 50pL of Temed were added 
simultaneously and mixed with a pipette tip. 
The gel solution was taken up in a 50mL syringe and applied between the top of the 
glass plates ensuring a constant flow of gel solution. When the gel solution reached the 
end of the plates, the comb was inserted. The comb was clamped between the top of the 
plates using three bulldog clips. Gels were left to set for a minimum of 45mins. 
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2.3.4.2 	Cycle sequencing using direct incorporation of 35S 
For each DNA template, four 0.5mL microfuge tubes (A G C T) were labelled, and to 
each 2jtL of the appropriate dideoxynucleotides (dJddNTP) mix was added. These were 
stored on ice [A]. 
FBI For each set of four sequencing reactions, the following reagents were mixed in a 
microfuge tube: 
Template DNA - approx 1 Vtg of purified plasmid DNA 
Primer - 25ng of a 24mer (3pmol) 
dH20 - made up to lOp.L 
ICI A mix was prepared for n sequencing reactions: 
DNA sequencing buffer 	 n x 5tL 
35s dATP 	 n x 1tL, (lOmci) 
OmnibaseTM Sequencing enzyme mixture n x lp.L 
7 pL of the mix from [C] was added to each mix in [B], and mixed by pipeting [D]. 4p.L 
of the enzyme/primer/template mixes from [D] were placed on the inside wall of each 
tube containing d/ddNTP made in [A]. 20p.L of mineral oil was added to all tubes, which 
were then briefly centrifuged. The reactions were placed in a preheated thermal cycler 
(95 0C), and subjected to the following cycle program. 
95°C x 2mins 
95°C x 30secs - 
42°C x 30secs 1 45 cycles 
70°Cxlmin - 
4°C Hold. 
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2.3.5 	Q-PCR - BY SYBR® Green 
2.3.5.1 	Primer design 
Design of primers was carried out using the Primer3 (Rozen & Skaletsky 2000) 
software, available online at http://www-genome.wi.mit.edu/cgi-bin/primer/pfimer3.cgi,  
using sequences that were selected from the MGSC Mouse Assembly 3. Primers were 
designed to amplify across exons as illustrated in Fig [2.3.2]. 
Forward 
5'-CGTACGTACGTACGTACGTA-3' primer 
CGTACGTACG 	 TACGTACGTA 
111111 III I 1111111111 
5'--ATGCATGCATGCnnnnn ---- nnnnnAT GCATflC ATGC---3' 




Figure 2.3.2 Schematic of primer design across exons for PCR of cDNA. Sequence of forward 
primer is shown to span adjoining sequence, hence avoiding the possibility of genomic DNA 
amplification. 
The rodent mispnming library was chosen as a constraint for improved primer design. 
Additionally, to reduce the likelihood of primer-dimer formation, the maximum 
complementarity option between primer pairs, were reduced to 5 (from default 8), and 
the maximum 3' complementarity reduced to 2 (from 3). 
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23.5.2 	DNase treatment of RNA 
In addition to designing primers across exons, RNA samples were DNase treated to 
avoid the possibility of genomic sequence being amplified and reducing the efficiency 
and accuracy of the Q-PCR. This was carried out using DNA-freeTM (Ambion, TX, 
USA) according to the method described here. 
RNA ethanol precipitates were spun at 13,000g for 20mm, then washed with 85% 
ethanol and re-spun at 13,000g for 5mm. The pellets were air-dried for 5min and 
reconstituted in 50jiL ddH20. 0.1 volume (5il) of lox DNase I Buffer was added with 
ljtL rDNase I (2U4iL). The mixture was mixed gently and incubated at 37 °C for 
20mins. 0.1 volume (5j.il) of DNase Inactivation Reagent was then added and incubated 
for 2min at room temp with occasional mixing. The samples were then spun at 10,000g 
for 2min at 4 °C and 55tL of the supernatant containing the clean RNA was transferred 
to sterile Eppendorfs. 
2.3.5.3 	First-strand cDNA synthesis 
The First-strand cDNA synthesis Kit (Amersham Biosciences) was used for first-strand 
cDNA synthesis. This is a Moloney Murine Leukaemia Virus (MMLV) reverse 
transcriptase based kit, and the protocol is described here. 
DNase treated RNA samples were ethanol precipitated, washed in 85% ethanol as 
described previously, and reconstituted in 1 Opt of ddH20. 1 tL was used to quantitate 
the RNA and 5 jig of RNA was removed to a final volume of 8pL made up with ddH20. 
The samples were heated at 65°C for 1 Omins then snap quenched on ice. To each 
sample, 5jtL of Bulk first-strand reaction mix (containing the MMLV and dNTPs), 1 jiL 
of DTT (dithiothreitol) solution, and ljtL of Not 1-d(T) 1 8 primer (which primes the 
generation of cDNA from the poly-A tail) was added. 
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The reactions were incubated for lhr at 37 °C then heated at 95°C for lOmins to 
inactivate the MMLV reverse transcriptase. Samples were then aliquoted into 2tL 
stocks and stored at —20 °C until required. 
2.3.54 	SYBR® Green Real-time quantitative-PCR (Q-PCR) 
This technique measures the accumulation of double stranded PCR product through 
continuous monitoring of a fluorescent signal. During PCR amplification, the 
fluorescent dye (in this case SYBR ® Green) intercalates into the double stranded DNA 
product and generates a signal that is proportional to the DNA concentration. 
Q-PCR terminology and concept 
There are three key points to the concept of Q-PCR. Firstly, PCR begins with a 'lag 
phase' where template concentration remains low, this is followed by a 'log phase' 
where the reaction proceeds exponentially, and ends with a 'stationary phase' when 
product accumulation ceases. In Q-PCR, the fluorescence measured during the lag phase 
cycles are used to set a threshold for systematic noise. When the fluorescence of a 
particular reaction enters the log phase, the fluorescence during that cycle of PCR 
crosses the pre-defined threshold generating the cycle threshold (CT) value. Q-PCR 
reactions are carried out in very small volumes (25pL) and so even small pipetting errors 
can affect C1 values. This is overcome by performing a minimum of four replicates for 
each reaction, and by correcting against the CT of a reference gene, which yields the 
change in CT (ACT) between the target and reference gene. 
A comparison between samples (which have each been corrected against their reference) 
is performed by observing the difference of ACT  between the two comparisons (AACT). 
Since the quantity of PCR product doubles with each PCR cycle, a difference of 1 cycle 
in AACT, indicates a 2-fold difference in the initial template quantities of the samples 
under comparison. The fold change is derived be calculating 
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SYBR® Green Q-PCR was performed using a kit (Applied Biosystems, CA, USA) on an 
ABI Prism 7700 Sequence Detector (PerkinElmer) with accompanied software 
(Sequence Detector vi .6.3). Reactions were carried out on 96-well MicroAmp®  optical 
plates and caps (Applied Biosystems). 
For each reaction, cDNA generated in section [2.3.5.3] was diluted 1:50 and lOp.L 
carefully pipetted into each well. Depending on the total number of reactions carried out, 
SYBR® Green reaction mixes were prepared so that each 25.tL reaction contained; 
5.125pL ddH20, 2.5.iL SYBR® Green solution, 3.OpL 25mM MgCl2  buffer, 2.OL 
12.5mM dNTPs, 0.25.iL Amperase CWG, 0.125jiL AmpliTaq Gold ®, 1.0.tL of the 
designed forward primer (10mM) and similarly for the reverse primer. 
For each reaction four identical replicates were carried out. For each gene examined, 
identical reactions were processed on the same 96-well plate with primers for the mouse 
f3-Actin gene, to normalise for variation in loading between samples. 
For each gene, dilution comparisons were performed between the gene under 
investigation and the control (J3-Actin). This was done to establish the working 
concentration (that is, dilution) of cDNA at which the comparison between test and 
controls were reliable. 
PCR reactions was carried out according to the following cycle conditions: 
50°C x 2mins 
95°C x lOmins 
95°C x l5secs  
60°Cxlmin - 40 cycles 
4°C Hold. 
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2.3.6 	Reverse transcription —PCR (RT-PCR) 
The AccuPrimeTM  Taq DNA Polymerase System (Invitrogen, Paisley,UK) was used for 
RT-PCR. RT-PCR was used as a tool to identify more of the sequence associated with 
the approximate 8kb Facl transcript. Primers were designed as described in section 
[2.3.5.1] from exon sequences mapping up- and down-stream of the mapped position of 
the H3066B12 EST clone. cDNA was generated using RNA from a single female (98 
day old) BAT sample, collected and extracted as described in [2.2.1 & 2.2.2]. 
Generation of cDNA - For each reaction the following was prepared: 
7.75tl RNA (5.tg) re-suspended in ddH 20 
4j.iL 25mM MgC12 
4.tL i OX buffer 
2pL dNTP (10mM) 
0.5iL RNAsin 
1 tL Random Hexamers (500p.g/mL) or Oligo dT. 
Samples were heated to 42 °C for 2mins then 0.75tL of reverse transcnptase was added 
to each sample. Reverse transcription proceeded under the following thermal program: 
42°C for 50mins 
70°C for 15mins 
4°C to hold 
After reverse transcription, 80tL of ddH20 was added to each sample and stored at - 
20°C. 
PCR of cDNA - For any particular reaction, the following 20tL reaction mixture was 
prepared and added to 5j.iL of cDNA: 
6.5jtL ddH20 
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0.5jtL Forward primer X (20pmoles) 
0.5pL Reverse primer X (20pmoles) 
12.5p.LTaq (Accuprime II) 
The following thermal program was applied for amplification to proceed. The extension 
step (*) was varied, depending on the size of fragments expected from the amplification 
under the primers used. 
94°C for 2mins 
94°C for 30secs 	1 
60°C for 30secs* 30 cycles 
68°C for 1mm 	- 
4°C to hold 
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CHAPTER THREE 
RESULTS 
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3.1 	QTL ANALYSIS - PILOT STUDY 
3.1.1 	INTRODUCTION 
Marker assisted selection (MAS) was used to introgress L-line alleles at the Fob3 
QTL, identified by Horvat et al. (2000), into the F-line background in order to 
generate an interval specific strain. After six backcrosses, a small-scale pilot QTL-
study was performed. This was done primarily to confirm that the Fob3 QTL had 
been introgressed successfully, since it is known that occasionally when it is 
attempted to transfer QTL into a particular background, the effects may be lost (Shen 
et al. 2001; Han et al. 1997). This is likely to be more common for QTL of small 
effect and can be caused by several factors such as overestimation of the QTL effect 
in the original analysis. It has also been suggested that if the estimate of the position 
of the original QTL was poor, then during MAS, if too few markers are used, the 
target region containing the QTL may not be transferred. Similarly, if too few 
markers are used, then the target region could be lost through undetectable double-
crossovers between markers. 
The methods and techniques used for the pilot study are given in section [2.1.1]. The 
results presented here show that the Fob3 QTL region was successfully introgressed 
and justified the further larger-scale QTL analysis discussed later. Additionally 
through use of composite interval mapping (CIM), Fob3 is shown to map between 
markers Dl5Mit209 and Dl5Mitl07, with evidence for a second QTL between 
markers Dl5Mitl75 and Dl5Mitl38 Table [3.1.1]. 
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3.1.2 	SINGLE MARKER ANALYSIS 
At the time during which this pilot study was performed, progressive screening for 
polymorphic markers had revealed 12 that were informative (Dl5Mitl75, 
D15Mitl38, D15MitOO5, Dl5M0 15, Dl5MitO63, Dl 5Mit209, D15MitO9O, 
Dl 5Mitl 07, Dl 5Mitl 84, Dl 5Mit068, Dl 5Mitl 05, Dl 5Mit039). All genotypes along 
with pedigree and family information spanning generations BC5F I , BC5F2, BC6FI 
and BC6F2 were processed through CriMap [Fig 2.1. 1B]. Recombination events were 
observed sufficiently between 8 of the 12 markers used, resulting in an unambiguous 
map order with cM positions close to those listed at the Mouse Genome Database 
(MGD - July 2001: http://www.informatics-jax.org/) . Informativeness of each of the 
12 markers genotyped is 100%. The final positions derived using CriMap are given 
in Table [3.1. 1],  along with the MGD estimates. 
Table 3. 1.1: Positions in cM of mapped polymorphic markers within the Fob3 QTL 
Marker 	Positions in cM 
CriMaD MCD 
D15mit175 5.5 5.5 
D15mit138 18.1 15.4 
D15mit5 24.3 22.2 
D15mit115 36.5 24 
D15mit184 Underived 25.4 
D15mit63 41.2 29.2 
D15mit209 43.7 32 
D15mit9O 48.9 36 
D15mit68 Underived 44.1 
D15mit105 Underived 47.9 
Dl 5mitl 07 57.6 49 
D15mit39 Underived 56.6 
Positions are given as calculated using CriMap, along with the Mouse Genome Database (MGD) 
positions. 'Underived', indicates that there was insufficient data to position the marker using CriMap. 
The first marker Dl 5Mitl 75 was positioned in CriMap to 5.5cM based on 
information from the MGD database. 
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Fig 3.1.1: Least square means for fat% at Marker D15Mit209. Standard error bars and standard 
error of means are given for each class (N=302, males = 160, females = 142). Difference is significant 
within females (P< 0.001). Genotypes are FF (homozygous F-Line background); FL (heterozygotes); 
LL (homozygous L-Line background). 
Single marker analysis of variance (ANOVA) on records of 302 phenotyped mice for 
fat% and 348 for the highly correlated Bw115 trait, was carried out as described 
[2.1.1.2]. Examination of the least square means (LSM), indicate that the effect may 
be sex specific, having up to a 45% effect in fat% between females possessing a 
homozygote L-line genotype compared to females with a homozygote F-line 
genotype. For fat%, the effect of the different genotypes between females is most 
pronounced at marker D15Mit2O9 (43.7cM), as illustrated in Fig [3.1.1]. For the 
same marker in males however, although the trend is similar, i.e. FF > FL > LL, 
there is considerable overlap of the error bars, and differences are not significant 
(P=0.374). 
ANOVA in males reveals no significant difference in either fat% or Bwl 15, at any of 
the markers used, except at Dl5Mit175, where it is significant for all traits examined 
(P = 0.003, 0.046 and <0.001 for Bwl 15, fat% and rGFPwt, respectively) [Table 
3.1.2]. 
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Fig 3.1.1: Least square means for fat% at Marker D15Mit2O9. Standard error bars and standard 
error of means are given for each class (N=302, males = 160, females = 142). Difference is significant 
within females (P< 0.001). Genotypes are FF (homozygous F-Line background); FL (heterozvgotes); 
LL (homozygous L-Line background). 
Single marker analysis of variance (ANOVA) on records of 302 phenotyped mice for 
fat% and 348 for the highly correlated Bw115 trait, was carried out as described 
[2.1.1.2]. Examination of the least square means (LSM), indicate that the effect may 
be sex specific, having up to a 45% effect in fat% between females possessing a 
homozygote L-line genotype compared to females with a homozygote F-line 
genotype. For fat%, the effect of the different genotypes between females is most 
pronounced at marker D15Mit2O9 (43.7cM), as illustrated in Fig [3.1.1]. For the 
same marker in males however, although the trend is similar, i.e. FF > FL > LL, 
there is considerable overlap of the error bars, and differences are not significant 
(P0.374). 
ANOVA in males reveals no significant difference in either fat% or Bw115, at any of 
the markers used, except at D15Mitl75, where it is significant for all traits examined 
(P = 0.003, 0.046 and <0.001 for Bwl 15, fat% and rGFPwt, respectively) [Table 
3.1.2]. 
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Table 3.1.2: P-Values for Bw115, fat% and rGFPwt - indicating significance between genotypes 
(FF, FL, LL). 
Marker All 
Bwl 15 





D15Mit175 0.380 0.003 0.153 0.246 0.046 0.04  
D15Mit138 0.225 0.541 0.017 0.438 0.759 0.084 0.964 
D15Mit5 0.197 0.058 0.619 0.417 0.900 0.369 0.004 
D15Mit115 0.350 0.950 0.017 0.160 0.870 0.130 0,39E 
D15Mit184 0.540 0.600 0.003 0.450 0.390 0.08€' 0.527 
D15Mit63 0.270 0.330 0.002 0.033 0.947 0.00€' 0.07 
D15Mit2O9 0.639 0.307 0.004 0.026 0.374 0.20 
D15Mit9O 0.274 0.340 0.017 0.013 0.720 0.057 0.17 
D15Mit68 0.210 0.260 0.016 0.288 0.850 0.160 0.121 
D15Mit105 0.550 0.310 0.330 0.100 0.410 0.530 0.677 
D15Mit1O7 0.185 0.255 0.440 0.918 0.860 0.407 0.001 
D15Mit39 0.059 0.185 0.165 0.650 O.00EJ 0.594 
P-values <0.05 are coloured light blue, <0.001 coloured dark blue. Bw115, N-300; fat%, N-275; 
rGFPwt, N-150). P-values are not corrected for multiple testing. 
For Bw115, the most significant marker is Dl5Mit39 for the female population (P < 
0.001), which again is not significant for the male or joint sex data. It appears that 
there are more markers that have significant differences between the genotypes in the 
Bw115 trait (Dl5Mitl75; D15Mitl38; D15MitIl5; Dl5Mitl84; D15Mit63; 
Dl5Mit2O9; D15Mit9O; D15Mit68; and 1315Mit39), compared to the fat% trait 
(D15Mitl75; D15Mit63; D15Mit2O9; and Dl5Mit39). However, the number of mice 
used in this data set are relatively small and hence this may reflect the differences in 
the power of the analysis, given that there are generally 10-20% more observations 
for the Bwl 15 trait than the fat% trait [Table 3.1.2]. 
Coat colour (CC) and rGFPwt were also examined. There was no significant effect 
found for CC, that is, at each marker tested CC did not have a significant effect on 
phenotype, given the genotype. The rGFPwt trait was only examined in males. For 
this trait, a significant difference between the genotypes is observed at markers 
D15Mitl75, D15Mit5, and D15MitlO7 (P=0.001, 0.004, and 0.001 respectively). 
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3.1.3 	INTERVAL MAPPING USING QTL 
CARTOGRAPHER 
Here CIM is applied to locate the position of Fob3, based on the revised 
microsatellite map given in Table [3.1.1]. Combined analysis of males and females 
(with sex fitted as a fixed effect), males alone and females alone, was implemented. 
This was done on the combined phenotyped progeny derived from the combined 
BC5F2 + BC6F2 as well as separately for each population [Fig 2.1.2]. Table [3.1.3] 
shows a summary of the highest LOD scores obtained from each analysis for fat%. A 
QTL is indicated for each score exceeding a conservative 2.0 LOD-threshold (given 
that a LOD score of 2.0 exceeds the maximum threshold under the dense-map 
approximation for a single chromosome model (Lander & Botstein, 1989)). 
Table 3.1.3: Summary of the main CIM analysis on fat%. 
No. Of Highest 
Population Progeny from: QTL LOD score 
ALL BC6F2 1 3.02 
FEMALE BC6F2 2* 4.71 
MALE BC6F2 0 1.03 
ALL BC6F2 + BC5F2 1 2.01 
FEMALE BC6F2 + BC5F2 1 3.98 
MALE BC6F2 + BC5F2 0 1.05 
The two peaks (*) have non-overlapping 95% confidence intervals. 
CIM analysis confirms the LSM single-marker analysis, that is, males are not 
strongly affected by the QTL, reinforced by analysis on the whole population using 
CIM. In the male population, LOD score plots with peaks within the expected 
interval, as indicated by analysis on the female populations, are observed. However, 
the peaks are relatively low (1.03 LOD score, BC6F2-male population) and therefore 
not significant. Analysis within the female populations only, reveal significant QTL, 
with the highest peak occurring in the BC6F2-female population, reaching a peak 
LOD score of 4.7 [peak P Fig 3.1.2A]. In fact, it appears that within this population 
there is a second QTL present (peak a). 
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Fig 3.1.2: CIM LOD score plots for fat%. [A] 89 phenotyped BC6F2 female progeny; [B] 302 
phenotyped BC5F2 and BC6F2 progeny, derived using QTL Cartographer. Significance threshold set at 
2.0 LOD scores (blue lines); a and P. indicate the peaks of the two possible QTL detected. 2-LOD-
support intervals are shown as black bars for each significant QTL. First marker is set to 0.0cM, and 
points ito viii, relate to marker positions of D15Mit175, D15Mit138, D15MitOO5, Dl5Mit1i5, 
D15MitO63, Dl5Mit209, Dl5Mit090, and Dl5Mit107, respectively. 
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In the combined male and female population from BC5F2 and BC6F2, a LOD score of 
4.0 is observed at peak P , and the second peak a crosses the significance threshold 
with a LOD score of 2.0 [Fig 3.1.213]. Bw115, DM and rGFPwt, were also examined. 
The combined population (males and females) LOD score plots for the Bwl 15 and 
DM traits are similar to that for the fat% given in Fig [3.1.213], only with reduced 
peak LOD scores. Similarly, as with the fat% trait, removing the male data, increased 
the LOD score above the significance threshold for the Bw115 and DM traits. CIM 
did not reveal any QTL for the rGFPwt trait. 
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3.1.4 	Discussion 
The aim of this pilot study was to confirm that the effect of the Fob3 QTL had been 
successfully introgressed. The analysis presented here, clearly shows that this has 
been achieved, and hence justifies the progression to a larger study to fine-map the 
location of Fob3. Since the analysis given here is based on a relatively small 
population size, with very few recombinants in the population, the power of the 
analysis is relatively low. This is illustrated by the LOD score of 4.7 in the female 
mice obtained through the CIM analysis, whereas in the original study there was a 
LOD score of 11.3 (Horvat et al. 2000). 
The results presented and discussed here, served therefore, as a rough guide when 
considering the approach for the larger main study [sections 2.1.2 & 3.2], and not as 
a refined analysis on which considerable emphasis was afforded. 
The Fob3 QTL effect was found to be female-specific, that is, no significant effect 
could be detected between the genotypic classes within the male population. This 
was not observed originally for Fob3. However, the QTL effect within the males 
may have been present, but not detectable with such a small population size. It would 
not be unusual if Fob3 was confirmed to be sex-specific - through the larger study - 
since Fob2 (mChrl 2) the second of four fat% QTL originally detected from the F 2 
QTL scan between the F and L-lines (Horvat et al. 2000), was shown to be female-
specific. On the merit of these preliminary results, female mice were chosen as the 
preferred sex for the microarray study [sections 2.2 & 3.3] 
The 12 markers used in the Pilot study indicate that F-line alleles towards the centre 
of the Fob3 QTL give rise to a greater fat%, than do the F-line alleles at the 
peripheries of the QTL. The region around marker Dl5Mit209 is correlated with the 
greatest observed increase in fat% (of the 12 markers available), with F-line alleles 
giving rise to 45% more body fat than the L-line alleles in females. 
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The use of CIM on female mice alone from the progeny of BC6F2 shows that the 
QTL maps to a region between markers Dl5Mit63 and Dl5MitlO7, with a peak near 
Dl5Mit2O9 [Fig 3.1.2A]. This is in keeping with the original localisation of Fob3 
that was found to be distal to maker D15Mit63. However, it also shows that there 
may be a second QTL mapping near marker Dl Wit l75. 
The indication of a second QTL is also revealed by CIM for the combined (both-
sexes) BC5F2+BC6F2 population. Here the a peak (LOD score 2.8) is almost as large 
as the P peak (LOD score 3.0) [Fig 3.1.213]. However, F-line alleles were 
preferentially selected for at marker D15Mitl75 during the recursive backcrossing, 
as the original target region was not thought to extend as far as this marker. 
Consequently, segregation at this marker does not follow the expected F2 
frequencies, with particularly few L-line homozygotes (for fat% - BC5F2+BC6F2, 
N=179 FF; 52 FL; 35 LL), and hence this maybe biasing the results at this marker. 
Furthermore, testing the effect at D15Mitl75 in the larger study would not be 
possible, as further selection for F-line alleles prior to these results, for the generation 
of the congenic lines [3.2.2], effectively fixed F-line alleles at Dl5Mitl75. 
Analysis using C1M on the Bw 115 trait shows an almost identical LOD plot, except 
for a marginally smaller ML estimate (data not shown), which is still significant. It 
should be pointed out here that Fob3 is not strictly a body weight QTL in the sense 
of those found by Cheverud et al. (1996) and Keightley et al. (1996) amongst others, 
since the differences in weight between the F, L and congenic lines, are obviously 
due to the differences in fat weight, not general body weight. Nevertheless, body 
weight is highly correlated with fat% between the F and L-line (Hastings and Hill, 
1989). Between the congenic Fth15t  and F-lines, correlation analysis confirms that 
Bw and fat% are closely correlated. The correlation is significant from Bw21 (r= 
0.32; P<0.001) with an increasing phenotypic correlation over time up to Bw115 
(r=0.78; P<0.001). In the larger 'main study' this basis was used to track the effects 
of the QTL through the development of the mice by taking and analysing Bw traits at 
various time points. 
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3.2 	QTL ANALYSIS - MAIN QTL STUDY 
3.2.1 	INTRODUCTION 
To generate greater power in QTL analysis, many recombinants and a large number 
of densely spaced markers are required, so that the recombinants can be precisely 
located. Having confirmed the successful introgression of the Fob3 QTL effect 
through MAS to the F-line, the aim of this main study was to fine-map the position 
of Fob3. This main study has aimed to increase the power of analysis in comparison 
to the pilot study in three ways. Firstly, the number of mice used is considerably 
larger; secondly this large population is composed of progeny from a diverse set of 
recombinants having varying lengths of L-line alleles in the Fob3 region; and finally 
the number of markers is increased to 16. 
Matings were set up as described in section [2.1.2.1], generating a large population 
of progeny from recombinants for progeny testing. A total of 989 were phenotyped 
and genotyped. The analysis of the data obtained is presented and discussed here. 
Extensive single marker and multiple-QTL analysis shows that the mChr15 obesity 
QTL Fob3, is in fact a composite of at least two smaller effect QTL, acting in the 
same direction. Fob3a is found to be a late-onset obesity QTL, located in a 10cM 
95% confidence interval (CI), flanked by markers D15Mitl50 and Dl5Mitl84. 
Fob3b, is found to be an early-onset obesity QTL - which itself may be composed of 
more than one QTL - with a 95% Cl spanning 26cM, flanked by markers 
D15Mitl 15 and D15Mitl. 
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3.2.2 	MARKER MAP & GENOTYPES 
A linkage map was generated as described previously [2.1.1.2 / 2.1.2.2], with the 
following additional markers added to the map: Dl5Mitl50, D15Mit234, D15Mitl56 
and D15Mitl. The final positions, along with the mapped Mb positions as derived 
from the MGSC map [http://www.ensembl.org/Mus_musculus/]  version 13.30.1, are 
presented in Fig [3.2.1]. The order of the markers positioned using CriMap match 
those derived from the MGSC database. 
During the recursive backcrossing [section 2.1.1.1, Fig 2.1.1], a lack of polymorphic 
markers at the proximal and distal ends of mChrl5 under L-line allele selection 
resulted in a number of slightly different congenic lines being created. These 
alternative lines were bred to homozygosity so that a large stock of congenic 
homozygotes could be available for breeding to generate the progeny of 
recombinants for the main QTL analysis. There were three main sub-lines and these 
were coded as A, B and D chrl FthI5B and chri  Sub-line chri  has L-line 
alleles between markers D15Mitl5O and Dl5Mitl07; F 5B has L-line alleles 
between D15Mitl84 and Dl5Mit39 and FCIrI5D  has L-line alleles between 
D15Mitl84 and D15Mitl07. F' 5D-line mice were used as the preferred congenic 
line for all further crosses, while F"5A & B-line mice were used where F' 5D-line 
mice were in short supply. A schematic of the three main sub-lines and differences 
between these lines is shown in Fig [3.2.1]. Detailed genotypes of the congenic lines 
and of the 41 recombinants are given in Fig [3.2.2]. 
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Fig 3.2.1: Chr15 map. Microsatellite marker positions are given in Mb and centimorgans (cM) as 
calculated using CriMap from the entire data set, Marker Mb positions are taken from the Mouse 
Genome Sequencing Consortium version 13.30.1. Dl5Mitl84 and Dl5Mitl remain unmapped by the 
MGSC and hence no Mb positions are given. Genotypes of the homozygous sub-lines and that of the 
common male ancestor for all recombinants are shown, (thick black line indicates regions 
homozygous for F-line alleles, thin lines are regions homozygous for the L-line alleles, and chequered 
lines are intervals of unknown genotype. 
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In Figure [3.2.2] sub-line D is highlighted as the main sub-line used, whilst sub-lines 
A and B were secondary sub-lines. 
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Fig 3.2.2: Genotypes of lines and recombinants. Microsatellite markers are given as Ml to M16 
from most proximal Dl5Mitl75 to most distal Dl5Mit39, as ordered in Fig [3.2.1]. Panel a lists the 
sub-lines used and schematises the genotypes where, yellow = FF; green=FL and blue =LL alleles. 
Panel b lists the 18 female (F) and 23 male (M) recombinants, with only the genotype of the 
recombinant chromatid schematised, where blue=L and yellow=F-line alleles. 
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3.2.3 	SINGLE MARKER ANALYSIS 
Single marker analysis was carried out as a first step to check the preliminary results 
obtained from the pilot study, and examine the effects of the new markers added with 
the much larger and powerful data set. This analysis was carried out on traits as 
described in section [2.1.2.3]. The data analysis is described here for each trait, 
however the analysis is not presented for the sexes separately (although sex effects 
are considered in the model, (equation [2]). More detailed sex-specific analysis was 
carried out for the IM analysis [3.2.4]. 
Although the total number of mice involved in this analysis is 989, the number (N) 
for any particular marker-by-trait analysis is lower than this due to occasional 
ambiguous genotypes (even after repeats) especially for markers Dl5Mit9O and 
D15Mit105. Also because several mice were used for line propagation and 
generation of new sub-lines, the number of phenotyped mice (fat%, rGFPwt & DM) 
was lower than the number of genotyped mice. In addition some phenotypic data 
were lost in a few batches during the freeze-drying process [2.1.3.3], which was 
occasionally compromised. 
3.2.3.1 	Analysis of fat% 
The single marker analysis for fat% for both sexes combined shows that there is a 
significant difference between the genotypes (P<0.05) at all the markers where all 
three genotypes are available. Applying a Bonferroni correction to account for 
multiple testing (Bonferroni, 1935; Lynch & Walsh, Chapter 15), a P-value of 0.0031 
is required for the 5% experiment wide significance threshold (given that there are 16 
markers 0.05/16). This correction is conservative, as the tests are not independent. 
Ten of the markers are shown to be significant at this threshold, as shown in Table 
[3.2.2]. 
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Table 3.2.2: Single marker (ANOVA) analysis within the Fob3 region - fat% trait. 
Marker Position CM N FF 
fat% 
FL LL P value 
D15Mit175 7 921 22.20±0.17 21.69±0.81 . 0.5458 
D15M1t15O 12.4 888 22.24±0.19 21.32±0.67 . 	. 0.2761 
D15Mit138 24.5 928 23.57±0.36 21.95±0.31 20.28±0.81 *0 . 0004 
D15Mit5 26.7 968 23.65±0.35 22.05±0.31 20.02±0.82 *0.0001 
D15Mit184 41.6 840 24.14± 0.94 22.49± 0.25 21.11 ± 0.41 0.0038 
D15Mitl15 42.5 967 23.97± 0.82 22.61 ± 0.24 20.99± 0.38 *0.0004 
D15Mit209 47.2 941 23.73±0.83 22.58±0.24 20.65±0.41 *0.0002 
D15Mit234 49.3 914 23.63±0.88 22.59±0.25 20.63±0.42 *0 . 0003 
D15Mit63 51.4 970 23.53±0.84 22.74±0.25 20.83±0.41 *0 . 0003 
D15Mit9O 55.2 620 22.68±0.93 22.35±0.26 20.78±0.37 *0.0031 
D15Mit156 61.4 937 23.22±0.77 22.59±0.21 21.14±0.32 *0.0005 
D15Mitl05 65.3 787 22.67±0.79 22.74±0.24 21.06±0.35 *0 . 0004 
D15Mit68 69.3 950 23.20±0.61 22.71±0.21 21.18±0.31 *0 . 0001 
D15Mitl 71.4 891 22.97±0.64 22.75±0.27 21.49±0.35 0.0071 
D15Mit107 76.7 904 22.65±0.55 22.58±0.24 21.35±0.35 0.0102 
D15Mit39 96.3 948 22.15±0.26 22.59±0.36 . 	. 0.3926 
Phenotypic least square means ± SE, for each genotype (FF = homozygote for F-line alleles; FL = 
heterozygote; LL = homozygote for L-line alleles) for percentage body fat (fat%) at each mapped 
rnicrosateflite marker on mChrl5. Sex, litter and parity effects are fitted. N indicates total number of 
mice phenotyped and genotyped at each marker. P-values were calculated by ANOVA testing the 
significance of the factor 'genotype'. Markers significant at the Bonferroni corrected experiment-wide 
a005 level are indicated by *• 
3.2.3.2 	Analysis of rGFPwt 
Table [3.2.3] shows the single marker analysis for rGFPwt in males. A significant 
difference between the genotypes (P<0.05) is seen from marker D15Mitl38 
(24.5cM) to marker D15Mit63 (51.4cM). However, significance at the Bonferroni 
corrected experiment-wide significance threshold (P<0.0031) is only observed 
between markers D15Mitl38 (24.5cM) and D15Mitl 15 (42.5cM). 
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Table 3.2.3: Single marker (ANOVA) analysis within the Fob3 region for the rGFPwt trait. 
Marker Position CM N FF 
rG FPwt 
FL 	LL P value 
D15Mit175 7 520 4.35±0.03 4.56±0.16 . 	 . 0.2291 
D15Mit15O 12.4 502 4.36±0.86 4.14±0.78 . 	 . 0.5612 
D15Mit138 24.5 517 4.67±0.09 4.22±0.06 4.13±0.17 *0 . 0003 
D15Mit5 26.7 546 4.65 ±0.08 4.26±0.06 4.13±0.18 *0 . 0008 
D15Mit184 41.6 464 5.00±0.21 4.36±0.05 4.08±0.09 *0 . 0014 
D15Mit115 42.5 547 4.80 ±0.19 4.41 ±0.05 4.09 ±0.09 *0 . 0026 
D15Mit209 47.2 531 4.84±0.19 4.38±0.05 4.12±o.w 0.0071 
D15Mit234 49.3 513 4.87±0.20 4.38 ±0.05 4.11±o.io 0.0085 
D15Mit63 51.4 549 4.85±0.19 4.37±0.05 4.17±o.io 0.0226 
D15Mit9O 55.2 343 4.46±0.22 4.30±0.06 4.23±o.og 0.6584 
D15Mitl56 61.4 534 4.78±0.18 4.35±0.05 4.28±0.07 0.0777 
D15Mit105 65.3 453 4.50±0.17 4.44±0.05 4.28±0.08 0.2598 
D15Mit68 69.3 540 4.50±0.13 4.38±0.05 4.32±0.07 0.5567 
D15Mitl 71.4 491 4.40 ±0.14 4.34 ±0.05 4.31 ±0.07 0.8786 
D15Mit1O7 76.7 508 4.39±0.12 4.35±0.05 4.39±0.08 0.8612 
D15Mit39 96.3 535 4.42±0.06 4.32±0.08 . 	 . 0.4096 
Phenotypic least square means ± SE, for each genotype (FF = homozygote for F-line alleles; FL = 
heterozygote; LL = homozygote for L-line alleles) for relative gonadal fat pad weight (rGFPwt) in 
males, at each mapped microsatellite marker on Chrl5. 'Litter' is fitted as a fixed effect. N indicates 
total number of mice phenotyped and genotyped at each marker. P-values were calculated by ANOVA 
testing the significance of the factor 'genotype'. Markers significant at the experiment-wide a o.oj level 
are indicated by * 
3.2.3.3 	Developmental weights (Bw21, Bw42, Bw70, Bw98 
& Bw115) 
Examination of the combined-sex single marker ANOVA analysis for the Bw traits 
reveals a similar trend to that observed for the fat% trait, that is, there is a significant 
difference between the genotypes at all the markers, except at the peripheral markers 
(1315Mitl75, D15Mitl5O and 1315Mit39). This is observed for all the Bw traits, 
including the earliest at 21 days in development (Bw21). The highest differences are 
seen at markers Dl5Mitll5, Dl5Mit2O9 and Dl5Mit68 (generally for all Bw traits 
P0.O001). 
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3.2.3.4 	Summary & brief discussion of single-marker 
analysis 
Single-marker analysis on this data set reveals that the Fob3 QTL region spans from 
marker Dl5Mitl38 (24.5cM; 40.0Mb) to marker D15Mit1O7 (76.7cM; 87.8Mb), for 
all traits other than rGFPwt. The effect of the QTL is significant at weaning age 
(Bw21), and it is not sex-specific, as indicated by the analysis in the pilot-study. 
The QTL effect in the rGFPwt trait extends from marker Dl5M1tl38 to marker 
D15Mit63 (51.4cM - 65.4Mb). This may indicate that there are two QTL, with the 
second QTL mapping between the markers Dl5Mit63 and Dl5MitlO7 (76.7cM - 
87.8Mb), which does not affect the GFP, but does contribute to the fat% and Bw 
traits. However, the single marker analysis is limited in its power of detection and 
precision of QTL mapping and hence interval mapping analysis has been applied for 
a more detailed genetic dissection of the Fob3 region. 
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3.2.4 	INTERVAL MAPPING (IM) 
3.2.4.1 	Normality tests 
The precision of mapping QTL when applying interval mapping depends on the 
normality of the phenotype (Lander & Botstein 1989). Trait data were assessed for 
normality against normal probability plots, and tests generated using a SAS system 
macro (NORMTEST) based on the procedure proc UNI VARIATE (D'Agostino et al. 
1990). The tests performed include the Kolmogorov-Smirnov and Anderson-Darling 
normality tests, as well as a test for skewness and one for kurtosis. 
Table 3.2.4: Summary of P-values of normality tests on the residuals for each trait measured. 
Test 
Trait 	Kolmogorov-Smirnov Anderson-Darling Skewness Kurtosis 
Bw21 0.010 0.005 0.713 0.002 
Bw42 0.054 0.085 0.000 0.000 
Bw70 0.045 0.095 0.000 0.000 
Bw98 0.072 0.052 0.000 0.000 
Bw115 0.133 0.011 0.001 0.000 
fat% 0.010 0.005 0.270 0.017 
rGFPwt 0.010 0.005 0.000 0.036 
rGFPwt* 0.020 0.005 0.375 0.012 
*Test results for the x 3  rGFPwt transformed residuals. P-values exceeding 0.05a are highlighted in 
yellow. 
Table [3.2.4] shows the P-values for each test carried out for each trait. Whilst the P-
values for most of the tests, specifically for skewness and kurtosis were significant, 
often the Kolmogorov-Smirnov or Anderson-Darling statistic are not significant. For 
each trait, histogram plots and normality plots were compared alongside the test 
statistics given in Table [3.2.4]. All the traits except for rGFPwt, were judged to be 
approximately normally distributed, based on the various tests carried out. 
Figure [3.2.3], shows the histogram for the residuals of the fat% trait. The curve is 
similar for all the other traits, except for the rGFPwt trait, which appears more 
negatively skewed than the other traits Figure [3.2.4]. 
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Fig 3.2.4: Histogram of the residuals of the rGFPwt trait (rGFPwtRes) - untransformed. 
Various transformations were applied to the residuals of the rGFPwt trait in an 
attempt to achieve greater normality, with a cubic transformation (x 3 ) generating the 
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most favourable test statistics [Table 3.2.4]. Figure [3.2.5] shows the histogram of 
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Fig 3.2.5: Histogram of the x 3 transformed rGFPwt residuals (crgf). 
Nonetheless, a comparison between the interval mapping results (using the maximum 
likelihood method [2.1.2.4.2]) of the transformed and untransformed data, showed 
very little difference, as shown in Fig [3.2.6]. 
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Fig 3.2.6: Maximum likelihood plot of transformed (black line) and untransformed (red line) 
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A number of different transformations (x 2 , x 3 , Log2 , Log 1o , 1/x) were applied to the 
other traits in an attempt to obtain less significant P-values for the normality tests 
carried out. None of these substantially changed the significance of the normality 
tests or produced histograms that appeared more normally distributed. All further 
analysis carried out on this data set was hence processed in its raw, untransformed 
state. 
3.2.4.2 Single-QTL analysis - by Maximum Likelihood (ML) 
A summary of the single-QTL ML analysis for each trait, along with the peak LOD 
score, the 1 -LOD support intervals in Mb, and flanking markers, are provided in 
Table [3.2.5]. 
Table 3.2.5: Single-QTL IM using ML analysis for Fob3. 
Support 
Interval 
Peak 	 (CM) 
Effects a 
Additive 	 Dominance 	% Variance b 
Position Lod 
Trait (CM) Score 1-LOD ar,, 2a,/s. af 23f/Sf dm dm/S m df df/sf Males Females 
Fat% 44.6 10.04 20.6 1.04 0.54 1.98 0.73 1.12 0.29 0.31 0.06 5.68 6.75 
rGFPwt 41.6 9.21 12.4 0.31 0.72 N/A N/A 0.21 0.24 N/A N/A 7.99 N/A 
Bw115 35.4 12.27 11.8 2.59 0.92 1.58 0.67 0.74 0.13 0.55 0,12 11.05 6.02 
Bw98 41.2 10.61 15.1 2.15 0.79 1.50 0.63 0.90 0.17 0.87 0.18 8.53 5.75 
Bw70 35.3 12.23 11.9 1.81 0.87 1.18 0.73 0.63 0.15 -0.05 -0.02 10.04 6.72 
Bw42 32.5 7.81 14.0 0.96 0.51 0.05 0.04 0.36 0.10 0.39 0.16 3.51 0.63 
8w21 33.0 3.86 13.4 0.26 0.22 0.14 0.13 0.45 0.19 0.31 0.15 1.48 0.77 
Fat%C 34.0 11.3 14.0 
Effects (a)  are given for the peak positions for each trait. The additive effects are calculated as half the 
difference between the homozygotes; dominance effects are calculated as the difference between the 
heterozygote and the mean of the homozygotes. Raw and standardised additive (a, 2a/) and 
dominance effects (d, dJc) for each trait at each QTL, calculated separately for males (m) and females 
(f). The % of the total variation for each trait explained by each peak within each sex, corrected for 
parity and litter effects (b).  Original data for Fob3 () from Horvat et al. (2000). 
As originally described by Horvat et al. (2000), the genetic effect of Fob3 is additive 
in nature (standardised fat% additive effect in males 0.54, females 0.73). 
Examination of the Bw data reveals that the effect of Fob3 is early onset, and 
appears to affect males considerably more in the early time points (Bw21 and Bw42) 
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than females, contributing 3.5% of the Bw42 variance in males and only 0.63% in 
females. Between 7 and 10 weeks however, the effect increases dramatically by three 
fold in males and ten fold in females, contributing 10% and 6.7% of the variance 
respectively. This may be indicative of two separate QTL, with an early-onset QTL 
affecting males more than females, and a late onset QTL affecting both sexes. 
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Fig 3.2.7: LOD score plots for mChr15 from single-QTL interval mapping of adipose traits and 
Bw traits in the recombinant progeny population generated between the F-line and congenic 
rhnlsiines. Positions of markers are indicated by black triangles, given in cM from the proximal to 
distal end of mChrl5 as listed in Fig 3.2.1]. (A) LOD score plots for fat%, rGFPwt, Bwl 15 and the 
original Fob3 QTL plot as reported in Horvat et al. (2000). (B) LOD score plots for Bw21, Bw42, 
Bw70, Bw98 and Bwl 15. Horizontal black lines indicate the 1-LOD-support intervals for Fob3. 
Figure 3.2.7] shows the LOD score plots for each trait analysed. The original fat% 
LOD-plot generated by Horvat et al. (2000), is also shown in Fig [3.2.7A], although 
as this plot was generated using a different linkage map, the plots are not directly 
comparable. Nevertheless, the two fat% plots are similar in the respect that they both 
appear to have a second peak at the proximal end of mChrlS and that the main large 
peak spans a large interval with a peak between 30-40cM. 
The 1-LOD-support interval for the Fob3 QTL (fat% trait) is shown to map to a 
region of approximately 21 Mb, between markers D15Mit5 and D15Mit9O, with a 
peak LOD score of 10.04 [Fig 3.2.7A]. At weaning age (Bw21), the Fob3 QTL is 
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already suggestive with a maximum LOD score of 3.9, again indicating that the 
effect of Fob3 is early onset. At 42 days, Fob3 is highly significant with a maximum 
LOD score of 7.8 and by 10 weeks the maximum LOD score increases to 12.2 [Fig 
[3.2.7B]. Beyond 10 weeks, the maximum LOD score remain at about the same 
level. 
In addition to the main Fob3 QTL peak, there are peaks in the LOD-plots that may 
be suggestive of other linked QTL [Fig 3.2.7]. However, given the caveat involved in 
this analysis [2.1.2.4.2], that the genotypes at the ends of the chromosome are not 
fully incorporated into the analysis, these peaks require further clarification. The 
regression analysis and multiple-QTL regression analysis that follow, address these 
points, in addition to further analysing the effects and behaviour of the Fob3 QTL 
region. 
3.2.4.3 	Single-QTL analysis - by regression 
The effect sizes and positions from this single-QTL analysis using the regression 
approach are summarised for each trait in Table [3.2.6]. The additive nature of Fob3 
(fat% trait) is again confirmed (as in the ML analysis), whereby the additive effect is 
significant (P < 0.001), but the dominance effect is not (P = 0.1). Significance 
thresholds were determined empirically by permuting the marker data, as described 
by Churchill and Doerge (1994). Thresholds were obtained from 1000 permutations 
and are presented as F 005 and F001 for significance at a = 0.05 and a = 0.01, 
respectively. Interestingly, for all the Bw traits, both the additive and dominance 
effects are significant at (P < 0.001), however examining the sexes separately for the 
3w traits, reveals that in addition to significant additive effects, there also seem to be 
significant male dominance effects, although not female dominance effects. The sex 
by additive interaction is significant for Bw42 and Bw70. 
The results from this analysis are similar to the ML analysis, demonstrating that at 
Bw21 the Fob3 QTL is already significant (F-value = 18; P<0.001) [Fig 3.2.8], 
indicating that the effect of Fob3 is early onset. The significance rises with age 




[Table 3.2.6] and seems to stabilise at 10 weeks (Bw70) where the F-value rises to 
58.9; P<0.001. Beyond 10 weeks, the F-value seems to remain at the same level. Fig 
[3.2.8] shows the single QTL analysis plots, for the Bw traits examined, giving the F-
value for the additive and dominance terms combined. The peak becomes broader, 
over time, indicating that there may be more than one QTL in the region, especially 
at the terminal traits Bw 115 and fat%. 
Table 3.2.6: Single-QTL IM using regression analysis for Fob3. 
Sex 
Peak 
Additive Dominance additive mt 
effect effect 
Trait cM F-value P-value 
fat% 31 44.3 2.01 ± 0.22c 0.83 ± 0.43 0.97 
rGFPwt 31 49.2 0.51 ± 0.05c 0.25 ± 0.108  N/A 
Bw115 46 52.6 2 . 05 ± 0 . 27c 1.30±0.34c 0.061 
Bw98 53 56.3 2.06 ± 0.27c 1.77 ± 0.36c 0.25 
Bw70 45 58.9 1 . 58 ± 0 . 18c 0.89±0.23c 0.0036 
Bw42 54 42.5 1 . 09±0 . 17c 0.83±0.22c 0.0055 
Bw21 54 18.0 0.43 ± 0.12c 0.57 ± 0 . 16c 0.17 
fa t%* 	34.0 11.3** 2.31 ± 0.33 -0.47 ± 0.43 
Male Male 
Female Female additive dominance 
additive  effect 
ominance 
effect effect effect 
2.03 ± 0.25c 0.58 ± 0.47 1.97 ± 0.38c 1.24 ± 0.75 
0.51 ± 0.05c 0.25 ± 0.10a N/A N/A 
2.48 ± 0.38c 1.62 ± 0.48c 1.69 ± 0.38c 0.87 ± 0.47 
2.33 ± 0.39c 2.51 ± 0.51c 1.86 ± 0.38c 1.14 ± 0 . 50a 
2.05 ± 0.27c 1.30 ± 0.34c 1.15 ± 0.23c 0.39 ± 0.30 
1.46 ± 0.26c 1.15 ± 0.34c 0.75 ± 0.19c 0.46 ± 0.25 
0.55 ± 0.17'  0.87 ± 0.23c 0.34 ± 0.17a 0.23 ± 0.23 
Effect sizes are 'raw', i.e., not scaled by the standard deviation. *original  data for Fob3 from Horvat 
et al. (2000); **Lod  score. F-values greater that 7.38 indicate significance at the 5% threshold, whilst 
F-values greater than 11.42 indicate significance at the 1% threshold. P<0.05 a; P<0.01 b; P<0.001 c. 
Additive effects calculated to 1 degree of freedom. 
Figure 3.2.8: Graphs of single-QTL regression interval mapping analysis of Fob3 for the Bw 
traits: Dashed line indicates significance level at the 1% level F 001 , dotted line indicates 5% level 
F005 [A] Bw21, [B] Bw42, [C] Bw70, [D] Bw98. 
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Figure 3.2.9: Graphs of single-QTL regression analysis of Fob3. Dashed line indicates 
significance level at the 1% level 17 001 , dotted line indicates 5% level 17005 [A] fat%, [B] Bw115, [C] 
rGFPwt. 
[A] 
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In contrast to the plots generated from the ML analysis, there only appears to be one 
peak for each trait in this analysis [Figs 3.2.8 & 3.2.9]. Although the fat% and 
rGFPwt plots appear to have a staggered plot, which may allude to multiple QTL 
[3.2.8 A & C]. The fat% plot for instance has a main peak around 30cM, followed by 
smaller peak at -45cM and at 60cM. The rGFPwt plot similarly appears to have a 
second peak at -45cM, but lacking the third peak at 60cM. As shown, the Bw plots 
are generally similar to each other, having one large peak [Fig 3.2.91. 
3.2.4.4 	Multiple-QTL analysis - by regression 
Multiple QTL analysis was performed on all traits fitting epistatic interactions when 
a significant additive-by-additive interaction was present. In the two-QTL analysis 
the additive-by-additive interaction term for the 'best pair' of locations (that is, the 
pair of locations that explain the largest amount of variation), is significant only for 
the traits Bw42 and Bw70. In all other cases the additive-by-additive interaction is 
not significant (P > 0.05) even without correcting for multiple tests. 
Two significant QTL were found for all traits except for Bw21 and rGFPwt. The 
'best pair' of locations identified in the two-QTL analysis for each trait is 
summarised below [Table 3.2.7]. 








(cM) F-\/alue Effect ±SE 
Dominance 
F-Value Effect ±SE 
Cl 
(M) 
Peak 	Additivity 	Dominance 
(CM) F-Value Effect ±SE F-Value Effect ±SE 
Cl 
(cm) 
;t% 2 27 70.7 1.62 ±0.19 5.1 0.68 ±0.30 22-32 68 7.7 0.71 ±0.26 5.6 0.77 ±0.33 44-70 
wl 15 2 29 45.6 1.56 ±0.23 13.7 1.50 ±0.41 20-46 67 21.5 1.36 ±0.29 11.6 1.26 ±0.37 44-70 
N98 2 29 39.7 1.49 ±0.24 9.6 1.28 ±0.42 22-47 64 17.7 1.26 ±0.30 18.2 1.59 ±0.37 47-76 
N70 2 34 45.3 1.68 ±0.25 11.3 1.46 ±0.43 21-46 65 1.1 0.28 ±0.26 21.1 1.45 ±0.32 24-75 
N42 2 28 4.0 0.43 ±0.21 10.40.90 ±0.28 14-95 54 11.7 0.75 ±0.22 17.3 1.03 ±0.25 26-69 
N21 1 N/A 54 19.5 0.56 ±0.13 15.3 0.63 ±0.16 38-68 
_FPwt 1 	1 27 47.3 0.38 ±0.05 3.1 0.13 ±0.07 21-38 N/A 
Absolute effect sizes given with standard error (±SE) and confidence intervals (Cl) for QTL locations 
(cM). Additive effects calculated to 1 degree of freedom. 
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The significance thresholds were calculated at the F 005 and F001 levels (as discussed 
in section [2.1.2.4.4]), which were generally similar for all traits, both for additive 
and dominance effects. F-values greater that 7.38 and 11.42 indicate significance at 
the F0.05 and F0 . 01 threshold respectively (taken as the highest thresholds across all 
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Fig 3.2.10: Contour plot of the two-QTL regression analysis. Bwl 15 [A], fat% [B]. Contour lines 
indicate the F-value from a general linear model fitting additive and dominance effects for QTL at two 
positions simultaneously, the 'peak' indicates the combination of positions for which the model 
explains the most variation. The contour plot would be symmetrical about the 1:1 line, and therefore 
only one half of the plot has been shown for clarity. 
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The 'best pair' of locations for Bwl 15 was at 29 cM (QTL-A) and 67 cM (QTL-B) 
[Fig 3.2.1 OA]. The additive and dominance effects are roughly similar for both QTL 
[Table 3.2.7], and are significant in all cases (QTL-A additive F = 45.6 vs. 17001 = 
10.9; QTL-A dominance F = 13.7 vs. 17 001 11.0; QTL-B additive F = 21.5 vs. 17001 
= 10.9; QTL B dominance F = 11.6 vs. F001 11.0). 
mChrl5 (cM) 
4 	DI5MiZ/50 14.J.i4bp; 12.4cM 
20 
4 	D,tu)$. 	4O 	. 4 f./i. M \lbps Gene symbol synorl)IIis) Reference 
.t 4--- i)J5.\1!5 434p, . 	1 ' 36.0 Cox6c Hoffman et al. (1998) 
30 44.2 Trhr Duthie et al. (1990)   
40 
DI5Mitl84 41.6cM 
-DJSMit115 560fbp; 42.5cM 
1 	D15Mit209 61. 9Mhp; 47.2cM 
-D/5Mi1234 65.3Mbp; 49.3cM 
I 
I 59.1 Ndufb9 Gti Ct al. (1996) 
.4 	I.)J5.tf,63 	51.4a1 59.5 Sqle Kosuga et al. (1995) 
4 	D15MiI9O 69.3Mbp. 55.2c'iJ ..Q 62.2 Myc (c-Myc. Myc2, Niard, Nird) Chawla & Lazar. (1994) 
66.1 0c90 (Ocii.95. PLA2L. Pla211) Wang et al.( 1998) 
.4- DI5Miil56 71.5Mbp; 61.4cM 67.0 Tgn (cog, congenital goiter) Taylor & Rowe. (1987) 
75.9 Rhpnl Hasegawa et al. (1999) 
4 	D15M4105 72.7Mbp; 65.3cM 76.7 Dgal 1 Cases et al. (1998) 
70 
4-  D/5M1168 77.131/'p; 69.3c.11 
4- DISMitI 71.46f; 
'4- 	D15,tIit107 84. 7-t.Thp 	76. 'c.tI 
SO 
If] 
4 	[)Ji.tI:t39 )( (t//'p; 
Fig 3.2.11: Summary of two-QTL analysis for fat% on mChrl5. Microsatellite marker positions 
are given in Mbp and centiMorgans (cM) as calculated using CriMap from our data. Thick lines with 
intersections indicate the 95% Cl and positions of the peaks for each of the QTL based on the fat% 
trait. Candidate genes mapping to the Fob3a and Fob3b QTL intervals, are listed along with their 
symbols and positions in Mb. All marker and gene Mbp positions are taken from the Mouse Genome 
Sequencing Consortium version 13.30.1, 
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The two-QTL analysis of fat% yielded a similar combination of positions as Bwl 15, 
that is, 27 cM and 68 cM [Table 3.2.7 & Fig. 3.2.I0B]. The estimated additive effect 
of fat% QTL-A is approximately twice that of fat% QTL-B, but both are significant 
(QTL-A additive F = 70.7 vs. F001 = 11.4; QTL-B additive F = 7.7 vs. F005 = 7.4). 
The dominance effects are not significant for either of the fat% QTL (QTL-A 
dominance F = 5.1 vs. F0 05 = 7.6; QTL-B dominance F = 5.6 vs. F0 .05 = 7.6). The CI 
for the positions of the QTL determined by bootstrapping that are presented in Table 
[3.2.7] are also shown schematically in Fig [3.2.11]. 
In the three-QTL analysis, summarised in Table [3.2.8], the triad of locations that 
explained the most variation (TMV) for Bw115, is 24 cM, 47 cM and 67 cM, 
whereas that for fat% is 27 cM, 61 cM and 62 cM; the F-value for the triad 27 cM, 
61 cM and 67 cM has the second highest value, which is extremely close to the 
highest value (F 27 ,612 = 38.04; F27,61,67 = 38.03). Thus, the inclusion of a third QTL 
in the model does not substantially affect the estimated position of the first two QTL 
for either trait. For both Bwl 15 and fat%, the additive and dominance effects of the 
third QTL are not significant. 
Table 3.2.8 Three-QTL IM using regression analysis for Fob3. 
Trait F max F (A*B) 
Epistasis 
F  (B*C) 	F (A*C) 
QTL A 
Pos F add F dom 
QTL B 
Pos F add F dom 
QTL C 
Pos F add F dom 
Fat% 29 1.42 10.56 2.50 27 36.31 5.25 54 0.40 3.86 63 1.63 2.16 
Bwl 15 116 1.03 2.43 5.04 31 0.97 15.30 67 0.38 13.63 84 7.96 6.8 
Bwl 15a 152 Without epistasis 24 18.66 11.03 47 2.04 1.44 67 5.30 4.02 
Bw98 105 0.26 5.99 4.08 27 23.31 12.15 51 0.02 0.35 67 5.98 0.76  
Bw98a 139 Without epistasis 22 0.43 7.45 33 11.61 0.74 64 0.95 24.81 
Bw70 113 2.61 1.55 0.12 28 13.97 14.56 43 6.13 3.00 64 0.03 9.8 
Bw70a 148 Without epistasis 24 7.80 11.46 43 14.78 0.19 66 0.77 10.32 
Bw42 65.40 9.22 1.49 0.15 23 11.06 9.65 28 13.67 2.58 54 4.06 18.98 
Bw42b 65.39 10.05 1.31 0.33 23 8.79 10.36 27 11.11 1.95 54 9.93 19.50 
Bw42b 65.12 11.26 0.25 10.12 29 8.01 15.96 53 1.46 18.71 77 4.53 4.48 
F max indicates the highest F-value for the best triad of positions (where positions were not in the 
same or adjacent intervals (i.e., there had to be at least two markers between positions). F-values of 
epistatic interactions (A*B, B*C and A*C),  as well as for the additive (F add) and dominance (F dom) 
values. All significant F values are highlighted in yellow, where 7.38 and 11.42 indicate significance 
at the 5% and 1% threshold respectively. Where no epistasis was detected, the analysis was repeated 
modelling without epistasis (a). For Bw42 (b) the three best combinations are given for comparison. 
Positions (Pos) are given in cM. 
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As in the two-QTL analyses, the additive-by-additive interaction terms are not 
significant in the three-QTL analysis of Bwl 15 (P > 0.05 using threshold F value 
from single-QTL analysis). Without epistasis, the TMV for Bwl 15 remain as 24 
cM, 47 cM and 67 cM, but the additive and dominance effects of the third QTL are 
not significant (F <2.0). 
In the three-QTL analysis of fat% however, there is evidence of epistasis. The TMV 
is 27 cM, 54 cM and 63 cM and as in the two-QTL analysis, the additive effect of the 
QTL at 27 cM is highly significant (F = 36.3 vs. F 0 , 01 = 11.4), but its dominance 
effect is not (F = 5.3 vs. F005 = 7.6). The additive (54 cM) by additive (63 cM) 
interaction term is significant (F = 10.6 vs. F 0 , 05 = 7.4 for additive term from single-
QTL analysis), although the additive and dominance effects themselves are not 
significant for either of these positions (F <4.0 in all cases). The lack of significance 
of the two QTL involved in the epistatic interaction is difficult to interpret, although 
it could be that the two QTL identified in the two-QTL analysis are real, and there is 
a third locus which is a modifier of QTL B. 
For Bw42 the results are partly consistent with the other traits, that is, there is one 
QTL at 27 cM (late onset), and one at 54 cM (early onset). However, there could also 
be a third QTL, although the position is unclear as indicated in Table [3.2.8] by the 
top three F-max scores. Interestingly, there is also a third QTL for Bw70, although at 
a different position. Possibly there might be an 'intermediate growth' QTL that is 
affecting both Bw42 and Bw70, but this would need to be tested further with the 
population and analysis design addressing specifically this issue. 
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3.2.5 	DISCUSSION 
Originally, Fob3 was detected in an F 2 cross as a large effect QTL with a LOD score 
of 11.3 and a two-LOD support interval spanning 10cM - 45cM. Using an increased 
number of markers and progeny testing of recombinants from a cross between 
congenic lines, and a detailed single and multiple-QTL analysis, the Fob3 QTL (fat% 
trait) has been dissected into two QTL regions. These are Fob3a (27cM; 22 - 32cM;) 
and Fob3b (68cM; 44 70cM;). The effects on the fat% and Bw115 traits measured 
contributed by each of the QTL separately are reduced. This demonstrates the effect 
that smaller closely liked QTL can have in overestimating a single-large QTL effect, 
as shown previously in silico (Visscher & Haley 1996), and in in-vivo mouse models 
(Legare at al. 2000). 
Analysis also shows that these QTL have correlated effects on Bw, and that the 
effects of the two QTL appear at different developmental stages. In addition, there 
are indications, especially with regards to the Bw data at 42 and 70 days, that there 
may be a third QTL, that is, that Fob3b is itself actually a constituent of two QTL. 
QTL for Bw with changing effects over age have been previously identified, for 
instance by Cheverud et al. (1996), in an F 2 intercross between LG/J and SM/J inbred 
lines, although in that case there was no indication that the effects were correlated to 
obesity. Similarly in an F2 cross between C57BL/6J x DBAI2J, Morris et al. (1999) 
found a mChrlS Bw QTL with evidence of increasing effect with age. 
Fob3b is an early onset obesity QTL, detectable at 21 days, and having a 95% CI 
from 38 - 68cM. Fob3b affects fat% and Bw traits through development (fat% from 
44 - 70cM). The peak and size of the CI for Fob3b seems to fluctuate slightly, 
especially between the early Bw traits, compared to the later traits [Table 3.2.7]. This 
is probably either due to the Fob3a QTL influencing the analysis, or since Fob3b 
may be a constituent of two QTL that they may be forming complex epistatic 
interactions, as indicated by the three-QTL analysis [Table 3.2.8]. 
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Fob3a is detected as a late-onset obesity QTL. It has a significant effect by Bw42, at 
which point there is significant epistatic interaction between Fob3a and Fob3b, 
which is still present at Bw70. It is not until the later Bw stages and the fat% trait, 
where it is possible to isolate Fob3a to a 10cM region (22 - 32cM), ranking amongst 
the most tightly mapped mouse obesity QTL reported thus far [see section 4.1 for 
discussion]. Interestingly, only the Fob3a QTL is detected in the rGFPwt trait, this 
may indicate that Fob3a is specific for the GFP depot, or that the Fob3b QTL is 
more specific for Bw rather than obesity, since Fob3b is only significant at the 0.05ct 
level in the fat% trait. Clearly more phenotypic analysis would be needed to confirm 
this in any future fine-mapping study. 
A search for candidate genes was carried out, based on the flanking markers of the 
95% CIs for the Fob3a and Fob3b QTL, detected in the fat% trait - hence a slightly 
broader interval than the 95% Cl was examined. The interval for Fob3a, spans from 
marker D15Mitl50 to D15Mitl84, and reveals what appears to be a gene poor area 
with only 175 features, 73 of these are listed as unknown or ambiguous genes, whilst 
102 are predicted or known genes. Of these, two are linked to metabolism or 
adipocyte regulation; firstly, cytochrome c oxidase -subunit Vic (Cox6c), this protein 
forms part of the Cytochrome c oxidase complex, the terminal enzyme in the 
respiratory chain (Hoflnann et al. 1998); and thyrotropin-releasing hormone receptor 
(Trhr) which is involved in the thyroid hormone pathway, and is known for affecting 
obesity (Duthie et al. 1993; Taylor and Rowe. 1987). 
Fob3b spans an interval flanked by markers D15MitI15 and D15Mit]. Within this 
region, 220 features are listed, of which 78 are known genes. A total of seven 
potential candidates are located within this region, these are; NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex-9 (NduJb9) as its name implies, is involved in the 
oxidative phosphorylation of NADH to ubiquinone (Gu et al. 1996); Squalene 
monooxygenase (Sqie) - involved in the sterol biosynthesis pathway (Kosuga et al. 
1995); the myelocytomatosis oncogene (Mvc) - shown to inhibit adipocyte 
differentiation (Freytag and Geddes 1992); the otoconin 90 precursor (000) - 
suggested to be involved in lipid catabolism (Wang et al. 1998); thyrotroph 
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embryonic factor (TeJ) which transactivates thyroid stimulating hormone, and hence 
is involved in the thyroid hormone pathway (Drolet et al. 1991); Rho-GTPase 
binding protein-i (Rhpnl) - found to bind to the glucose response element and hence 
triggers genes for lipogenesis (Hasegawa et al. 1999); and finally, diacylglycerol 0-
acyltransferase-i (Dgatl), which is an enzyme known to function in triacyiglycerol 
synthesis (Cases et al. 1998). These candidates and their positions on mChrlS are 
summarised in Fig [3.2.11]. 
Prior to further mapping analysis of the Fob3 region, a small-scale candidate gene 
study was carried out by Lodge et al. (unpublished), examining differential gene 
expression between the F-line and congenic F chr15D-line. Some candidates, Trhr, 
somatostatin receptor-3 (Sstr3) and peroxisome proliferator activated receptor-alpha 
(Ppara), which all fell within the original QTL region, were examined by Northern 
analysis. None showed significant differential gene expression. 
The dissection of the Fob3 region into at least two QTL, reflects the complexity one 
would expect to see in a polygenically obese population as seen in humans, that is, 
many loci having small effects. Any further mapping attempt of the two QTL will 
inevitably be more formidable, since the smaller effects will make the segregation of 
the individual QTL (Fob3a and Fob3b) harder to track down. 
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3.3 	MICROARRAY STUDY 
3.3.1 	INTRODUCTION 
Analysis of the microarray data was performed in two ways. The first involved a 
preliminary analysis using the Venn-diagram facility of GeneSpring analysis 
package, to filter common ESTs that met two strict selection criteria (henceforth 
termed the 'GeneSpring-method'). Selection criteria were applied for identifying 
reliably differentially expressed ESTs, with the aim of minimising false positive 
detection. First, differential expression must be of the order of 2-fold or more (2-
fold+), and second, this must be repeated in at least three of the four (or more) repeat 
array hybridisations. Where three or more array repeats were available, all the 
possible permutations were analysed to reveal ESTs that met the selection criteria. 
Simple t-test P-values are given for within-slide differences, as calculated using 
GeneSpring. 
The second analysis is a t-test significance analysis for each EST on an experiment 
wide level based on a mixed model as described in section [2.2.4.4]. There is no 
laboratory 'standard' for analysing microarray data that if followed faithfully, will 
produce the correct answer to the experimental question (Morrison & Ellis, 2003). 
As a consequence, we have applied two data analyses and a novel data 
transformation to identify possible candidates and pathways. 
A number of differentially expressed candidates have been identified, with one 
known metabolic Chr15 gene (Squalene epoxidase - Sqie) which maps within the 
Fob3b QTL region, and an unknown Chr15 EST mapping just proximally to Fob3b. 
A number of potential candidate pathways have also been identified, with the 
cholesterol biosynthesis pathway (involving the SqIe gene product) featuring 
prominently. 
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3.3.2 	CONTENTS OF 15K cDNA SLIDE SET - 
BLAST RESULTS 
The cDNA microarray used in this study, are not well annotated, as half of the ESTs 
are from uncharacterised genes. A BLAST search was performed using the GenBank 
ID numbers associated with the EST clones spotted on the microarrays, as described 
in section [2.2.3.11. The general findings, in addition to the annotation provided by 
the NIA-NIH (file available at http://lgsun.grc.nia.nih.gov ), are presented here, and 
used to describe the results of the microarrays later in this chapter. 
Of the 15,090 recognisable GenBank IDs distributed across the two NIA 15K cDNA 
arrays, a total of 573 spots corresponded to genes assigned to mChr15. Each of these 
matched at least 100 base pairs (least significant P value 3.4 x 1010).  Of these, 291 
were on the first set of arrays and 282 were spotted on the second set of arrays. The 
data retrieved from the microarray analysis is presented both in the context of the 
entire 'global' genome data retrieved, and in the context of mChr15 expression 
analysis. 
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3.3.3 	RNA and cDNA 
RNA was extracted in 'batches' as described in [2.1.2.1] and quantitated as described 
in [2.1.2.2]. 1O.tg from each RNA sample was separated on a denaturing agarose gel 
[2.3.2.1] and the quality assessed by ethidium bromide staining. This was also done 
for the pools of RNA made from each 'batch', see figure [3.3.1]. RNA in agarose 
gels was then transferred by capillary transfer to nitrocellulose membranes for 
northern analysis [2.3.2.1]. 
The identity of each RNA sample, i.e., the mouse line from which each sample was 
supposed to be derived from, was confirmed by genotyping with the D15Mitl56 
microsatellite marker pair as described in section [2.1.3]. This was performed as an 
additional housekeeping check to ensure that at no point were mouse, tissues or RNA 
samples confused. 
[B] 
1 	2 	3 	4 	5 	6 	M 
Fig 3.3.1: 1% agarose gels stained with ethidiurn bromide [A- RNA, B- cDNA]. Pools listed here 
were used for the hybridisations on the 1 array set described below (experiments 1 & 2). M indicates 
marker; Lanes 1-4 are un-purified RNA pools, lanes 5-6 were Qiagen column purified. 1=LF1, 
2=LD1, 3=LF2, 4=LD2, 5=LF2. 6=LD2 (Where L indicates liver derived RNA, F indicates F-line and 
D indicates congenic F 5'-line. 
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The quality of RNA is determined by the ratio of intensity from 28s RNA to 18s 
RNA bands on an ethidium bromide stained agarose gel. A 2:1 ratio is an indicator of 
good quality un-degraded RNA. Two RNA liver pools [lanes 5 & 6, Fig 3.3.1] were 
purified on Qiagen columns, and the electrophoretic profiles were compared against 
four un-purified RNA liver pools on a 1% agarose gel. The purified samples 
generated 28s RNA and 18s RNA bands of greater intensity, than two of the four un-
purified samples [Fig 3.3.IA]. 
When these samples were processed for cDNA generation, no significant difference 
was found in the cDNA quality and yield between samples [Fig 3.3.I13]. 
Consequently, further RNA samples were not purified by Qiagen column 
chromatography. All cDNA samples were analysed by 1% agarose gel 
electrophoresis. Samples were compared to cDNA samples known to have given rise 
to both good and bad hybridisations on the 15K NIA-slide set (Clare Pritchard, 
personal communication). All pools generated in the present study resembled the 
'good' control more closely than the 'poor' control. 
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3.3.4 	HYBRIDISED ARRAYS 
Notation. (L = liver; B = BAT; F = F-line; D = phr/ 5D4ine ; I = 1" pool; 2 = 2"poo1). 
Prior to proceeding with the experimental hybridisations, two test-control self-self 
hybridisations were carried out. The first was between two independent pools of 
male F-line liver [LFIm][GREEN]  V [LF2m]IREDI, using a NIA 1' 6K array (Array 1: 
0205018027), while the second was a duplicate using a NIA 1 7.5K array (Array 2: 
2801028002). The 0 NIA 7.5K set, are the arrays used for the experimental 
hybridisations [3.3.4.1/3.3.4.2], along with the 2 1d  7.5K set [3.3.4.3/3.3.4.4]. These 
self-self controls served as indicators of the expected amount of variation due to 
inherent systemic noise. Both controls, after background-subtracted normalisation, 
indicated that the system was generating very little noise. As would be expected in a 
self-self hybridisation, very few ESTs showed differential expression (data not 
shown). 
As these test hybridisations involved male derived RNA, and the experimental 
hybridisations involved female derived RNA, the data generated from the male 
hybridisations have not been used for the analyses discussed in this study. 
Experiment 1: Liver - Vt set of arrays 
[LD2 d[RED]  v [LF2 f][GREENJ  array ID: 0904028065 (Array 3) 
[LF2 d[RED]  v [LD2 d[GREEN]  Array ID: 0904028091 (Array 6) 
[LDI fJ[REDJ  v [LF1 d[GREEN]  Array ID: 0904028092 (Array 7) 
[LF1 f][REDI V [LD1 d[GREEN]  Array ID: 0904028093 (Array 8) 
Self-self control hybridisations: 
[LFlf][RED] v [LF!f][GREENI array ID: 0904028096 (Array 11) 
[LDI d[RED]  v [LDlf](GREENJ  array ID 12: 0904028097 (Array 12) 
The four experimental hybridisations are effectively four repeats to examine the 
differential gene expression in liver between the F-line female mice and congenic 
I 15D-line female mice. Two self-self within-pool control hybridisations were also 
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processed, providing additional information on the amount of noise we would expect 
from same-sample hybridisations. As with the male test hybridisations discussed 
above (Arrays 1 & 2), these self-self controls indicated that variation within samples 
was very low, providing more confidence in the experimental procedure (scatter 
plots not shown). 
Experiment 2: BAT - 1st set of arrays 
[BD1 d[RED]  v [BFI fl[GREEN]  slide ID: 0904028088 (Array 4) 
[BF1 d[RED]  v [BDI fl[GREEN]  slide ID: 0904028089 (Array 5) 
[BF2 d[RED]  v [BD2 d[GREEN]  slide ID: 0904028094 (Array 9) 
[BD2 d[RED]  v [BF2 fl[GREEN]  slide ID: 0904028095 (Array 10) 
As with the liver hybridisations in experiment 1, four repeats were performed for the 
I" slide-set (15K NIA) as listed above, but with BAT derived labelled cDNA. No 
control self-self hybndisations were processed due to the scarcity of available RNA. 
Experiment 3: Liver - 2nd set of arrays 
[LDI d[GREEN]  v [LFI d[RED]  slide ID: 0904028067 (Array 13) 
[LFI fI[GREENJ V [LDI fJ[RED  slide ID: 0904028068 (Array 14) 
[LDB d[GREEN]  v [LFB d[RED]  slide ID: 0904028069 (Array 15) 
[LFB fl[GREEN]  v [LDB d[RED]  slide ID: 0904028070 (Array 16) 
[LD1 fl[GREEN]  v [LFB d[RED]  slide ID: 0904028075 (Array 17) 
[LFI f][GREENJ  v [LDB d[RED]  slide ID: 0904028076 (Array 18) 
Self-self control hybridisations: 
[LC1 fl[GREEN]  v [LC2 d[RED]  slide ID: 0904028073 (Array 13) 
[LF1 d[GREEN]  v [LF2 fl[RED] slide ID: 0904028074 (Array 14) 
As with the 0 NIA 15K set, the above experiments are effectively six replicates 
screening genes expressed in the livers of F-line female mice and congenic Frl5D 
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line female mice for differentially expressed transcripts. Two more repeats than in 
the l slide set were carried out, as there was sufficient RNA to do so. Also, two 
self-self control-hybndisations were performed as described for the first experiment. 
These differ slightly in their set-up from those in experiment 1, in that they are cross-
pool self-self hybridisations, providing additional information on the degree of 
background noise expected from cross-pool hybridisations. The amount of noise 
observed was slightly higher than that observed in the same-sample hybridisations 
(Arrays 11 & 12), but still generally low, i.e. no EST had greater than a 2-fold 
differential on either array (data not shown). 
Experiment 4: BAT- 2m1  set of arrays 
[BD1 f][GREENJ  v [BFI f][ RED] slide ID: 0904028071 (Array 19) 
[BFI fI[GREENJ  v [BDI d[GREEN]  slide ID: 0904028072 (Array 20) 
Due to the low amounts of RNA present in BAT tissue and the large quantity of 
RNA required to carry out a single hybridisation, only two BAT hybridisations were 
performed for the second set of arrays, the pools of which were made from the two 
pools of BAT described previously [2.2.3.2], i.e. for each line the pool was 
composed of ten individual mice. 
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3.3.5 	GENESPRINGTM ANALYSIS 
3.3.5.1 	Exp 1: Liver - 1St Array set 
Table [3.3.1] lists the ESTs that appeared differentially expressed on all four arrays, 
and all the ESTs that were differentially expressed in at least three out of four 
hybridisations. As shown, there is only one feature H3066B12, common in four 
arrays that has a 2-fold higher expression in the F-line compared to the congenic line. 
This EST represented an unknown EST that maps to genomic sequence on mChrlS. 
Two additional features were differentially expressed in three of the four arrays (A3-
A7-A8). H3080D03 represented an unknown EST localising to mChrl, and 
H3020H04 - an EST matching to sequence of the mChr15 gene squalene epoxidase 
(also known as squalene mono-oxygenase, Sqie). 
Table 3.3.1: Exp 1 - List of consistently differentially expressed ESTs 2-fold+ in liver. Analysis 
on 1st  15K array set. 
Expression 
	
No of Systematic 	Gene 	 relative to F- 
Array codes ESTs NIA code symbol Gen Bank ID Chr 	line 
A3 A6 A7 A8 	1 	1­130661312 	None BG081526 	15 
A3 A7 A8 	2 	H3080D03 None BG069808 1 	
Up 
H3020H04 	Sqie BG077950 15 
A3A6A7A8 2 	H3005G01 Gpd2 BG076772 	2 
H3011C07 None AW539113 2 	Down 
A3 A6 A7 	1 	H3003A09 	None BG076478 10 
Sqie - squalene epoxidase; Gpd2 - glycerol phosphate dehydrogenase 2. 
For each EST, the normalised mean signals (taken from the two identically spotted 
ESTs on each array) and ratios are given for all three features across the four arrays 
in table [3.3.2]. The ratios are given in the Lo9 2 scale hence a ratio of 1 (or —1) 
indicates a 2-fold differential (negative ratios indicate down-regulation in the F' 5D-
line and positive ratios indicate up-regulation). 
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Table [3.3.21, shows that for all four arrays, feature H30661312 repeatedly 
demonstrates a greater than 2-fold difference in gene expression, higher in the F-line, 
with a range of 2.3 - 4.7 fold increase. However only one measurement is significant 
at the 0.05 level, based on within array t-test scores (A8), with two measurements 
from other arrays approaching significance to the 0.05 level. For both the remaining 
features, H3080D03 and H3020H04, three of the four experiments have a 2-fold or 
greater difference. For H3080D03 only measurements from one of the four arrays is 
significant at the 0.05 level, whilst for H3020H04 three of four are significant. 
Table 3.3.2: Exp 1 - Lo92 ratio, fold difference and t-test P-values of the differentially expressed 
ESTs in liver (up-regulated in the F-line). 
L092 	Fold 	Normalised intensities 
Ratio Difference F-line 	Congenic P-value 
1­130661312 A3 -2.24 4.74 5,891 1,244 0.08 
A6 -2.10 4.27 1,213 284 0.06 
A7 -1.52 2.87 337 118 0.3 
A8 -1.22 2.33 2,203 945 0.04 
H3020H04A3 -1.02 2.03 7,651 3,770 0.01 
(Sqie) 	A6 -1.38 2.61 1,554 596 0.01 
A7 -2.51 5.71 287 50 0.2 
A8 -0.55 1.46 1,493 1,021 0.05 
H3080003 A3 -1.07 2.10 2,962 1,410 0.07 
A6 -1.27 2.42 1,444 598 0.03 
A7 -1.48 2.79 127 46 0.1 
A8 -0.67 1.59 947 594 0.09 
P-values are given for each EST within each array. Sqie - squalene epoxidase. 
A screen for ESTs more highly expressed in the congenic F' 5D-line compared to 
the F-line, reveals three ESTs consistently upregulated 2-fold or higher, as listed in 
[Table 3.3.1]. Two of these, H3005G01 and H301 1C07, are common to all four 
arrays and the third EST, H3003A09 is common to the triad of arrays A3-A6-A7. 
Whilst none of the three map to mChrl5, H3005G01 blasts to the known metabolic 
gene, glycerol phosphate dehydrogenase 2 (Gpd2, formally Gdrnl), however in later 
analysis this EST does not appear to be differentially expressed [3.3.6.1]. Table 
RESULTS - MICROARRAY ANALYSIS: 3.3 	 181 
[3.3.3], gives the F-line and congenic-line mean normalised signal intensities for the 
ESTs upregulated in the congenic line. 
Table 3.3.3: Exp 1 - Lo92 ratios and t-test P-values of the consistently differentially expressed 
ESTs in liver (upregulated in the F 5D-line). 
L092 	Fold 	Normalised intensities 
Ratio Difference F-line Congenic P-value 
H3005G01 A3 1.58 3.00 775 1,607 0.004 
(Gpd2) 	A6 1.23 2.34 397 928 0.021 
A7 1.28 2.42 37 90 0.263 
A8 1.33 2.52 483 1,214 0.054 
H3011C07 A3 1.08 2.12 221 468 0.090 
A6 1.33 2.52 435 1,094 0.145 
A7 1.87 3.66 23 83 0.298 
A8 2.33 5.04 72 364 0.157 
H3003A09 A3 1.57 2.96 179 530 0.089 
A6 1.45 2.73 285 777 0.029 
A7 0.89 1.85 286 530 0.150 
A8 1.61 3.06 191 586 0.097 
P-values are given for each EST within each array. Gpd2 - glycerol phosphate dehydrogenase 2. 
For H3005001, although all four arrays are above the 2-fold threshold, only two of 
these four are significant on an array-by-array basis at the 0.05 level. The EST 
H301 1C07 similarly has 2-fold differences for all arrays, although none of the 
differences are significant on an array-by-array basis. Finally, EST H3003A09 has 2-
fold differences across three of the four arrays, but only one of these is significant at 
the 0.05 level. 
3.3.5.2 	Exp 2: BAT - 1st Array set 
In this data set, there was one EST that was consistently differentially expressed 2-
fold higher in the F-line compared to the congenic line, across all four arrays [Table 
3.3.4]. 1­130251303 is an EST from the metabolic mChr19 gene, stearoyl -coenzyme A 
desaturase 2 (Scd2), and on this basis would warrant further investigation. 
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Several other ESTs were found to be repeatedly upregulated in the F-line, however 
the signal intensities were generally very low for these particular ESTs (below 200 
units, after background subtraction), which distorts the ratios. Of these, the most 
reliably up-regulated ESTs were H3048C08 and H30201404. H3048C08 is an 
unknown EST blasting to mChrl5, and hence of interest that warrants further 
investigation. H3020H04 is an EST from the Sqie gene, which is also upregulated in 
F-line liver (Exp 1) [Table 3.3.1 & 3.3.2]. 
Table 3.3.4: Exp 2 - List of consistently differentially expressed ESTs 2-fold+ in BAT. Analysis 
on l 15K array set. 
Expression 
No of Systematic 	Gene 	 relative to 
codes 	ESTs 	NIA code symbol GenBank ID Chr F-line 
A4 A5 A9 	AlO 1 H30251303 Scd2 BG064900 19 
A4 A5 AlO 1 H3048008 None BG066896 15 	Up 
A4 A9 AlO 1 H3020H04 Sqie BG077950 15 
A4 A5 A9 1 H3048H09 None BG066956 4 	Down 
Sqie - squalene epoxidase; Scd2 - stearoyl-Coenzyme A desaturase 2. 
Although for 1430251303 all four arrays meet the 2-fold threshold, the array-by-array 
significance of differential expression reaches the 0.05 significance level for only 
one of the arrays (A5) [Table 3.3.5]. Therefore it may be that H30251303 is a false 
positive, even under the strict selection criteria applied here. 
H3048CO8 does not strictly meet the selection criteria, as only one of the ratios 
meets the 2-fold threshold. However, two of the other ratios are close to this 
threshold, whereby perhaps, under a different normalisation algorithm the 2-fold 
threshold might be achieved. Nonetheless, it matches to mChrlS and thus warrants 
further analysis [Table 3.3.5]. 
RESULTS - MICROARRAY ANALYSIS: 3.3 	 183 
Table 3.3.5: Exp 2 - Lo9 2-ratios and West P-values of the consistently differentially expressed 
ESTs in BAT. 
Expression 
L092 	Fold 	Normalised intensities 	 relative to 
Ratio Difference F-line 	Conaenic P-value 	F-line 
1­130251303 A4 -1.10 2.14 770 360 0.1 
(Scd2) 	A5 -2.22 4.67 7336 1570 0.03 
A9 -4.04 16.39 66 4 0.9 
AlO -1.29 2.45 291 119 0.3 
H3048C08 A4 -0.91 1.88 1,144 610 0.3 
A5 -0.99 1.99 7,186 3,613 0.4 
Up 
A9 -0.77 1.70 699 411 0.5 
AlO -1.14 2.20 579 263 0.06 
H3020H04 A4 -1.31 2.49 399 160 0.01 
(Sqie) 	A5 -0.25 1.19 1695 1427 0.3 
A9 -1.88 3.68 265 72 0.02 
AlO -1.80 3.48 201 58 0.2 
H3048H09 A4 1.12 2.17 15 32 0.396 
A5 1.44 2.71 90 245 0.294 	Down 
A9 1.24 2.36 304 717 0.241 
AlO 0.67 1.59 198 315 0.622 
P-values are given for each EST within each array. Sqie - squalene epoxidase; Scd2 - stearoyl-
Coenzyme A desaturase 2. 
The Sqie EST (H3020H04) has a relatively low expression level, nonetheless two of 
the four within array P-values are significant, and since it has been detected in both 
Exp 1 and 2 (i.e. in liver and BAT), it is clearly a strong candidate for further 
analysis. 
One further differentially expressed EST was found up-regulated in the congenic 
Fd 5Dline  compared to the F-line [Table 3.3.4]. This is an unknown mChr4 EST, 
H3048H09, found from the triad of arrays A4-A5-A9. However, this EST again has a 
low expression profile in both channels [Table 3.3.5], resulting in non-significant 
within array differences (P > 0.05 for all arrays). 
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3.3.5.3 	Exp 3: Liver - 2 nd Array set 
Here, the same strict selection criteria were applied as previously. However, in this 
experiment remarkably few features are found that are upregulated by 2-fold+ in the 
F-line compared to the congenic line. From 7,567 features, only two ESTs 
H3101Al2 and H3098E12 are consistently detected as upregulated in the F-line, 
across three or more of the potential six arrays [Table 3.3.6]. Examining the 
expression ratios in the opposite direction, that is, looking for up-regulated 
expression in the congenic Fth5Dline  compared to the F-line, revealed no ESTs that 
met the selection criteria. In fact no EST was found differentially expressed 2-fold+ 
across more than one array, with very few features actually meeting the 2-fold 
threshold for any of the six arrays. 
Table 3.3.6: Exp 3 - List of consistently differentially expressed ESTs 2-fold+ in liver. Analysis 
on 2' 15K array set. 
No of 	Systematic 	Gene 
Array codes 	ESTs NIA code symbol GenBank ID Chr 
A15 A16 A18 	2 	
H3101Al2 	Ccrn4I BG071607 	3 
H3098E12 Ccrn4I BG071409 3 
2-fold greater expression (or more) in the F-line compared to the F' 5D-line. Ccrn4l - carbon 
catabolite repression 4-like. 
For H3101Al2, differential expression was seen on five of the six arrays, with an 
expression range of 1.3 to 2.4-fold difference. The expression differences are 
significant within one array (A15) [Table 3.3.71, and approach significance for two 
others. The expression-difference of these two ESTs (H3101Al2 and H3098E12) is 
very similar and array-by-array examination shows that the ratios are almost 
identical. For H3098E12, three of the six arrays show significant differential 
expression (P<0.05). The close correlation of expression profile is explained by the 
fact that these ESTs originate from the same gene, the circadian rhythm gene Ccrn4l 
on mChr3 (CCR4 carbon catabolite repression 4-like (S. cerevisiae)), also known as 
Noctumin (Green & Besharse, 1996). 
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Table 3.3.7: Exp 3 - Lo92 ratios and West P-values of the consistently differentially expressed 
ESTs in liver (up-regulated in the F-line) 
Lo92 	Fold 	Normalised intensities 
Ratio Difference F-line Congenic P-value 
H3101Al2A13 -0.231 1.17 111 94 0.5 
(Ccrn4() A14 0.119 1.09 180 195 0.9 
A15 -1.255 2.39 1949 816 0.04 
A16 -1.293 2.45 1001 409 0.1 
A17 -0.375 1.30 479 369 0.5 
A18 -1.174 2.26 443 196 0.1 
1­13098E12 A13 -0.258 1.20 410 343 0.3 
(Ccrn4I) 	A14 -0.206 1.15 338 293 0.5 
A15 -1.204 2.30 2704 1173 0.01 
A16 -1.142 2.21 1647 745 0.01 
A17 -0.402 1.32 876 663 0.3 
A18 -1.273 2.42 698 289 0.05 
P-values are given for each EST within each array. 
3.3.5.4 	Exp 4: BAT- 2d  Array set 
As can be seen from table [3.3.8], a total of seven ESTs were found to meet the 
selection criteria, six up-regulated in the F-line and one down-regulated. Although 
these results are only from two hybridisations, the differences within arrays for some 
of these are significant at the 0.05 level, as for H3098E12 and H3139E07 [Table 
3.3.9]. 
The two Ccrn4l ESTs H3101Al2 and H3098E12 appear to be significantly 
differentially expressed in BAT in addition to liver [Table 3.3.6 & 3.37], only in this 
case all the ratios exceed the 2-fold threshold. Another interesting result from this set 
is that of a mChr15 EST H3135H04, relating to the thiosulfate sulfurtransferase 
mitochondrial gene (Tst), also known as rhodanese. This gene is shown to be 
significantly upregulated in BAT of the F-line, but appears not to be differentially 
expressed in the liver. 
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Table 3.3.8: Differentially expressed ESTs in BAT (across both arrays A19 and A20). Analysis on 
2" 15K array set. 
Expression 
Systematic Gene relative to 
NIA code symbol GenBank ID Chr F-line 
H3098E12 Ccrn4I BG071 409 3 
H3101Al2 Ccrn4I BG071607 3 
H3135H04 Tst BG074498 15 	
U p 
H3113D06 Adcy3 BG072654 12 
H3138F12 Sdc4 BG087362 2 
H3139E07 SgpIl AW554387 10 
H3136E12 Ucp2 	BG087187 	7 Down 
Ccr14l - carbon catabolite repression 4-like; Tst - Thiosulfate sulfurtransferase; Adcy3 - Adenylate 
cyclase 3; SgplI - sphingosine phosphate lyase 1; Sdc4 - Syndecan 4; Ucp2 - Uncoupling protein-2. 
Of the other three ESTs upregulated in the F-line, H3113D06 may be of further 
interest, as it matches to adenylate cyclase 3 (Adcy3), a gene involved in the 
conversion of intracellular ATP to cyclic AMP (cAMP) - a disruption in this 
mechanism may contribute towards an obese phenotype (Patel et al. 2001). 
H3138F12 matches to the mChr2 gene Syndecan 4 (Sdc4), also known as 
amphiglycan and ryudocan. The syndecans are a family of four cell surface heparan 
sulfate proteoglycans that mediate aspects of cell behaviour in vertebrates, including 
cell adhesion and the action of growth factors (Spring et al. 1994). 
Finally, examining the features that are differentially upregulated in the congenic line 
compared to the F-line, only one EST meets the selection criteria, H3136E12. This is 
a mChr7 EST that matches to uncoupling protein-2 (Ucp2), a potential obesity target 
discussed in section [1.1.2.3.2]. Across the two arrays, the within slide differences 
are significant (P<0.05), with expression 2.5 times greater in the congenic line [Table 
3.3.9]. 
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Table 3.3.9: Exp 4 - Lo92-ratios and t-test P-values of the consistently differentially expressed 
ESTs in BAT 
Expression 
	
Lo92 	Fold 	Normalised intensities 	 relative to 
Ratio 	Difference F-line Conenic P-value 	F-line 
H3098E12 A19 -1.16 	2.23 	3,163 	1,419 	0.002 
(Ccrn4() A20 -1.17 2.25 	2,599 1,154 0.006 
H3101Al2 A19 -1.16 	2.24 	1,783 	795 	0.3 
(Ccrn4t) A20 -1.24 2.36 	1,157 491 0.09 
1-131351-104 A19 -1.63 	3.09 	2,206 	715 	0.06 
(Tst) A20 -2.20 4.61 4,521 983 0.05 
Up 
H3113D06 A19 -1.02 	2.03 	3,898 	1,919 	0.2 
(Adcy3) A20 -1.07 2.10 6,412 3,057 0.07 
H3138F12 A19 -1.22 	2.33 	4,923 	2,115 	0.1 
(Sdc4) A20 -1.45 2.72 	7,177 2,632 0.1 
H3139E07 A19 -1.16 	2.24 5,456 	2,433 	0.04 
A20 -1.18 2.27 	4,550 2,004 0.003 
H3136E12 A19 2.55 	5.87 	5734 	14646 	0.04 	Down 
(Ucp2) A20 2.51 5.71 8632 21691 	0.008 
P-values are given for each EST within both BAT arrays. Ccrn4I - carbon catabolite repression 4-like; 
Tst - Thiosulfate sulfurtransferase; Adcy3 - Adenylate cyclase 3; Sdc4 - Syndecan 4; Ucp2 - 
Uncoupling protein-2. 
3.3.5.5 	Summary 	of GeneSpringTM analysis 
Under the GeneSpring analysis a total of 16 different ESTs are seen to be 
consistently differentially expressed. Of these, 11 are upregulated in the F-line 
compared to the congenic line, and four of these match sequences on mChr15. Two 
further ESTs match to the same gene (Ccrn4l) and are upregulated in both liver and 
BAT [Fig 3.3.21. 
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EST Gene name GenBank ID Chr 
H3101Al2 Ccrn4I 	BG071607 	3 
H3098E12 Ccrn4l BG071409 3 
EST 	Gene name GenBank ID Chr EST Gene name (3enBank ID Chr 




Adcy3 B72654 12 
I-0139E07 None AW554387 10 
I-0138F12 Rcp BG087362 2 
/ 2 
EST 	Gene name Gen Bank ID Chr - 	EST 	Gene name GenBank ID Chr 
I-t3066B12-3 None 	BG081526 	15 I H31351-C4 	Tst BG074498 	15 
F-t3020H04-3 Sqie BG()77950 	15 t-t3048C08 	None BG066896 	15 
mChrl5 
Fig 3.3.2: Venn diagram showing the total number of differentially expressed ESTs detected 
across the 2-slide NIA 15K microarray set (upregulated in F-line) 
Five of the 16 differentially expressed ESTs are repeatedly down regulated in the F-
line [Fig 3.3.31. None of these are from mChr15, however two are from known 
metabolic genes on other chromosomes, Ucp-2 and Gpd2. 
All these candidates are discussed in greater detail in section [3.3.7] in conjunction 
with the results and candidates identified through the mixed model significance 
analysis 
EST 	Gene name GenBank ID Chr 
I-0005G01 Gpd2 	BG076772 	2 
I-0011C07 None AW539113 2 
I-K3003A09 None 	BG076478 	1 
EST 	Gene name GenBank ID Chr 
I-t3048H09 None 	BG066956 	4 
I-t3136E12 Ucp2 BG087187 7 
Liver BAT 
mChrl5 
Fig 3.3.3: Venn diagram showing the total number of differentially expressed ESTs detected 
across the 2-slide NIA 15K microarray set (ESTs upregulated in the congenic FnlSDline). 
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3.3.6 	MIXED MODEL SIGNIFICANCE ANALYSIS 
3.3.6.1 	Exp 1: Liver - 1st Array set 
For this analysis, the data from the two control self-self hybridisations are included 
in the mixed model analysis, providing greater power. The summary statistics for 
Exp 1 are presented in the volcano plot below [Fig 3.3.4] and discussed here briefly 
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Fig 3.3.4: Volcano plot of Exp 1. Red line indicates 0.05 significance level, green line indicates 
corrected Bonferroni 0.05 corrected level (6.51x10 6). Red squares are mChrl5 ESTs; blue triangles 
are non-mChrl5 ESTs. A negative LSM indicates upregulation in the F-line whilst a positive LSM 
indicates upregulation in the F°' 5 D-line. 
Summary statistics - Global 
. 1331 of 7680 ESTS (17.3%), have a least square mean (LSM) estimate, equating 
to 2-fold (or more) differential expression (all values <1 or >1). 
890 ESTs (11.6%) are significantly differentially expressed at the 0.05 level. 
2 ESTs are significant at the Bonferroni 0.05 experiment wide corrected level 
(6.5 lx 10 6) .  
• 434 ESTs have an LSM equating to 2-fold (or more) differential expression and 
are significant at the 0.05 level, however none are significant at 6.51x10 6 a 
level. 
Q. 
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Table 3.3.10: Exp 1- List of the top 10 ESTs displaying [A] most significant differences and [B] 
most significant 2-fold+ differences, between the F- and congenic r' -'D-line 
Systematic 




SE Difference P-value 
Gene 
symbol 
*1 H301 1 F08 4 0.67 0.07 1.59 0.000000018 None 
*2 H3064F09 7 0.60 0.08 1.52 0.0000013 CInsla 
3 H3066B12 15 -1.87 0.28 3.67 0.000014 None 
4H3015G10 6 -0.75 0.12 1.68 0.000021 Fkbp4 
5 H3008C09 17 -0.87 0.15 1.82 0.000024 None 	A 
6H3080D03 13 -0.71 0.13 1.64 0.000037 Tubb2 
7 H3065E07 5 -0.66 0.13 1.58 0.00011 Ugdh 
8 H3024H06 9 -0.89 0.17 1.85 0.00011 Srprb 
9 H3059F10 12 0.47 0.10 1.38 0.00019 None 
10 H3042C05 12 0.98 0.20 1.97 0.00020 None 
1 H3066B12 15 -1.87 0.28 3.67 0.000014 None 
2 H3042E03 3 1.74 0.38 3.34 0.00030 None 
3 H3047C10 6 -1.04 0.23 2.05 0.00034 S1c6a6 
4 H3079G07 6 -1.06 0.23 2.08 0.00048 Fkbp4 
5 H3037A02 10 -2.52 0.58 5.73 0.00050 Lss 	B 
6 H3020H04 15 -1.12 0.26 2.18 0.00055 SqIe 
7 H3003G07 7 3.29 0.77 9.80 0.00059 Ercc2 
8 H3062G09 3 -1.58 0.37 2.99 0.00060 None 
9 H3046E09 7 1.61 0.38 3.05 0.00064 Nfatc2ip 
10 H3041 G03 16 1.96 0.46 3.89 0.00064 Scf15 
ESTs that are significant at the 6.51x10q level are indicated by * Lo9 2 ratio of LSM is given with 
standard error (SE). None' indicates that the EST has no currently defined gene name. Candidates of 
interest are highlighted in bold typeface. Cinsla - Chloride channel nucleotide-sensitive IA; Fkbp4 - 
p59 immunophilin / FK506 binding protein 4; Tubb2 - tubulin beta 2; Ugdh - UDP-glucose 
dehydrogenase; Srprb - signal recognition particle receptor B subunit; S1c6a6 - solute carrier family 6 
(neurotransmitter transporter, taurine) member 6; Lss - lanosterol synthase (oxidosqualene cyclase); 
Sqie - squalene epoxidase; Ercc2 - excision repair cross-complementing rodent repair deficiency 
complementation group 2; Nfatc2ip - nuclear factor of activated T-cells cytoplasmic 2 interacting 
protein; Scfl5 - solute carrier family 15 (1-1+/peptide transporter). 
Summary statistics - mChrlS 
. Of 291 mChr15 ESTs, 27 are significant at the 0.05 level, 0 at the experiment 
wide 6.5 lx 10 6a significance level. 
• 49 have a 2-fold+ differential, of which 10 are significant at the 0.05 significance 
level [Table 3.3.11]. 
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Table 3.3.11: Exp 1 - List of 10 mChr15 ESTs displaying most significant 2-fold+ differences, 
between the F- and congenic r'5D-line 
Systematic 




SE Difference P-value 
Gene 
symbol 
11­130661312 55.4 -1.87 0.28 3.67 0.000014 None 
2H3020H04 59.5 -1.12 0.26 2.18 0.00055 SqIe 
3H3069C10 40.4 2.07 0.61 4.20 0.0036 None 
4H3057E01 99.2 -1.69 0.56 3.23 0.0086 Prkagl 
5H3069E03 11.0 1.54 0.52 2.91 0.0092 None 
6H3050E08 83.4 -2.03 0.76 4.07 0.017 Dial 
7H3036E08 100.2 -1.46 0.57 2.75 0.020 Eplin 
8H3042A09 103.0 -1.58 0.65 3.00 0.027 None 
9H3078G01 99.1 1.64 0.70 3.12 0.032 None 
10H3069E04 24.5 1.45 0.68 2.73 0.050 None 
Significance is at the 0.05 level. Mb is the blast position to mChrl5 in mega base pairs. Lo9 2 ratio of 
LSM is given with standard error (SE). 'None' indicates that the EST has no currently defined gene 
name. Sqie - squalene epoxidase; Prkagl - protein kinase AMP-activated gamma 1 non-catalytic 
subunit; Dial - NADH-diaphorase; Eplin - epithelial protein lost in neoplasm-a. 
Discussion 
The three ESTs detected upregulated in the F-line using the GeneSpring-method 
(H30661312, H30801)03 and H3020H04), feature prominently in the significance 
analysis, with P-values ranking 31(1 ,  6th and 22 d  most significant respectively [Table 
3.3.10]. However none of the ESTs identified down-regulated in the F-line using the 
GeneSpring-method were identified in the significance analysis [Table 3.3.12]. 
The two ESTs displaying the most significant differences, H301 1F08 and H3064F09, 
and that are also significant at the Bonferroni corrected level, were missed in the 
GeneSpring analysis as expression was only upregulated by 50-60% in the congenic 
line relative to the F-line [Table 3.3.10]. 
Only two of the top ten differentially expressed ESTs are located on mChr15. These 
are H3066B12, which is also the most significant 2-fold+ EST [Table 3.3. lOB]; and 
H3020H04, which matches to Sqie. EST H3037A02 [Table 3.3.1013] is of further 
interest, as it matches the Lanosterol gene (Lss) on mChrlO. Lanosterol is an enzyme 
involved in the cholesterol biosynthesis pathway, as is squalene epoxidase. The EST 
H3065E07 [Table 3.3.I0A] identified from the significance analysis, is of additional 
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interest as it matches to the metabolic gene UDP-glucose dehydrogenase (Ugdh) on 
mChr5. 
Table 3.3.12: List of the GeneSpring derived differentially expressed ESTs from Expi 
Expression 
Systematic Gene 	L092 	Fold 	 relative to 
NIA code symbol Chr Ratio Difference P-value Rank F-line 
1-130661312 None 15 -1.87 3.67 0.000014 3d 
H3080D03 None 1 -0.71 1.64 0.000037 61h 	Up 
H3020H04 SqIe 15 -1.12 2.18 0.00055 22' 
1.00 
H3005G01 Gpd2 2 -1.63 3.09 0.21 2431 
H3011C07 None 2 1.56 2.94 0.046 761 s' 	Down 
H3003A09 None 10 2.42 5.36 0.062 
9681F  
Rank refers to the position of the EST for overall significance (out of 7680). SqIe - squalene 
epoxidase; Gpd2 - glycerol phosphate dehydrogenase 2. 
Where there are two or more independent ESTs for the same gene showing 
differential expression, as in the Ccrn4l gene discussed above [section 3.3.5.3 & 
3.3.5.4], then the evidence that the gene is truly differentially expressed is more 
convincing. Here, although two ESTs (H3057E01 & H3078G01) are positioned close 
to each other on mChr15 (99.2 and 99.1Mb respectively), they are differentially 
expressed in opposite directions (H3057E01 is upregulated in the F-line, whilst 
H3078G01 is down regulated in the F-line), and an examination of the Ensemble 
Mouse Genome database reveals that they are members of distinctly separate genes 
[Table 3.3.11]. 
3.3.6.2 	Exp 2: BAT - 1st Array set 
Due to the poor yield of BAT RNA, control self-self hybridisations were not 
performed. As a result of this, degrees of freedom are reduced relative to Exp 1, and 
differences are generally less significant. 
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Summary statistics - Global 
• 1287 of 7680 ESTS (16.8%) have a LSM estimate, equating to 2-fold (or more) 
differential expression. 
• 621 ESTs (8.1%) are significantly differentially expressed at the 0.05 level. 
• 1 EST is significant at the experiment wide 6.51x10 6ct level. 
• 178 ESTs have an LSM equating to 2-fold (or more) differential expression and 
are significant at the 0.05 significance level - however, none are significant at 
the experiment wide 6.51x10 6ct significance level. 
Table 3.3.13: Exp 2 - List of the top 10 ESTs displaying [A] most significant differences and [B] 
most significant 2-fold+ differences, between the F- and congenic r 15D-line 
Systematic 




SE Difference P-value 
Gene 
symbol 
*1 H3027E08 2 -0.973 0.114 1.96 0.0000068 Enol 
2 H3011G11 9 -1.109 0.137 2.16 0.000010 None 
3 H3008H10 4 -0.711 0.088 1.64 0.000011 None 
4 H3073H11 14 -1.198 0.160 2.29 0.000021 Fdftl 
5 H3080D01 5 -0.868 0.127 1.82 0.000044 Ubc 	A 
6 H3038B06 16 -1.473 0.217 2.78 0.000048 None 
7 H3019E08 8 -0.912 0.141 1.88 0.000073 Itgbl 
8 H3012C06 5 -0.875 0.158 1.83 0.00025 Scarbi 
9 H3003B05 10 -0.969 0.175 1.96 0.00025 U2af26 
10 H3078CO3 N  0.680 0.123 1.60 0.00026 None 
1 H3011G11 9 -1.109 0.137 2.16 0.000010 None 
2 H3073H11 14 -1.198 0.160 2.29 0.000021 Fdftl 
3 H3038B06 16 -1.473 0.217 2.78 0.000048 None 
4 1­130061306 15 -1.538 0.318 2.90 0.00069 None 
5 H3063D10 16 -1.060 0.241 2.08 0.0013 Gbel 	B 
6 H3030G06 N  -1.456 0.331 2.74 0.0014 None 
7 H3020H04 15 -2.022 0.469 4.06 0.0015 SqIe 
8 H3066B12 15 -4.639 1.096 24.92 0.0017 None 
9 H3061E01 16 1.295 0.310 2.45 0.0019 None 
10 H3012A11 M -1.271 0.308 2.41 0.0021 Gapd 
ESTs that are significant at the 6.51x10 6q level are indicated by *• Lo9 2 ratio of LSM is given with 
standard error (SE). 'Nm' indicates that there was no-match to the current mouse genome sequence. 
'M' indicates multiple blast hits to entire genome. 'None' indicates that there is no currently defined 
gene name for this EST. Interesting candidates are highlighted in bold typeface. Enol - enolase 1; 
FdftI - farnesyl diphosphate farnesyl transferase 1; Ubc - ubiquitin C; 11gb 1 - integrin beta 1; Scarbi - 
scavenger receptor class B member 1; U2aJ26 - U2 auxiliary factor 26; GbeI - glucan (1,4-alpha-) 
branching enzyme 1; SqIe - squalene epoxidase; Gapd - glyceraldehyde-3-phosphate dehydrogenase. 
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Fig 3.3.5: Volcano plot of Exp 2. Red line indicates 0.05 significance level, green line indicates 
corrected Bonferroni 0.05 corrected level (6.51x10 6 ). Red squares are mChr15 ESTs; blue triangles 
are non-mChrl5 ESTs. 
Summary statistics - mChr15 
• Of 291 mChr15 ESTs, 32 are significant at the 0.05 level, none at the experiment 
wide 6.51x10 6ct significance level. 
• 60 have a 2-fold+ differential, of which 14 are significant at the 0.05 significance 
level [Table 3.3.141. 
Table 3.3.14: mChrlS 2-fold+ significantly differentially expressed ESTs in BAT 
Systematic L092 Fold Gene 
NIA code Mb Ratio SE Difference P-value symbol 
11-130061306 51.9 -1.54 0.32 2.90 0.00069 None 
2H3020H04 100.2 .2.02 0.47 4.06 0.0015 SqIe 
3 H306661 103.0 -4.64 1.10 24.92 0.0017 None 
4H3071G04 6.1 1.05 0.35 2.07 0.014 None 
5H3075D12 99.3 -2.78 1.03 6.86 0.022 Limr 
6H3059D11 81.2 .2.14 0.80 4.41 0.024 None 
71-130751-112 76.6 -1.67 0.65 3.19 0.028 Hpa 210 
81-13003C12 82.3 2.04 0.81 4.12 0.030 Soat2 
9 H303160 100.6 2.15 0.88 4.45 0.034 None 
10H3005H11 34.2 1.18 0.50 2.27 0.039 Lyric/3D3 
11 H3064H09 60.5 1.68 0.72 3.20 0.041 None 
12H3051E06 89.7 2.18 0.96 4.52 0.046 A1dr16 
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13 H30671305 30.2 2.22 0.99 	4.65 	0.049 None 
14H3065F02 	71.8 1.19 0.53 2.28 0.050 	None 
Significance is at the 0.05 level. Mb is the blast position to mChr15 in mega base pairs. Lo9 2 ratio of 
LSM is given with standard error (SE). Sqie . squalene epoxidase; Limr - lipocalin-1 interacting 
membrane receptor; Hpa 210 (HPA1) repetative DNA sequence; Soat2 - sterol 0-acyltransferase 2; 
AIdr16 - aldehyde reductase-like 6. Genes denoted by * are mouse homologes of human genes. 
Discussion 
Of the top ten ESTs showing the most significant differences in expression between 
the F- and congenic-lines, none match with mChrlS sequences [Table 3.3.13A]. 
However, there are a number of candidates of notable interest due to their metabolic 
activities. These are; enolase 1 (Eno]) the gene product of which is a multifunctional 
protein with a key function in glycolysis and gluconeogenesis (Pancholi, 2001); and 
glyceraldehyde-3-phosphate dehydrogenase (Gapd), the gene product of which is 
also involved in the glycol ysis/gluconeogenesis pathway (Hanauer & Mandel, 1984). 
Two further differentially expressed genes generate products involved in the 
cholesterol biosynthesis pathway, farnesyl diphosphate famesyl transferase 1 (Fdftl, 
also known as squalene synthase, Sqs) (Soltis et at. 1995) and Sqie [see section 
3.3.8.2]. Finally an additional candidate glucan (1,4-alpha-) branching enzyme 1 
(Gbel) is involved in the metabolism of complex carbohydrates (Barker et al. 1949). 
Of the top ten ESTs displaying a significant 2-fold+ difference [Table 3.3.13B], three 
are from mChr15, and two of these have already been identified as differentially 
expressed in liver (H3066B12 and Sqie) [Table 3.3.10, 3.3.11]. However, the third 
mChr15 EST (H3006B06) appears to be specifically differentially expressed in BAT 
(P-value in liver = 0.84). 
A total of 14 mChr15 ESTs were found to have a P-value of less than 0.05 [Table 
3.3.14]. From this list, one gene of interest is sterol 0-acyltransferase 2 (Soat2) 
which is involved in the esterification of cholesterol (Joyce et at. 1999); and another 
is aldehyde reductase-like 6 (Aldr16), which is involved in the metabolism of 
complex lipids (Amer et at. 2001). 
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Of the four ESTs identified using the GeneSpring analysis in Exp 2 [Table 3.3.4, 
3.3.5], those corresponding to Sqie (H3020H04) and Scd2 (H30251303) are also 
identified in the significance analysis, and are both significant to the standard 0.05 
level, having fold differences of four and six respectively. They rank 39th and 65th 
overall in significance, and 7th  and 17th  respectively of the most significant 2-fold 
ESTs [Table 3.3.151. Of the two further ESTs identified in the GeneSpring analysis, 
the unknown EST H3048C08 is estimated to be upregulated slightly less than 2-fold 
(1.85) in the F-line, with and a P-value that meets the standard 0.05 level. 
H3048H09, the final EST from the GeneSpring analysis, has —3-fold change, but this 
is not significant with a P-value exceeding 0.05, and is outwith the QTL region on 
mChrlS [Table 3.3.15]. 
Table 3.3.15: List of the GeneSpring derived differentially expressed ESTs from Exp2. 
Expression 
Systematic Gene L092 Fold relative to 
NIA code symbol Chr Ratio Difference P-value Rank F-line 
H3020H04 SqIe 15 -2.02 4.06 0.0015 29 
H30251303 Scd2 19 -2.42 5.36 0.0039 65 	Up 
H3048C08 None 15 -0.89 1.85 0.011 166 
H3048H09 None 	4 	1.53 	2.89 	0.11 1148 Down 
Rank refers to the position of the EST for overall significance (out of 7680). SqIe - squalene 
epoxidase; Scd2 - stearoyl -coenzyme A desaturase 2. 
The GeneSpnng analysis did not detect two other important ESTs identified through 
the significance analysis, the unknown mChrlS EST, H30061306, and H3012A11 
that corresponds to Gapd. 
3.3.6.3 	Exp 3: Liver - 2nd Array set 
As in Exp 1, the data from the two control arrays were combined with the data from 
the six experimental arrays in the mixed model to generate a more robust analysis. 
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Summary statistics - Global 
• 62 of 7567 ESTS (0.8%), have a least square mean (LSM) estimate, equating to 
2-fold+ difference in gene expression. 
• 396 ESTs (5.2%) are differentially expressed at the 0.05 significance level. 
• 10 ESTs are differentially expressed at the experiment wide 6.51x10 6 a level. 
• 31 ESTs have an LSM equating to 2-fold+ difference in gene expression at the 
0.05 significance level - none at the experiment wide 6.51x10 6 a level. 
Table 3.3.16: Exp 3 - List of the top 10 ESTs displaying [A] most significant differences and [B] 
most significant 2-fold+ differences, between the F- and congenic r'5D-line 
Systematic L092 Fold Gene 
NIA code Chr Ratio SE Difference P-value symbol 
*1 H3095E04 11 0.848 0.08 1.80 0.0000000010 None 
*2 H3131A03 11 -0.619 0.09 1.54 0.00000035 Hspbl 
*3 H3138D03 1 0.519 0.08 1.43 0.00000064 None 
*4 H3131 B05 10 -0.596 0.09 1.51 0.0000010 None 
*5 H3118A10 8 0.465 0.07 1.38 0.0000010 None 	A 
*6H3126A10 11 0.414 0.06 1.33 0.0000016 Hba-a1 
*7 H3158E10 X 0.545 0.09 1.46 0.0000029 None 
*8 H3098E12 3 0.823 0.14 1.77 0.0000040 Ccrn41 
*9 H3155A03 2 0.535 0.09 1.45 0.0000044 None 
*10 H3132G12 11 -0.471 0.08 1.39 0.0000053 Fasn 
1 H3149B01 12 -1.545 0.52 2.92 0.0073 None 
2 H3148H01 2 2.356 0.80 5.12 0.0075 None 
3 H3134A01 9 -1.403 0.51 2.64 0.011 None 
4 H3089A01 8 1.227 0.45 2.34 0.013 None 
5 H3148H03 14 -1.707 0.64 3.26 0.014 None 	B 
6 H3159D10 14 -1.066 0.42 2.09 0.018 None 
7 H3158H06 5 1.589 0.62 3.01 0.018 None 
8 H3128H09 11 -1.382 0.56 2.61 0.021 None 
9 H3108G04 12 -1.005 0.40 2.01 0.021 Cripi 
10 H3119C01 6 1.556 0.64 2.94 0.023 VhIh 
ESTs that are significant at the 6.51x10 6çz level are indicated by *• None' indicates that there is no 
currently defined gene name for this EST. Interesting candidates are highlighted in bold typeface. 
Hspbl - heat shock protein 1 alpha; Hba-al - haemoglobin alpha adult chain 1; Ccrn4l - carbon 
catabolite repression 4-like; Fasn - fatty acid synthase; Cripi - cysteine-rich protein 1; Vhlh - von 
Hippel-Lindau syndrome homolog. 
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Summary statistics - mChr15 
282 mChr15 ESTs, 18 are differentially expressed between the F- and congenic-
line the 0.05 significance level, while none are differentially expressed at the 
experiment wide 6.51x10 6 (X significance level. 
• Two have a 2-fold+ difference in expression between the F- and congenic-line, 
one is significant at the 0.05 significance level [Table 3.3.17]. 
Table 3.3.17: Exp 3 - mChr15 ESTs with a 2-fold+ difference in expression in liver between the 
F. and congenic FdJISD.line 
Systematic L092 Fold Gene 
MA code Mb Ratio SE Difference P-value 	symbol 
1 H3118F01 86.2 	1.540 0.72 	2.91 0.043 	Gtsel 
2H3110008 12.8 	1.022 0.63 2.03 0.12 Rnase3 
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Fig 3.3.6: Volcano plot of Exp 3. Red line indicates 0.05 significance level, green line indicates 
corrected Bonferroni 0.05 corrected level (6.51x10 6). Red squares are mChrlS ESTs; blue triangles 
are non-mCh15 ESTs. 
Discussion 
The GeneSpring analysis is similar to the significance analysis, in that there are very 
few differentially expressed candidate ESTs from this experiment. As with the 
0. 
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previous experiments, the most significantly differentially expressed ESTs, do not 
differ by more than 2-fold. 
Of the top ten most significantly differentially expressed ESTs [Table 3.3.16A], all 
significant at the Bonferroni experiment-wide level (6.51x10 6a), none match 
sequences on mChr15. However, the mChr3 candidate 1-131281109 (Ccrn4l) gene, 
identified though the GeneSpring analysis [Table 3.3.6], is identified as the 8th  most 
significantly differentially expressed EST, just short of a 2-fold differential. The 
second Ccr14l EST - identified through GeneSpring analysis - is the 100th  most 
differentially expressed EST (Lo92 estimate = 0.76; P=0.007). 
A second candidate, (No.10 [Table 3.3.16A]) H3132G12, matches to the mChrll 
metabolic, fatty acid synthase gene (Fasn), which may be a likely candidate, 
although there is only a 39% increase in expression in the F-line compared to the 
congenic F' 5D-line. Four of the top ten significant ESTs match sequences on 
mChrll, however all are likely to be independent genes given that they match to 
distinctly separate regions on the chromosome (5.9, 78.1, 32.4 and 121.7Mb 
respectively for each EST in rank order). 
Using 	the 	data 	from 	the 	FANTOM 	database 	(http://fantom . 
gsc.riken.go.jp/viewer/index.html),  a gene annotation search was carried out using 
the gene ontology terms 'metabolic' and 'energy'. This revealed a list of 2158 
annotated genes within the mouse genome. This list was then queried to determine 
the metabolic gene number, and ratio per Mb for each chromosome [Fig 3.3.91. 
Whilst mChrl 1 has an above average ratio of metabolic genes per Mb, it neither has 
the highest net number of metabolic genes, nor the highest density of metabolic 
genes. Why mChrl 1 should have so many significantly differentially expressed ESTs 
is difficult to interpret, it may just be an incidental artefact. 
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Fig 3.3.7: Ratio of metabolic genes per Mb for each mChr. Metabolic genes are characterised by 
either a gene ontology hit to the word metabolic' or energy' in the FANTOM database. Net  number 
of hits for each chromosome is given above bars. 
Of the top ten ESTs with 2-fold+ difference in expression between the F- and 
congenic-lines, none match to mChr15, and none match known metabolic genes 
[Table 3.3.16B]. Of the 18 significantly differentially expressed mChrlS ESTs (P < 
0.05), one shows a 2-fold+ difference in expression, while the remaining 17 show 
little variation in expression, ranging from 2-64%, with a mean of just 15% [data not 
shown]. 
To summarise, although there are ten ESTs that are clearly highly significant (i.e. 
meet the Bonferroni adjusted significance level), none match to mChrlS, and as a 
result the most interesting candidates for this study are the Ccr141 gene-associated 
ESTs, and the Fasn EST. 
3.3.6.4 	Exp 4: BAT- 2 nd  Array set 
As a result of the low yield of BAT RNA, as in Exp 2, no control self-self 
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Consequently, the power of this analysis is reduced, and P-values are generally less 
significant. 
Summary statistics - Global 
• 494 of 7567 ESTS (6.5%), have a least square mean (LSM) estimate, equating to 
2-fold+ differential expression between the F- and congenic-lines. 
627 ESTs (8.3%) are significantly differentially expressed at the 0.05 level. 
• No EST was found to have a significant difference at the experiment wide 
6.51x10 6 a level. 
• 19 ESTs have an LSM equating to a 2-fold+ difference in expression between 
the F- and congenic-lines and are significant at the 0.05 level. 
Table 3.3.18: Exp 4 - List of the top 10 ESTs displaying [A] most significant differences and [B] 
most significant 2-fold+ differences, between the F- and congenic FchrI5D-line 
Systematic L092 Fold Gene 
NIA code Chr Ratio SE Difference P-value symbol 
1 H3101C10 10 -0.499 0.03 1.41 0.000046 Gapd 
2 H3085A03 M 0.568 0.03 1.48 0.000073 None 
3 H3089G11 M 0.591 0.04 1.51 0.000081 None 
4 H3135H04 15 1.946 0.12 3.85 0.000083 Tst 
5 H31 33B1 0 M 0.469 0.03 1.38 0.00011 None 	A 
6 H3153C09 11 0.394 0.03 1.31 0.00014 Timp2 
7 H31461310 7 0.420 0.03 1.34 0.00015 Bcat2 
8 H30891310 6 0.285 0.02 1.22 0.00018 None 
9 H3138A02 7 0.340 0.03 1.27 0.00018 Pak4 
10 H3124G09 11 0.318 0.02 1.25 0.00021 Fbfl 
1 H3135H04 15 1.946 0.12 3.85 0.000083 Tst 
2 H3098E12 3 1.288 0.11 2.44 0.00027 Ccrn4I 
3 H3087005 M 1.077 0.10 2.11 0.00036 None 
4 H3090F04 5 -1.005 0.10 2.01 0.00065 Chst12 
5 H3136E12 7 -1.183 0.14 2.27 0.0011 Ucp2 	B 
6 H31 00H06 2 1.241 0.17 2.36 0.0018 None 
7 H3139E07 10 1.459 0.24 2.75 0.0039 SgpIl 
8 H3101Al2 3 1.346 0.23 2.54 0.0042 Ccrn4I 
9 H3138F12 2 1.409 0.26 2.66 0.0060 Sdc4 
10 H3136C07 7 1.576 0.32 2.98 0.0082 Bnip3 
ESTs that are significant at the 6.5100 69. level are indicated by * 'None' indicates that there is no 
currently defined gene name for this EST. 'M' indicates multiple blast hits to whole genome. 
Interesting candidates are highlighted in bold typeface. Gapd - glyceraldehyde-3-phosphate 
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dehydrogenase; Tsr - thiosulphate sulfurtransferase mitochondrial; Titnp2 - tissue inhibitor of 
metal loproteinase 2; Bcat2 - branched chain aminotransferase 2, mitochondrial; Pak4 p2! 
(CDKN1A)-activated kinase 4; FbfI - fas binding factor 1; Ccrn4J - carbon catabolite repression 4-
like; ChstI2 - carbohydrate sulfotransferase 12; Ucp2 - uncoupling protein 2; SgpII - sphingosine 
phosphate lyase 1; Sdc4 - syndecan 4; Bnip3 - BCL2/adenovirus E1B l9kDa-interacting protein 1, 
NIP3. 
Summary statistics - mChrlS 
Of 282 mChr15 ESTs, 22 are significantly different at the 0.05 level, with none 
at the experiment wide 6.51x10 6a level. 
. 20 have a 2-fold+ differential, with one significant at the 0.05 level (H3135H04 - 
78.6Mb; see Table [3.3.18]). 
a 
- 
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Fig 3.3.8: Volcano plot of Exp 4. Red line indicates 0.05 significance level, green line indicates 
corrected Bonferroni 0.05 corrected level (6.51x10 6 ). Red squares are mChrl5 ESTs; blue triangles 
are non-Ch 15 ESTs. 
Discussion 
The analysis of experiment-4 is limited by the lack of hybridisation repeats. 
Nonetheless a number of ESTs are identified to be of particular interest. Of the six F-
line up-regulated ESTs identified through GeneSpring analysis [Table 3.3.8], all are 
confirmed through the significance analysis and (with the exception of H3113D06), 
are in the top ten list of 2-fold+ differentially expressed ESTs [Table 3.3.18131. The 
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most highly significant is the mChr15 EST H31351104, which corresponds to the Tsr 
gene (P=0.00083). The two Ccrn4l ESTs identified in the GeneSpring analysis 
(H3098E12 & H3101Al2), are not in the top list of differentially expressed ESTs 
[Table 3.3.18A], however they are both in the top ten list of ESTs showing a 2-fold+ 
difference [Table 3.3.18B]. The three remaining F-line up-regulated ESTs identified 
in the GeneSpring analysis (H3113D06, H3138F12 & H3139E07) are all confirmed 
to show a 2-fold+ difference, although the P-values while significant at the 
0.05 level, are relatively low compared to other ESTs in this experiment (P= 0.02, 
0.006 and 0.004). These three ESTs rank in overall significance at positions 347, 137 
and 93 respectively. The single EST identified as down-regulate (H3136E12: Ucp2) 
is confirmed in the significance analysis and is the 5th  most significant 2-fold+ 
differentially expressed EST [Table 3.3.18131. However the P-value is still relatively 
low (P=0.001). 
The ESTs [table 3.3.18] H3I01C1O showing the most significant differential 
expression in this experiment, is of particular interest as it matches to the metabolic 
gene gi yceraldehyde-3 -phosphate dehydrogen ase (Gapd). However, sequence from 
this gene matches with extremely high homology to over 300 different mouse 
genomic locations, six of which are on mChr15. Due to the number of 
homologues/pseudogenes, further analysis of the expression profile of this gene 
would constitute a major undertaking. 
3.3.6.5 	Summary of mixed model significance analysis 
Use of the GeneSpring analysis readily identified candidates showing considerable 
differences in gene expression between the F- and congenic-lines. However, the 
significance analysis has generally proved more thorough, identifying ESTs with 2-
fold+ differences that were missed by the GeneSpring analysis, and identifying 
potentially important significantly differentially expressed ESTs that do not 
necessarily reach the order of 2-fold. 
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As the overall aim is to identify genetic components of the Fob3b obesity QTL on 
mChr15, we have concentrated primarily on mChr15 candidates. However, we have 
also considered metabolic genes of known identity, and also other ESTs showing 
highly significant differences in expression between the F- and congenic-lines. 
Across the four experiments, 13 ESTs were found to be differentially expressed at 
the Bonferroni 0.05 corrected significance level [Table 3.3.19], although none of 
these are mChr15 ESTs, and none had a 2-fold+ differential expression profile. 
Nonetheless, two of these are potential candidates as they match to genes involved in 
metabolic pathways - H3098E12 (Ccrn4l) and H3027E08 (Eno]) [Table 3.3.19] 
(discussed in more detail in section [3.3.7]). In total there are 99 significantly 
differentially expressed mChr15 ESTs (P<0.05), and of these, 27 also have a 2-fold+ 
differential. 
Table 3.3.19: ESTs displaying a difference in expression between the F- and congenic 	' 5D- 
line at the experiment wide 6.51x10 6a significance level (P-values are given to a Log 10 scale) 
Systematic L092 Fold Log 10 P- Gene 
MA code Chr Ratio Difference SE value symbol 
H3095E04 11 0.848 1.80 0.084 -9.00 None 
H301 1 F08 4 0.673 1.59 0.065 -7.74 None 
H3131A03 11 -0.619 1.54 0.086 -6.46 Hspbl 
H3138D03 1 0.519 1.43 0.075 -6.19 None 
1-131311305 10 -0.596 1.51 0.089 -6.00 None 
H3118A10 8 0.465 1.38 0.070 -5.99 None 
H3064F09 7 0.602 1.52 0.081 -5.88 CInsla 
1-13126A10 11 0.414 1.33 0.064 -5.79 Hba-al 
1-13158E10 X 0.545 1.46 0.088 -5.55 None 
H3098E12 3 0.823 1.77 0.135 -5.39 Ccm4I 
H3155A03 2 0.535 1.45 0.088 -5.36 None 
H3132G12 11 -0.471 1.39 0.079 -5.28 None 
H3027E08 2 -0.973 1.96 0.114 -5.17 Enol 
Hspbi - heat shock protein I alpha; Cinsia - Chloride channel nucleotide-sensitive 1A; Hba-al - 
haemoglobin alpha adult chain 1; Ccrn4l - carbon catabolite repression 4-like; Enol - Enolase 1. 
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3.3.7 SIGNIFICANCE OF FOLD CHANGE (Sf) 
ADJUSTMENT 
In order to identify ESTs that have both a large difference in fold change and a 
highly significant P-value, the significance of fold change (SO adjustment has been 
applied [section 2.2.4.5] to all ESTs from all the experiments. A total of 44 different 
ESTs (two being significant in both liver and BAT) were found to have an Sf value 
of less than 6.51x10 6. From table [3.3.20] it can be seen that of the total 15,000 
ESTs examined, the most highly relevant differentially expressed EST is that of the 
mChr15 EST H3066B12, which is highly relevant in both BAT and liver (positions 1 
and 3 respectively). Tst (8th)  and Sqie (26th)  also rank highly and are both on 
mChr15. Two additional non-mChr15 genes, Lss (5th)  and Fdftl (30th),  appear high 
up in the list, and along with Sqie, code for proteins involved in consecutive steps of 
the cholesterol biosynthesis pathway [3.3.8.3]. Scd2 is also prominent in the list, and 
is known to influence and be influenced by cholesterol metabolism (Ntambi & 
Miyazaki, 2004). 
As half of the ESTs listed in table [3.3.20] are derived from genes that are as yet 
uncharacterised, these cannot be correlated with pathways that may be involved in 
the Fob3b QTL effect. Further analysis of these ESTs and their potential 
involvement in the Fob3b QTL await better annotation of the mouse genome. 
Table 3.3.20: ESTs showing differences in expression between the F- and congenic r'5D-line at 
the 6.51x10 6a significance level (after significant-fold (SO transformation). GenBank IDs for both 
forward and reverse sequences for each EST were manually blasted against NCBI and Ensemble 
databases. 
Systematic Log2 Fold Gene 
Exp Tissue 	NIA code Chr Ratio SE Difference P-value St symbol 
1 2 BAT H3066B12 15 -4.639 1.10 24.92 0.0017 1.6E-13 None 
2 1 Liver H3003G07 7 3.293 0.77 9.80 0.00059 2.3E-11 Ercc2 
3 1 LiverH3066B12 15 -1.875 0.28 3.67 0.000014 7.5E-10 None 
4 1 LivorH3Ol3EO9 14 3.438 1.02 10.84 0.0038 4.9E-09 None 
5 1 LiverN3O37AO2 10 -2.518 0.58 5.73 0.00050 4.9E-09 Lss 
6 1 Liver H3O46Dl2 10 3.011 0.80 8.06 0.0020 7.5E-09 Daxx 
7 4 BAT 1-131351-104 15 1.946 0.12 3.85 0.000083 1.1E-08 Tst 
8 1 LiverH3O63AO9 1 -2.705 0.68 6.52 0.0014 1.9E-08 Rassf5 
9 3 LiverH3095EO4 11 0.848 0.08 1.800.0000000010 2.3E-08 None 
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10 2 BAT H3060B05 4 -2.931 0.80 7.63 0.0043 1.1E-07 None 
11 1 LiverH3O69CO3 3 -2.301 0.60 4.93 0.0015 3.OE-07 None 
12 2 BAT H3062F09 5 -2.757 0.76 6.76 0.0046 3.7E-07 None 
13 2 BATH3038B06 16 -1.473 0.22 2.78 0.000048 4.3E-07 None 
14 1 LiverH3O44EOl 2 2.061 0.50 4.17 0.00085 4.7E-07 None 
15 1 LiverH3O77CO9 1 -2.422 0.68 5.36 0.0025 4.8E-07 Naplil 
16 1 Liver H3O6lGO4 16 -2.935 0.95 7.65 0.0072 5.1E-07 Nit2 
17 2 BATH3O14AO6 16 3.345 1.11 10.16 0.013 5.2E-07 Hspbapl 
18 1 Liver H3041 G03 16 1.960 0.46 3.89 0.00064 5.5E-07 Scf15 
19 1 LiverH3O42EO3 3 1.742 0.38 3.34 0.00030 7.5E-07 None 
20 1 Liver H3042E04 18 3.250 1.17 9.51 0.013 7.8E-07 None 
21 1 Liver H3050A10 3 2.373 0.67 5.18 0.0028 8.4E-07 None 
22 1 LiverH3004EO6 11 2.560 0.76 5.90 0.0045 9.8E-07 None 
23 1 LiverH3O22AO4 11 2.230 0.61 4.69 0.0021 1.1E-06 Pgsl* 
24 1 LiverH3045H12 12 -3.170 1.14 9.00 0.014 1.2E-06 None 
25 2 BATH3025BO3 19 -2.422 0.65 5.36 0.0039 1.5E-06 Scd2 
26 2 BATH3O2OHO4 15 -2.022 0.47 4.06 0.0015 2.1E-06 Sqie 
27 1 LiverH3O43CO3 6 2.219 0.63 4.66 0.0028 2.2E-06 None 
28 1 LiverH3070A03 8 2.107 0.58 4.31 0.0021 2.3E-06 S1c18a1 
29 2 BAT H3039F12 11 2.366 0.64 5.16 0.0043 2.5E-06 Eif4enhf 1 
30 2 BAT H3O73H11 14 -1.198 0.16 2.29 0.000021 2.5E-06 Fdftl 
31 1 LiverH3004GO6 17 3.659 1.54 12.63 0.030 2.8E-06 28SrRNA 
32 2 BATH3011G11 9or14 -1.109 0.14 2.16 0.000010 3.OE-06 Tkt 
33 2 BAT H3001 A04 11 -3.275 1.19 9.68 0.021 3.OE-06 Clqbp 
34 1 Liver H3063F03 6 -2.507 0.80 5.68 0.0063 3.1E-06 None 
35 1 Liver H3073G03 4 -2.424 0.76 5.37 0.0055 3.4E-06 Nasp 
36 1 LiverH3079CO1 Nm -2.785 0.97 6.89 0.011 3.6E-06 None 
37 2 BATH3004GO6 17 3.088 1.09 8.51 0.017 3.7E-06 28SrRNA 
38 2 BAT H3049G08 3 -2.676 0.83 6.39 0.0094 3.7E-06 Nargi 
39 2 BAT H3O41GO7 Nm -2.671 0.83 6.37 0.0095 3.9E-06 None 
40 1 Liver H3036F01 9 -2.742 0,95 6.69 0.011 3.9E-06 Sc5d 
41 1 LiverH3O54CO7 5 2.206 0.65 4.61 0.0036 4.1E-06 None 
42 1 Liverl-13056C12 1 2.953 1.08 7.74 0.015 4.1E-06 Bpagl-n 
43 2 BAT H3015H01 Nm -2.911 0.99 7.52 0.015 4.5E-06 None 
44 4 BAT H3159G07 Nm -2.574 0.53 5.95 0.0086 4.8E-06 None 
45 1 Liver H3OlOEO9 8 -2.259 0.68 4.79 0.0049 6.OE-06 Mt2 
46 1 Liver H3011FO8 4 0.673 0.07 1.59 0.000000018 6.2E-06 Mig-6 
Possible Human orthologs (*). 'Nm' indicates that there was no-match to the current mouse genome 
sequence. Ercc2 - excision repair cross-complementing rodent repair deficiency, complementation 
group; Lss - lanosterol synthase; Daxx - fas death domain-associated protein; Tst - thiosulfate 
sulfurtransferase mitochondrial; Rassf5 - Ras association (RaIGDSIAF-6) domain; Naplil - 
nucleosome assembly protein 1-like 1; NO - Nit protein 2; Hspbapl - Hspb associated protein 1; 
Scfi5 - solute carrier family 15 (H+/peptide transporter); Pgsl - Phosphatidylglycerophosphate 
synthase; Scd2 - stearoyl -coenzyme A desaturase 2; SqIe - squalene epoxidase; SIc/8a1 - solute carrier 
family 18 (vesicular monoamine) member; Eif4enif! - eukaryotic translation initiation factor 4E 
nuclear import factor 1; FdftI - farnesyl diphosphate farnesyl transferase 1. Tkt - transketolase; Clqbp 
- complement component 1, q subcomponent binding protein; Nasp - histone binding protein NASP; 
Nargi - NMDA receptor-regulated gene 1; Sc5d - sterol-05-desaturase; Bpagl-n - dystonin; Mt2 - 
metallothionein 2; Mig-6 - mitogen-inducible gene 6. 
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Fig 3.3.9: Significance of fold (SO plot for all 568 mChr15 ESTs from all 4 experiments. 
Figure [3.3.10] shows all the mChr15 ESTs that are spotted on both slides of the 15K 
set. The EST with the smallest Sf value (1-130661312) maps slightly proximal to the 
Fob3b 95% CI. The second smallest (Tst) maps distally and the third (Sqie) maps 
within the interval. 
Each chromosome was examined graphically for ESTs which had unusually small 
Sf-values compared to the rest of the chromosome. No unusually peaking or 
clustering of ESTs were detected on mChr2, 12 or X; the chromosomes on which the 
other Fob QTL (Fob], 2 and 4 respectively) were detected in the original screen 
(Horvat et al. 2000) [Fig 3.3.11]. 
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Fig 3.3.10: Significance of fold (Sf) plots for mChr2, 12 & X. 
On mChr17 a cluster at 38.3Mb contains matches to the mouse 28s ribosomal gene. 
No other clusters or trends were observed across the remainder of the genome. This 
is reflected in the Table [3.3.20] where the EST matching to the 28s ribosomal gene 
ranks highly within both tissues examined 31" (liver) and 
37th  (BAT). 
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Fig 3.3.11: Significance of fold (Sf) plots for mChr17. Top three hits are for ESTs that match to the 
mouse 28s ribosomal gene. 
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3.3.8 	DISCUSSION OF CANDIDATES GENES 
A number of genes and unknown ESTs have been identified as differentially 
expressed between the F- and congenic-lines, through the use of the GeneSpnng 
analysis, the mixed model significance analysis (MMSA) and the transformed 
significance analysis. Some of the candidates proposed through the GeneSpring 
analysis, have been supported and some excluded as candidates by the MMSA, while 
additional candidates have been identified through the Sf analysis. Here each 
potential candidate is discussed and a hierarchy of candidates to be pursued further is 
proposed. 
3.3.8.1 	Uncharacterised mChr15 EST candidates 
Four mChrl5 ESTs have been identified as differentially expressed from the various 
screening methods employed. These are: H3066B12 (GeneSpringfMMSAISf), 
H3048C08 (GeneSpring), H30061306 (MMSA) and H3069C10 (MMSA). The most 
reliably differentially expressed of these is clearly 1-130661312. H3048C08, which 
maps within 1500bp of H3066B12, may be part of the same gene, and hence 
warrants further investigation along with 1-130661312 [Fig 3.3.10]. Given that both 
H3069C 10 and H3006B06 map further from the Fob3b QTL region, and that the P-
values (and also Sf values) are relatively poor, these unknown ESTs will not be 
further investigated within the scope of this study. 
Table 3.3.21: Uncharacterised mChrl5 ESTs identified as potentially differentially expressed 
candidates 
Systematic L092 Fold 
NIA code Rank Tissue Ratio Difference SE P-value Mb St 
2 BAT -4.64 24.92 1.10 0.0017 55.4 1.6E-13 
H3066B12 
4 Liver -1.87 3.67 0.28 0.000014 55.4 7.5E-10 
H3069C10 57 Liver 2.07 4.20 0.61 0.0036 40.4 8.5E-06 
H3006B06 63 BAT -1.54 2.90 0.32 0.00069 51.9 1.4E-05 
H3048C08 1020 BAT -0.89 1.85 0.29 0.011 55.4 1.9E-02 
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Rank refers to position of Sf value overall across all four experiments and with 	being the most 
significant and 29,8750' being the least significant. 
3.3.8.2 	Characterised mChr15 candidates 
Just two ESTs corresponding to characterised mChrl5 genes have been identified as 
potential candidates for further investigation. H31351-104 which corresponds to Tst, is 
significantly down regulated in BAT of the F-line, relative to the congenic-line, and 
H3020H04 which corresponds to Sqie, ranks highly in both tissues, upregulated in 
the F-line, and lies within the Fob3b QTL region [Table 3.3.22 & Fig 3.3.10]. 
Table 3.3.22: ESTs for previously characterised mChr15 genes identified as potentially 
differentially expressed candidates 
Systematic Gene 	 L092 	Fold 
NIA code symbol Rank Tissue Ratio Difference SE P-value Mb Sf 
H3135H04 	Tst 	8BAT 	1.95 	3.85 0.12 0.000083 78.6 1.1E08 
H3020H04 SqIe 
	
27BAT -2.02 4.06 0.47 0.0015 59.5 
 2.1E-06 
146 Liver 	-1.12 	2.18 0.26 	0.0005 	2.2E-04 
Rank refers to position of Sf value overall across all four experiments and with l being the most 
significant and 29,875th  being the least. 
Sale: Sqie is located on mChr15 (59.5Mb) and codes for a flavoprotein 
monooxygenase found on the endoplasmic reticulum (Ono & Bloch 1975). The 
function of SQLE is to help convert squalene, a 30-carbon linear isoprenoid, to 
lanosterol, a tetracyclic compound. This conversion occurs in two steps, the first step 
of which is catalysed by SQLE, (squalene to squalene-2-3-epoxide) acting as an 
oxidoreductase. Lanosterol is then further processed to cholesterol [Fig 3.3.13]. To 
date, no mutation has been detected in Sqie that gives rise to an impaired cholesterol 
pathway. In fact, for the 19 biosynthetic steps required to generate cholesterol from 
Acetyl-CoA, only 6 mutations (or disorders) have been identified in humans and 
mice (Moebius et al 2000). Sqie is hence a strong candidate for Fob3b and its gene 
expression in the F, L and congenic lines is analysed further in section [3.4.2]. Sqie 
and other non-mChrlS genes involved the cholesterol biosynthesis pathway, are 
further discussed below [Section 3.3.8.3]. 
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Tst - thiosulphate sulfurtransferase, mitochondrial, shown upregulated in F-line BAT, 
but not in liver. Tst is located distally to the Fob3b region at 78.6Mb. TST is a 
mitochondrial enzyme involved in forming iron-sulphur complexes and cyanide 
detoxification [thiosuiphate + cyanide = sulfite + thiocyanate]. The wider biological 
role of Tst and its protein family (rhodanese/Cdc25 phosphatase superfamily) is 
unknown, and there are no known direct links with Tst and obesity phenotypes or 
adipose related pathways (Bordo & Bork 2002). 
3.3.8.3 	Non-mCh05 candidates and Candidate pathways 
The non-mChr15 metabolically relevant candidates that have been identified are 
involved in three separate metabolic pathways. Genes that have been identified, and 
thought to be important in metabolism, but do not fall within one of these categories 
are discussed below in section [3.3.8.4]. These pathways are discussed in connection 
with data obtained from the Kyoto Encyclopaedia of Genes and Genomes (KEGG) at 
http://www.genome.ad.jplkegg/pathway.html,  and KEGG pathway numbers are 
provided in parentheses. 
The three metabolic pathways identified relate to lipid sterol biosynthesis (00100), 
metabolism of complex carbohydrates starch and sucrose metabolism (00500), and 
carbohydrate gl ycol ysi s/gl uconeogenesi s (00010). 
1) Lipid sterol biosynthesis (PATH: mmu00 100) 
This pathway was identified as a potential candidate as three of the genes involved 
are listed in table [3.3.20] and hence are amongst the highest ranking for P-value and 
fold change. Further examination of the genes involved in this pathway, reveals five 
additional genes to be significantly differentially expressed between the F- and 
congenic-line. With the exception of one gene, cytochrome P450, family 7, 
subfamily b, polypeptide 1 (Cyp7bl) all the genes are upregulated in the F-line 
relative to the congenic-line. However, different genes for products involved in the 
pathway are being regulated in different tissues, with Lss and ScSd being 
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differentially expressed in liver, Cyp7bl and Fdftl in BAT, and Sqie in both tissues. 
All of these genes are up-regulated in the F-line relative to the congenic line 
containing the Fob3b QTL, potentially leading to greater cholesterol synthesis, 
which may in turn contribute to obesity in the F-line [Table 3.3.23]. 
Table 3.3.23: Genes involved in the lipid sterol biosynthesis pathway 
Gene 
Symbol Chr Rank Exp 
Systematic 




Difference P-value Sf 


















Fdftl 14 30 2 BAT H3073H11 -1.20 0.16 2.29 0.000021 2.5E-06 
Sc5d 9 40 1 Liver H3036F01 -2.74 0.95 6.69 0.011 3.9E-06 
Hmgcr 13 109 1 LiverH3032C10 -1.82 0.57 3.54 0.0057 8.1E-05 
Idil 13 616 1 LiverH3046C10 -1.61 0.74 3.05 0.044 6.6E-03 
Mvd 8 1491 1 Liver H3O4lBll -1.05 0.48 2.07 0.046 3.9E-02 







Mvk 5 Not on arrays 
Pmvk 3 Not on arrays 
Ebp X Not on arrays 
Lss - lanosterol synthase (oxidosqualene cyclase); Sqie - squalene epoxidase; Fdftl - farnesyl 
diphosphate farnesyl transferase; Sc5d - sterol -05 -desaturase; !-Inzgcr - - hydroxy-3-methylglutaryl-
Coenzyme A reductase; Idil - isopentenyl -di phosphate delta isomerase; Mvd - mevalonate 
(diphospho) decarboxylase; C'yp7bl - cytochrome P450, family 7, subfamily b, polypeptide 1; Ggpsl 
- geranylgeranyl diphosphate synthase 1; Dhcr7 - 7-dehydrocholesterol reductase; Mvk - mevalonate 
kinase; P,nvk - phosphomevalonate kinase; Ebp - emopamil;. (*) genes not significant in either BAT 
or liver. Rank refers to position of Sf value across all four experiments with l being the most 
significant and 29,875 h being the least significant. 
The gene products of Lss, Sqie, and Fdftl are involved in three consecutive 
intermediate steps of the cholesterol biosynthesis pathway. These are, the conversion 
of farnesyl pyrophosphate to squalene (Fdftl), squalene to squalene-epoxide (Sqle), 
which is apparently a rate limiting step (Nagai et al. 1997), and squalene epoxide to 
lanosterol (Lss) [Fig 3.3.13]. Lanosterol is then converted to lathosterol by emopamil 
binding protein (Ebp, also known as sterol isomerase EC: 5.3.3.5). The gene for this 
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enzyme is located on the mChrX 4.4Mb, however there is no EST for this gene 
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Fig 3.3.12: Sterol biosynthesis pathway (KEGG path:00100). Reproduced from the public KEGG 
pathway database (lit p : // gcn mic.ad.jt/kc/puhwav/map/maoO0lOO.htmI). Numbers in closed boxes 
refer to EC (enzyme commission) numbers. White boxes are enzymes with unknown genes; grey 
boxes are known genes that are not differentially expressed, or are not on the arrays gene symbols in 
italics; red boxes are enzymes with differentially expressed genes (P<0.05). Idil - isopentenyl-
diphosphate delta isomerase; Mw! - mevalonate (diphospho) decarboxylase; FdflI - farnesyl 
diphosphate farnesyl transferase; Sqie - squalene epoxidase; Lss - lanosterol synthase (oxidosqualene 
cyclase); Sc5d - sterol-05-desaturase; Cyp7bI - cytochrome P450, family 7, subfamily b, polypeptide 
1; Hmgcr - -hydroxy-3-methylglutaryl-Coenzyme A reductase; Mvk - mevalonate kinase; Pmvk - 
phosphomevalonate kinase; Ggpsl - geranylgeranyl diphosphate synthase 1; Ebp - emopamil; Dhcr7 - 
7-dehydrocholesterol reductase. 
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Lathosterol is oxidised by the gene product of Sc5d, lathosterol oxidase (also known 
as delta7-sterol delta5-dehydrogenase and del ta7-sterol 5-desaturase) into 7-di hydro-
cholesterol. Finally, 7-dihydro-cholesterol is converted to cholesterol through a 
reduction step catalysed by the gene product of Dhcr7 (7-dehydrocholesterol 
reductase EC: 1.3.1.21) a mChr7 gene (132.9Mb). There are two ESTs coding for 
sequences for the Dhcr7 gene (H3006A11 and H31091705), however these do not 
appear to be differentially expressed between the F- and congenic lines, as all P-
value are greater than 0.05 [Table 3.3.23]. 
All the steps described here, in addition to alternative fates of lanosterol are given in 
figure [3.3.13] reproduced from the public KEGG pathway database 
(http://genome.ad.jp/kegg/pathway/map/ma000  100. html). 
2) Metabolism of complex carbohydrates, starch and sucrose (PATH: mmu00500) 
Ercc2 (excision repair cross-complementing rodent repair deficiency 
complementation group 2) has a primary function in nucleotide excision for DNA 
repair mechanisms (Thompson, 1991). It is shown to have a high level of differential 
expression, with an almost ten-fold increase in the congenic line. According to the 
KEGG database, the functional domains of the protein product of Ercc2, indicate that 
it should function as a hydrolase, acting on phosphorus-containing anhydrides (EC 
3.6.1-) This means Ercc2 theoretically may be involved in two metabolic pathways 
leading to starch and sucrose metabolism (mmuOOSOO), and folate biosynthesis 
(mmu00790). However there appears to be no published evidence to support either of 
these possibilities. 
No other genes involved in folate biosynthesis have been identified as being 
differentially expressed in this study. However, two genes have been identified as 
differentially expressed involved in the metabolism of starch to sucrose, Gbel and 
Ugdh [Table 3.3.24; Fig 3.3.14], the evidence for this pathway being involved in the 
Fob3b QTL effect is relatively week. 
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Table 3.3.24: ESTs for known genes identified as potentially differentially expressed candidates 
in the metabolism of complex carbohydrates, starch and sucrose 
Gene 	 Systematic L092 	Fold 
Symbol Chr Rank Exp Tissue NIA code Ratio SE Difference P-value Sf 
Ercc2 	7 	2 	1 Liver H3003G07 3.29 0.77 	9.80 	0.00059 2.3E-1 1 
Gbel 16 272 1 Liver H3063D10 -1.06 0.24 2.08 0.0013 8.9E-04 
Ugdh 	5 410 	1 Liver H3065E07 -0.66 0.13 	1.58 	0.00011 2.4E-03 
Ercc2 - excision repair cross-complementing rodent repair deficiency complementation group 2; GbeI 
- glucan (1,4-alpha-), branching enzyme 1; Ugdh - UDP-glucose dehydrogenase. Rank refers to 
position of Sf value overall across all four experiments and with I s ' being the most significant and 
29,875th being the least. 
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Fig 3.3.13: Starch and sucrose metabolism (KEGG path:00500). Reproduced from the public 
KEGG pathway database (p;//icn mc.ad.Ip/kci.i.!pIh\\ d\ /I11dI)/mt ( 1(1 ()O.html). Numbers in 
closed boxes refer to EC numbers. Red circles indicate the sections of pathway that may be affected 
by the genes identified as differentially expressed between the F- and congenic lines. Ercc2 - excision 
repair cross-complementing rodent repair deficiency complementation group 2; Gbei - glucan (1,4-
alpha-), branching enzyme 1; Ugd/i - UDP-glucose dehydrogenase. 
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3) Carbohydrate gi ycol ysi s/gl uconeogenesi s (PATH: m mu000 10) 
The third pathway which may be affected by the Fob3b QTL, is the glycolysis I 
gluconeogenesis pathway [Fig 3.3.15]. Two genes upregulated in the congenic-line 
(Eno] and Gapd), code for enzymes involved in the reversible steps that lead to 
either increased glycolysis or gluconeogenesis. Glycolysis is the breakdown of 
glucose for the creation of energy (ATP molecules), whilst gluconeogenesis is the 
assimilation of glucose from non-carbohydrate precursors. The primary reason to 
assume glycolysis is affected rather than gluconeogenesis is that gluconeogenesis 
occurs in the liver, and differential expression was observed occurring only in BAT. 
An examination of ESTs matching the genes for enzymes in the glycolysis and 
gluconeogenesis pathways reveals several points. First, there is no evidence for an 
effect on gluconeogenesis, in that two of four gluconeogenesis specific genes spotted 
on the arrays are not differentially expressed [Table 3.3.25]. Secondly, six of the ten 
genes coding for enzymes involved in glycolysis are differentially expressed in BAT, 
but not in liver. Interestingly, one step, the conversion of 3-phosphoglycerate to 2-
phosphoglycerate, shows no increased gene expression of the EST coding for the 
requisite enzyme. 
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Fig 3.3.14: Glycolysis & gluconeogenesis (modified from KEGG path:00010). Gene symbols 
given in parentheses for all enzymes involved. Enzymes involved in glycolysis are given in green, and 
gluconeogenesis enzymes are given in red. Spots: black indicates no EST for this gene on arrays; 
yellow indicates presence of EST but not differentially expressed; red indicates presence of spot with 
P-value <0,05. 
That this pathway, and the previous pathways discussed are involved cannot be 
confirmed without further biochemical analysis. 
*Footnote: the NIA-NIH annotation file for the ESTs has seven ESTs listed as being transcripts of the 
Hkl gene. However only one of these blasts to mChrlO - the location of Hkl - and this EST does not 
blast within Hkl, rather it may be part of a rare 3'-UTR. 
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Table 3.3.25: ESTs for characterised genes identified as potentially differentially expressed 
candidates in the metabolism of Carbohydrate glycolysis/gluconeogenesis 
Systematic Gene L092 Fold 
NIA code Rank 	Tissue symbol Ratio SE Difference P-valueChr 




-068 0.20 1.60 0.0044 8 
4451 BAT -0.35 0.09 1.27 0.018 
H3125B04 
l4358 Liver 0.14 0.12 1.10 0.23 
1904 BAT -0.56 0.17 1.47 0.0077 
H3025D11 PN 10 
2982 Liver 0.53 0.22 1.45 0.026 
863 BAT -0.96 0.31 1.94 0.011 
H3031003 AIdoA 
13740 Liver 0.29 0.37 1.22 0.44 
6010 BAT -0.25 0.06 1.19 0.017 6 H3149C10 
15620 Liver -0,11 0.09 1.08 0.22 
H3012A11 
187BAT -1.27 0.31 2.41 0.0021 Un 
16451 Liver -0.27 -0.54 0.69 0.60 
23994 BAT 0.18 1.35 1.13 0.90 H3102H07 
10890 Liver 
Bpgrn 
0.24 0.17 1.18 0.18 6 
13444 BAT 0.21 0.18 1.16 0.30 
H3142C11 
15923 Liver 0.10 0.08 1.07 0.22 
H3024C04 
13345 BAT pqilm -0.30 0.36 1.23 
0.42 19 
11683 Liver - -0.31 0.30 1.24 0.32 
58 BAT -0.97 0.11 1.96 0.0000068 
H3fl2 7 FOR Eeel 2 
Liver 0.08 0.08 1,06 0.37 
0 . 4 
"H 
Rank refers to position of Sf value overall across all four experiments and with 1 being the most 
significant and 29,875th being the least. Green - glycolysis; Red - gluconeogenesis; Green bold - 
significant glycolysis genes where P<0.05. SUn' refers to the unknown genomic location of Gapd due 
to multiple blast hits. Gpi - glucose phosphate isomerase; PA - phosphofrucrokinase; A!doA - aldolase 
1; Tpi - triosephosphate isomerase; Gapd - glyceraldehyde-3-phosphate dehydrogenase; Bpgm - 2,3-
bisphosphoglycerate mutase; Pgatn - phosphoglycerate mutase; Enol - enolase 1, alpha non-neuron; 
Fbpi - fructose bisphosphatase; Pck - phosphoenolpyruvate carboxykinase 1; Pcx - pyruvate 
decarboxylase. 
RESULTS - MICROARRAY ANALYSIS: 3.3 	 220 
3.3.8.4 	Other characterised non-mChrl5 candidates 
From the GeneSpring, MMSA and Sf analyses, a number of non-mChr15 candidates 
have been identified that either are not involved in metabolic pathways, or do not 
share any pathway with the other candidates identified. 
Ccrn4l - carbon catabolite repression 4-like is up-regulated in F-line liver and BAT. 
Ccrn4l is located on mChr3, and given that two independent ESTs for this gene were 
found differentially expressed in both tissues, this is a highly significant candidate. 
The main known function of Ccrn4l is as a circadian rhythm gene (Green & 
Besharse, 1996; Green & Besharse, 1996b). Obviously, more energy is expended 
during active awake periods than at rest/sleep periods. A small change in periodicity 
therefore, resulting in a shorter sleep-period in the congenic hrI5L line, could 
conceivably result in a decrease in body weight, or vice-versa. Alternatively Ccrn4l 
may be involved in other as yet unknown mechanisms leading to obesity. 
(Jcp2: The curation of the NIA-15K EST file indicates that this is an EST from the 
mChr7 mitochondrial specific uncoupling protein 2 (Ucp2). However, as there are 
various homologs of this gene, discussed previously [1.1.2.4], a sequence alignment 
of the forward and reverse sequences deposited for this clone (BG087 187 and 
BG074553) were carried out against the Ensemble database. The results showed that 
for the 5' sequence, the highest homology was indeed to the Ucp2 clone, with lower 
matches also to the Ucp3 homolog that is also on mChr7, and to the Ucpl homolog 
on mChr8. The 3' sequence revealed that the highest match was again to the Ucp2 
homolog, with weak similarity to Ucp3, but with no similarity to the Ucpl homolog. 
From these blast results, it can be concluded that this clone is in fact for the Ucp2 
homolog. However, even though this clone is Ucp2, given that there is high sequence 
similarity between the other Ucp homologs, and given that there are no other ESTs 
across the two arrays (according to the Mass-blast analysis carried out [2.2.3.1]), 
corresponding to the other homologs, the possibility that this result represents 
differential expression at one of the other homologs cannot be discounted. 
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Scd2: Several stearoyl-CoA desaturase gene isoforms exist in the mouse (Scdl, 
Scd2, Scd3). As with Ucp2, ESTs from the other two isoforms are not present on the 
arrays, and hence this may represent differential expression in any of the three 
isoforms. The protein products of the Scd genes catalyse the rate-limiting step for the 
synthesis of monounsaturated fatty acids, mainly oleate (18:1) and palmitoleate 
(16:1). These represent the major monounsaturated fatty acids of membrane 
phospholipids, triglycerides, wax esters and cholesterol esters. The ratio of saturated 
to monounsaturated fatty acids affects phospholipid composition and alteration in 
this ratio has been implicated in a variety of disease states including cardiovascular 
disease, obesity, diabetes, neurological disease, and cancer (Kim & Ntambi, 1999). 
Many factors regulate Scd expression (reviewed in Ntambi & Miyazaki, 2004), 
including cholesterol levels (Ntambi, 1999; Kim et al. 2002). Hence the differential 
expression of the cholesterol pathway genes [3.3.8.3] may be affecting Scd gene 
expression. 
Transketolase (TKT) is a ubiquitous enzyme used in multiple metabolic 
pathways, including an off-shoot of the glycolysis pathway (KEGG pathway 
mmu00030). A recent study has determined a direct link between obesity and the Tkt 
gene product through generation of TKT-null mice. It has been determined that null 
mouse embryos are not viable and that disruption of one TKT allele can cause 
growth retardation (-35%) and preferential reduction of adipose tissue (-77%) (Xu 
et al. 2002). 
3.3.8.5 	Other positional candidates for Fob3b QTL 
As discussed in section [3.2.5], a search for possible positional candidate genes for 
each of the two QTL regions (Fob3a and Fob3b) was performed [Fig 3.2.11]. As the 
microarray study is only examining gene expression differences between the F-line 
and congenic line containing the Fob3b QTL, only candidates identified within this 
QTL region are discussed here [Table 3.3.26]. Of the seven positional candidates 
identified previously, one (Sqie) has been shown to be differentially expressed, and 
has already been discussed. Three of remaining six potential candidates have ESTs 
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spotted on the arrays corresponding to their gene sequences, one of which (Myc) has 
two different ESTs. The evidence [Table 3.3.261 suggests that none of these three 
genes are differentially expressed, and may therefore be discounted as potential 
candidates for the Fob3b QTL effect. However, we cannot eliminate any of these 
positional candidates as possible causal genes for Fob3b solely on the basis of non-
differential expression - it is still possible that the causal mutation affects the quality 
of the gene product (e.g., protein folding, phosphorylation, activity) rather than 
quantity of RNA transcription. 
Table 3.3.26: ESTs for positional candidates within the Fob3b QTL region, identified from a 
literature search of genes within that region. 
Gene Systematic Lo92 Fold 
Mb symbol NIA code Tissue Rank Ratio SE Difference P-value 
Liver 21917 0.097 0.24 1.18 0.69 
59.1 Ndufb9 H3144B03 
BAT 21938 0.142 0.47 1.38 0.78 
Liver 10556 0.186 0.11 1.08 0.10 
H3089H1 1 
BAT 29249 -0.006 0.16 1.12 0.97 
62.2 Myc 
Liver 1565 -1.047 0.50 1.41 0.051 
H3076D1 0 
BAT 8862 -0.206 0.10 1.07 0.058 
66.1 0c90 Not on arrays 
67.0 Tgn Not on arrays 
75.9 Rhpnl Not on arrays 
Liver 7998 -0.639 0.65 1.56 0.34 
76.7 Dgatl H3034B09 
BAT 13442 0.285 0.33 1.26 0.41 
NduJb9 - NADH dehydrogenase (ubiquinone) 1 beta subcomplex-9; Sqie - squalene monooxygenase; 
Myc - niyelocytomatosis oncogene; 0c90 - otoconin 90 precursor; Tef - thyrotroph embryonic factor; 
Rhpnl - Rho-GTPase binding protein-1; Dgatl - diacylglycerol O-acyltransferase-1. 
RESULTS - MICROARRAY ANALYSIS: 3.3 	 223 
3.3.9 CONCLUSION 
The use of multiple analysis methods has been useful in identifying multiple 
candidates and pathways for the Fob3b effect. MMSA identified many of the 
candidates - especially the more significant candidates - that were identified in the 
GeneSpring analysis. This serves as confirmation that the MMSA analyses described 
[2.2.4] is functioning as expected. The use of the Sf transformation has also proved 
useful, especially for identification of ESTs involved in the cholesterol biosynthesis 
pathway that may have otherwise been overlooked if P-values and fold-changes were 
considered independently. 
The analysis here has also revealed a number of highly significant unknown ESTs on 
non-mChr15 genes. These may be used at some future point to help characterise the 
Fob3b pathway and identify new targets for the control of obesity. Given the large 
amount of work required to characterise unknown ESTs, these will not be analysed 
further within the scope of this thesis. 
This analysis has successfully identified a number of candidates and pathways for the 
Fob3b QTL effect. The most promising candidates have been chosen for 
confirmation of differential expression and further characterisation. These are: the 
unknown mChr15 EST H3066B12, which appears to be a particularly strong 
candidate mapping close to the QTL interval, and has the highest ranking Sf value; 
and Sqie and its associated cholesterol pathway, as these are clearly of particular 
interest, especially as Sqie maps within the Fob3b interval. This analysis is presented 
in the following chapter. 
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3.4 	POST MICROARRAY ANALYSIS 
This chapter confirms the differential expression of some of the ESTs identified by 
microarray analysis. These are investigated further, with specific focus on the 
uncharacterised mChrl5 H3066B12 and H3048C08 ESTs. A discussion of the results 
for each clone is provided along with bioinforrnatics and results from data mining. 
Plasmid clones for each EST were ordered through HGMP. These were cloned and 
their sequences confirmed as described in sections [2.3.3 & 2.3.4]. In addition, 
preliminary analysis of candidates from the cholesterol biosynthesis pathway is 
provided using real-time quantitative PCR (Q-PCR). 
The analysis performed here (unless otherwise stated) was on tissues and resources 
obtained from the second mouse dissection experiment (detailed in sections [2.3.3 & 
2.3.4]). Thus, where the results are confirmed, this indicates that the differences are 
consistent across generations, since the mice uscd for the microarray hybridisations 
were from the first dissection. 
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3.4.1 	UNCHARACTERISED Fob3b EST 
CANDIDATES H30661312 & H3048C08 
3.4.1.1 	Mined data 
The 5' and 3' sequences of H306613 12 were confirmed to be homologous to those 
deposited in GenBank. The 5' and 3' sequences of the 1 -130661312 EST are 
overlapping with a unique sequence length of 884bp that matches to exons 9 and 10 
of the predicted gene sequence in Fig [3.4.1]. 
Information 	obtained 	from 	the 	Ensembl 	database 
(http://www.ensembl.org/Mus_musculus/)  indicates that sequence from EST 
H30661312 has a high sequence identity with exons 9 and 10 on an 2059bp-long 
transcript predicted by Ensembi (ENSMUST00000023056) [Fig 3.4.1]. Northern 
analysis shown below [3.4.1.2], however, indicates that the transcript is closer to 8kb 
in length. For the purpose of this thesis, this gene will henceforth be referred to as 
Fad (Fob3b associated candidate 1). 
The 3' sequence of EST H3048C08 matches to sequence lSOObp downstream of the 
predicted 10th  exon of Fad. Northern analysis indicates that the transcript is larger 
than that which has been predicted, so H3048C08 may be part of unpredicted 
upstream or downstream exons of Fad. RT-PCR presented below [3.4.1.5] was 
performed in order to identify a link between the sequences of H306613 12 and 
H3048C08, which would indicate that H3048C08 was part of Facl gene. 
-1 	 t26.16 Kb 
Fig 3.4.1: Predicted gene structure of Fad. Vertical bars represent exons. Exported from the 
Ensembi database (Build 32: http://www.ensembl.orglMus_musculus/geneview? 
gene=ENSMUSG000000224 19&db=core). 
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The 2059bp sequence of Facl has no similarity to any known genes and contains just 
two DEP domains (Dishevelled, Egi-10, and Pleckstrin). DEP domains have an 
unknown function, and are present in signalling proteins including Dishevelled, Egl-
10, and Pleckstrin proteins. This may indicate that Facl is a novel signalling 
molecule. 
Sequence conservation 
A BLAST search of the 884bp sequence of the 1 -130661312 EST and the 2059bp 
predicted sequence of Facl was performed against the genornic sequences of various 
species to ascertain the conservation of this gene. Analysis shows that it is indeed a 
highly conserved gene, with orthologs in the human and rat genomes. There is also 
evidence of homologous sequences in species as diverse as Fugu, Zebrafish and the 
Fruitfly, but not in the worm Caenorhabditis elegans [Table 3.4.1]. BLASTp 
analysis, examining the homology of the translated protein sequence from the 
2059bp fragment, yields similar results to the nucleic acid sequence homology 
analysis (data not shown). However, there is no further annotation from these 
species' genomes that may provide more information relating to the possible function 
of Fad. 
Table 3.4.1: Potential Fad orthologs 
Species 	 Chromosome(s) 	Homology (%)a 
Rat (Rattus norvegicus) 	 7g31 95 
Human (Homo sapien) 8g24 	 88 
Cow (Bos taurus) 	 EST match (BM089001b) 83 
Chicken (Gal/us gal/us) 	 EST match (BU3871 66b) 	 83 
Zebrafish (Danio rario) 16 	 77'  
Puffer fish (Fugu rubripes) 	 scaffold 101 72 '  
Mosquito (Anopheles gambiae) 	 X 	 58d 
	
3L 56 d 
Drosophila melanogaster 	 AlIc 	 77d 
a 
Best homology score (%) to whole or part of the predicted 2049bp murine sequence of Fad; b 
GenBank accession number; C  multiple matches; d  short sequence matches of 200-400bp. 
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QTL associations 
The rat orthologous sequence for Facl maps to a region that is associated with a 
number of QTL, reported in other studies, which are relevant to the Fob3b QTL 
effect [Table 3.4.2]. Knowledge of these traits being associated with the same 
genomic region as Facl may be used to help better characterise Facl phenotypically 
in future studies. 
Table 3.4.2: Rat QTL associated with the Facl ortholog 
Trait 	QTL name/No. 	Reference 
NIDDM Niddm19 Moralejo et al. (1998) 
Body weight 	Bw9 	Kato et al. (1999) 
Blood pressure Bp38 Garrett et al. (1998) 
NIDDM - Non-insulin dependent diabetes mellitus. 
3.4.1.2 	Northern analysis - Tissue expression 
A tissue blot analysis was performed to examine the distribution of expression of the 
H3066B12 EST representing Fad [Fig 3.4.2]. This demonstrated that its transcript is 
approximately 8kb in size, with a possible second transcript at around 7kb, which 
appears in several tissues as shown in the long exposure of Blot-2. With the 
exception of the pancreas, Facl is expressed in all tissues examined at varying 
degrees of abundance. Phosphorimager analysis was used to quantify the gene 
expression profile across the tissues. 16 different tissues were examined, however it 
was not possible to carry this out on the same blot, so the tissues were examined 
across two blots with overlapping tissue comparisons. Ethidium bromide staining of 
the gels indicated that there were differences in the loading of the RNA samples. 
Consequently both blots were stripped and re-probed with 18S rDNA so that the 
gene expression of Facl could be corrected for loading differences against the 
expression of 18S rRNA, which is generally regarded to be uniformly expressed 
between the different tissues. 
Across all the tissues examined, expression of Facl is highest in BAT and brain 
tissue, while there is only around 40% of Facl in liver as compared to BAT. 
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Fig 3.4.2: Tissue expression Northern analysis of H30661312. 1Og of RNA pooled from five 
individual F-line female mice loaded in each lane. As all the tissues could not be analysed on the same 
blot additional tissues were analysed on a second blot (Blot 2) with duplicated samples from Blot 1. 
The exposure time of Blot 2 shown here is twice that of Blot 1. Brain sample is without 
hypothalamus. 
A further two blots containing 14 of the tissues presented above (jejunum and ileum 
omitted) from congenic F 5D-line and L-line mice were prepared. Each blot also 
contained F-line liver and BAT samples for comparison (figures not shown). Each 
blot was probed with 1-130661312 and 18S rDNA to examine the tissue-by-tissue 
expression relative to expression of F-line BAT and liver samples. Figure [3.4.3] 
provides a graph of the relative expression pattern to F-line BAT expression, with 
each tissue from each line normalised to 18S rRNA. Generally Facl is down-
regulated in all L-line and congenic hrl5  tissues compared to F-line tissues, 
with the least amount of expression observed in L-line tissues. Large differences can 
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be seen within the BAT, adrenal, brain and hypothalamic tissues. Expression is 
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Fig 3.4.3: Tissue expression profile of 1-130661312 between the F-, L- and congenic F 15D-
congenic line. Profiles are normalised to 18S rRNA expression and are presented relative to F-line 
BAT expression. * no comparison available to L-line WAT as the sample was degraded on the gel. 
3.4.1.3 	Northern analysis - Time series expression 
A time series northern analysis was performed with mice taken at time points of 28, 
49 and 98 days of age [Section 2.2.1]. Facl expression was examined in liver, BAT 
and WAT between the F-, L- and congenic Fc5Dlines [Fig 3.4.41, using the EST 
1130661312. The second smaller transcript (-7Kb) can be clearly seen here in the 
WAT RNA profile, especially at the earlier developmental time points of 28 and 49 
days. Greater expression in the F-line can clearly be seen in BAT and WAT relative 
to both the congenic F 5D-line and the L-line. However, there does not appear to 
be a difference in the liver tissue, as indicated by the microarray analysis. 
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98 days 	49 days 	28 days 
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Fig 3.4.4: Phosphorimager time-series expression profile of H3066B12 between the F-, L- and 
congenic r 5D-lines, in liver, BAT and WAT. F indicates F-line. D indicates congenic FSDline 
and L indicates L-line. Each lane is loaded with lOtg of RNA from pool of five individuals each 
contributing 24g. Each tissue blot is presented with a panel showing the ethidium bromide staining of 
the gel's 28S and 18S bands. 
3.4.1.4 	Characterisation of EST H3048C08 
For H3048C08, only the 3' sequence is publically available. The 3' sequence was 
confirmed, however, after three attempts at cloning (from plated single-colonies), the 
5' sequence could not be obtained, since each time the 5' sequence returned was 
inconclusive. A restriction digestion of the plasmid-prep, run on a high-resolution 
gel, reveals two distinct fragments of similar size within this clone (Figure not 
shown). It is known that within the clone library (used for the microarray), some 
clones are chimeric, i.e. double inserts (Dr. Minoru Ko, personal communication). 
Before confirmation of the sequences and further analysis can be correctly 
performed, each fragment would require to be isolated and cloned separately. 
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A Northern analysis was performed with a probe prepared from the chimeric clone, 
prior to knowledge of its usual characteristic, yielding information that may be of 
some benefit for future analysis [Fig 3.4.5]. This shows hybridisation to three bands, 
the upper band appearing to have the same size (-8kb) and expression profile as that 
of the probe prepared from 1-130661312 shown in Fig [3.4.2 & 3.4.4]. That is, 
expression is consistently higher in the F-line when compared to the congenic 
F 15D-line. The mean expression of H3048C08 from five individuals of each line 
(corrected againstl8S rRNA expression) is 0.72 in the congenic line, compared to 













Conqenic FhrlSD line 	- 	F-line 
i4 ,I S l'i 	18Kb 
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rDNA 
PE3.4.5: Phosphorimager expression profile of H3048C08 in the BAT of 5 individual congenic ' 5D-line (D1-135) and 5 F-line females (F1-F5). Graph (top panel) shows the relative expression 
(to 18S rRNA) for each individual, mean congenic rhr  D-line and mean F-line relative expression 
are given in the dark yellow and dark blue bars respectively. Each lane is loaded with lOjtg of RNA. 
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This provides additional evidence to that generated from the RT-PCR (discussed 
below), that sequence from H3048C08 forms part of the same extended —8kb 
transcript for Fad. Two ESTs end-to-end within one clone when spotted on an 
array, could create interference. This may explain why the microarray analysis 
detected H3048C08 as having a lower significant difference in expression (between 
the F- and congenic FthnI5DIine)  as that generated by H3066B12 (see table [3.3.21]). 
3.4.1.5 	RT-PCR 
As mentioned, from Northern analysis, the main transcript of Facl is approximately 
8kb in length. However, database and GenScan prediction information indicates that 
it is approximately 2kb. In an attempt to connect the predicted exons of Fad [Fig 
3.4.61 to neighbouring sequences, and hence derive a more accurate image of the 
gene structure of Fad, RT-PCR was performed. Various primers were designed and 
PCR performed on cDNA generated from F-line RNA. Various controls were 
performed that validate the results presented here, however further verification of 
these results would be required before full cloning of the Facl can be attempted. 
DL Chromosome band II - 	 - 
pw 	5v.II Mb 	S.O• M 	 $5. 14 b 	 35.20 Mbn5.O b 	 5S.vM Mb 	 55.5. Mb 	 55.60 Mb 	 55.70 Mb 
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O axon Iredcliun of 	EST 
Fad 	 H3048C08 
Fig 3.4.6: Ensembl map of the genomic region on mChr15 of Fad. Bottom panel in red shows the 
10 exon predicted structure of Fad, flanked by two unknown predicted genes. Sequence from the 
H3048C08 EST (green) maps between the predicted 
10th  exon of Facl and the 1 ° exon of the 
unknown gene (R). Unknown gene (L) is predicted to lie on the opposite strand to Facl and unknown 
gene (R). 
Primers were designed to amplify sequences from the predicted exons at the termini 
of each predicted gene. No match was detected between the 2 n exon of Facl and the 
thoucL 	
- 
Unknown novel gene (R) 
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last exon of unknown gene (L). Additionally, no PCR product was detected between 
the 2 °c' exon of Facl and the last exon of the unknown gene upstream of unknown 
gene (L) as shown in the upper panel of Fig [3.4.6]. 
A PCR product was detected between the 8 1h  exon of Facl and H3048C08 
cryptically generating two products of —2.5kb and 2kb, which may indicate 
alternative splicing. Additionally a product of —2.9Kb was detected between 
H3048C08 and the first exon of the unknown gene (R) [Fig 3.4.7]. No product was 
seen from Fad exon 8 to the unknown (R) gene, although this is may be because the 
distance is too far to amplify across. A schematic is shown in figure [3.4.7] for some 
of the attempted PCR reactions described here, and gel below shows the results of 
these reactions [Fig 3.4.8]. 
10 exon prediction of 
Unknown novel gene (L) 	 Fad 
I/LLLvUJ.I 7 
Lane No. 2 —, 
3 .4— 	 .4—. 
5' sequence 
10 exon prediction of 	of EST 	 Unknown novel gene (R.) 
















Exon 6 of 	Exon 1 of 
Unknown alternative 
R gene 	transcript of 
unknown 
R gene 
Fig 3.4.7: Primer set-up for RT-PCR of reactions 2-14 shown in figure [3.4.8] 
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The PCR products from reactions 6 and 14 would need to be cloned and sequenced 




Fig 3.4.8: 1% Agarose gel showing PCR reaction products from various primer combinations as 
listed in table [3.4.3]. Lanes 1 presents Ladder X; lane 15 presents 1Kb ladder. Lane 6 shows the 2 
bands generated from primers for exon 8 of Facl and H3048C08; lane 14 shows the product from 
primers extending from H3048C08 to the first exon of unknown gene (R). 
Table 3.4.3: Primer sequences used for RT-PCR shown in Fig [3.481 
Lane 
no. F primer name Sequence R primer name Sequence 
2 Uk(L)-t CGAGCTGTGTGCATC1TCAT Foaci -E2-r GGCTGGAGGAGTGTAGTTTCA 
3 Uk(L)-r ATGTACCCTGCCTTCAAACG Foacl-E2-r GGCTGGAGGAGTGTAGTTTCA 
4 Uk(L)-f CGAGCTGTGTGCATCTTCAT Foacl-R8-r TGCAATGTCCCAATTATCCA 
5 Foacl -E8-f GAGGAAGTAAACCATGCCACA H3048C08-r GGGTTGGTTCGTCATATGCT 
6 Foaci -E8-f GAGGAAGTAAACCATGCCACA H3048C08-f ACACCTCAATCCCAGCACTT 
7 Foacl-E8-f GAGGAAGTAAACCATGCCACA Uk(R )-Elr GGUCTTAGCGAACCACTGC 
8 Foacl-E8-f GAGGMGTAAACCATGCCACA Uk(R )-Elf GGTTCTTAGCGAACCACTGC 
9 Foacl-E8-f GAGGAAGTAAACCATGCCACA Uk(R )-E6r GAACGCTGTGACCAGGTTTT 
10 Foacl-E8-f GAGGAAGTAAACCATGCCACA Uk(R )-E6f GAACGCTGTGACCAGGTTTT 
11 Foaci -E8-f GAGGAAGTAAACCATGCCACA Uk(R2 )-E1 r CATTCCCTCTGAAAGGCTTG 
12 Foacl-E8-f GAGGAAGTAAAGCATGCCACA Uk(R2 )-Elf CTGTGAGCCATGGAGGAGAT 
13 H3048C08-r ACACCTCAATCCCAGCACTT Uk(R )-Elr GGTTCTTAGCGAACCACTGC 
14 H3048C08-f GGGTTGGTTCGTCATATGCT Uk(R )-E1 r GGUCTTAGCGAACCACTGC 
3.4.1.6 	Summary 
The analysis presented here confirms the microarray results that the EST sequence 
H3066B12 is differentially expressed, being upregulated in the F-line compared to 
the congenic Fchrl  (and the L-line) in BAT. However the 2-fold+ microarray 
difference seen in liver, is not confirmed. This may be caused by it being more 
highly variable in the liver, since 10 mice were pooled together for the array 
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experiments. A quantitative analysis of individual's mRNA expression may help to 
clarify this point further. 
It is shown that the EST is part of a larger -'8kb transcript named here as Facl and 
with the exception of the pancreas, is expressed in all tissues examined, showing 
higher expression in all F-line tissues compared to the other lines. Evidence from the 
H3048C08 clone and preliminary RT-PCR experiments, indicate that the H3048C08 
EST may form part of the Facl gene, and that Facl may extend further to the 
neighbouring downstream gene, which is currently assigned in the Ensembl database 
as a separate unknown gene. 
Evidence from the rat genome mapping project indicates that the orthologous 
sequence for Facl maps in a region comprising three QTL that are involved in the 
wider 'metabolic syndrome'. This information, coupled with the analysis presented 
here, provides a good framework for the further investigation into this potential 
obesity and obesity-related-phenotype gene candidate. 
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3.4.2 	PRELIMINARY ANALYSIS OF Sqie & 
CHOLESTEROL BIOSYNTHESIS PATHWAY 
CANDIDATES 
In this chapter, preliminary analysis using real-time quantitative PCR (Q-PCR) was 
performed to assess various candidates identified as differentially expressed between 
the F- and congenic F chrl5 D-hne that are involved in the cholesterol biosynthesis 
pathway. In addition, the gene SrebJ2 was investigated as a potential transcription 
factor controlling the expression of the genes involved in this pathway. 
3.4.2.1 	Confirmation by Q-PCR 
The intention in performing Q-PCR, as opposed to northern analysis to validate these 
candidates, was that the candidates were to he analysed in liver and BAT, and at two 
time-points (98days and 29days), so that the changes in expression could be tracked 
developmentally and correlated to the change in the effect of Fob3h during 
development. Thus the high-throughput 96-well format of the ABI sequencer was 
chosen for Q-PCR analysis, rather than repeated probing and stripping of Northern 
blots. Preliminary analysis from three genes has been performed, and is presented 
here. The genes analysed are the mChrl5 gene Sqie, Lss and the mChrl5 cholesterol 
biosynthesis transcription factor SrebJ2. 
Table 3.4.4: Primer sequences used for Q-PCR 
Fragment 
Direction Sequence size (bp) 















Sqie - Squalene epoxidase; Lss - Lanosterol synthase; SrebJ2 - Sterol regulatory element binding 
factor 2; Acth - 3-Actin. 
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The expression of each gene under investigation has been normalised to the 
expression of 13-Actin (Actb). Table [3.4.4] lists the primer sequences used here, 
which were designed as described in section [2.3.5.1]. 
Relative efficiency of candidate gene and reference genes 
For the quantitation of relative gene transcription to be valid, the efficiency of the 
candidate gene amplification (Sqie, Lss or SrebJ2) and the efficiency of the reference 
gene (Actb) must be approximately equal. This has been assessed for each candidate 
by looking at how the ACT (change in cycle threshold) varies with eDNA template 
dilution. Table [3.4.5] shows the average CT values calculated for each candidate 
gene from four replicates at three dilutions. The lower panel shows the ACT relative 
to the reference gene, which in this case is Acth [I1  The lower panel shows that the 
ACT values for each gene, over a 10-fold dilution does not deviate by more than 1 
cycle. 
Table 3.4.5: Average CT value for each candidate gene and Actb at different dilutions 
Approximate Fold Candidate genes Reference gene 




dilution Average CTSD± Average CT a± Average CTSD± Average CTSDI  
67 1 30.07 0.77 24.81 	0.10 20.51 o.og 21.57 	o.ic 
13.4 5 32.95 0.34 27.00 0.02 22.94 0.22 24.10 o.o 
6.7 10 33.25 0.22 27.20 	0.44 23.75 0.12 24.960.0€ 
Srebf2 - Actb 
ACTSD± 
Lss - Actb Sqie - Actb 
ACTSD± ACTSD± 
67 	 1 	8.50 	0.03 3.24 	0.01 -1.06 	0.01 
13.4 	5 	8.84 	0.01 2.90 	0.01 -1.17 	0.01 
6.7 	10 8.290.01 2.240.02 -1.220.01 
Sqie - Squalene epoxidase; Lss - Lanosterol synthase; SrebJ2 - Sterol regulatory element binding 
factor 2; Actb - - Actin. 98d female F-line cDNA from a 5-mouse RNA pool was used for this 
analysis. 
/3-Actin (Acib) was chosen as the reference gene because it is a standard control gene commonly 
used for Q-PCR, and also because nine different ESTs for this gene were spotted on the array, none 
showing differential expression between the lines examined in either liver or BAT tissues (P>0.05) 
[H3002D02, H3010D02, H3011E09, H3011G02, H3012A02, H30181309, 1-130181310, H3041F03, 
H3045E09]. 
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The results show that primers designed for the three candidate genes discussed here 
generate a reliable relative comparison of gene expression (to Actb) over the 10-fold 
dilution range of the working cDNA dilution. Figure [3.4.9] illustrates the relative 
efficiency plots, with all candidate genes showing slope close to zero as 
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Fig 3.4.9: Relative efficiency plots for SrebJ2, Lss and Sqie 
Squalene epoxidase (Sqie) 
Table [3.4.4] shows the raw CT values for each of the four replicate reactions from F-
congenic F' 5D-line and L-line, liver eDNA for the expression of Sqie, corrected 
against the expression of Actb. The ratio of F-line expression to congenic FrI5D..line 
expression of Sqie at 98days (F:D) is 0.42, i.e. Sqie is upregulated 2-fold in the 
congenic line - indicating a reversal of the observation seen in the microarrays, 
where at 98 days, there was a 4-fold increase in the F-line. At 28 days, there is no 
difference in expression levels between the F- and congenic line (ratio = 1.02), 
although it is higher in both F- and congenic 1' 5D-line compared to the L-line. 
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Table 3.4.6: Q-PCR - Sqie in liver 
Sqie 	I Actb 
F D L F D L 
21.5 20.48 21.12 19.65 19.87 19.53 
21.21 20.43 21.04 19.12 20.04 19.36 
20.73 20.19 21.09 ' 19.48 19.9 19.51 
21.21 20.4 20.64 19.5 19.85 20. 
21.16 20.38 20.97 19.44 19.92 19.68 
19.611 20.53 20.341 1 9.231 19.171 20.11 
28d 20.04 20.38 20.17 18.98 19.38 19.81 
19.96 20.17 19.96 19.13 19.53 20.1C 
19.86 20.451 20.Ubj 18.49 19.71 19.5 
mean! 19.87! 20.381 20.131 18.96 19.45 
ACT 	 LILICr 
Sqie - Actb 
F 	D 	L F-D F-L D-L 
1.73 0.46 1.301 1.27 	0.43 -0.84 L092 
0.42 0.74 1.79 Fold 
0.91 0.94 0.241 -0.03 	0.67 0.69 L092 
1.02 0.63 0.62 Fold Change 
98d 
mean 
F indicates F-line, D indicates congenic F"'D-line and L indicates L-line. L-line 
The expression of Sqie was studied in an identical comparison examining the 
differences in BAT. Here, it is shown that there is no difference in the expression of 
Sqie in BAT between the F-line and congenic F'' 5 D-line at either time points (-1.1 
fold change for both time points). From the microarray analysis, a 4-fold 
upregulation was expected [Table 3.3.23]. However expression is approximately 8-
fold greater in both F- and congenic F 5 D-line compared to the L-line at 98 days, 
and approximately 4-fold at 28 days. 
These assays were repeated twice, and in each case similar results were obtained. 
This trend was also seen in northern analysis performed using the EST H3020H04 on 
the liver, BAT and WAT blots shown above in figure [3.4.4] (data not shown). A 
decision was taken to assay the RNA from mice used in the microarray experiments, 
to ascertain if the expression differences of Sqie are at least consistent within that 
population. RNA was pooled from the five mice from each of the first 98day old 
pools (Pool 1) as described in section [2.2.3.2]. 
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Table 3.4.7: Q-PCR - Sqie in BAT 
ACT ALIC1 
Sqie Actb Sqie- Acth 
F D L 	F D L F 	D 	L F:D 	F:L D:L 
26.11 31.18 	19.99 22.68 24.43 
98d 	
23.54 25.85 20.6 22.32 25.13 
23.45 25.96 31.081 20.42 22.18 23.97 
23.7 25.92 30.47 20.04 22.9 24147 
fl8.fl 	23.561 25 , 961 30.91 	20.261 22.52 24.501 3.30 	3.44 	6.41 -0.14 	-3.11 -2.97 Lo92 
1.10 8.63 7.84Fold 
29.02 	3373j 27.21 	29.31 
280 	30.03 34.35 27.11 	29.13 32.57 24.18 
29.28 33,99 26.83 	28.51 34.03 24.33 
29 69 27.36 	28.91 33.48 24.56 
meanl 29.511 34.02! 27.131 28.971 33.361 24.361 	0.54 0.66 2.771 -0.12 -2.23 -2.11 Log2 
1.09 4.69 4.31 Fold Change 
F indicates F-line. D indicates congenic F 5D-line and L indicates L-line. L-line. Replicates marked 
with ' were widely divergent from the comparative measurements and hence were excluded from the 
analysis to avoid bias. 
Table 3.4.8: Q-PCR - Sqie in liver & BAT from original 98day microarray comparisons. F 
indicates F-line, D indicates congenic Fdhnt5Dline and L indicates L-line. L-line RNA used here were 
isolated in collection 1, but not used in the microarray experiments. 
Sqie 	I Actb 
F D L 	F D L 
20.19 20.14 20.641 20.22 18.16 18.66 
20.53 20.89 20.85 20.15 18.47 18.8 
Liver 
20.1 20.43 20.41 20.12 18.26 18.8 
20.28 20.5 20.451 20.16 18.11 19.01 
-nean 20.281 20.491 20.591 20.16 18.25 18.82 
ACT 	 LiZICT 
Sqie - Actb 
F 	D 	L F:D F:L D:L 
0.11 2.24 1.77 -2.13 	-1.66 0.47 L092 
4.37 3.15 1.3g Fold Chan 
20.83 23.02 22.29 19.24 19.09 19.47 
BAT 21.54 2334 22.44 19.17 18.91 19.87 
20.95 23.35 22.55 19.32 19.17 19.75 
21.83 23.24 2209 19.22 19.12 19.44 
mean 21.29 23.241 22.33 19.24 19.07 19 . 63 1  2.05 	4.17 	2.69 -2.12 	-0.64 	1.47 L092 
4.33 	1.56 2.78 Fold Change 
F indicates F-line, D indicates congenic F 5 D-line and L indicates L-line. L-line 
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Analysis on this pool indeed confirms the differential expression observed in the 
microarray results, showing an upregulation of 4.37 and 4.33 fold in liver and BAT 
respectively in the F-line relative to the congenic F 5D-line. 
Lanosterol synthase (Lss) 
As mentioned previously, the original intention was to investigate the eight members 
of the cholesterol biosynthesis pathway, identified as differentially expressed 
between the F- and congenic F' 5 D-line. However, given that expression of the 
candidate Sqie was inconsistent, in that mice from the dissection did not display 
differential expression, detailed expression profiling has instead been focused on 
Sqie, and Lss - the cholesterol biosynthesis candidate with the most significant Sf 
value [Table 3.3.231. 
Table 3.4.9: Q-PCR - Lss in liver. 
ACT AACT 
Lss Actb Lss -Actb 
F L F D L F 	D 	L F:D 	F:L 	D:L 
23.18 23.41 22.95 19.65 19.87 19.53 
23.6 22.9 19.12 20.04 19.36 
98d 
22.9 23.99 23,07 19.48 19.9 19.51 
23.3 24.02 2309 19.5 19.85 20.3 
nean 23.251 23.81 23.00 19.441 19.921 19.681 3.81 	3.89 	3.33 -0.08 	0.48 	0.56g2 
1.06 1.39 1.48 Fold 
22.18 22.62 21.88 19.23 19.17 20.11 
28d 22.03 22.80 22.03 18.98 19.38 19.81 
21.87 23.02 22,151 19.13 19.53 201C 
22.04 22.55 22.07 18.49 19.71 19.5 
nean 22.03 22.751 22.031 18.96 19.45 19.& 3.07 3.30 2.151 -0.23 	0.93 1.16 L092 
1.17 1.90 2.23FoldChange 
F indicates F-line, D indicates congenic F'D-line and L indicates L-line. L-line. Replicates marked 
with ' were widely divergent from the comparative measurements and hence were excluded from the 
analysis to avoid bias. 
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As seen with Sqie, the expected 5.7 fold increase of Lss in F-line relative to congenic 
D-line  liver expression was not observed in mice from the second dissection 
[Table 3.4.7]. Ratios of F-line to congenic F rI5D.4ine  expression are approximately 
equal for the 98d and 28d time points, 1.06 and 1.17 respectively. An examination by 
Q-PCR of the expression differences in one of the original set of microarray pools 
(Pool 1 for each line) reveals a closer trend to the expected, specifically F-line 
expression of Lss is approximately 50% greater compared to the congenic line (fold 
difference of 1.46) [Table 3.4.7]. This is still considerably lower than the expected 5-
fold difference, however it may be that the difference is considerably greater when 
comparing the second pools (Pool 2). 
An additional interesting observation, is that comparisons using RNA from the 
original mice used for the array experiments (Pool is) and mice from the second 
dissection experiment indicates that there is a consistent 2-3 fold upregulation of Lss 
in F-line BAT, relative to the congenic line [Table 3.4.8, and data not shown]. 
Differential expression of Lss in BAT was not significant in the microarray 
experiments (P=0.52). 
Table 3.4.10: Q-PCR - Lss in 98d liver and BAT from same mice used for the microarrays 
ACT 
Lss - Actb 
F D L 
4.36 3.82 2 
Lss 	I 	Actb 
F D L  D L 
22.62 21.82 	20.22 18.16 18.66 
24.79 21.66 20.81 	20.15 18.47 18.8 
Liver 
24.01 22.32 20.48 	20.12 18.26 18.8 
24.77 21.67 21.37 	20.16 18.11 19.01 
me8n1 24.521 22.071 21.12! 	20.161 18.251 18.82 
22.26 24.22 23.44 19.24 19.09 19. 
Bat 21.66 22.98 23.98 19.17 18.91 19. 
22.74 23.71 23.33 19.32 1917 19. 
22.03 22.93 23.35 19.22 19.12 19. 
iean1 22.171 23.461 23.531 19.241 19.071 19.  
LILICT 
F:D F:L D:L 
0.54 2.06 1.52 L092 
1.46 4.17 2.86Fold 
I -1.45 -0.96 0.501-0g2 
2.74 1.94 1.41 Fold Change 
F indicates F-line, D indicates congenic F' 5D-line and L indicates L-line. L-line. Replicates marked 
with '' were widely divergent from the comparative measurements and hence were excluded from the 
analysis to avoid bias. 
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Sterol regulatory element binding factor 2 (SrebJ2) 
Gene expression of SrebJ2 was assessed along with Sqie and Lss expression, to 
determine if there was a correlation between the expression patterns. Fig [3.4.11] 
shows the ratio of F-line to congenic F' 5D-line gene expression for Sqie, Lss and 
Srebf2, examined in livers extracted from the mice used for the microarrays (1st 
dissection), and mice from two time-points from the second dissection. 
In all three cases, Srebf2 expression is higher in the F-line. However, when the 
difference in SrebJ2 expression is highest, as shown in the 98d 2' dissection mice, 
Sqie (and Lss) expression is lowest in the F-line relative to the congenic-line. When 
the difference of Srebf2 expression is lowest (as in the 
1st  dissection mice), the 
difference in expression of Sqie and Lss are at their highest, with considerable 












Sqie 	 Lss 	 Srebf2 
Fig 3.4.11: Gene expression ratios in liver [F-line (F) to congenic F"" -';D-line (D)] for Sqie, Lss 
and SrebJ2. A ratio of 1 indicates equal expression between the two lines. 
Given that mice in both dissections are genetically identical, and were processed 
under the same strict protocol [2.2.1.1], it is surprising that such large differences are 
present between the two groups 
(1s1  and 2'" dissections). It would be interesting to 
investigate these genes and the other members of the cholesterol biosynthesis 
pathway further, perhaps examining individuals rather than pooled RNA. 
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3.4.2.2 	Summary 
The results from the microanay analysis for the expression profile of Sqie have been 
confirmed through Q-PCR using RNA from the same mice used in the microarray 
experiments. This provides further validation of the microarray results and analysis 
that was implemented. However, this difference does not appear to be consistent, as 
no difference is observed at the 98day time point in the mice collected in the second 
dissection population. 
Despite implementing a strict procedure for preparing mice and collecting tissues, in 
order to limit environmental variance, it would appear that the expression of Sqie and 
other members of the cholesterol biosynthesis pathway are nonetheless variable. The 
method of collection may not be suitable for minimising environmental variance for 
the genes in this pathway. This may be because the pathway in general, is susceptible 
to small fluctuations in food consumption - an approach to examine this further may 
involve fasting the mice overnight. Certainly this inconsistency needs further 
clarification, before a link between the Fob3b QTL effect and the cholesterol 
biosynthesis pathway can be established. 
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3.4.3 DISCUSSION 
In chapter [3.3] results for the microarray gene expression analysis from liver and 
BAT transcripts between the F- and the congenic Fth15Dline, which contains the 
Fob3b QTL, were presented. The microarray analysis identified many potential 
candidates, including multiple genes from two metabolic pathways, the cholesterol 
biosynthesis pathway and the glycolysis pathway. 
The aim of this chapter was to validate some of the more interesting candidates that 
were identified as differentially expressed between the two lines, using robust 
gene/EST specific assays. The candidates that have been chosen are the 
uncharacterised mChrl5 ESTs 1-130661312 and H3048C08, the mChr15 cholesterol 
biosynthesis pathway gene squalene epoxidase (Sqie), lanosterol synthase (Lss - 
mChrlO), and the sterol regulatory binding factor-2 (SrebJ2 - mChrl5). 
1-130661312 was chosen since the microarray analysis indicated that this EST is 
upregulated in the F-line liver and BAT, and maps close to the Fob3b QTL region. 
H3048C08 was selected as again there was evidence of differential expression, 
although considerably less significant than H3066B12, it mapped just 1500bp 
downstream of H30661312, and thus potentially could be an EST from the same gene. 
Northern analysis presented in this chapter confirms that H306613 12 is upregulated in 
the F-line, and that it is part of an -8kb transcript referred to here as Fad. In 
addition RT-PCR analysis indicates that H3048C08 may indeed be part of the same 
8kb gene as H3066B12. This information can now be used to help clone the full 
sequence of Fad. Once this has been achieved, various in vitro and in vivo 
experiments can be performed to assess this gene's function and any potential role it 
may have in obesity 
Q-PCR analysis of the cholesterol biosynthesis candidate Sqie, confirms that indeed 
it is also differentially expressed in both BAT and liver tissues. However the 
differences are only seen in the mice used for the microarray experiments, and not 
from mice harvested in the second larger dissection population. In contrast, the 
differences in Facl are seen in mice from both populations. There is also evidence of 
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a negative correlation between the expression of the cholesterol biosynthesis 
pathway transcription factor SrebJ2 with Sqie and Lss, which is dependent on which 
dissection-group of mice are being tested. These findings are interesting but difficult 
to interpret without further analysis. 
It is known that the regulation of cholesterol biosynthesis is diurnal, both in animal 
models (Back et al. 1969) and human subjects (Miettinen, 1982). In rodent models, 
the rate of cholesterol biosynthesis is highest after midnight and lowers during the 
morning and early afternoon, in both liver and in the intestine, where most of the 
body cholesterol is synthesised (Kandutsch & Saucier, 1969). The circadian control 
of cholesterol biosynthesis variation is also closely associated with food intake, with 
peak production at around six hours after the presentation of food (Edwards et al. 
1972; Shefer et al. 1972; Goldfarb & Pitot, 1972). 
One reason for the inconsistency observed between dissection-groups, may reside in 
potential highly variable expression of the genes in this pathway within individuals, 
which may be dependent on how much food the individual consumed prior to 
fasting, and how close to the kill-time it was consumed. 
A gene expression comparison of candidates in this pathway between the F- and 
congenic FD-line, may be better examined by comparing expression at distinct 
time points after the presentation of food, with mice being sacrificed within a shorter 
time frame, than the 1 hour window used for mice in this study. As this pathway is 
heavily influenced by circadian rhythms, the circadian rhythm gene Ccrn4l, which is 
indicated to he differentially expressed between the F- and congerlic F ( nI SDlines in 
the microarray study, may be an unknown or indirect controller of the cholesterol 
biosynthesis pathway, and should also be investigated further. 
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CHAPTER FOUR 
SUMMARY & DISCUSSION 
QTL ANALYSIS 
The results and analysis presented in this thesis contribute to a long-term project 
initiated over 20 years ago to investigate the polygenic basis of obesity. Through a 
long-term selection experiment in mice the Fat (F) and Lean (L) lines were 
developed, and these have been used as a model for the genetic dissection of obesity. 
These lines seem to more closely resemble the polygenic nature of obesity in human 
populations than do other models for obesity such as the monogenic mutants 
described in section [1.1.2.2]. Horvat et al. (2000) determined from a genome-wide 
scan that four QTL accounted for almost 50% of the variation in body fat, in an F2 
population generated from the F and L-lines. This thesis has used congenic lines and 
progeny testing of recombinant individuals, finer QTL mapping, microarray 
technology and general molecular techniques, to help refine one of these QTL 
regions, the mChrl5 Fob3 QTL, and to identify possible candidate genes and 
metabolic pathways that may be responsible for this QTL effect. 
Fob3 QTL region from the L-line was successfully introgressed into the F-line and 
further mapped into two smaller QTL: Fob3a (22 - 32cM) & Fob3b (P44 - 70cM) 
An interval specific congenic line for Fob3 was created, and a small-scale analysis 
was performed to show that the QTL effect had been successfully introgressed. The 
congenic line was then used to generate new recombinants within the target interval 
on mChrlS. The recombinants were progeny tested and a detailed single and 
multiple-QTL analysis, was performed. This analysis has shown that the original 
Fob3 QTL (fat% trait) is a composite of at least two smaller QTL - Fob3a (27cM; 22 
- 32cM;) which has a late-onset effect relative to that of the second Fob3b QTL 
(68cM; 44 - 70cM;), which appears to be early-onset [Fig 4.1]. Evidence for a third 
QTL has also been shown through the analysis of the body weight traits through 
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development. Significant age-dependent interaction effects between these smaller 
QTL, as indicated by the body weight QTL analysis, further emphasise the 
complexity of the Fob3 region. Despite the success in identifying these smaller QTL 
regions, the resolution of the refined intervals are still relatively large. This may be 
partly explained by the potential third QTL, which has a 95% confidence interval 
overlapping that of the Fob3b interval, preventing the two regions from being clearly 
dissociated. Further analysis within this region may well reveal that Fob3b is 
composed of two or more QTL. 
QTL studies, particularly in obesity but also for body weight traits, generally have 
yielded low-resolution intervals. A recent large-scale F 2 genome wide scan by Rocha 
et al (2004a), using almost 1000 animals, identified QTL with a confidence interval 
of about 20cM long. Whilst several body weight and growth QTL have successfully 
been mapped to smaller intervals (Liu et al. 2001), finely mapped obesity and 
adiposity QTL have been elusive. Rocha et al. (2004b) report two QTL on mChr2 for 
subcutaneous fat pad and epididymal fat pad weights (Scfql/Epfql and Epfq2 
respectively) spanning just 8.1cM and 6.9cM, respectively. The most finely mapped 
obesity related QTL, i.e. not fat-depot specific, is a 10cM multigenic obesity QTL 
again on mChr2, which does not appear to co-localise with Scfql/Epfql and Epfq2 
(Estrada-Smith et al. 2004). As Fob3a has been mapped to a 10cM interval, Fob3a 
ranks amongst the obesity QTL with highest resolution reported to date. 
Adiposity - using related traits and alternative phenotyping 
That obesity QTL are proving elusive to fine map and ultimately clone, probably 
resides in the nature of this highly variable trait. Adipose-specific weight is likely to 
fluctuate within an individual, more so than non-fat weight. This is due to a larger 
environmental influence on the demands of adipose storage than on brain weight or 
bone density for instance, which are also major contributors to total body weight. As 
QTL are more finely mapped, revealing ever smaller-effect QTL, the noise generated 
by small environmental differences, perhaps even small changes in ambient room 
temperature, may be vital in elucidating the smaller loci. 
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Similarly, as the QTL are reduced in size and effect, the accuracy of phenotyping 
measurements becomes more important. Consequently, more accurate and specific 
phenotypic measurements of obesity and related traits could be applied. In this thesis, 
we used body weight measurements as an indicator of obesity through development. 
A more accurate approach could be to apply quantitative magnetic resonance. This is 
based on the principle that different tissues such as adipose tissue, generate different 
signals in response to various radio frequency pulses at distinct static magnetic fields. 
Using this technology, total body fat measurements on conscious live mice could be 
taken, and different fat types, such as BAT and WAT quantities could be 
differentiated and assessed separately (Tinsley et al. 2004). Similarly, magnetic 
resonance imaging is being adapted from medical applications to mouse 
phenotyping, providing three-dimensional images of conscious live mice. This could 
have the additional advantage of allowing visual tracking of the development of each 
fat depot through development (van Furth et al. 2003). 
Such cutting edge technology could be applied with more standard phenotyping 
assays, such as plasma biochemical screening, that would measure circulating levels 
of cholesterol and triglycerides, for instance (Hough et al. 2002). This would only be 
appropriate at terminal stages, as such an invasive procedure is likely to stress and 
affect the homeostasis of the mouse. 
From single Q TL to smaller Q TL - to yet smaller Q TL? 
The dissection of the Foh3 region into at least two QT  reflects the complexity one 
would expect to see in a polygenically obese population as seen in humans, that is, 
many loci each having small effects. However, as the target intervals of both smaller 
QTL (Fob3a and Fob3b) are still relatively large, further mapping would be 
desirable to reduce these regions down to intervals containing a smaller number of 
genes, that can each be assessed on an individual basis, both in terms of gene and 
protein expression differences. Nonetheless, any further fine mapping attempt of the 
two QTL will inevitably be more formidable, since the smaller effects will make the 
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segregation of the individual QTL harder to track down. Moreover, evidence from 
our three-QTL analysis indicates that the Fob3b region is itself composed of multiple 
QTL, which interact at different developmental stages. 
Any "high resolution genetic mapping" approach would have to anticipate a complex 
multiple QTL eventuality. Interval specific congenic strains (ISCS) created from 
recombinants from a population of less than 300 F 2 mice (generated from crosses 
between the F- and congenic F 15D-line) could theoretically reduce the Fob3b 
region to 1cM (Darvasi, 1997). Resolution will depend on the number of different 
ISCS strains generated and tested, and the distance between the linked epistatic QTL. 
Alternatively, advanced intercrossed lines could be used, however this technique 
could require in excess of 10 intercrosses to reduce the Fob3b interval to a 4cM 
region (Darvasi & Soller, 1995). Consequently, if further mapping was performed, 
improved resolution could be achieved, resulting shorter intervals containing fewer 
candidate genes that could be examined further. However, further mapping may 
reveal that Fob3b contains two, three or more QTL, with a combined interval size 
that would not dramatically reduce the number of candidate genes. In such a case, the 
amount of effort required to improve the resolution of the Fob3b region, may not be 
offset by the lack of genes that have been eliminated as possible candidates. 
From this study, as discussed below, a number of good candidate genes have been 
identified that should be investigated further, and assessed as possible causative 
agents for the Fob3b QTL, including the uncharacterised Facl gene. Rather than 
attempt to further dissect the complex Fob3b QTL region, future studies may prove 
more fruitful by focusing on these candidates, and redirecting efforts to further-
mapping Fob3a which has been resolved to a 10cM interval, and the other Fob QTL 
on chromosomes 2, 12 and X (Horvat et al. 2000), which may prove to be less 
complex and simpler to resolve than Fob3b. 
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M ICROARRAYS 
From QTL to candidate genes - choosing microarrays 
After further mapping for the Fob3 region had revealed the two smaller Fob3a and 
Fob3b QTL, various paths of investigation to identify candidate genes could have 
been pursued. These included differential display (DD), serial analysis gene 
expression (SAGE) and a number of other techniques that have been discussed in 
section [1.3.2]. Identifying and examining possible candidates within the intervals, 
one-by-one, was not feasible as the intervals were still relatively large, containing 
hundreds of genes. Consequently, microarrays were chosen as the preferred 
technology to complement the QTL further-mapping, for a number reasons. Using 
the NIA-NIH cDNA arrays enabled the examination of the expression profiles of a 
large number of genes. As all the spotted ESTs had been sequenced, and half the 
ESTs identified as transcripts of known genes, we were able to look for and identify 
genes in particular metabolic pathways that may be involved in obesity. A DD or 
SAGE analysis would have required a large sequencing effort on our behalf to derive 
the same amount of information. 
The arrays that were used were spotted with 15,000 ESTs from pre- and pen-
implantation mouse embryos, with more or less an even distribution of ESTs from 
each chromosome (per Mb of sequence). An alternative approach may have been to 
use a mChr15 specific array, or an array containing only sequences from transcripts 
within the Fob3b QTL interval. Whilst this may have been a more focused approach 
in terms of interrogating all genes within the Fob3b interval for differentially 
expressed genes, limited information would have been extracted in terms of 
perturbed pathways, and a wider understanding of the expression differences caused 
by the QTL interval. In addition, such a bespoke array was not available at the time 
of this study and would have been required to be generated and tested prior to our 
study. An assessment of the time and effort required to generate such a customised 
array, precluded this approach from being a practical option within the available 
timeframe. 
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A microarray analysis was performed to examine gene expression differences 
between the F-line and a congenic line containing the early-onset Fob3b QTL, which 
was shown to contribute to a greater proportion of the variance relative to Fob3a. 
From a list of 15,000 different ESTs, numerous differentially expressed candidates 
were identified. As well as genes discussed later, these included a number of genes 
that have no reported links to obesity or body weight phenotypes such as the mChrl 1 
heat shock protein 1 alpha (Hspbl) gene, and the mChr3 circadian rhythm gene 
nocturin (Ccrn4l) [Table 3.3.16]. These genes may well have a role in the QTL effect 
and should be further investigated. In addition, a number of highly differentially 
expressed ESTs, with relatively small fold-changes, belonging to unknown genes 
have also been identified. These would represent good candidates for novel 'obesity' 
genes. 
Data interpretation - P-values, fold changes, and the Sf transformation 
Ideal candidates for Fob3b would be both highly differentially expressed (i.e. a large 
fold change between the two lines), and highly-significantly different. The best 
means of identifying candidates from microarray data that satisfy both of these 
requirements remain unresolved. Many research groups favour a 2-fold cut-off 
coupled with adjusted P-values that limit the proportion of false positives. In this 
study, we used a 2-fold cut-off method (GeneSpring method), a significance analysis 
approach (mixed model analysis) and we also introduce a novel and simple 
(significance & fold - Sf) transformation which helps identify ESTs that are both 
significant and highly differentially expressed. 
A total of 16 ESTs were identified using the 2-fold criteria of the GeneSpring 
approach, summarised in figures [3.3.4] and [3.3.5]. In the mixed model analysis, as 
each EST was examined in two tissues, a total of 30,000 t-tests were performed, and 
from these only 13 ESTs were found to meet the experiment-wide 0.05 significance 
threshold [Table 3.3.19]. 2491 tests were significant at the nominal 0.05 threshold 
(this does not represent 2491 different ESTs, as some were significant in both 
tissues). 
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Clearly, using stringent approaches for identifying candidates from a possible list of 
15,000, such as the 2-fold cut-off, or the Bonferroni experiment-wide adjusted level 
of significance, will result in rejecting many truly differentially expressed ESTs. 
Similarly, accepting the nominal 0.05 threshold will result in identifying hundreds of 
false positive results. 
Rather than stringently using the experiment-wide level, and applying a 2-fold cut-
off, ESTs were ranked by P-value and fold change and the highest ranking were 
examined more closely, in terms of function and pathways that they may be involved 
in. In addition, ESTs were ranked according to Sf values. This enhanced the mixed 
model analysis, aiding the discovery of the perturbed cholesterol biosynthesis 
pathway, identifying genes from the pathway such as Lss, Sc5d and Fdftl that had 
not been previously highlighted in the ranked P-value and fold-change lists. When all 
the genes known to be involved in the cholesterol biosynthesis pathway were 
examined, eight often that were spotted on the arrays were significant at the nominal 
level (P<0.01) and each had a relatively high Sf rank. 
However, by examining the ranked P-value and fold-change tables from the mixed 
model analysis for each tissue independently (presented as experiments I to 4), the 
two genes, enolase 1 (Eno]) and glyceraldehyde-3-phosphate dehydrogenase (Gapd) 
were identified as being upregulated in BAT tissue of the F-line relative to the 
congenic FnI5Dline.  Both of these genes are involved in the glycolysis pathway. 
When other genes in the same pathway were examined, it was determined that four 
additional glycolysis genes (Gpi, PJk, AldoA & Tpi) were significant at the nominal 
(P<0.02) level, bringing the total to 6 of a possible 8 that were spotted on the arrays. 
None of the eight genes were significantly different in the liver tissue, indicating that 
this may be a pathway that is perturbed in a tissue specific manner. As the P-values 
for each of the four genes Gpi, PJk, AldoA and Tpi are all relatively low, examined 
individually, each would have been disregarded using stringent selection thresholds, 
however, when considered in the cluster of glycolysis pathway genes, the evidence 
for their differential expression is strengthened. 
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This demonstrates that microarray data should not be analysed with pre-defined 
thresholds and cut-off points, as clearly valuable data may be overlooked. Rather, 
data should be analysed by multiple means, examining significance, fold changes and 
any supporting evidence, such as the expression profiles of genes in common 
pathways. 
Cholesterol biosynthesis and glycolysis pathways - how disruption of these 
pathways may lead to differences in adiposity or may be indicators to the causes of 
the differences due to the Fob3b QTL. 
It may not be immediately apparent how increased cholesterol biosynthesis may lead 
to increased obesity, given that cholesterol is not metabolised and hence is not a 
mechanism for storing energy that may be used at a later date in the way that fatty 
acids are. However, cholesterol is a main constituent of adipocytes where cell size is 
directly correlated to the quantity of cholesterol, ergo the greater amount of 
cholesterol the larger the adipocyte. In humans over half of all body cholesterol is 
stored in adipose tissue (Krause &Hartman, 1984). 
Differences in cholesterol biosynthesis may be associated with the Fob3b obesity 
QTL in several ways. For instance, the causative agent or agents of the Fob3b QTL 
may act directly on the cholesterol biosynthesis genes in the F-line to increase 
cholesterol deposition in adipose cells resulting in increased adiposity. The causative 
agent in this scenario may be a polymorphism at the Sqie gene. Alternatively, the 
causative agent may be acting on the cholesterol biosynthesis pathway, resulting in 
increased plasma cholesterol, which then acts as an activator of fatty-acid synthesis, 
which in turn results in increased obesity (Bennett et al. 1995; Ntambi, 1999). 
Finally, the target of the causative agent that leads to obesity may be entirely 
independent of the cholesterol biosynthesis pathway, yet the cholesterol biosynthesis 
genes are perturbed because they share a common transcription factor. Such a 
scenario may be demonstrated by the SrebJ2 transcription factor, which has been 
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shown to act on the cholesterol biosynthesis genes, as well as Fasn and Scd2, each of 
which have been shown to give rise to obesity independently (Taboret al. 1998). 
Increased expression of the glycolysis pathway genes in the F-line could lead to a 
greater rate of the end product - acetyl-CoA, which is a precursor for both cholesterol 
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Fig 4.1: Summary diagram of the Fob3b QTL region and positions in mega base pairs (Mb) of 
potential candidates. Thick black lines indicate F-line alleles, thin line indicates L-line alleles, and 
chequer is unknown genotype. * Markers that have not yet been mapped by the Mouse Genome 
Sequencing Consortium. 
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POST MICROARRAY ANALYSIS 
Having identified candidates that our microarray analysis showed were differentially 
expressed, a number of these were chosen for confirmation and further analysis. We 
chose Facl as the most promising candidate to confirm and further characterise, as it 
maps close to the Fob3b QTL region on mChrl5. In addition, the gene expression of 
Sqie, which also maps to mChrl 5 and is involved in cholesterol biosynthesis, and Lss 
as an additional representative gene of the cholesterol biosynthesis pathway were 
chosen for confirmation (the transcription factor Srebf2 that was absent from the 
arrays yet maps to mChrIS, was also investigated further as it is a known regulator of 
the genes involved in cholesterol biosynthesis). 
All three genes (Fad, Sqie and Lss) were confirmed to be differentially expressed, 
indicating that our experimental design, and microarray analysis achieved the desired 
goal to identify reproducibly differentially expressed genes between the F-line and 
the congenic Fhr  containing the Fob3b QTL region. 
However, Northern analysis on Facl and Q-PCR analysis on Sqie and Lss, reveals 
that the fold differences detected by microarray analysis are inflated. This is 
particularly prominent for the expression difference seen in BAT for Fad, where the 
difference shown by array analysis is 25-fold, yet the difference shown by Northern 
analysis is closed to 1.6-fold. Northern analysis and Q-PCR are technologies that 
generate reliable accurate quantitation of gene expression, and our results 
demonstrate that microarray technology, although clearly capable of identifying 
differentially expressed transcripts, is still susceptible to large variation due to 
systematic noise. 
Fad - a promising novel uncharacterised candidate gene 
Differential expression of the 1-130661312 EST indicated by the array analysis, was 
confirmed by northern analysis. It was shown that the H3066B 12 EST belongs to an 
8kb transcript, whose gene was provisionally named Fad. In terms of identifying a 
SUMMARY & DISCUSSION: 4 	 257 
novel obesity target, Facl is a strong and interesting candidate. The reported 2kb of 
sequence is entirely novel, while 6kb of the sequence remains unidentified. The only 
domains present within the available sequence (DEP domains) have no known 
function, but are found in signalling molecules, speculatively implicating Facl in a 
signalling pathway, such as described for Leptin in section [1.l.2]. 
Analysis of Facl should logically begin with the cloning of the full gene. Once this 
has been achieved it can be assessed for SNP differences between the F and congenic 
Fth15Dlines. These SNPs could be used in finer genetic mapping analysis to 
demonstrate the linkage of these polymorphisms with the segregation of the QTL 
effect. A knock-out could then be produced to assess the impact of this gene in a 
non-F-line background. Similarly, in vitro analysis using RNA interference could be 
performed to determine molecular functions, for instance by examining the activity 
levels of proteins in metabolic pathways such as the cholesterol biosynthesis 
pathway, and the glycolysis pathway. 
Cholesterol biosynthesis - a potential complex pattern ofgene expression, sensitive 
to feed intake and circadian rhythm, requiring specifically designed experimental 
conditions. 
Q-PCR on candidates from the cholesterol biosynthesis pathway was performed. 
Interestingly, the differential expression was only observed in the mice used for the 
microarray experiments, but not for the mice from a second dissection. The mice 
from the two dissections were genetically identical, and tissue collections were 
performed under similar environmental conditions, where great care was taken to 
avoid introducing environmental differences from the moment of birth through to 
tissue processing, even taking care to avoid a 'seasonal' effect by harvesting 12 
months apart. Nonetheless, the approach taken may not have been optimal for 
assessing this particular pathway, given that cholesterol biosynthesis is under the 
control of circadian rhythms and is strongly affected by food intake. There has been 
very little reported in terms of gene expression profiles of the cholesterol pathway 
genes, however it is likely that the expression of these genes are under the same 
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control mechanisms and undergo a circadian rhythm control (Berkowitz et al. 1995). 
As there is evidence from the arrays that these genes are being differentially 
expressed between the F- and congenic F 5D-lines, experiments can be better 
designed to specifically monitor the gene expression profiles of these genes in both 
lines, and assess the protein level or differences in protein activity. 
In future experimentation, genes from the cholesterol and glycolysis pathways, in 
addition to the other genes described here that have been identified as differentially 
expressed between the F- and congenic Fthi5Dlines,  can be specifically examined 
for differences in mRNA expression, and protein abundance and activity levels. 
These experiments can be performed on new interval specific congenic Fob3b lines 
that contain smaller QTL-containing segments with fewer positional candidates, 
using small-scale arrays containing multiple repeats for each candidate, and 
performed on individuals rather than pools to gauge the range of variation between 
individuals. 
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APPENDIX 
APP A Interval mapping regression analysis: SAS code 
This is the SAS code used for single-QTL analysis, and for generating 95% 
confidence intervals for each interval. File names need to be changed according to 
location on hard drive. The example given if for body weight at 115 days (Bw115). 
data pheno; 
infile PHNufIHb 
input ID Sex LITNO N0ADJ Parity Bwt2l Bwt42 Bwt70 Bwt98 
BwtllS GFPWt DBwt DMRatio Fat rGFPW; 
mouseiD 	is an ar:b.iary integer for each individual 
Sex 	"1" female; "2' male 
LITNO Litter number code 
N0ADJ 	Litter Quantity after weaning 
Parity 1 or 2 (where 2 is also used for 3rd and 4th 
parities also) 
Traits are: 
Bwt2l Bwt42 Bwt70 Bwt98 Bwt115 : Body weight 
measurements 





infile 	H 	H 
input ID addO doinO addi doml add2 dom2 add3 dom3 add4 dorn4 






addli domil add12 dom12 add13 dom13 add14 dom14 add15 dom15 






add2l dom2l add22 dom22 add23 dom23 add24 dom24 add25 dom25 
add26 dom26 add27 dom27 add28 dom28 add29 dom29 add30 dorn30; 
proc sort; 
by ID; 




add3l dom3l add32 dom32 add33 dom33 add34 dom34 add35 dom35 






add41 dom4l add42 dom42 add43 dom43 add44 dom44 add45 dom45 






add5l dom5l add52 dorn52 add53 dom53 add54 dom54 add55 dom55 






add6l dom6l add62 dom62 add63 dorn63 add64 dom64 add65 dom65 






add7l dom7l add72 dom72 add73 dom73 add74 dom74 add75 dom75 




inf i le 	-fr - i8 1 
input ID 
add8l dom8l add82 dom82 add83 dom83 add84 dom84 add85 dom85 




merge pheno genoO genol geno2 geno3 geno4 geno5 geno6 geno7 
geno8; 
by ID; 
* John- you have to remove the lrlls3ing values tul whatever trait you 
are doing, or else it 
will resample missing values; 
if Bwt115 = 	then delete; 
9macro boot; 	e!ie :ver 	buni: 	- ihjs gust generates the 
bts 	.-n 	n 
data bootsamp; * clear whatever was in this data set before; 
APPENDIX 	 A-2 
* John you have to change the second number (1038 here) to whatever 
the sample size is for the particular trait; 
%do sample = 1 %to 1038; 
data ransamp; set all; random = uniform(0); 
proc sort; by random; 
data ransamp; set ransamp; if _N_ = 1; 
data bootsamp; set bootsamp ransamp; 
%end; 
data bootsamp; set bootsamp; 
96nend; I enO ()f DOOL lvi ye; 
%inacro interval; 
data allF; 
%do posQ = 1 %to 89; 	fri-it marker is at. 7 cM, last marker 




additive = add&posQ; dominanc = dom&posQ; 
and dominance coeffients at 
p051 t 1 011  
proc glm data = bootsamp outstat = new noprint; 
class Parity Sex; 
John- you need to chanqe the I ra I ncrnu here; 
model Bwt115 = Parity NoADJ sex additive 
dominanc/ ssl; 
data err; 
set new; if _SOURCE_ = 	. ., .. •; 	DF_err = DF; 
SS_err = SS; 
data add; 
set new; if _SOURCE_ = 	 •; DF_add = DF; 
SS—add = SS; 
data dom; 
set new; if _SOURCE_ = ., . 	; DF_dom = DF; 
SS_dom = SS; 
data calcF (keep = position F_adddom F_add); 
merge err add dom; 
F_adddom = 
((SS_add4-SS_dom) / (DF_add+DF_dom) ) I (SS_err/ (DF_err)); 
F_add = (SS_add/DF_add) / (SS_err/DF_err); 
position = &posQ; 
APPENDIX 	 A-3 
data aliF; 
set aliF calcF; 
%end ; 	'rc1 of 
proc sort data = aliF; 
by descending F_adddom; 
data aliF; 
set aliF; 
if _N_ = 1; 
%awnd; * 	n 	r, 	r 
%macro iter; 	hH 	 :Ltiple hootstrapped samples; 
data all_iter; 
* John von chanqe the number 	rrj however many if - erat ions you 
want to do- you cn dc 	Iudn nrat 'hu; 
'*,do iter = 1 t:o 250; 
%put Starting iteration number &iter; 
%boot; 
%interval; 
data ali_iter; set all_iter aliF; 
%end; 
96ITtend; 	 1 
% it Cr; 
data all_iter; 
set all_iter; 
if F_adddoxn = 	then delete; 
proc print data = all_iter; 
proc f req data = all_iter; 
table position; 
run; 
APPENDIX 	 A-4 
This is the SAS code used for 2-QTL analysis, and for generating 95% confidence 
intervals for each interval. File names need to be changed according to location on 
hard drive. The example given if for body weight at 115 days (Bwl 15). 
data pheno; 
infile 
input ID Sex LITNO N0ADJ Parity Bwt2l Bwt42 Bwt70 Bwt98 
Bwtll5 GFPwt DBwt DMRatio Fat rGFPW; 
mouselD 	is an arbitary integer for each individual 
Sex 	"1' female; "2" male 
LITNO Litter number code 
N0ADJ 	Litter Quantity after weaning 
Parity 1 or 2 (where 2 is also used for 3rd and 4th 
parities also) 
Traits are: 
Bwt2l Bwt42 Bwt70 Bwt98 Bwt115 : Body weight 
measurements 






input ID addO domO addi doml add2 dom2 add3 dom3 add4 dom4 






addil domil add12 doml2 add13 dom13 add14 dom14 add15 dom15 






add21 dom2l add22 dom22 add23 dom23 add24 dorn24 add25 dom25 






add3l dom3l add32 dom32 add33 dom33 add34 dom34 add35 dom35 
add36 dom36 add37 dom37 add38 dorn38 add39 dom39 add40 dom40; 






add4l dom4l add42 dom42 add43 doin43 add44 dom44 add45 dom45 






add5l dom5l add52 dom52 add53 dom53 add54 dom54 add55 dom55 






add6l dom6l add62 dom62 add63 dom63 add64 dom64 add65 dom65 




infile 	. 	.. - 
input ID 
add7l dom7l add72 dom72 add73 dom73 add74 dom74 add75 dom75 






add8l dom8l add82 dorn82 add83 dom83 add84 dom84 add85 dom85 




merge pheno genoO genol geno2 geno3 geno4 geno5 geno6 geno7 
geno8; 
by ID; 
* analysis with epistasis - don't do if epistasis is not 
si gri I f i cant 
proc gun data = all; 
class Parity Sex; 
model Bwt115 = Parity s 
add23*add6O N0ADJ/ss3; 
estimate 'ad , ; r, 	add23 
estimate dorn 2. dom23 
estimate 'add ir add60 
estimate 'dom 60' dom60 
* analysis without enisi: 
proc gum data = all; 





APPENDIX 	 A-6 
class Parity Sex; 
model Bwt115 = Parity sex add22 dom22 add60 dom60 NoADJIss3; 
estimate 	 acId22 1; 
estimate dom22 1; 
estimate 'add 6" add60 1; 
estimate rkrn 61' dom60 1; 
run; 
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APP B 	FINAL LIST OF THE mChr15 HITS WITH P-VALUES 
LESS THAN NOMINAL 5% (0.05) 
Table APP B-i: Final list of the mChr15 EST hits with P-values less than nominal 5% (0.0). 
Systematic Fold 
Exp Tissue NIA code Lo92 change Std Err Accession Bp start St Probt 
1 Liver H3066B1 2 -1.8749 3.67 0.28 BG081 526 55369352 7.5E-10 0.000014 
4BAT R31351-104 1.9455 3.85 0.12 BG074498 78633867 1.1E-08 0.000083 
1 Liver H3020H04 -1.1224 2.18 0.26 BG077950 59490877 2.2E-04 0.00055 
2BAT F13006B06 -1.5378 2.90 0.328G063349 51866482 1.4E-05 0.00069 
3Liver H3120A07 0.4008 1.32 0.10BG073211 39027805 5.9E-02 0.00084 
3Liver H3092A05 -0.2937 1.23 0.08AU017395 89151134 1.3E-01 0.0011 
1 Liver H3017E02 -0.7149 1.64 0.18 BG077609 58029584 8.8E-03 0.0013 
2BAT I-13020H04 -2.0216 4.06 0.47 BG077950 59490877 2.1E-06 0.0015 
1 Liver H3024D08 -0.6740 1.60 0.18 BG064838 99296384 1.3E-02 0.0017 
1 Liver I-13019E12 0.2185 1.16 0.06 BG077769 4949590 2.5E-01 0.0017 
2BAT H3066B12 -4.6391 24.92 1.10BG081526 55369352 1.6E-13 0.0017 
4BAT H3086G04 0.1599 1.12 0.02BG070382 36019707 3.7E-01 0.0019 
3Uver H3156F07 0.3783 1.30 0.11 BG076188 76845741 1.1E-01 0.0029 
2BAT H3015E12 -0.6632 1.58 0.17BG064109 64376894 2.1E-02 0.0030 
2BAT H3054D03 0.5455 1.46 0.14 BG067431 81719551 4.5E-02 0.0034 
2BAT H3037E07 0.7304 1.66 0.19BG065978 15346097 1.6E-02 0.0034 
1 Liver 1-130231308 -0.3570 1.28 0.10 BG064747 76933042 1.3E-01 0.0036 
1 Liver H3069C10 2.0707 4.20 0.61 BG068787 40427552 8.5E-06 0.0036 
2 BAT H3003G02 -0.3579 1.28 0.09 BG076622 76304760 1.3E-01 0.0037 
4BAT H3140E11 0.4982 1.41 0.09BG074887 10212476 7.OE-02 0.0048 
2BAT H3061D10 0.5372 1.45 0.15 BG068072 62802961 6.OE-02 0.0053 
4BAT H3152A08 0.3922 1.31 0.07 BG075806 82299107 1.3E-01 0.0057 
4BAT H3124B12 -0.9570 1.94 0.18BG073567 79595234 8.OE-03 0.0064 
4BAT H3116E09 0.3851 1.31 0.08 BG085705 62415079 1.5E-01 0.0068 
1 Liver H3076F06 -0.5666 1.48 0.18 BG069374 67301378 6.3E-02 0.0077 
2BAT l-13019E12 -0.7540 1.69 0.23 BG077769 4949590 2,6E-02 0.0078 
2BAT H3077A08 0.6363 1.55 0.19BG069499 73608885 4.6E-02 0.0079 
1 Liver I-13007C06 0.3452 1.27 0.11 BG063439 4949026 1.9E-01 0.0085 
1 Liver H3057E01 -1,6901 3.23 0.56BG067722 99176890 3.2E-04 0.0086 
4BAT 113142802 0.2876 1.22 0.06AW555036 17444877 2.6E-01 0.0091 
1 Liver l-13069E03 1.5406 2.91 0.52 BG068804 11036287 7.2E-04 0.0092 
1 Liver H3022B02 -0.5698 1.48 0.19 8G064632 83510726 6.9E-02 0.0092 
3Liver H3118C08 0.4945 1.41 0.18BG073068 102761774 1.OE-01 0.010 
Exp - Experiment no. (1-4) as described in main body of text; Std Err - standard error; Bp Start refers 
to current base pair estimated position on mChrl5; Sf - is the significance and fold transformation 
value. 
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Table APP B-i: Continued from above 
Final list of the mChr15 EST hits with P-values less than nominal 5% (0.0). 
Systematic Fold 
Exp 	Tissue NIA code Lo92 change Std Err 	Accession Bp start St Probt 
3Liver H3150D10 0.2615 1.20 0.09BG088235 76831084 3.OE-01 0.010 
2BAT H3048C08 -0.8852 1.85 0.29BG066896 55371568 1.9E-02 0.011 
4BAT H3104F03 0.3314 1.26 0.08AU045358 90564523 2.4E-01 0.013 
4BAT H3092A05 0.4483 1.36 0.11 AU017395 89151134 1.4E-01 0.013 
1 Liver H3006E03 -0.9470 1.93 0.34 BG076814 76576985 1.7E-02 0.014 
2BAT I-13071G04 1.0462 2.07 0.35BG069010 6132186 1.1E-02 0.014 
4BAT H3106G07 0.4019 1.32 0.10BG072103 102669086 1.8E-01 0.014 
2BAT H3017Al2 -0.6782 1.60 0.23 BG077578 80345896 5.7E-02 0.014 
3Liver H3145E10 0.2383 1.18 0.09BG075292 76603005 3.8E-01 0.017 
2BAT H3056B04 -0.6058 1.52 0.21 C86857 38731659 8.4E-02 0.017 
1 Liver H3050E08 -2.0255 4.07 0.76 BG080169 83449925 2.7E-04 0.017 
1 Liver H3004B06 -0.5358 1.45 0.20 BG076653 83855411 1.1E-01 0.018 
3Liver H3113C06 0.5321 1.45 0.21 BG072644 97023512 1.2E-01 0.018 
1 Liver H3075D12 -0.7427 1.67 0.28 BG069429 99269064 5.4E-02 0.020 
1 Liver H3036E08 -1.4598 2.75 0.57 C77316 100171309 3.4E-03 0.020 
4BAT H3146G08 0.3024 1.23 0.08BG075403 103433564 3.1E-01 0.020 
1 Liver H3035C06 0.7560 1.69 0.29 BG065786 76880286 5.3E-02 0.021 
3Liver H3108A08 -0.3508 1.28 0.14BG085048 79010356 2.6E-01 0.021 
2BAT 1-13075D12 -2.7780 6.86 1.03BG069429 99269064 2.5E-05 0.022 
4BAT H3082G08 -0.3633 1.29 0.10BG082952 25763206 2.5E-01 0.023 
2BAT H3059D11 -2.1413 4.41 0.80BG067897 81178043 3.4E-04 0.024 
4BAT H3101B05 0.3996 1.32 0.11 BG071611 10325683 2.2E-01 0.024 
4BAT H3123E03 0.1635 1.12 0.05 BG073512 40842034 5.4E-01 0.024 
1 Liver H3047E08 -0.9402 1.92 0.38 BG066838 86409661 3.1E-02 0.025 
2BAT H3023B02 0.9574 1.94 0.37BG064720 35598982 3.1E-02 0.026 
1 Liver H3042A09 -1.5844 3.00 0.65 BG066357 102962986 3.2E-03 0.027 
2BAT 1-130751-112 -1.6723 3.19 0.65 BG069476 76576020 2.5E-03 0.028 
3Liver H3105E06 0.3980 1.32 0.17BG071995 39030300 2.4E-01 0.028 
4BAT H3130G09 -0.4641 1.38 0.14BG086808 73782766 1.9E-01 0.029 
2BAT H3003C12 2.0415 4.12 0.81 BG063123 102617132 8.OE-04 0.030 
2BAT H3075E06 0.4569 1.37 0.18 BG069435 10208294 2.1E-01 0.031 
1 Liver H3078001 1.6408 3.12 0.70 BG069658 99087929 3.4E-03 0.032 
4BAT H3124E06 0.5399 1.45 0.17BG086322 80500202 1.6E-01 0.032 
Exp - Experiment no. (1-4) as described in main body of text; Std Err - standard error; Bp Start refers 
to current base pair estimated position on mChrl5; Sf- is the significance and fold transformation 
value. 
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Table APP B-i: Continued from above 
Final list of the mChri5 EST hits with P-values less than nominal 5% (0.0). 
Systematic Fold 
Exp 	Tissue NIA code L092 change Std Err 	Accession Bp start St Probt 
2BAT H3010B02 1.7699 3.41 0.71 AW538653 102689335 2.3E-03 0.032 
2BAT H3031B05 2.1543 4.45 0.88BG065435 100555312 6.9E-04 0.034 
4BAT H3153E12 0.4584 1.37 0.14BG088476 84464824 2.1E-01 0.034 
4BAT H3109E09 0.2511 1.19 0.08 BG072352 84221047 4.3E-01 0.035 
4BAT H3138A04 0.2375 1.18 0.08BG074679 79909746 4.5E-01 0.035 
1 Liver H3056B04 0.4558 1.37 0.20 C86857 38731659 2.2E-01 0.036 
3Liver H3125G05 -0.1483 1.11 0.07BG086412 91096025 6.1E-01 0.036 
2BAT H3005H11 1.1838 2.27 0.50BG063336 34170667 2.1E-02 0.039 
2BAT H3032A09 0.8145 1.76 0.34BG078796 81595733 7.2E-02 0.040 
2BAT H3072D07 -0.1676 1.12 0.07BG069070 86457636 5.8E-01 0.041 
2 BAT 1-130641-109 1.6793 3.20 0.72 BG068388 60458433 4.7E-03 0.041 
2BAT H3006E10 0.2154 1.16 0.09BG063377 59520069 5.OE-01 0.041 
3Liver H3118F01 1.5385 2.91 0.72BG073090 86160806 7.9E-03 0.043 
2BAT H30101-112 -0.5009 1.42 0.21 BG077119 82125284 2.1E-01 0.043 
3Liver H3157F03 -0.2817 1.22 0.13BG088791 103087535 4.2E-01 0.045 
3Liver H3115A08 -0.3425 1.27 0.16BG072793 75201977 3.5E-01 0.046 
1 Liver H3025B05 0.5631 1.48 0.26 BG078223 35184406 1.8E-01 0.046 
3Liver H3113A02 -0.8017 1.74 0.38BG072618 73298626 8.4E-02 0.046 
4BAT H3127C05 0.1953 1.14 0.07BG086521 102948792 5.5E-01 0.046 
2BAT H3051E06 2.1760 4.52 0.96BG080253 89665630 1.3E-03 0.046 
3Liver H3134B03 0.1689 1.12 0.08BG074353 82232571 6.OE-01 0.047 
4BAT 1-130871-108 0.2696 1.21 0.10BG070490 59521301 4.4E-01 0.048 
3Liver H3149E07 -0.5590 1.47 0.27AW556660 55024316 1.9E-01 0.049 
2BAT H3067B05 2.2168 4.65 0.99BG068584 30164508 1.2E-03 0.049 
1 Liver H3069E04 1.4503 2.73 0.68 BG068805 36180717 1.3E-02 0.050 
3Liver H3096A05 -0.1683 1.12 0.08BG084087 31230209 6.OE-01 0.050 
2BAT H3065F02 1.1868 2.28 0.53BG068446 71810281 2.9E-02 0.050 
4BAT H3129F10 0.2031 1.15 0.07BG073999 36638576 5.5E-01 0.051 
1 Liver H3076D10 -1.0472 2.07 0.50 BG082459 62185619 4.5E-02 0.051 
1 Liver 1-130381304 -0.7611 1.69 0.36 BG066054 59050877 1.OE-01 0.051 
2BAT H3030F06 -0.5259 1.44 0.24 BG078679 34472500 2.2E-01 0.054 
1 Liver H3059A07 -0.6913 1.61 0.33 BG080920 100786630 1.3E-01 0.055 
3Liver H3113H12 0.1535 1,11 0.08BG072704 78990191 6.4E-01 0.055 
Exp - Experiment no. (1-4) as described in main body of text; Std Err - standard error; Bp Start refers 
to current base pair estimated position on mChr15; Sf- is the significance and fold transformation 
value. 
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